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This thesis explores the process of technological change in the pharmaceutical
industry. Although pharmaceuticals are crucial in modern society, the shaping
process of this technology is not fully understood. In particular, the social aspect of
the process is seldom examined. Despite the lack of close empirical studies, the
process is often assumed to be a linear process from scientific research through
technological and clinical development to market. This thesis demonstrates that this
is not the case, through a comparative, multiple case study including sixteen cases of
major drug innovation in Japan and the United Kingdom. The shaping process of
pharmaceuticals is not linear but interactive and multilateral. Four aspects of the
process are identified, namely the shaping of the compound, of the application, of
organisational authorisation and of the market. In each aspect, various social groups,
non-human entities, and historical, structural and cultural factors are differently
involved. Different aspects of drug shaping also interact with each other. In addition,
three types of drug innovation are identified, namely, paradigmatic innovation,
application innovation and modification-based innovation. Each type of innovation
has distinctive features. Historical, structural and cultural factors, which significantly
affect the shaping process of drugs but are often invisible, are also considered
through a comparison between Japanese and British drug innovations.
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1.1. Understanding Technological Change in the Pharmaceutical Industry
Technology is a crucial factor in modern society, which has an enormous influence on
our lives. Our actions and relationships have always been transformed by
technological change. On the other hand, technology is something people shape: it
does not emerge without human beings. In particular, companies in the private sector
nowadays play a major role in the creation ofmost technologies. Research and
development (R&D) for innovation is now a key activity for many companies.
This study is an attempt to explore the process of technological change, particularly in
the pharmaceutical industry. Pharmaceuticals are important products for our lives.
Especially, they are indispensable for patients. They are often lifesaving. At the same
time, they are potentially dangerous. Their wrong administration may cause death or
handicap. Mainly because of this potential risk, modern governments strictly regulate
every aspect of the industry: research, development, manufacturing, marketing and
delivery. In addition, the pharmaceutical industry is the most research-intensive
industry. R&D costs in the industry are more than 10 % of sales. (The Association of
the British Pharmaceutical Industry 1997, p. 29; Japan Pharmaceutical Manufacturers
Association 1997, p. 1-35) Modern pharmaceutical products are on the cutting edge
ofbiomedical sciences, though it should be noticed that it takes about 10 years from
their discovery to appearance on the market. Thus, pharmaceuticals can be regarded
as one of the most crucial technologies in modern time.
Despite this, people other than experts understand the shaping process of drugs
poorly. This is probably partly because people regard pharmaceuticals as very difficult
to understand. The molecular structure of a drug is invisible. Even though it is
described as a chemical formula, it is still hard for lay people to imagine what it is
actually like. The names of chemicals are also very unfamiliar to outsiders. In addition,
because drugs work in the living body, knowledge not only of chemistry but also of
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biology is needed to understand their mechanism of action. Another possible reason
for the lack of knowledge about the shaping process of drugs is the high
confidentiality of pharmaceutical companies. Because they are fiercely competing with
each other on the cutting edge, they are unwilling to make the details of their research
and technological activities public. An anonymous interviewee working for a
pharmaceutical company stated that they also fear that the disclosure of internal
information can lead to sensationalist discussion about their drugs. Thus, in spite of
being crucial in modern society, the innovation process in the pharmaceutical industry
remains relatively unexplored. This research is an attempt to fill in the gap between
the demand and the supply of knowledge in this area.
Innovation in the pharmaceutical industry is interesting from the viewpoint of social
studies of technology because it is sometimes regarded as following the linear model
even by those who doubt the model's general applicability. The linear model of
technological change suggests that technological change starts from scientific research,
goes through technological development and production, and ends with consumption.
An alternative version of the linear model implies that technological change starts
from social needs, followed by research and development, production and marketing,
and ends with the satisfaction of the initial needs. Nowadays, these linear views of
technological change are in general regarded as too simple to represent the actual
process of technological change. However, the pharmaceutical industry is sometimes
seen as an exception. Indeed, the process of innovation in the industry appears to be
linear, because the government strictly regulates the formal process of research and
development of drugs. Nevertheless, there remains a doubt because the formal and the
actual aspects of social phenomena are often different. Without sufficiently detailed
empirical studies, how can we say that the innovation process of pharmaceuticals is
linear?
The shaping process of pharmaceuticals is also interesting from a sociological point of
view, because various social groups seem to be involved in the process. As a result,
pharmaceuticals have several different meanings. Roughly speaking, there are at least
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five meanings within a drug. Firstly, for researchers, they are chemicals. Secondly, for
patients and doctors, they are therapies. Thirdly, for companies, they are products for
sale. Fourthly, for regulators, they are objects of their regulation. Fifthly, for some
industrial workers, they may be the means of intra-organisational politics. Ifwe divide
relevant people into smaller social groups, there are probably even more meanings.
For example, chemists and biologists probably attribute different meanings to the
same chemical. Patients and doctors probably regard the same medicine as having
different therapeutic value. The production and marketing divisions of the same
pharmaceutical company probably see the same product from different points of view.
Thus, different social actors with different interests seem to be involved in the shaping
process of drugs. How do they interact with each other?
Non-human entities can also be seen to have a role in the shaping process of drugs.
There is a large body of literature discussing the relationship between people and
artefacts in the sociology and philosophy of science and technology. (Collins and
Yearley 1992; Callon and Latour 1992; Latour 1992 [1999]; Bloor 1999; Latour
1999) Although the metaphysical controversy is beyond the scope of this study, it is
also interesting for us to look at the roles various non-human entities play in the
innovation process of pharmaceuticals. What kinds of non-human entity are involved
and how do they interact with human actors?
In addition, historical, structural and cultural factors cannot be ignored in the process
of drug shaping. There are the social relationships which are beyond the interactions
between the "relevant" human and non-human actors. Such relationships, however,
constitute the background against which actors play their part. They have an influence
on the positions and activities of actors. Without taking them into consideration, we
cannot sufficiently understand the shaping process of pharmaceuticals. Thus, it is
interesting as well to investigate the influences of these factors. What kinds of
historical, structural and cultural factors affect the process and how do they do so?
This study has the following purposes: to fill the gap between necessity and reality of
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outsiders' knowledge of technological change in pharmaceuticals; to provide a close
description of drug innovation process; to understand how various social groups with
different interests interact with each other in the shaping process of drugs; to know
what kinds of non-human entities are related to the innovation process ofmedicines:
and to learn how historical, structural and cultural factors influence the process of
technological change in the pharmaceutical industry.
1.2. Two Significant Features of This Study
In order to accomplish the purposes mentioned above, this study attempts a close
examination of a number of historical cases of innovation in the pharmaceutical
industry in Japan and the United Kingdom. It possesses two uncommon features
compared with most other innovation studies. First, I venture into the contents of
relevant academic literature in medicine, physiology and pharmacology. This is
potentially risky because I have limited basic knowledge about them. However,
academic literature has a lot of historical evidence and information to help us
understand the process of drug innovation. To minimise the misunderstanding, I
conducted interviews with key researchers and corporate staff who were involved in
the discovery and development of the drugs. I also consulted other sorts of literature
such as review articles, textbooks, biography, and corporate history. I emphasise
again that I used the contents of academic literature only as evidence for a
sociological and historical study of drug innovation, and that I have no intention of
discussing the contents themselves.
The second unique feature of this study is that I also explore the organisational
processes inside pharmaceutical companies. This was achieved by interviewing
relevant people and consulting some internal documents which were obtained by
courtesy of these people or their companies. As mentioned above, pharmaceutical
companies are especially sensitive about confidentiality. However, probably because
of their awareness of the importance of public relations and because most of the cases
I examined were not on the cutting edge of research any longer, they were generally
4
cooperative. All the researchers I met seemed proud of their achievements in drug
discovery and happy to talk about them to me. There is again potential risk as regards
the accuracy of their stories. To reduce this risk, I also consulted academic papers,
patents, and other sources of information. This study demonstrates that a company is
not a monolithic unit but that there are a lot of conflicts and politics within it.
1.3. The Structure of This Thesis
This thesis consists of eight chapters. Chapter 2 reviews various perspectives on
technological change, in particular, the linear model and several sociological strands
of non-linear perspective on technological change. The chapter also describes some
basic features ofR&D activities in the pharmaceutical industry. In addition, it reviews
the literature on drug R&D. At the end of the chapter, the objectives, methods and
areas of this study are set out.
In each chapter from Chapter 3 to Chapter 6, several cases of drug innovation in the
same therapeutic area are described. Each chapter includes at least one British and
one Japanese case. Chapter 3 deals with cardiovascular drugs, especially the ones that
are used for the treatment of hypertension. The innovation processes of two
p-blockers, namely propranolol and atenolol, and of one Ca-antagonist, nicardipine,
are examined. Chapter 4 addresses the cases of anti-asthma drugs including
(3-stimulants such as salbutamol, salmeterol and procaterol, and inhaled steroids such
as beclomethasone dipropionate inhaler and fluticasone propionate. Chapter 5
describes the cases of drugs called histamine H2-antagonists, used for the treatment of
peptic ulcer. They include cimetidine, ranitidine and famotidine. Chapter 6 depicts the
R&D process of two LHRH analogues, leuprorelin and goserelin, which are used in
the treatment of prostate and breast cancer and several gynaecological diseases.
Chapter 7 explores three more cases of pharmaceutical innovation which took place in
Japan. These cases include an HMG-CoA reductase inhibitor, mevastatin, which
reduces the level of cholesterol in the blood, an aic-receptor antagonist, tamsulosin,
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which is used for the treatment of urination disorder accompanying benign prostatic
hypertrophy, and an cephalosporin antibiotic, cefotiam. Each case in this chapter has
distinguishable characteristics from the others. Mevastatin is the exemplary compound
of other HMG-CoA reductase inhibitors such as lovastatin, simvastatin, and
pravastatin, which are at present the top selling drugs in the world. It was
paradigmatic as a compound and as a therapy. Tamsulosin was not very novel as a
compound. There had been some a-receptor antagonists when the drug was
discovered. However, its application was innovative. It was used for the treatment of
urination disorder whereas existing a-receptor antagonists had been used for the
treatment of hypertension. Although cefotiam had some unique structure in its
molecule, it was not a paradigmatic drug in the same sense as mevastatin. It had
exemplary compounds and its application was the same as the exemplars. These cases
in the chapter are intentionally varied in order to confirm the findings of previous
chapters, especially those about types of innovation. In addition, they particularly go
into the details of the organisational process to identify properties of each type of
innovation.
Chapter 8 concludes this study by integrating the findings of previous chapters. First,
general features of the shaping process of pharmaceuticals are described. The complex
interaction between various actors, factors and activities in the process are revealed.
Second, three different types of innovation in the pharmaceutical industry, namely
paradigmatic innovation, application innovation and modification-based innovation,
are proposed. The chapter explores several distinguishable characteristics of each type
of innovation. Third, distinctive features of Japanese pharmaceutical innovation are
discussed. Several historical, structural and cultural factors affecting the innovation
process are considered. Finally, this study ends by summarising its several implications
for innovation studies and for innovation management in the pharmaceutical industry.
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Chapter 2: Technological Change and the
Pharmaceutical Industry
2.1. Perspectives on Technological Change
2.1.1. Linear Model of Technological Change and Its Criticism
Among various perspectives on technological change, there is a simple dichotomy
between two extreme positions. One of these is "hard" technological determinism,
which regards scientific progress and its natural consequence, technological change,
as autonomous phenomena and as the ultimate factors that decide the style of society.
(Marx and Smith 1994, pp. ix-xii) Another simple perspective is the exact opposite
of "hard" technological determinism - what I will call "hard" social determinism.
"Hard" social determinism views society as the absolute planner of scientific and
technological change. (Williams and Edge 1996, 866) We can find several sub¬
versions of this perspective, including "demand-pull" theory of innovation (Coombs,
Saviotti and Walsh 1987, pp. 94-97), "mode of production" determinism and
organisational choice perspective (Thomas 1994, pp. 1-9). Either the "hard" version
of technological determinism or that of social determinism can be put as a linear
model. (Figure 2.1)
Figure 2.1: "Hard" Technological Determinism and Social Determinism
Scientific - Technological — Product —► Production — Marketing —► Social
Research Development Development and Sales Impacts
"Hard" Technological Determinist Linear Mode
Social —* Scientific - Technological —► Product - Production - Marketing
Needs Research Development Development and Sales
Hard" Social Determinist Linear Model
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However, few researchers in social sciences nowadays seem to believe in either
version of the linear model. Most believe that there are both aspects in the process of
technological change. These include, for example, economists of technological
change (Nelson and Winter 1977; Dosi 1982; Coombs, Saviotti and Walsh 1987,
pp. 102-103; Rothwell 1994; Steinmueller 1994; Nelson 1996; McKelvey 1996;
Freeman and Soete 1997), historians of technological change (Rosenberg 1976;
Rosenberg 1982; Hughes 1983; David 1985; Rosenberg 1994) and researchers on
technology management (Abernathy 1978; Kline 1985; Tushman and Anderson
1986; Henderson and Clark 1990; Tushman and Rosenkopf 1992; Utterback 1994;
Thomas 1994; Christensen 1997)
Sociologists of science and technology1 also deny the linear model of technological
change, especially its technological determinist version. In the next section, we
examine several variations of opposition to the technological determinist linear
model, because their criticism is both detailed and theory-oriented, which helps us
understand how the linear model is distant from the reality of technological change.
2.1.2. Interpretative Flexibility and Closure: the Social Construction of
Technology
The first variation of sociological criticism against the linear model of technological
change is done by the social construction of technology approach (SCOT). SCOT,
like most of the other strands of sociology of technology, stems from the sociology
of scientific knowledge, especially the empirical programme of relativism (EPOR)
developed by Harry Collins. (Pinch and Bijker 1987; Collins 1981) Pinch and Bijker,
the leading proponents of SCOT, regard the process of technological change as an
evolutionary process, that is to say, an alternation of variation and selection. As a
result, they advocate a "multidirectional" model of technological change and deny
the linear model. (Pinch and Bijker 1987, p.28)
1 For an overview of the sociology of (science and) technology, see, for example, Bijker, Hughes
and Pinch (eds.) (1987), Webster (1991), William and Edge (1996) and MacKenzie and
Wajcman (eds.) (1999).
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The essential concepts of SCOT are "relevant social groups", "interpretative
flexibility" and "closure mechanisms." A relevant social group is the social group in
which all members share a meaning of a certain artefact. Different relevant social
groups often give different meanings to the same artefact. For example, in the history
of bicycle development, the high-wheeler had the meaning of the "macho machine"
for young men ofmeans and nerve, but for older people and women it had the
meaning of the "unsafe machine." This divergence of meanings is named
interpretative flexibility. A relevant social group gives a specific meaning to an
artefact and perceives a set of specific problems with respect to the artefact. Around
each problem, several different solutions can be developed. As a result, a number of
variants of the artefact are developed. This is the explanation of variation of an
artefact by SCOT. (Pinch and Bijker 1987, pp.30-44; Pinch 1996, pp.24-25)
However, variation based on interpretative flexibility does not continue forever.
Some artefacts appear to have fewer problems than others and become increasingly
dominant forms of the technology. This closure and stabilisation of technology occur
through closure mechanisms. It is not necessary that all relevant social groups be
convinced of a certain interpretation of the artefact: what is required is that each
major group can see its own problem as being solved. Pinch and Bijker suggest two
types of closure mechanisms of technological change. One is what Pinch and Bijker
call rhetorical closure, which we can typically observe in advertisements. With
rhetoric, advertisements try to convince people belonging to various relevant social
groups that a particular design is superior to others. The other is what is called the
redefinition of problems. For example, the low-wheeled bicycle with air tyres was
regarded as the "safer bicycle" by some people including the designer and women
cyclists. But other people such as racers and male cyclists regarded it as the "high¬
speed machine." Although the interpretations were different, the design solved
different problems of different relevant social groups and became dominant. The
closure and stabilisation of technology, however, may not mean the disappearance of
all rivals, and a few different technologies may coexist. In addition, it does not mean
that the technology reaches its final form. New problems can emerge and lead the
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technology to another session of interpretative flexibility. (Pinch and Bijker 1987,
pp.44-46; Bijker 1995, pp.84-88; Pinch 1996, p.25)
The SCOT perspective indicates that social diversity prohibits technological change
from being developed in such a way as the technological determinist linear model
assumes. At the same time, it also indicates that various social processes, called
closure mechanisms, lead technological change in a specific direction, though the
driving forces of closure mechanism are not necessarily clear. However, SCOT
provides us with an alternative perspective, which seems to be much richer in content
and closer to the reality of technological change than the technological determinist
linear model.
2.1.3. Non-Human Actors: Actor-Network Theory
Although SCOT is a very strong opponent of the technological determinist linear
model, it does not seem to be a strong opponent of the social determinist linear
model to the same degree. However, it is obvious that technological change is by no
means free from the laws of nature. Although most scholars probably recognise this,
it is actor-network theory (ANT) that most strongly emphasises the role of non-
human elements of nature in the process of technological change. According to ANT,
technology should be seen as a product shaped by an actor-network in which not
only human actors but also non-human actors such as electrons, catalysts,
electrolytes, and lead accumulators are playing their roles. (Callon 1986, p.22, pp.28-
33; Latour 1987, pp. 121-144; Law 1987) An actor-network is also a dynamic
network, which can connect up further heterogeneous elements, redefine itself, and
transform itself constantly. (Callon 1986, pp.28-33; Callon 1987, p.93) The activity
that builds a relatively stable system (or network) within an indifferent and unstable
environment (or field) from various human and non-human actors is named
"heterogeneous engineering" (Law 1987, pp.113-116) or "translation." (Callon 1986,
pp.24-28) In heterogeneous engineering, or in actor networking, society is not given
a higher position than nature. (Law 1987, p. 130; Latour 1992 [1999]) There has
been a controversy over this symmetrical position on human and non-human actors.
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(Collins and Yearley 1992; Callon and Latour 1992; Latour 1992 [1999]; Bloor
1999; Latour 1999a) In addition, recent discussion amongst ANT proponents is
developing beyond these issues. (Law 1999; Latour 1999b) However, what is
important here is that the view ofANT is incompatible with the social determinist
linear model. Rather, their perspective on technological change is more reciprocal
and simultaneous: society, technological artefacts and knowledge of nature are co-
evolving. (Callon 1986, p.20)
Thus, ANT provides us with another alternative perspective on technological change:
a co-evolutionary model between society and science and technology. In contrast
with the perspective of SCOT, it rejects not only the technological determinist linear
model but also the social determinist linear model. At the same time, this view also
reminds us of the active side of technological change through the notions of
heterogeneous engineering and translation.
2.1.4. Structural and Historical Context: the Social Shaping of Technology
Both SCOT and ANT help us understand the complexity of technological change,
but some social scientists have criticized them for their tendency to disregard the
structural and historical context. For example, Russell and Williams (1988, 7-10, 26)
point out that actors must be shaped not only by a tangible relationship to other
actors, but also by an intangible historical and structural context. They argue that the
historical and structural context is important in technology studies because there are
several differences between science and technology. First, technological practitioners
are more heterogeneous than scientists because they often work beyond the
boundaries of the disciplinary community. Second, technological knowledge is more
directly concerned with economic and political purposes than science. Third,
technology consists of not only knowledge but also material: in technology studies, it
is necessary to investigate the implementation and the use of technology.2 These
2 It should be noted that science is also based on not only knowledge but also material. See, for
example, Collins (1992), Latour and Woolgar (1986) and Pickering (ed.) (1992). I think that this
difference is a matter of degree.
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differences force technology studies to embrace various institutional, structural and
historical matters more than science studies. (Russell and Williams 1988, 4-6)
This (re-) attention to structural and historical context as well as to interacting actors
in technological change is the key characteristic of an approach called the social
shaping of technology (SST). (MacKenzie and Wajcman 1985, p.23; MacKenzie
1988; Williams and Edge 1996; MacKenzie and Wajcman 1999, p.22) Structural and
historical context concretely includes, as we know from the literature of SST, classes,
modes of production, markets, gender, democracy and so on. By taking these into
consideration, SST can enjoy various intellectual fruits from existing social studies
on technological change including Marxist technology studies (E.g. Braverman 1974;
Noble 1984), the economics of technological change (see Section 2.1.1), studies of
innovation management (see Section 2.1.1), feminist technology studies (see
Wajcman 1995) and critical studies of technology policy (William and Edge 1996,
870-871).
It is important to note that SST is not the "hard" social determinism of technology.
The proponents of SST explicitly recognize the following two things. First, social
actors cannot construct technology at will because nature also limits technology.
(MacKenzie and Wajcman 1999, pp.16-18) Second, technology, as an element of the
structural and historical context, restricts the behaviour of social actors. (Williams
and Edge 1996, 866-867; MacKenzie and Wajcman 1999, pp.22-23) They are not
arguing that society determines technology, but that it is important for us to
understand the myriad ways in which society shapes technology (MacKenzie and
Wajcman 1985, p.24). They stress the room for technological and social choices, the
negotiability of technology, the temporary stability of technology and the
reversibility of earlier choices. (Williams and Edge 1996, 866-867) This flexible
view of SST is mostly compatible with both the perspective of SCOT and that of
ANT. In contrast, it is completely at odds with both the technological determinist
linear model and the social determinist linear model. What is unique to SST is that it
enriches the potential causes of the variation and convergence of technology beyond
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visible social groups and actors, by taking structural and historical context into
consideration.
Thus, the SST perspective seems to be the broadest and most balanced theoretical
approach. However, this may reduce the sharpness of the perspective, that is to say,
because the SST perspective takes more factors into consideration, it is more difficult
to decide what is the most important based on the perspective. Despite this dilemma,
in order to understand technological change, I think it necessary to tolerate this
ambiguity, because what is the most important factor in technological change does
not seem to be a question that can be given a single general answer. On the contrary,
this position may go further: the social shaping of technology is still limited by the
word social. As Latour andWoolgar did in the second edition of their book (Latour
and Woolgar 1986), I think that it is all right to remove "social" from SST: the
shaping of technology. This is obviously very broad, maybe too broad. However, at
least as a starting point of empirical investigation into technological change, it seems
better to be free from the priority of the social.
2.1.5. Science and Technology
The relationship between science and technology is important here in two ways. First,
it is often believed that technology is just the application of science. This is one of
the core assumptions of the linear model of technological change. Second,
technology studies often directly apply notions and theories developed by science
studies to research on technology, as we can see in SCOT and ANT. Is there a
problem here? In this section, we briefly examine the relationship.
Case studies and historical investigation of technological change revealed by the
early 1980s that technology is not just applied science. Technologists have their own
cultural resources. Technologists inherit a good part of their culture in non-verbal
ways. Technologists actually use the findings and theories of science, but scientists
also use the ideas and artefacts of technology. Scientific knowledge is often full of
uncertainty when an invention is achieved, and the achievement of the invention
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often reduces the uncertainty in scientific knowledge. (Barnes and Edge 1982,
pp.149-150; Faulkner and Senker 1995, pp.26-29) The linear model regarding
technology as applied science has been replaced by an interactive, symmetrical
model. (Barnes 1982; Barnes and Edge 1982, pp.151-152; Pinch and Bijker 1987,
pp. 19-21; Faulkner and Senker 1995. pp.27-29)
This parallel between science and technology can be used to justify the application of
science studies to technology studies, in particular, within sociology. (Faulkner and
Senker 1995, p.29) Recent studies including some historical studies of technological
change, however, tend to highlight the distinctiveness of technology from science.
This is not a return to the linear model. Given the horizontal, interactive relationship
between science and technology, their differences are stressed. (Faulkner and Senker
1995, p.27, pp.29-34) Faulkner and Senker (1995) identify three closely related areas
in which technology is distinguished from science: purpose or orientation;
sociotechnical organisation; and cognitive and epistemological features. In purpose,
technology is more practice-, or artefact-oriented than science. In organisation,
technology is more structurally organised. In cognitive and epistemological
orientation, technology is more design-oriented, more heterogeneous, more local and
more tacit, (pp.31-34)3 However, they are sceptical about the claims that science is
more theory-based and technology more empirical, and that scientific theory is closer
to mathematical theory and technological theory is closer to phenomenological
theory. Hamlin (1992) also indicates that in technology material constraint is more
significant than in science, that in technology people do more than what they know
scientifically, that technological knowledge is dispersed among a greater number and
diversity of people, that in technology solutions sometimes search for problems, that
technology inherently intervenes in the world and the change is irreversible, and that
it is impossible to imagine a final optimised technology. Pavitt (1987), too, argues
that technology is more specific, more complex, more tacit, more cumulative and
more expensive than science. Historical studies of technological change such as
Constant (1980), Vincenti (1990) and McKelvey (1996) demonstrate these
distinguishable characteristics of technology. Thus, these works emphasise that
3 This is, again, to some extent the case in science. (Collins 1992)
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science and technology are closely interactive but distinguishable. This view is also
shared by proponents of SST, who argue that technology studies require more than
just the application of science studies. (See Section 2.1.4) This is why the SST
proponents insist on taking the historical and social context into consideration. Given
the described differences between science and technology, SST seems to be most
suitable perspective on technological change. However, the SST perspective
excludes neither SCOT nor ANT perspectives. Both SCOT and ANT perspectives
are as useful as historical, structural, and institutional perspectives.
Technological studies should be more than an application of science studies. But, this
does not mean that the application of science studies to technological studies is not
useful. On the contrary, it is still very useful. Although SCOT and ANT apply
science studies to technology studies to some degree, we may be able to take it
further. MacKenzie (1996b) suggests that we apply the sociology of (scientific)
knowledge to understand the (functional) properties of artefacts, for example,
whether artefacts work, how well they work and how safe they are. Knowledge about
the properties of artefacts is part of knowledge, which is defined as any shared belief
system, not necessarily correct belief by sociologists of knowledge. (MacKenzie
1996b, p.248) He insists that the general means for obtaining knowledge, namely,
authority, induction and deduction, are also applicable to the knowledge about the
properties of artefacts. That is to say, we can know the properties of artefacts by
authority (people whom we trust tell us the properties), by induction (we learn the
properties by testing or using artefacts) and by deduction (we infer the properties
from theories or models), but none of these can guarantee the correct properties of
artefacts, as is the case in any other knowledge creation. Authority may lose people's
confidence. Testing conditions may be crucially different from conditions of use.
Conditions of use are so complex that we cannot know exactly the properties of
artefacts. Real conditions may be different from the ones that are assumed in theories
or models. In addition, deduction is also accompanied by inference and trust, both of
which are socially conditioned. MacKenzie argues, therefore, that our knowledge of
the properties of artefacts is socially contingent, that controversy over the properties
of artefacts is pervasive in technological change and that knowledge of the properties
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of artefacts is no less social even when there are no such controversies to be seen.
(MacKenzie 1996b, p.263) This thought underpins the idea that technological change
is not linear even if it appears linear. However, intellectual effort is required to reveal
this. About this, MacKenzie suggests that only historical analysis makes it possible
for us to see how we were able to take for granted the knowledge of the properties of
artefacts we now take for granted. (MacKenzie 1996b, p.263)
2.1.6. Linear Model Still Exists!
As we can see in the sections above, the linear model has been criticised by various
disciplinary groups of social scientists. Rothwell (1995) suggests five generations of
innovation model: technology-push model as the first generation (1950s - mid
1960s); market-pull model as the second generation (late 1960s - early 1970s);
"coupling" model as the third generation (mid 1970s - early 1980s); integrated
model as the fourth generation (mid 1980s - 1990s); and system integration and
network model as the fifth generation (1990s - ). Among them, the first two can be
seen as the technological determinist linear model and the social determinist linear
model. This clearly suggests that the linear model of technological change is being
regarded as obsolete.
However, the linear model, especially its technological determinist version, still
persists as a policy driver and as a standard model in several specific industries. Tait
and Williams (1999, 2) suggest four reasons why the linear model has been resilient
in the minds of policy makers: first, some policy makers are still unaware of its
reputed problems; second, it is attractive as a metaphor for policy makers who want a
simple understanding of technological change; third, existing policy repertories
based on the model are well-entrenched in the minds and relationships of policy
makers; fourth, the model matches the interests of academic research scientists and
some research councils because it justifies the expenditure of large amounts of public
money on basic research. (E. g. "Government focuses on science base," Financial
Times, July 26 2000) Tait and Williams (1999, 2-3) indicate that a revised version of
the linear model, named the "linear plus" model, has emerged. The "linear plus"
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model stresses the relationship between academia and industry and the cooperation
between various disciplinary groups, though it still assumes linearity from research
to market.
The linear model is often regarded as reality in several exceptional industries such as
the chemical industry (Cadogan 1997, 938) and the pharmaceutical industry. Fleck
(1996, 14) writes, "In practical terms [the linear model] is applicable to situations
characterised by a mature market structure and the presence of a scientific research
intensive infrastructure, as is found in biotechnology and pharmaceuticals." Faulkner
and Senker (1995, 211) also state, "pharmaceutical innovation conforms more to the
linear model." This view is also reflected in the word "pipeline," which is often used
in the pharmaceutical industry as below:
SmithKline Beecham will today announce it is buying rights to a cancer drug
as part of continuing efforts to improve its product pipeline. ("SB and Glaxo
take stock of drugs' cabinet," Financial Times, 25 July 2000)
Yamanouchi's formidable R&D pipeline is its engine of future growth.
(Yamanouchi, Annual Report 1999, p.4)
BMS is confident it has enough in the pipeline to more than offset any
shortfall. ("Bristol-Myers remedies scepticism," Financial Times, November
29 1999)
The linear-model-like appearance of the pharmaceutical industry is created by
regulation in the industry to a considerable degree. (Tait and Williams 1999, 8) Each
step of research and development (R&D) process of pharmaceuticals in modern
society is strongly regulated by the government. Without satisfying requirements of
the current stage, the pharmaceutical company cannot advance its drug to the next
stage. In sum, the linear model of technological change has been criticised by various
disciplines of social science. But, in the practical world, it is still believed and used.
In particular, even social scientists who in general criticise the linear model seem to
believe that it is still applicable to a few industries including pharmaceuticals.
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The claims that technological change in the pharmaceutical industry is like the linear
model, however, do not seem to be based on detailed study on the innovation process.
Therefore, it is still questionable whether the R&D process in the pharmaceutical
industry is truly the one that is described by the linear model. This question gives us
an opportunity for re-evaluating the linear model as one perspective on technological
change. This question is also practically important because the pharmaceutical
industry is one of the key industries for such countries as the UK, the US and Japan.
It may have further significance when we consider that the industry may represent a
group of "research-intensive" industries, which are expected to sustain economy and
culture in "advanced" countries. Therefore, to answer the question, "Is it the case that
the linear model of technological change can at least be applied to the pharmaceutical
industry?" is an excellent challenge in attempts to understand technological change
in modern society. And this is the objective of this research. I try to find an answer to
the question by examining some cases of the R&D process in the pharmaceutical
industry in detail. However, before we move to case studies, let us glance at the
general characteristics of the pharmaceutical industry and the literature on it.
2.2. Research and Development in the Pharmaceutical Industry
2.2.1. Visiting Laboratories4
Thefirst room This room is well lighted and partitioned into booths by frosted
acrylic boards. Science equipment is crammed and piled into quite a large booth.
Perhaps these machines are used for measuring or analysing chemicals. Most of them
seem to be computerised. Machinery analyses chemicals and the display conveys the
results to people. There are, however, few people apart from us. Maybe it is because
strangers are looking at the laboratories. Maybe it is because it is not the time to
check the results. Anyway, the laboratory is not an automation system, because each
machine looks separated, unconnected to others. Each machine, however, looks very
expensive. In fact, they are expensive, according to the director who shows us the
laboratory. I have been hearing continuous sounds ofmotors and compressors. In the
4 This visit to the laboratory, which was located in England, was conducted on 15 February 2000.
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next booth, I can smell chemicals. I see several ordinary refrigerators. There are also
a number of bottles of chemicals on racks, cupboards and laboratory benches. They
are neither very tidy nor a mess. Then, there are several smaller booths, which look
like personal offices. Women are not in the minority. The next booth is again full of
science equipment and personal computers. Various logos ofmakers on the machines,
but most of them are unfamiliar. Then, we go out of the room. There are a lot of
doors before we get to the next room.
The second room This room is dark. A female researcher sitting in front of a
sophisticated microscope and a display beside the microscope demonstrates how to
use the apparatus to us. On the display, we can see a part of a cell. According to her,
they can analyse a microscopic image on the computer screen by dying different
proteins within cells with different colours. When she chooses a particular colour, we
can see the distribution of a particular protein in the cell. It is said that the
microscope can secure images every thirty seconds. If you get interested in a
movement of proteins inside the cell, you can reconstruct images. You can also
analyse the movement because it is digitally coded. You can download the data into a
disk, and bring it with you and observe the movement anywhere you can open your
laptop computer. Because it is digital, you can erase visual noises so that you can get
a clearer image than with an ordinary microscope. The researcher explains
everything cheerfully and proudly. The software of the apparatus looks very
specialised and customised, and the operator seems to be well accustomed to it. It is
said that they bought the software but they also modified and improved it.
The third room This room is well lighted, again. In the centre of the room there is
a large table with a large, transparent plastic box on it, which occupies quite a large
part of the space of the room. The box is very roughly 30 feet in length, 10 feet in
width and 6 feet in depth. In the box, a robot is working. The robot does not look
very flexible. Its thee-dimensional motions are rectilinear. The robot first picks up a
sample case from the storeys of them at the end of the box. Then it takes it to a bar¬
code checker. Then it takes the case to the point where some sort of reagent is put in
the samples. Finally, the robot takes the case to an analyser. And then, it goes back
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and repeats these motions. This equipment is connected to a computer and the results
of analysis can be seen on the display. By the side of the plastic box, there is a set of
red, amber and green pilot lamps, which are often seen in a modern factory. But there
is neither the loud noise nor the alarming music you can hear in the factory. On a
bench by the wall, there are a lot of things: pipettes, sample cases, something looking
like an electronic thermometer, a roll of sellotape, a pair of scissors, papers, a
calculator and so on.
2.2.2. Talking with Researchers in the Pharmaceutical Industry5
Interview A
Mr A is a chemist, Japanese, male and 39 years old. I hear about his daily life at the
laboratory.
Hara: What do you do in an ordinary day?
Mr A: I do almost the same things every day. There's a target compound, but
of course I can't get it all at once. So, I do that step by step and day by day.
Each step includes reaction, purification and isolation, and then I go on to the
next step. I can get a target only after I repeat this a lot of times. So, this is
what I do every day. Each chemical operation is basically the same as what
students do at the university. What I do in spare moments away from these
chemical operations is thinking about what sort of compound I should make
next, or investigating what other researchers are doing either from reading in
the library, or from discussion with my colleagues.
Hara: Are you working alone?
Mr A: Yes, normally, one chemist is working on one compound in the early
stage of research. I mean the one compound includes its analogues and
derivatives. When it becomes clear that the work requires more manpower, or
that we must hurry, our boss decides to attach more people to the work and
organise them by the division of labour. But at first, when it is unclear
whether the compound works or not, one chemist does all tasks related to it.
Hara: What kinds of instruments do you use in your research? I guess that
you are working with test tubes, beakers, and so on. Am I right?
5 These interviews were conducted on 8 November 1999.
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Mr A: Yes (laughs). These days, we have a specialised section using the
combinatorial chemistry [the robotic equipment for high-speed chemical
synthesis]. But our section is using the same kinds of glass instruments as
were used several decades ago. We add reagents to chemicals in test tubes,
heat it or just stir it, and observe the result. I'm afraid we don't see any
progress in these operations. What is different from the old days is that
reagents improve in variety and in quality. The control of temperature of a
heater is much more accurate than before. But what we are doing is basically
the same.
Hara: How long do you spend on discussion in a day?
Mr A: Well, I may have no discussion and concentrate on experiments all day
long. Or I may spend more than half a day on discussion. It depends. When I
was young, I spent most ofmy time on operations. But as I get older and
begin to take the initiative in research, I spend longer on discussion. I am in
discussion not only with chemists but also with biologists who conduct
bioassays or animal experiments over the results of the biological tests.
The following question and answer shows us the typical difference between
academic research and industrial research.
Hara: Do you publish the results of your research?
Mr A: Yes, well, if I can get permission. To publish research, we have to get
permission from our company. We can't make all of our findings open to the
public. When we find something to be developed, we file for its patent as
soon as possible. Even after we secure the patent, it is often forbidden to
publish the findings for a while.
Interview B
Dr B is a pharmacologist, Japanese, male and 41 years old. Again, I hear first about
his normal everyday activities. Here, we can see the characteristics ofmeetings in
pharmaceutical research laboratories. We can also hear him talking about the flow of
drug R&D.
Hara: What do you usually do every day?
Dr B: Well, it's different now from in the past. I've been a research manager
since last year, so I'm not doing animal experiment now, except on the
occasions when I am asked to help. I'm usually working in the office. I'm
now in charge of two projects. One is a drug for arteriosclerosis, and another
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is a drug against blood clots. My task is to supervise the progress of these
research projects. So, mostly my present job is a desk job.
Hara: Do you have a lot ofmeetings?
Dr B: Yes. Every day, there are one or two, one in the morning, another in the
afternoon. Some meetings are informal and small. Some are formal.
Hara: Who attends the meetings apart from you?
Dr B: Well, so, at the most informal level, I meet my subordinate researchers
and listen to their reports. I, in turn, report the progress of the projects to my
bosses at the higher-level meeting.
Hara: Do you have meetings with chemists, manufacturing experts or
marketing staff?
Dr B: Yes. There is a flow in the evaluation of compounds, though it depends
on the theme of projects. Chemists synthesize compounds and then we
pharmacologists assay them and produce the results. The chemists examine
the results and synthesize the next bunch of compounds. Chemists and
pharmacologists repeat this many times. At that stage, we meet chemists each
time the results come up, plus regularly, for example, once a month. At the
later stage, when we need mass production of a compound, we have meetings
including people synthesizing it on a plant level scale. But most of our
meetings are related to the earlier stage.
Hara: Don't you have meetings with marketing staff?
Dr B: Yes. Several problems usually arise in the process of development of a
drug, even in the process of its clinical trials. On those occasions, we are
asked for our opinion by the staff of the development division, and we
respond to them. If telephone or e-mail is good enough, it's OK. But
sometimes meetings are necessary. We sometimes hold them in our
laboratories, and are sometimes called to come to headquarters.
Dr B talks to me about how the methods of drug research have changed recently.
Dr B: Before, the mechanism of action of a drug was often revealed after the
drug was found to be effective. We had to find an explanation as to why the
drug worked. Nowadays, we first speculate about the mechanism of action
and a related gene. To confirm that, we can make the mice without a specific
gene or ones which are apt to activate a specific gene. By using the mice, we
can find out whether the gene is related to the disease. So, nowadays, it is
becoming more common that the drugs whose mechanisms of action are
clearly known are developed clinically. It is also getting harder to obtain the
approval of regulators without a clear explanation of the mechanism of action.
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... When we want to exploit a new mechanism of action, we propose it to the
board of the research division. If they approve the proposal, the specialised
department does the mass screening of hundreds of thousands of compounds
in the compound library6 by using robots. Even though the idea is very good,
the screening often hits nothing in the library. If, by good fortune, it hits one
or a few compounds, we examine the compounds in cells. Ifwe confirm the
results, we then ask the chemistry department for further synthesis of its
analogues. Amongst these analogues, we choose the most potent compound.
Hara: Where do you get your new ideas?
Dr B: Formally, we get information from academic conferences and literature,
but that's often too late. So, we get information directly from academic
researchers we get acquainted with at conferences, by keeping in touch with
them. Especially, being in contact with leading scientists is very helpful
because they know where are the frontiers of each research area and what
kinds of research are accepted in leading academic journals before they are
published. In reality, however, it depends on research areas how much we can
get information in this way. And, of course, we have to offer our original
information to the academic researchers ifwe want to get some from them.
Without that it doesn't work.
2.2.3. Formal Process of Research and Development of Pharmaceuticals
In this study, I deal with the innovation process of prescribed drugs. Prescribed drugs,
or ethical drugs, are normally given to patients either by pharmacists based on the
prescription issued by doctors or directly by medical practitioners in hospitals and
clinics. Large pharmaceutical companies earn most income from their prescribed
drugs. (Davis 1997, p. 8; The Association of the British Pharmaceutical Industry 1997,
p. 13; Japan Pharmaceutical Manufacturers Association 1997,1-5) Almost all major
product innovations in the pharmaceutical industry are those of prescribed drugs. To
secure profits from novel prescribed drugs, pharmaceutical companies file patents for
new compounds, often together with their analogues and derivatives, immediately
after they discover the compounds and their potential clinical applications. Therefore,
newly discovered prescribed drugs are sometimes called patented drugs. These drugs
are normally given brand names on the market. This is why they are also called
6 A compound library is a collection of compounds possessed by a pharmaceutical company.
Pharmaceutical companies collect the compounds through their own research or by acquisition
from other organisations. It is said that each large pharmaceutical company has a compound
library with hundreds of thousands of compounds. (Thomke, von Hippel and Franke 1998, 324)
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brand-name drugs, in contrast with generic drugs, which are marketed by other
manufacturers after the relevant patents have expired.
Most prescribed drugs currently used work through their interactions with receptors
within our bodies. The human body, as well as other animals' bodies, is regulated by
various chemicals, such as hormones and neurotransmitters. These chemicals are
used for communication between different cells and different organs in the body. On
the membrane around cells, there are a lot of special proteins called "receptors."
There are also some types of receptors inside cells. Each receptor catches a specific
kind of hormone or neurotransmitter as if they were a lock and a key, and then sends
a specific signal inside the cell, which will cause the cell to respond in a specific way.
(Stone and Darlington 2000, pp. 1-10) Drugs combine with these receptors and
promote or inhibit the reaction of cells. A drug which has the same actions as a
natural hormone or transmitter is called an agonist or stimulant. Normally, a
clinically used agonist possesses stronger potency and/or longer duration of action
than a natural hormone or transmitter. In contrast, a drug which inhibits the actions
of a hormone or transmitter is called an antagonist or blocker. Although agonists and
antagonists of the same receptor have opposite functions, their molecular structures
are often very similar, because they have to combine with the same receptor. (Patrick
1995, pp.61-63) All of the drugs I examine in the case studies in this research belong
to this type of drug, except mevastatin and cefotiam which inhibit specific enzymes
in the body or bacteria cell walls, and nicardipine which blocks specific channels
(also made by proteins) in the cell walls. There are also other types of drug, which
target transport enzymes, nucleic acids and specific types of cells such as cancer cells.
In the near future, drugs ofwhich the targets are specific genes are likely to appear.
(Stone and Darlington 2000, pp. 12-13) All drugs have potentially harmful side
effects partly because chemicals within the body normally play more than one role,
partly because they have to be metabolised, that is to say, be transformed into other
chemicals, which may have toxic effects within the body, and partly because the
body sometimes rejects strange chemicals (allergic reaction). Prescribed drugs are
normally more potent than non-prescribed, so-called over-the-counter drugs, but, at
the same time, potentially more dangerous because their side effects are often
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stronger. This is one of the main reasons medical and regulatory authorities in
modern countries strictly control the manufacturing and distribution of prescribed
drugs, although it is not the only reason. (Abraham 1995, pp.36-86; Davis 1997,
p. 120)
R&D in the pharmaceutical industry is conventionally split into two stages:
"research" and "development." According to the conventional view, research
activities in pharmaceutical companies are aimed at the "discovery" of drugs,
whereas development activities mainly refer to clinical trials. (Chiesa 1996) A drug
discovery is defined as a discovery of the "fact" that a natural or synthesised
chemical has a profile of biological activity which can be applied for the treatment of
diseases. The "fact" does not necessarily include a clear explanation about the action
mechanisms. Until recent times, drugs were able to be approved for use without a
clear explanation about the mechanisms. Nowadays, this is more difficult, as we can
see in Interview B above, but even so, there must still exist potential uncertainty
about the mechanisms. Strictly speaking, therefore, the "fact" is a system ofbeliefs.
(Barnes, Bloor and Henry 1996, pp. 69-73; MacKenzie 1996b, p.248) Sometimes, a
drug discovery is regarded as a discovery of a chemical which has a profile of
biological activity, but this view may be misleading, because the chemical is often
not naturally occurring, but intentionally synthesised. Invention is a more appropriate
word here and should be distinguished from discovery. In this research, however, I
use the word "discovery," referring to the first learning of the causal relationship
between the chemical and the biological activities, not to the chemical itself. My
using the word discovery implies no ontological commitment to the correspondence
between that learning and reality.
Both chemists and biologists play a core role in the research process and that the
interaction between the two disciplines is the key to the achievement of drug
discovery. However, it should not be ignored that other disciplines such as physics,
mathematics, statistics, computer sciences, electronics, mechanical engineering and
material engineering also support the process of drug discovery, as we can see in the
"laboratories" in Section 2.2.1.
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After a drug discovery, the compound is examined in detail by using different
animals. The toxicological, pharmacological and pharmacokinetic properties of the
compound are investigated. This process is often called pre-clinical tests or pre¬
clinical development. At this stage, initial studies on the production process of the
compound start, because it is necessary to supply a larger amount of the compound
for clinical trials and the development of preparations. (Pisano 1997, p. 122)
Development of preparations is more important today than before because now the
notion of drug delivery systems is taken seriously into consideration. (See Chapter 6)
If the data of the pre-clinical tests are favourable, the compound goes into clinical
trials. Before that, however, a managerial decision is made because clinical trials
require an enormous amount ofmoney. Also, an approval by the regulatory body is
needed, because clinical trials use humans. (Mclntyre 1999, p.73; The Ministry of
Health and Welfare 1996, pp.85-105)
Clinical trials before marketing, which are conventionally a synonym of drug
development, are normally divided into three phases. In phase I, a drug candidate is
given to healthy volunteers to investigate its toxicological and pharmacological
profiles. In phase II, the drug is given to a small number of patients at various dosage
levels and with different dosage forms in order to examine its efficacy and safety,
and to determine the appropriate dosage profiles. In phase III, the drug is given to a
much larger number of patients at multiple sites for quite a long time in order to
confirm its efficacy and safety. The trials in phases II and III are normally controlled
and the drug is compared with a placebo and/or an existing major therapy. (Chiesa
1996, 693-640; Pisano 1997, p.119, pp.123-124) The governmental authority strictly
regulates these phases of clinical trials. Phases can be overlapped with the permission
of the authority but cannot be waived. This regulatory system of clinical trials has
been constructed in particular since the disaster caused by thalidomide in the early
1960s. The relevant institutional changes happened first in 1962 in the US, and
around 1967 in the UK and Japan. (Temin 1980, p.125; Abraham 1995, pp.66-74;
Nihon Yakushi Gakkai ed. 1995, p.132; Kaufer 1990, 154; Timmermans and Leiter
2000, 45-46) Most of the drugs I will examine in case studies in this research
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experienced these phases of clinical trials. It is also important to notice that clinical
trials are conducted by a number of doctors and patients who are outside the control
of the pharmaceutical company. Factors such as protocols, organising doctors,
schedule management and informed consent are necessary. (Smith 1985. pp.80-88)
Statisticians also play a significant role in clinical trials because results of controlled
studies are statistically analysed and interpreted. (Marks 1997, pp. 129-248)
As a matter of course, a drug must be produced on a much larger scale than the
laboratory level before the large-scale clinical trials and commercialisation.
Therefore, process development must be done between the discovery of a drug and
the large-scale clinical trials. A specialised process R&D group in the pharmaceutical
company normally conducts this function in parallel with product development.
Process development is not a once-for-all sort of activity, but a continuing effort.
Each stage of pre-clinical and clinical studies requires a certain amount of the drug.
At each moment, the production of the required amount of the drug must be achieved,
even if the process is far from the optimum one for large-scale production. Regarding
the values in process development, cost reduction is in general important. However,
reduction of development time is also important especially in the pharmaceutical
industry because it may constitute the bottleneck of the whole process of drug R&D,
which is crucial in terms of competition in the market. Flexibility is also required
because changes of product profiles often arise in the process of drug development.
(Pisano 1997, p.81, pp.95-102) Process development includes identification of a lot
of alternative routes of synthesis and selection of the best route among them in terms
of quality, safety, simplicity and costs. It also includes high uncertainty because
scaling-up means the entry of further heterogeneous factors, both the material and the
social. (Pisano 1997, pp.125-134; Smith 1985, pp.111-116) Human actors such as
chemists, chemical engineers, system engineers, electricians, mechanics, operators
and managers play a role in a plant. Non-human entities such as tanks, pipes, censors,
thermometers, pressure gauges, cables, computers, software, terminals and clocks
also play a role.
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When clinical trials and process development of a drug are successfully completed,
the manufacturer applies for the approval of its manufacturing and marketing to the
regulatory body. The application requires the detailed results of pre-clinical tests and
all clinical trials, detailed description of the clinical protocols, statistical analysis of
the results, expert opinions on the data, detailed description of the manufacturing
process and other prescribed data and analysis. (Pisano 1997, pp. 124-125; Reich
1986; The Japan Ministry ofHealth and Welfare 1996, pp. 127-206) When the
regulatory body approves the application, the company can "basically" launch the
drug. The word "basically" is used because a further procedure may be needed in
some countries. In Japan, for example, without obtaining an official price determined
by the Ministry ofHealth and Welfare, it is virtually impossible to sell the drug in the
country. (Reich 1986, 23; Campbell and Ikegami 1998, p.154) It is reported that the
whole process ofR&D of a drug except the research before the discovery took more
than 10 years and cost more than $350 million in the early 1990s. (Weisbuch and
Moos 1995, 244)
Thus, the formal R&D process of a drug consists of a number of stages: very roughly,
research, pre-clinical tests, clinical trials (phase I, II, III), process development in
parallel with product tests, and filing. The R&D process of a drug is strictly regulated
by the governmental authority stage by stage. Given the regulation and huge
investment required in the later stages of development, the management of
pharmaceutical companies also strictly controls the progress of the R&D process by
the milestone approach. This explains why the R&D process in the pharmaceutical
industry is regarded as similar to the linear model. It can be schematised as in Figure
2.2.
Figure 2.2: Formal Drug R&D Process Schematised by the Linear Model
Research — Pre-clinical - Clinical - Application for -» Marketing and —► Use
Drug Tests Trials Approval Sales
Discovery Process Development
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However, even though the formal R&D process can be schematised in a linear
process, there is a question ofwhether this is the case in the real process of drug
R&D. To what extent do previous studies answer the question? How do they deal
with the process of drug R&D? We will review the relevant literature in the next
section.
2.2.4. Literature on Technological Change in the Pharmaceutical Industry
Because innovation is a crucial problem for the pharmaceutical industry, many
researchers in economics and organisation studies write on innovation in the
pharmaceutical industry. In contrast, literature on this topic by sociologists seems to
be limited in number.
2.2.4.1. From the Economic Viewpoint
According to Comanor (1986), there are three strands in economic studies ofR&D in
the pharmaceutical industry, namely, the determinants of research expenditure, scale
economies in R&D and the costs and returns from R&D. On the determinants of
research expenditure, factors including firm size, research productivity, product
diversification, the level of internally generated funds, the level of research and the
direction of research have been suggested as determinants of research spending
(Comanor 1986, 1190-1191).
On the scale economies in R&D, there is disagreement among researchers about
whether larger pharmaceutical companies have an advantage in innovation over the
smaller ones. Comanor provides two alternative views about this: the disagreement
may be due to the difference of the periods of data collection; or maybe due to the
definition of innovation, that is to say, "larger firms are relatively more important
when all new drugs are included but not so in regard to the most important
innovations" (Comanor 1986, 1192-1193). However, more recent studies tend to
support the importance of firm size for R&D productivity (Jensen 1987; Thomas
1990; Alexander 1996; Henderson and Cockburn 1995). Jensen (1987) and
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Alexander (1996) argue that increase of firm size does not affect or possibly
negatively affects the marginal productivity ofR&D while it positively affects the
average R&D productivity. Henderson and Cockburn (1995) argue that economies of
scope are as important as the economies of scaleper se. Two different but related
economies are included in their economies of scope. One is from the 'free-riding'
effect among different research projects based on the public goods aspect of
knowledge; the other is from internal spillovers of knowledge between projects that
benefit each other.
On the problem ofwhether the returns generated by R&D are sufficient to cover their
cost, a body of literature by the mid 1980s indicates that the average returns for new
drugs have declined and may be less than average development costs in recent years.
(Comanor 1986, 1195) Diminishing average returns in the pharmaceutical industry is
also indicated in more recent works. (E.g. Alexander, Flynn and Linkins 1995)
Comanor, on the other hand, points out that the returns from a small number of very
successful products are now especially critical to success in this industry (Comanor
1986, 1195). This also seems to be consistent with the results ofmore recent studies.
(Grabowski and Vernon 1990; Grabowski and Vernon 1994, 398-400)
There seem to be two more strands of research on the economics ofR&D in the
pharmaceutical industry. One strand is concerned with the effects of regulation on
innovation, in particular, on the R&D productivity defined as the number of new
chemical entities discovered and introduced in market per R&D expenditure. While
Grabowski, Vernon and Thomas (1978), Wiggins (1981) and Jensen (1987) suggest
the negative effect of regulation on innovation, Thomas (1990) later argues that the
larger US pharmaceutical firms benefited from FDA regulation due to reduced
competition though smaller firms suffered reductions in research productivity
because of regulation. The other strand of research is on the general trend of decline
of research productivity. Henderson and Cockburn (1995) and Gravis and Langowitz
(1993) can be categorised into this strand.
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These works on the economics ofR&D in the pharmaceutical industry indicate that
there seem to be economies of scale, economies of scope, the declining trend of
return, the declining trend of research productivity and the effect of regulation in the
pharmaceutical R&D. Although quantitative relationships between various empirical
data related to technological change in the industry are shown by these studies, the
process of technological change remains untouched.
McKelvey (1996) is, however, an exception. Although it might be inappropriate to
classify her work into the economic literature because she declares that her approach
is multi-disciplinary (p.298), I put it here because it is more closely related to
"evolutionary economics" established by economists of technological change
including Nelson, Winter and Dosi, than organisation studies of technology and
innovation or sociology of technological change. She argues that a fundamental
assumption of evolutionary economists that technological change is evolutionary has
been little examined in detail by empirical studies, (p.257) She, therefore, shifts the
focus of research from innovations as objects to those as processes (p.2) and
examines a case history ofR&D process of genetic engineering, in particular that of
human growth hormone made with recombinant DNA techniques (rDNA hGH) as
her empirical base. She identifies in the process various agents, including academic
scientists, biotech firms, established pharmaceutical companies, governments,
doctors and general public. She describes the shifts of knowledge-seeking activities
of these agents from scientific to scientific-economic and techno-economic
environments, with the advance of the process towards practical uses. She concludes
that the innovation process of rDNA hGH is more accurately described as
evolutionary, that is to say, including the dimensions of diversity, retention and
selection through the complex interactions among these agents and among agents and
environmental conditions, rather than as linear, which appears to be the case on a
hasty reading, (pp.26-36, p.258) She also emphasises the cross-stimulating
relationship between science and technology. This relationship became more obvious
when the knowledge-seeking activities of agents entered scientific-environment and
techno-economic environments. In particular, she emphasises the importance of
production, where interaction between science and technology is very crucial, in the
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process of biotechnological innovation, (pp.291-294) Thus, McKelvey's work is
especially close to my interest, and partly answers my question about the linearity of
the drug R&D process. However, her answer is still insufficient in several points.
First, her work does not include sufficient examination of the social process of drug
R&D inside organizations. Second, the economic aspect of social processes is
particularly emphasised, whereas sociological and political aspects are only briefly
inspected in her study. Third, her work is based on only one area of pharmaceuticals.
The area is relatively new area in the pharmaceutical industry and may be
problematic to be regarded as a representative area. Although her conclusions seem
quite convincing, it is necessary to examine them through further detailed case
studies with a more balanced viewpoint. Literature from organisational and
sociological viewpoints below seems to be helpful in this regard.
2.2.4.2. From the Managerial and Organisational Viewpoint
Most of the recent works on the management and organisation of the pharmaceutical
industry highlight R&D and innovation, because they are regarded as the critical
factors of competitive advantage. I roughly categorise the discussions here into three:
discussions on the technology strategy; on the networking for innovation; and on the
management of research organisation.
Discussions on technology strategies in the pharmaceutical industry tend to identify
trends of technology as a crucial environmental factor and then discuss the strategy.
Bogner (1996) identifies several technology trajectories and other trends of
technology in the history of the US pharmaceutical industry. He identifies, for
example, the organic chemistry trajectory (p.54), the anti-infectant research
trajectory (p. 59), trajectories of non-antibiotic drugs (p. 82) and the trajectory related
to biotechnology (p. 117). Then he examines strategies of pharmaceutical companies
and identifies several strategic groups characterized as "traditionally antibiotic,"
"broad organic-chemistry focus," etc. in the 1970s, and "narrow focus research
firms," "broad focus research firms," "genetic firms," etc. in recent years (pp. 142-
144). Achilladelis (1993) focuses on the sector of antibacterial medicines, and from
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the historical analysis, identifies four technological trajectories in the sector, namely,
sulphonamides, natural product antibiotics, semi-synthetic antibiotics and synthetics.
He also found corporate technology traditions in several companies. The concept of a
corporate technology tradition, defined as the "concentration of a company's R&D
resources on a particular technology for a very long period of time leading to the
introduction ofmany innovations embodying this technology" (p.281), implies that
there may be further diversity of company strategies in a single therapeutic area.
Hara (1997) identifies similar trajectories and corporation technology traditions in
the development of antibacterial drugs in Japan. Galambos and Sewell (1995)
identify four scientific and technological cycles in vaccine development. Many
authors notice the impact of biotechnology on the pharmaceutical industry (E. g.
Sharp 1991; della Valle and Gambardella 1993; Whittaker and Bower 1994;
Gambardella 1995; Otero 1995; Sharpl995; Zucker and Darby 1997), and many
writers including Gambardella (1995), Whittaker and Bower (1994), Zucker and
Darby (1997) relate it to the discussion of strategic linking and networking. These
studies can be regarded as being based on the softer version of technological
determinism because they implicitly regard technological trajectories as an
environmental factor. Sapienza (1997) regards the strategy based on technological
trajectories as a shaping activity, (p.26) She regards technological trajectories as the
results of overall R&D as well as program- and project-specific decisions. And she
argues that technology strategy is the blue print for the technology trajectory, (pp.5-
7). Thus she seems to most explicitly regard technology trajectories as being shaped
by organisations.
The research on the external linking and networking of pharmaceutical R&D for
innovation is probably the most flourishing area in the organisation studies of the
industry. Most works in this area discuss it with reference to biotechnology.
Whittaker and Bower (1994) show that the R&D alliance between pharmaceutical
companies and biotechnology companies increased dramatically in the 1980s. They
argue that this is not temporary but long-standing because their relations shift toward
functional specialization. Gambardella (1995) also points out radical change in the
pharmaceutical R&D associated with the development of biotechnology and
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molecular biology, and its implication for the division of labour between the large
pharmaceutical companies and small-to-medium-sized biotech companies,
universities and other research institutions. He argues that because scientific
capability embedded in individuals is often the critical resource for drug discovery
on the one hand, and because the commercialisation of drugs needs solid financial
and managerial capabilities on the other, the division of labour between small
organisations with the former capabilities and large organisations with the latter
capabilities is very hopeful (pp. 163-164). Faulkner and Senker (1995) identify
changes in the relationship between the pharmaceutical industry and public sector
research (PSR) from the early era ofbiotechnology (1983-4) to more recent times
(1990-1). They identify that the role ofPSR in the linkage shifts from the somewhat
informal and random one towards the more formal and specialized one under the
growth and penetration of biotechnology in the industry. Powell, Koput and Smith-
Doerr (1996) indicate that when the knowledge base of an industry is both complex
and expanding and the sources of expertise are widely dispersed, as is seen in
biotechnology, innovation will stem from organisational learning in networks, not
individual companies. These studies argue that network-form organisations are
appropriate and sustainable in the era ofbiotechnology-based pharmaceutical
innovation.
Two more detailed studies on this issue provide us with rich information on the
process of innovation. Zucker and Darby (1997) provide a case study of the
transformation of a large incumbent pharmaceutical company by "the
biotechnological revolution." In the study, they notice the following issues: senior
management with the scientific ability to assess the technology championed the
transformation; many scientists embodying biotechnology were hired; collaborations
and joint ventures with university scientists and new biotechnology firms were used
to improve internal expertise; the existing related knowledge made for more effective
applications ofbiotechnology; the firm was able to hire star scientists. By detailed
observation through a case study, they reveal that formal networking is insufficient to
absorb the impact ofbiotechnology. Galambos and Sewell (1995) examine the
history of vaccine development in the US pharmaceutical industry. The most
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remarkable feature of this work is that they regard drug developments as consistently
being accomplished through networks. They identify four cycles in the history of
vaccine development, namely, the bacteriology cycle, the virology cycle, the cycle
associated with the new bacteriology of polysaccharide capsules and the cycle
grounded in biotechnology and molecular biology. According to them, new cycles
were accompanied with new science and medical networks and the vaccine
companies sought to accommodate them. They argue that over time the networks
have become more complex and differentiated both internally and externally. Thus,
the historical investigation reveals that external networking did not begin in the
biotechnology era, but had existed before that and that the era ofbiotechnology has
brought a new arena for networking.
The third interest of the research on the management of pharmaceutical innovation is
management of the R&D organization. The effective and efficient assimilation of
external knowledge seems to be one of the most important issues there. Specialised
scientific competence within the organisation is emphasised for evaluation and
absorption of external knowledge. Gambardella (1995) argues that companies with
better in-house knowledge assets in biotechnology use more intensively external
linkages (p.165). Faulkner and Senker (1995, p.97) and Sapienza (1997, p.188) also
emphasize the in-house assessment capability of external knowledge. Bierly and
Chakrabarti (1996) argue that technology cycle time, from initial development to
product launch, is shorter in internal knowledge exploitation than in external
knowledge utilization. They argue that this is because the relationship between
organisational learning and new product development is moderated by strategic
flexibility, controlled by flexibility in manufacturing, finance and marketing, and the
range of knowledge base. Fitzgerald (1992) indicates that the assessment process of
external technology involves many functions, namely, pharmacologists, toxicologists,
pharmacists, physicians, marketing, legal experts and representatives from the major
international markets. This heterogeneity might make prompt organisational learning
and accurate assessment much harder.
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One of the other issues in the management of pharmaceutical R&D is the difference
between research function and development function. Chiesa (1996) identifies
several differences between research and development. According to him, research in
the pharmaceutical industry is characterised by unpredictable timing, informality,
modest expenditure and unpredictable results, while development is characterised by
predictable timing, formality, huge expenditure, and planned results. He indicates
that these differences result in difference between research management and
development management. For example, research management has characteristics
such as direct communication and pressure from a sense ofurgency, while the
management of development has characteristics such as formal communication and
pressure on deadlines.
The literature on pharmaceutical innovation from the managerial and organisational
viewpoint highlights the relationship between technological change and corporate
strategy, the inter-organisational network as the key organisation form, the in-house
scientific capability as the key factor for success in the pharmaceutical business and
the differences between research function and development function in the industry.
The studies show us some aspects of the process of technological change in the
industry. However, the detailed interaction between various social and material
factors in the process is not sufficiently described in these studies. In particular,
social and political interaction within an organization, which has been described in
several studies of other industries (Whipp and Clark 1986; Thomas 1994), has not
yet been explored in this industry. Only several historical case studies such as
Galambos and Sewell (1995) and Zucker and Darby (1997) provide us with some
detailed aspects of the process of drug R&D.
2.2.4.3. From the Sociological Viewpoint
Despite the potential opportunities for sociological analysis, there does not seem to
be much literature on technological change in the pharmaceutical industry from the
sociological point of view. On the one hand, according to Bartley (1990), the
sociology of medicine has traditionally been outside the construction of medical
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knowledge. Rather, it has been concerned with the ways in which medical
knowledge is applied. In particular, how medicinal technologies are developed and
introduced into practice has often been viewed in a technological deterministic way.
(Elston 1997, p.4) Recently, however, the advent of the sociology of scientific
knowledge (SSK) and other strands of the sociology of science has extended the
opportunity for sociology to investigate the construction ofmedical science and
technology. This can typically be seen in the sociology of medical science and
technology, which has recently emerged. (Elston 1997) Nevertheless,
pharmaceuticals do not seem to be the dominant topic even in this area. They are at
most one of the major topics there. In this section, we review several examples of the
sociological studies closely related to the construction of pharmaceutical medicine.
Bodewitz, Buurma and de Vries (1987) analyse the drug regulatory process in which
the efficacy and safety of the drug are adjudicated. They identify four social groups,
each occupying a specific position in the social system of medical care and
expressing a specific perspective on drug regulation practices: the general public, the
pharmaceutical industry, the representatives of drug regulation agencies, and medical
scientists and practitioners. They argue that in this social system no matter how
present regulatory practices are evaluated, science provides the yardstick for
assessing their rationality for all groups. However, according to them, the asymmetry
between standards of efficacy (double-blind methodology) and standards of safety
(no commonly accepted standards) gives room for the diversity of assessments and
leads to a complex mixture of factual and value-laden judgements. They indicate that
standards of safety evolved along different lines between the US and European
countries: while the standards were developed somewhat voluntarily within
established professional thinking in the US, in Europe they are brought about by
outside pressure such as consumer organisations representing the general public.
They conclude that scientific procedures and certified knowledge are also outcomes
of the social process of acceptance.
Richards (1988) deals with the debate over the efficacy of vitamin C in the treatment
of cancer. She compares it with cases of two other drugs, namely, 5FU and interferon.
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According to her, whereas vitamin C was rejected by the medical society because of
the lack of "sufficient" evidence of its efficacy for the treatment of cancer, the other
two drugs were recognised as cancer treatment without the same level of evidence as
was required in the former case. Moreover, the methods of the "crucial" clinical trials
that showed the inefficacy of vitamin C were conventionally "rigorous" but
fundamentally inconsistent with the theory and ideology of the proponents. Richards
suggests that vitamin C was incompatible with the then established treatment of
cancer, the interest of the medical authority, the interest of funding organizations and
the interest ofmost of the pharmaceutical companies, whereas the other two drugs
were more compatible with them. She concludes that the evaluation of medical
therapies is inherently social and political and that this social character of medical
knowledge cannot be eliminated by methodological reform: the randomised,
controlled clinical trial, no matter how rigorously organised and operated, can neither
guarantee objectivity nor definitively resolve controversy over competing therapies
or technologies. (Richards 1988, 686-687)
Abraham (1995) also highlights drug testing. His interest is whether, and how,
corporate bias may influence the scientific processes of evaluating the safety and
effectiveness of a new drug (p. vii). He establishes a framework based on an
explicitly realist sociology of scientific knowledge. However, he also integrates some
conceptions which stem from relativist SSK strands ("strong programme", EPOR,
constructivists, ANT). Moreover, he adopts some conceptions from Marxist studies,
risk studies and the theories of the State and regulatory capture. He defines bias as
"the advocacy/practice of claims/actions that are non-credible because they are
inconsistent with the very scientific standards which the advocate/practitioner
accepts as legitimate, and are convergent with identifiable interests/values" (p.29).
He presumes (self) interests of profit maximization for the pharmaceutical industry,
and of good health for patients. He also presumes that "rational" companies and
consumers will pursue those respective interests. Based on several case studies, he
indicates that bias exists among many industrial scientists; that the bias coincides
with the commercial interests of the pharmaceutical company; that such corporate
bias becomes entangled with some reward systems of science; and that the British
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regulators are more biased than their American counterparts because of the close
institutional relationship in the UK. Based on these findings, he insists on reform to
reduce corporate bias.
Clarke and Montini (1993) examine how various actors were related to the
construction of an oral abortion-inducing drug, RU486, by using "arena analysis."
Arena analysis emphasises multiple views of various actors: it attempts to view the
constructed world metaphorically over the shoulders of all the actors, rather than
only of scientists and engineers. Thus, they identify various actors and their different
views ofRU486. For example, for reproductive scientists it is "the second generation
pill." For family planning, population control and abortion provider organisations, it
is a means ofmobilising women to fight for new birth control. For pharmaceutical
companies, it was a headache. For the clinicians who conducted its clinical trials, it
was a means of "doing science " For medical groups, it is a means for greater safety
in the practice of medicine and a means of fighting for medical autonomy. For
antiabortion groups, it is another means of killing the child in the womb and a means
of intentionally inducing a miscarriage. For feminist pro-choice groups, it is a means
ofmobilising feminists. For women's health movement groups, it is a means of safe
abortion for some women who so choose. For some politicians in California, it was a
strategy to become the governor. And so on. They conclude that a fuller and more
historicized arena of the construction of technology can be obtained by following all
these actors.
Prout (1996) describes the mutual constitution of the metered dose inhaler (MDI) and
various human actors by applying actor-network theory. Although the MDI is not a
drug, its actor-network seems similar to a drug's because it is used together with a
drug. Prout identifies both human actors including patients, doctors, technicians and
scientists, and non-human actors including aerosol gases, the Bernoulli principle,
metering valves and the lung in the actor-network. He describes the interactions
between these actors and transformation of the actor-network: configuring the users,
anti-programmatic actions of users and modifications of the MDI. He argues that
"ANT can help in understanding the intricate and mutually constitutive character of
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the human and the technological in the processes and relationships of sickness and
healing." (p. 214)
Epstein (1996) describes the social history of the production ofbiomedical
knowledge, specifically, knowledge on the causation of and the treatment ofAIDS.
His approach is a synthesis of conceptions coming from the sociology of scientific
knowledge, the social history of science and theories on social movement. In the
analysis, he especially focuses on the role of lay people, in particular, that of AIDS
activists in the formation of the biomedical knowledge. According to him, the role of
the activists in the treatment controversy was greater than that in the causation
controversy. He states that the activists have challenged the calculation of risks and
benefits by the traditional experts such as researchers, doctors and statisticians, and
have helped to change the rules governing the kinds of evidence required to
determine the efficacy of AIDS drugs by becoming "lay experts." He argues that
"analysts of science and medicine should attend to the strategies pursued by lay
actors in their attempts to speak credibly about science and medicine"(p .332),
because lay actors, as well as experts, can and do transform research.
Van Kammen (1999) examines the process in which the bodies of future users of
anti-fertility vaccines have come to be represented by female bodies while the drugs
have been researched and developed. Biological reasons are denied because both
men and women can use the vaccines. Rather, specific material and political factors
mainly constructed the presumed bodies of future users. For example, when
immunologists searched for the target of the vaccines, the hormone called hCG
gained from the placenta was highly available and ethically and politically less
problematic, because they are regarded as being separated from human bodies.
Spermatozoa were also easy to obtain and use for experiments. Both hCG and
spermatozoa became the targets (antigens) of the vaccines. The female body contains
both of them when the drugs work, whilst the male body contains only the latter. In
addition, one of the anti-sperm vaccines caused an adverse side effect in the male.
Moreover, in the choice of the sex of model animals, the female was chosen because
researchers in reproductive biology were more familiar with the female reproductive
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tract than the male organ. These researchers' choice of the female as the sex of future
users of anti-fertility vaccines was supported by the government, the funding
organizations and the pharmaceutical industry. Thus, the male as users of the vaccine
has gradually disappeared. Based on these findings, van Kammen argues that the
presumed sex of users of the technology was constructed by specific material and
political factors, rather than exclusively determined by biological or cultural factors.
Timmermans and Leiter (2000) examine how thalidomide, the notorious drug which
caused horrific disaster in the early 1960s, has reappeared as a life-saving drug for
the treatment of leprosy, Erythema Nodosum Leprosum, and AIDS wasting
syndrome in the US since the mid 1990s. A standardised drug distribution system,
which was newly devised by a pharmaceutical company called Celgene and the Food
and Drug Administration (FDA), played a key role in the transformation of the drug.
By the 1990s, the advantage of thalidomide for the treatment of those diseases was
known to patients, and its underground trade arose. The FDA called for the
cooperation of the pharmaceutical companies and Celgene took it up. The
distribution system that the company proposed and the FDA approved consisted of
several elements: education of physicians, pharmacists and patients; contraceptive
counselling; regimen of pregnancy testing; informed consent; managed distribution
and mandatory outcomes registry survey. (Timmermans and Leiter 2000, 48) This
system was constructed by not only the company but also other players, including
physicians, pharmacists, patients, thalidomide victims, the FDA, and the drug itself.
The jurisdictions and identities of the players were in turn redefined by the system.
The risk of the drug has not disappeared but become more controllable and
acceptable by the system of the standardisation of drug distribution.
These sociological studies of technological change in pharmaceuticals, together with
sociological investigations of related issues such as biomedical laboratory life
(Latour and Woolgar 1986), the genetics of cancer (Fujimura 1996) and the aetiology
of peptic ulcer (Thagard 1999), provide us with detailed pictures of various aspects
ofbiomedical research and development. They are obviously incompatible with
"hard" technological determinism and most of them are not reconcilable with "hard"
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social determinism. We can see how various human and non-human entities shape
the biomedical science and technology in these works. However, these works do not
necessarily show us the full process of drug discovery and development. The
processes of clinical trials and regulatory examination have been well investigated.
(Bodewitz, Buurma and de Vries 1987; Richards 1988; Abraham 1995; Epstein
1996) Marks (1997) describes in detail the history of clinical trials in the USA and
the controversy over the randomised, controlled clinical trials. The processes of
marketing and distribution of drugs and related instruments have also been examined
but to the lesser extent. (Clarke and Montini 1993; Prout 1996; Timmermans and
Leiter 2000) The process ofbiomedical research is described and studied in most
detail. (E.g. Latour and Woolgar 1986; Fujimura 1996; Thagard 1999) However,
amongst the literature mentioned above, only van Kammen (1999) examines both
research process and development process, but her focus is relatively narrow: on the
presumed sex of the future users. Therefore, the whole process of drug research and
development has been little explored. This lack of a full picture is serious when we
try to understand technological change in the pharmaceutical industry. In addition,
most of these works tend to regard pharmaceutical companies as monolithic. Even
worse, some regard the pharmaceutical industry as one unit of interest. However, as
organisation studies indicate, private companies consist of heterogeneous entities.
(Whipp and Clark 1986; Thomas 1994) A number of companies in the industry
compete with each other by adopting different approaches. Most processes of drug
research and development are conducted within pharmaceutical companies. We
cannot fully understand the process of drug research and development without
abandoning the monolithic view of pharmaceutical companies. Thus, we can now see
what we want. It is a full, detailed study of the process of drug research and
development. Both intra- and inter-organizational interactions should be examined.
However, the examination of observable interaction is probably insufficient to
understand technological change. We should take the historical and structural context
into consideration. For this, international comparison may help.
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2.3. Objectives and Research Design
2.3.1. Objectives
The main objective of this study is to answer the following question: Is it the case
that the linear model of technological change can at least be applied to the
pharmaceutical industry? If not, what is the process of technological change in this
industry like? One of the main issues in technological change in the pharmaceutical
industry is drug research and development, which includes research, pre-clinical tests,
clinical trials, process development, application for regulatory approval and initial
marketing activities. Although a lot of economic studies and organisation studies
have investigated innovations in the pharmaceutical industry, the process of drug
R&D has not been studied sufficiently in detail. Sociologists have revealed parts of
the process of drug R&D, such as biomedical research, clinical trials and marketing
activity, but the whole process including all these aspects has been little described
sociologically. To answer our main research question, we should study the full,
detailed R&D process in the pharmaceutical industry. As was seen in the literature
reviewed in Sections 2.2.4.2 and 2.2.4.3, there are many actors inside and outside
pharmaceutical companies involving in drug R&D. Therefore, we should examine
both intra- and inter-firm activities. Furthermore, to understand the process, we
should examine not only the interaction between relevant actors, but also the
influence of historical and structural context, as the proponents of the social shaping
of technology insist. (See Section 2.1.4) Thus, more specifically, we have the
following questions. How are drugs discovered and developed? What kinds of
interpretative flexibility exist in the process? How is the closure of interpretative
flexibility achieved? What kinds of human actors are related to the process? What
kinds of non-human factors are critical in the process? How do human and non-
human actors interact with each other? How does transformation of the network of
actors happen? Do structural and historical factors affect the process?
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2.3.2. Research Strategy
To explore the process of drug R&D, I use case studies. A case study is a detailed
investigation of a particular contemporary phenomenon with attention to its context
by using multiple sources of evidence and various methods of data collection.
(Robson 1993, p. 146; Yin 1994, pp. 12-13) One of the major strengths of the case
study as a research method is its thickness, that is to say, richness in both the quantity
and variety of information it includes. Because of the thickness, a case study
provides us with a means of retaining "the holistic and meaningful characteristics of
real-life events" (Yin 1994, p.3) The contextual thickness makes a case study
appropriate for "how" and "why" research questions because answering these
questions deals with operational links needing to be traced over time (Yin 1994, p.6).
Our main research objective is to understand the process of drug innovation, in
particular that of drug R&D, rather than to analyse its results, for example, the
relationship between specific organisational properties and R&D productivity. The
meaningful interactions of various actors and entities, which cannot be specified in
advance, should be captured. Most of our research questions belong to "how"
questions. Therefore, case studies seem to be more appropriate for this study than
survey and quantitative archival analysis. Because the control over events in real
drug R&D is impossible and we do not know how to simulate it, this research cannot
adopt an experimental approach. This study focuses on contemporary drug R&D.
Interviews with relevant actors are possible and should be conducted. Taking these
into consideration, I chose case studies as the research strategy of this research.
To obtain "analytic generalization" (Yin 1994, pp.30-32), I choose multiple case
studies. By comparing different cases with different situational profiles, I try to
clarify relevant actors and their specificity and generality. I compare different drug
R&D processes in the same therapeutic area. I also compare drug R&D processes in
different therapeutic areas. In addition, I compare drug R&D processes in two
different countries, to understand in particular the influences of historical and
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structural context. In these comparisons, I investigate what kinds of difference there
are and how and why these differences arose.
2.3.3. Choice of Cases and Data Collection
I chose P-blockers and Ca antagonists (drugs for hypertension and other
cardiovascular diseases), H2 antagonists (anti-ulcer drugs), P-stimulants and inhaled
steroids (anti-asthma drugs), LHRH analogues (anti-prostate cancer drugs), HMG-
CoA reductase inhibitors (anti-cholesterol drugs), a cephalosporin antibiotic and an
a ic-blocker (a drug for urination disorder) as areas of case studies. They were
chosen partly because they were new types of drug based on receptor and enzyme
studies, which have been the main stream of drug R&D until very recently and partly
because they were created by R&D in the pharmaceutical industry rather than in
academic circumstances. These are essential because our interest is in modern drug
innovation, which is mainly conducted by R&D in the industry. In addition, they
were chosen partly because they have been extremely successful on the market and
partly because they were properly "mature." They were discovered and developed in
the period from the 1960s to the early 1990s. Most of them became the world or
national top selling drug in each area. Although they are now mature products on the
market, they are still widely used. The great success and maturity of these drugs also
facilitated access to the information necessary for this research to cover the full
process ofR&D, partly because the relevant literature on such drugs is rich both in
amount and in range, and partly because relevant people and companies feel easy to
talk about their R&D process. Newer cases might have been more appropriate to
provide insights into current and future drug R&D. In addition, newer cases might be
less likely to be selective and glorified. However, if the cases were newer, it might be
difficult to obtain a full picture ofR&D process, and it would be much more difficult
to gain access to relevant information because of the confidentiality surrounding
pharmaceuticals R&D.
For the case studies, I used various published matters related to the cases, including
academic articles, patents, textbooks, biographies, corporate histories, business
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journal articles, newspaper articles, statistics, publications of companies, and those of
industrial associations. From these, I obtained scientific, historical, chronological,
causal and analytical information about the cases of drug shaping processes. I also
conducted interviews with key researchers and staff related to the discovery and
development of the drugs we examine here. I obtained causal information and
situational information related to meaningful interactions between actors from
interviews. Unfortunately, most internal documents related to cases were not
available for reasons of confidentiality. Direct observation and participant
observation were impossible because our cases are historical ones. Therefore, I
mainly relied on the two sources of information: published materials and interviews.
The quantity and quality of data used in each case study are not the same, mainly
because of differences in the degree of publicity and confidentiality.
To select scientific papers, typically, I used review papers on the relevant drugs in
medical journals, which I found in MEDLINE™. I also used textbooks in medicine,
medicinal chemistry and pharmacology for this purpose. Then I collected papers
written by the original researchers of each drug. Older papers were discovered from
the references of these papers and interviewees. I also studied papers on the drugs
written by other authors. Papers on results of clinical trials and different review
papers were also studied. MEDLINE™ was fully used to search for these papers. I
checked the references of these papers carefully and tried to cover often-cited papers.
Key original researchers often wrote the story of drug discovery and development as
journal articles or chapters of books. I used these writings as well. Some papers were
offered by interviewees or companies. However, they were only a part of the
literature used in each case study. I studied all these papers to reconstruct the process
of drug R&D, and when I came across controversial issues, I sought further literature
to understand the controversies fully.
Interviewees were selected by the author and/or relevant pharmaceutical companies.
They include one or two key researchers of each drug except in the case of atenolol,
other relevant researchers and development/marketing staff. The number of
interviewees in each case study is: 4 in the cases of leuprorelin and cefotiam, 3 in the
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cases of ranitidine and procaterol, 2 in the cases of mevastatin, salbutamol, BDP
inhaler, salmeterol and fluticasone propionate, and 1 each in the case of propranolol,
nicardipine, cimetidine, famotidine, goserelin and tamsulosin (in total 21
interviewees plus two anonymous interviewees related to Section 2.2.2). Key
researchers were the project leaders of the relevant drug R&D and who might
therefore be regarded as having detailed knowledge of the R&D process. Other
interviewees were mainly chosen by companies as spokespersons of the development
process of their drugs. Although there was little opportunity for the author to take
part in the selection of such interviewees, these spokesperson-interviewees were also
familiar with relevant drug development processes and greatly helpful. Each
interview lasted for one to four hours, about two hours most commonly. Most
interviews were individually conducted, but in a few cases, group interviews were
conducted, for the convenience of companies. All interviews were tape-recorded and
transcribed. The author also communicated with interviewees later by e-mail, fax or
postal mail in order to obtain specific information related to the drug R&D process.
There was also an opportunity to choose which countries should be dealt with in the
international comparison in this study. My choice here is Japan and the United
Kingdom. There are two reasons. First, most of the literature on technological change
in the pharmaceutical industry reviewed in the previous section deals with American
cases. This may be due to the "fact" that a relatively small number of American
companies virtually dominate recent innovation in pharmaceuticals. This may reflect
greater interest in the pharmaceutical industry in the United States, may also be due
to the fact that I look only at literature written in English. In any case, it is almost
certainly true that both British and Japanese cases are much less investigated than the
American cases. This makes research on the British and Japanese pharmaceutical
industry interesting and useful.
Second, although Japanese products such as automobiles and electronics have often
enjoyed competitive advantage in overseas markets, that does not seem to be the case
in pharmaceuticals. (Howells and Neary 1995, p. 1) Hawkins and Reich (1992) argue
that Japanese pharmaceutical companies possess the potential to create innovative
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products and have indeed created some world-class drugs, based on the analysis of
Japanese-originated drugs in the US from 1960 to 1989. But, the overseas sales of 81
large- and medium-sized Japanese pharmaceutical companies contributed only 2.5%
of their total sales in 1996. Even those of 20 leading Japanese companies accounted
for only 7.2% of their total sales. (Japan Pharmaceutical Manufacturers Association
1997,1-21) Nevertheless, Japanese companies dominate the domestic market, which
is the second largest single market for pharmaceuticals. Japanese companies
accounted for about three quarters of Japanese pharmaceutical sales in 1996.7 In
contrast, the UK is one of the leading exporters of pharmaceuticals in the world.
(Owen 1999, p.360) Exports amounted to 41% of gross output. (The Association of
the British Pharmaceutical Industry 1997, p. 13) Thus, the British pharmaceutical
industry's performance in the world market is outstanding, though its machinery and
electronics counterparts are only modestly successful. (Howells and Neary 1995, p.l)
Several further contrasts between the British pharmaceutical industry and the
Japanese pharmaceutical industry are reported. Firstly, British pharmaceutical
companies have faced international competition since the late 1940s with the
presence of American companies, but their Japanese counterparts were protected
before the 1980s from international competition through the national health policy
and industrial policy. Secondly, the British government has been close to the industry
but has required world-class, innovative new drugs. By contrast, the Japanese
government has not always been close to the industry but has approved even
incrementally modified drugs. Thirdly, the British companies have focused on
research but their Japanese counterparts have focused on marketing rather than
research. (Howells and Neary 1995; Reich 1990; Owen 1999, pp.360-387) Finally,
the linkage between public/academic research and the companies seems to be
stronger in the UK than in Japan. (Hicks, Isard and Martin 1996) Because of these
contrasts, the comparison between Japan and the UK is very interesting.
7
The author's estimation based on Japanese Pharmaceutical Manufacturers Association (1997,1-
5) and Yakuji HandoBukku (2000, p.97)
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2.3.4. Data Analysis
For the understanding of the process of drug R&D, I reconstructed the cases by
organising collected information historically and qualitatively. In order to reconstruct
the process of drug R&D, written information and verbally obtained information
were both used. The written stories of drug R&D were checked against the contents
of interviews. The unwritten stories of drug R&D process, in particular the social
aspect of the process, which is rarely conveyed in the scientific literature analysed,
were obtained through interviews. On the other hand, the contents of interviews were
also checked against and supplemented by the contents of relevant literature. I also
tried to use the writings by authors other than interviewees when they were available
in order to obtain more-balanced picture of the drug shaping processes. In this way, I
tried to minimise the danger ofmisunderstanding due to my limited scientific
expertises, the tendency toward the conventional realist explanation of drug R&D,
the risk of lapses in interviewees' memories and the biases of interviewees' views.
Because my work was informed by theoretical perspectives in which innovation is
seen as a process involved in heterogeneous human actors and non-human entities
(see Section 2.1), it was essential in my data analysis to uncover the "social" as well
as the "technical"8 aspects of the shaping of drugs. First, therefore, when I was
involved in the reconstruction of the drug shaping process, I paid attention to making
it a detailed one including almost all relevant actors, factors and activities about
which I had information. Second, I also paid attention to controversies, conflicts,
competitions, collaborations, networking activities and other "social" interactions in
the drug shaping process. Although they were rarely seen in most scientific papers,
some papers included information on these "social" aspects of drug shaping.
Interviews were particularly helpful in this regard. In addition, even if each paper did
not talk much about "social" interactions, careful, comparative investigation into
multiple papers sometimes revealed them. Third, during the reconstruction of the
8
My findings support the claim of actor-network theory that innovation is intrinsically
heterogeneous, and that technology is a seamless web (Hughes 1988) of "technical" and "social"
actors and relations. These terms - "technical" and "social" - are therefore used here only as a
shorthand convenience.
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drug shaping process, I tried to understand each player's actions and the flows and
causal relationships of events in as well-rounded a way as possible. When I did not
understand something, I either asked interviewees or consulted further literature.
After I reconstructed each case of drug shaping, I compared different cases with
others in the same therapeutic area, in different therapeutic areas, and in different
social settings, i.e. the UK and Japan, to find similarities and differences. These
comparisons helped me try to generalise my findings to some extent. On the basis of
my preliminary data analysis, I also introduced several concepts including different
aspects of drug shaping and different types of drug innovation, in order to contribute
to the theorisation of the shaping of drugs and to understand the process better.
2.3.5. Reflexivity about Research Design
Although I believe that the case study is the most appropriate research strategy to
improve our limited understanding of the process of drug innovation, there seems to
be several alternatives in the way of data collection and analysis. First, the focus of
research is on R&D rather than production and marketing. Although it would be
better if the study included more information about production and marketing of each
drug, I gave priority to R&D in the belief that it is the core of drug innovation and
poorly understood so far. In any case, I do not ignore production and marketing
because interests arising from these activities are reflected in the process ofR&D.
We can observe them when we examine the process carefully, as will be shown in
case studies.
Second, the use of scientific papers in this study as one of the main sources of
information might be taken as hampering a symmetrical, "relativist" treatment of
scientific and technological knowledge because such papers usually incorporate a
view of science as objective, cumulative and progressive.9 Nonetheless, some of
those papers explicitly suggest the existence of uncertainty and controversy in their
9 On the relativist, symmetrical treatment of scientific and technological knowledge, see Bloor
(1991), Collins and Yearley (1992) and MacKenzie (1996a, 9-18).
50
research areas. In such cases, I investigated a lot of literature in order to uncover
uncertainty and controversy surrounding drug R&D, as will be shown in the cases of
the risk of regular use of (I-stimulants (Chapter 4), the role of histamine in gastric
acid secretion (Chapter 5), the efficacy ofLHRH analogues (Chapter 6) and the
efficacy and safety ofmevastatin (Chapter 7). Therefore, it seems wrong to say that
the contents of scientific literature are completely incompatible with a relativist view
of science and technology. If they are carefully examined, I believe, they can
constitute useful evidence for relativist studies of science and technology. In this
study, the uncertain and controversial aspects of drug R&D were also confirmed by
and elaborated through the interviews.
Third, this research might be criticised for being a "great men" account, because it
appears to be too dependent on interviews of key researchers. Interviews with other
researchers must have countered this risk. However, it would have been extremely
difficult to achieve this without the help of relevant pharmaceutical companies,
which are very sensitive about confidentiality. Some companies were more
cooperative than others in this respect, but even in such cases, I was unable to obtain
many informants for a single case study. To minimise the potential biases and the
lapses ofmemory of interviewees, therefore, I checked the contents of interviews
with relevant literature as much as possible. Nevertheless, I think that there still
remains room for a richer account in which the complexity of innovation process is
better represented. If broader and deeper investigation into the cases had been
possible, richer accounts, very likely giving greater weight to the roles of those other
than R&D project leaders, would no doubt have emerged. However, I believe that
this potential bias is not significant enough to undermine the major findings of this
study.
Based on the research objectives and research design described above, we examine
several cases of drug research and development in the same therapeutic area,
including at least one British case and one Japanese case, in each of the following
chapters up to Chapter 6. The next chapter deals with the cases of cardiovascular
drugs.
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Chapter 3: Cardiovascular Drugs
3.1. Introduction
In this chapter, we will see three cases of drug discovery and development in the
cardiovascular area. Two of them, propranolol and atenolol discovered by ICI in
Britain, are what are called beta-adrenergic receptor antagonists, commonly known
as (3-blockers. The third one, nicardipine discovered by Yamanouchi Co. Ltd. in
Japan, is a drug classified as a calcium antagonist. Propranolol (Inderal®) was
discovered in 1962, eventually became the first practically used beta-blocker and is
still widely used. Atenolol (Tenormin®), which was discovered in the early 1970s, is
the successor of propranolol and the best selling beta-blocker in the world.
Nicardipine (Perdipine®) was discovered in 1971 and is one of the most frequently
prescribed calcium antagonists in Japan. Of the four categories of anti-hypertension
drugs, namely, diuretics, beta-blockers, ACE (angiotensin-converting enzyme)
inhibitors and calcium antagonists, P-blockers are the most frequently used group of




The first beta-blocker that was investigated clinically was pronethalol. Pronethalol
was discovered by (Sir) James Black and John Stephenson of ICI in 1960. Although
it showed efficacy for the treatment of angina pectoris in clinical trials, it was
replaced by propranolol partly because of its toxicity. Propranolol was discovered by
Black's team in 1962. It showed about ten times higher potency than pronethalol and
no serious side effects. Its clinical trials started in 1964 and it was marketed in 1965
under the trademark of Inderal. It was developed for the treatment of angina and
arrhythmias at first, but later its usefulness as an anti-hypertension drug was also
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found. It was highly successful in the market, and many pharmaceutical companies
including ICI itself rushed into syntheses of its analogues.
Table 3.1: Major Events Related to the Discovery and Development of
Propranolol
Year Events
1958 Research project on beta-blocker started at ICI
1960 Synthesis of pronethalol
1962 Clinical trials of pronethalol
Synthesis of propranolol
1963 Launch of pronethalol under restriction
Clinical trials of propranolol
1965 Launch of propranolol
3.2.2. Discovery of |3-Blockers
At a symposium on the history and the future of beta-blockade in Amsterdam in
September 1975, James Black stated that his discovery of beta-blockers was based on
the adrenergic receptor theory ofR. P. Ahlquist and the discovery ofDCI
(dichloroisoproterenol) by researchers ofEli Lilly, an American pharmaceutical
company. (Black 1976) Ahlquist examined responses of various organs to several
sympathomimetic amines, which mimic the actions of noradrenalin (which is
released from the sympathetic system and causes stimulatory or inhibitory responses
of various organs). He found that there were two different orders of activity of the
amines on various organs and suggested that there were two distinct types of
adrenergic receptors, namely, the alpha and beta-receptors. (Ahlquist 1948) This
theory however had been almost ignored until the discovery ofDCI. (Black 1976)
Ahlquist himself later in 1973 described the adverse circumstances when he
published the paper:
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The original paper was rejected by the Journal ofPharmacology and
Experimental Therapeutics, was a loser in the Abel Award competition, and
finally was published in the American Journal ofPhysiology due to my
personal friendship with a great physiologist, W. F. Hamilton.
Bursting into print in 1948, it was ignored for more than 5 years except
when someone referred to the methods used or the result obtained, but never
to the concept. The reasons for this are obvious today: the concept did not fit
with ideas developed since the 1890s on the actions of epinephrine.
(Ahlquist 1973, 121)
Black offered a more detailed explanation. According to him, Ahlquist's concept
"can be seen to have been hidden in the long shadows cast by two giants—H. H.
Dale, in England and W. B. Cannon, in the USA." (Black 1976, 11) Dale, who
intensely investigated the activities of sympathomimetic amines on the body in the
early 1900s, came close to Ahlquist's receptor idea. He wrote with G. Berger in
1910: "[tjhere must evidently be something in those cells, or connected with them
and them only, which has a strong affinity for these amines."(Barger and Dale 1910,
55) However, in the same paper, they also commented that the theory of receptive
side-chains was very difficult to apply to their results because of the lack of common
chemical characteristics among examined amines that plausibly explained the
different affinity to specific site of tissue where specific receptive side-chains were
assumed to exist. (Barger and Dale 1910, 56-57)1 According to Black, Dale never
referred to receptors again in his writing and never gave receptor theory the benefit
of his huge scientific support. Because Dale was one of the most influential figures
of his time, his neglect of receptor theory functioned as a strong negative signal from
scientific orthodoxy.
1
Receptors are not simple side-chains as Dale thought, but protein molecules and are flexible
enough to bind many different substances. Therefore, agonists and antagonists exist. See, for
example, Patrick (1995, pp.45-67).
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Another and equally strong negative sign against receptor theory was an alternative
explanation offered by Cannon. In 1933, he and A. Rosenblueth suggested new
hypothetical substances: sympathin E and sympathin I. Black explained their idea
plainly: a transmitter substance A was released at sympathetic nerve endings, and A
then combined with either excitatory E or inhibitory I substances in the tissues to
form complexes AE or AI (sympathin E and sympathin I). (Black 1976, 12) They
elaborately explained the excitatory and inhibitory actions of sympathomimetic
amines without using the concept of different receptors. It worked like the phlogiston
theory. (Kuhn 1970) Thus, Black wrote: "the contemporary combined forces of a
theory of multiple transmitters and a low regard for receptor theory as a basis for
classifying drug actions were too much for the new hypothesis to overcome on the
first round." (Black 1976, 12)
Then came the discovery ofDCI. When a group of researchers at Lilly Research
Laboratories ofEli Lilly, in Indianapolis in the US, discovered the compound, they
were not looking for an adrenergic receptor antagonist but for a long-acting
bronchodilator compound. (Maxwell and Eckhardt 1990, pp.6-7; Sneader 1985,
pp. 111-112; Shanks 1984) They synthesized a series of analogues of isoprenaline, a
bronchodilator, and assayed them. They found that one of the compounds, DCI,
blocked selectively some of effects of adrenaline and isoprenaline. They suggested
that DCI was combining with certain "adrenergic inhibitory receptor sites" without
itself causing much physiological effect, and yet was competing for these sites with
physiologically active amines (Powell and Slater 1958, 488), such as adrenaline and
isoprenaline. They reported their discovery at a scientific meeting in 1957. Neil
Moran at Emory University in Atlanta, Georgia, became interested in the report and
asked Eli Lilly for a sample ofDCI. (Sneader 1985, p. 112; Shanks 1984) He and M.
E. Perkins tested it immediately and confirmed that DCI antagonized the changes in
heart rate and muscle tension produced by adrenaline in 1957. They also found that
DCI blocked the cardiac responses to adrenergic stimuli after the initial increase in
heart rate, which indicated its partial adrenergic agonist activity. What was very
important was that they linked this phenomenon with the Ahlquisf s receptor theory.
These results were published in 1958. (Moran and Perkins 1958) However, at that
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stage, they had not yet labelled DCI a "beta-adrenergic blocking agent" as they did
later in 1961. Neither did Eli Lilly fully seem to notice the value of their discovery of
DCI at that time. According to Black, this was also related to the dominant idea at
the time, mainly developed by Walter Cannon. Cannon developed the idea of
homeostasis. He thought that the function of the sympathetic nervous system was the
mediation of the "fight, fright and flight" reaction, that is to say, the sympathetic
nervous system was working for survival. (Black interview; Black 1976)2 For the
people who believed the idea, it was not very wise to think about blocking the action
of sympathetic nervous system.
It was Black who clearly saw the values of the Ahlquist's theory, the discovery of
DCI and the initial combination of these two events by Moran and Perkins. He had
been a senior lecturer of physiology at the Veterinary School of the University of
Glasgow since 1950 until he joined the ICI Pharmaceutical's laboratory at Alderley
Park in Cheshire in July 1958. (Kennedy 1993, p. 130) During this period he had been
interested in the treatment of angina pectoris. At the time, angina was treated by the
strategy of increasing the supply of oxygen. (Black interview; Shanks 1984) Though
there were surgical ways of doing this, pharmacologists started with nitro-glycerine,
which was and has been widely used to treat angina. Nitro-glycerine dilates blood
vessels, which was believed at that time to help the increase of the supply of oxygen
to the heart. (Sneader 1985, p. 142) Many attempts were made to find a new
vasodilator drug that was specific for the coronary artery, but they were not fruitful.
Black came to examine another approach. When he worked with George Smith, a
vascular surgeon in Glasgow, he saw Smith's experiment with dogs to increase the
small amount of oxygen in the plasma to stop ventricular fibrillation. Black raised a
question: "if a small increase of oxygen works, would the small decrease in the need
of the heart for oxygen do the same thing?" He then directed his attention at the heart
rate and sympathetic nervous system. His knowledge in clinical medicine helped
there. On the one hand, he knew that not only exercise but also stress caused pain to
patients with angina. On the other hand, he also knew from observations of surgical
2 This interview with Sir James Black was conducted on 3rd March 1999
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operations that stopping the heart beating faster would relieve angina. Thus, he
wondered if it was possible to decrease the need of the heart for oxygen by slowing
down the heart rate, which was known to be controlled by the sympathetic nervous
system. He put it: "could one make the heart go a bit more slowly by stopping the
activity in the sympathetic nervous system?" Thus, he began to look at adrenaline
and came across Ahlquist's theory of the two types of adrenergic receptors in a
textbook of pharmacology.3 Although neither endocrinologists nor physiologists
made much use of the concept of receptors at that time because of the reasons stated
above, pharmacologists used the concept because it could explain beautifully the
relationship between the concentration of a drug and its effectiveness on the body.
He came to realize that what he wanted was a beta-adrenergic receptor antagonist.
(Black interview)
In 1958, Black moved to the ICI Pharmaceutical's laboratories at Alderley. ICI had
established all its pharmaceutical business in a separate division at the new site in
1957 to strengthen the business, especially, in the cardiovascular drug area. Garnet
Davey, the then Head ofBiological Research of the new Pharmaceutical Division of
ICI, had learned ofBlack's interests and offered him a job. (Kennedy 1993, p. 130)
Before long Black came upon the discovery ofDCI and Moran's report on it. (Black
interview; Black personal communication, January 2000; Kennedy 1993, pp. 130-
131) In January 1959, he proposed a new project, saying: "the search for compounds
which will block cardiac sympathetic responses constitutes a clear-cut
pharmacological problem." (Shanks 1984) He and his colleagues made their own
sample ofDCI and tested it on the heart. They saw that the compound stimulated the
heart rate, which meant that it would not work for the treatment of angina. However,
it otherwise worked as a beta-adrenergic receptor antagonist. He decided to search
for beta-adrenergic receptor antagonists devoid of the heart-rate-stimulating effect.
In February 1960, John Stephenson, a chemist at Alderley Park, synthesized a new
compound, by replacing the two chlorine atoms in DCI with another phenyl ring.
3 Ahlquist wrote the chapter on adrenergic drugs in Drill's Pharmacology in
Medicine published in 1954 from McGraw-Hill, which Black read.
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(Sneader 1985, p.112; Shanks 1984, p.131; British Patent No. 909357) Black found
that "the compound blocks the cardiac rate of tension changes produced by
catecholamines, but differs from DCI in being free from intrinsic sympathomimetic
[agonist] activity," (Black and Stephenson 1962, 314) in other words, that the
compound was an effective antagonist of beta adrenergic receptors. The compound
was named pronethalol (or nethalide, Alderlin®). It was subsequently tested on
humans by A.C. Dornhorst and B.F. Robinson at St. George Hospital, London. In
1962, they confirmed that the drug blocked the cardiac action of catecholamines
effectively in man and that exercise tolerance was increased in patients with angina
pectoris by the drug. (Dornhorst and Robinson 1962) Furthermore, the full-scale
clinical trials of pronethalol showed that the drug was effective for angina (Alleyne,
et al. 1963), arrhythmias (Stock and Dale 1963), and hypertension (Prichard 1964).
However, frequent occurrences ofminor side effects of the drug were reported.
(Alleyne, et al. 1963) Moreover, long-term toxicity tests revealed that the drug could
cause cancer of the thymus gland in mice. (Paget 1963; Shanks 1984; Sneader 1985,
p. 112)4 The British Government and British people in general became very sensitive
about the safety of drugs after the revelation of the thalidomide disaster in 1962. The
toxicological problem of pronethalol, therefore, was a major setback for the
marketing of the drug. Eventually, the drug was marketed in the UK in November
1963, but under a restricted license. (Shanks 1984)
Meanwhile, Black did not stop searching for a better beta-blocker, because he was
not convinced that he had obtained the ideal drug in pronethalol. He put it thus:
The first one was what is called a prototype. And a prototype is just good
enough. So, out of the principle, these studies in man showed in principle
this thing would work. But it had many problems with it. One was that a
quite number of patients got their bad dreams and also it was then found to
be a carcinogen in mice. But, we didn't wait. We were trying to get
something, which should be more potent and more selective and less toxic.
We kept going. (Interview)
Elsewhere, Black stated: "I don't think there were any pressures to market
4 According to Sir James Black, no one has ever repeated this observation. (Personal
communication, January 2000)
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pronethalol as a drug, rather than use it as a stepping-stone or probe, but if there were,
Garnet [Garnet Davey, the research director] kept them away from me." (Kennedy
1993, p. 132)
After a large number of compounds were made (Black et al. 1964), Leslie Smith and
Albert Crowther, chemists at Alderley Park, at last synthesized an analogue of
pronethalol in 1962 (British Patent No. 994918; Shanks 1984), which was later
shown to be about ten times as potent as pronethalol, with less side-effects, and not
to be a carcinogen, by Black and his colleagues. (Black et al. 1964) The compound
was named propranolol (Inderal®). Shortly after the synthesis of propranolol, the
pronethalol's carcinogenic effect in mice was first reported in December 1962
(Shanks 1984), and the weight ofR&D efforts rapidly shifted from pronethalol to
propranolol. The first pharmacological and toxicological report of propranolol by
Black and his colleagues was published in May 1964 (Black et al. 1964), and the
clinical trials of the drug commenced in the summer of the same year, which soon
indicated that propranolol was a safe and effective drug for the treatment of angina
pectoris, hypertension and cardiac arrhythmias with a low incidence of side-effects.
(Srivastava, Dewar and Newell 1964; Gilliam and Prichard 1965; Rowlands, Howitt
and Markman 1965; Sloman, Robinson and McLean 1965; Various papers in the
American Journal ofCardiology, Volume 18, Number 3, September 1966; Shanks
1984) The drug became the first beta-adrenergic receptor antagonist on the market
when launched in July 1965. It took only two years and eight months from the first
experiment of propranolol in an animal to its market launch. (Shanks 1984) It is
obvious that the experience in pronethalol shortened the time for propranolol to clear
the required criteria for the approval. Pronethalol was withdrawn from the UK
market in October of the same year. (Shanks 1984) Then, on 10th and 11th November
1965, a major symposium entitled "Symposium on Beta Adrenergic Receptor
Blockade" was held in Buxton, England, with sponsorship from ICI. (Braunwald
1966) The success of propranolol aroused rival companies to the search for a better
analogue of the drug. (Sneader 1985, p. 113)5 ICI also continued the research on p-
5
Consequently, the market of beta-blockers got into the situation described as an "overcrowded
field" by 1975. See the Lancet, April 26, 1975, 961-962. Another factor that promoted the rush of
research into the area was the relative simplicity of the synthesis of an agent that has a good
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blockers without interruption. (Howe et al. 1968; Crowther and Smith 1968; Howe
and Rao 1968; Howe et al. 1969; Crowther et al. 1969; Howe 1969; Dunlop and
Shanks 1968) Black left ICI in the middle of 1964. He put it thus:
When a company has made a discovery of a new compound, what they want
the scientists to do is to help them to promote the drug. So [ICI] wanted me
to go to meetings and give papers... And they did not want me to stop
working on beta-blockers. I wasn't interested in marketing. And I got
interested in [histamine receptor antagonist], so I said I wanted to do this,
and they didn't want me to do. So, I said, "all right. I'll go." (Interview)
Later, it was learned that propranolol had previously been synthesized by H. Koppe
of C.H. Boehringer and Company, Ingelheim, shortly before pronethalol had been
discovered. However, the company did not recognize the clinical potential of the
compound, and no patent was claimed at that time. (Sneader 1985, p. 113; Shanks
1984) Black recognized the value of the compound, and ICI took the patents related
to it. Shanks wrote, "Black had made the crucial contribution to the discovery of [3-
adrenoceptor blocking drugs by realizing that they might be of value in the treatment
of cardiac diseases and instituted a research programme to develop acceptable
drugs." (Shanks 1984) Other authors also wrote, "[t]he major contribution ofBlack
was to appreciate the possible value of developing compounds to inhibit the
sympathetic to the heart, and to then persuade, and then lead a team of scientists at
ICI to translate the idea into reality."(Cruickshank and Prichard 1987, pp.2-3)
Propranolol was very successful in the market. The biggest share of its sale was due
to its efficacy in the treatment of hypertension, though the original researchers did
not expect this use. The anti-hypertension activity of beta-blockers was discovered
by Brian Prichard, when he was testing pronethalol in hypertensive patients at
University College Hospital Medical School, London, in 1963. (Prichard 1964) He
and P.M.S. Gillam found that propranolol also had an anti-hypertensive action in
man in 1964. (Prichard and Gillam 1964) However, the anti-hypertensive activity of
propranolol was not accepted immediately. There were some negative results. Gillam
and Prichard attributed these negative results to an inadequate dose of the drug. They
chance of being a B-blocker. See Le Count (1982, p. 120).
61
suggested that confusion arose from the misconception following the observation
that showed that a relatively low dose of a beta-adrenergic blocking drug would
completely work for another application. (Gillam and Prichard 1976, 71-72) The use
of propranolol for the treatment of hypertension was well established by the early
1970s (Morrelli 1973; Simpson 1974, 90; Fitzgerald 1982, 104; Beevers and
MacGregor 1999, pp. 159-160), though the mode of the anti-hypertensive action of |3-
blockers has not yet been completely understood. (Lewis 1976; Kaplan 1998, p. 206)
|3-blockers had been the second most popular anti-hypertensive drugs after diuretics
until 1991 (Kaplan 1998, p. 189, p. 205), and propranolol had been the leading (3-
blocker until it was superseded by new generation of P-blockers such as atenolol.
Garnet Davey, the then research director, stated that the discovery of the application
for anti-hypertension was "absolute luck." (Kennedy 1993, p. 133) Hypertension
became the largest single use for propranolol and has enormously increased its
market. (Kennedy 1993, p. 133) Black modestly commented that "commercial
success has nothing to do with the quality of the science. It's the fact that so many
people suffer from high blood pressure that has led to the attention. If high blood
pressure had been as uncommon as multiple sclerosis, there wouldn't have been the
same amount of notice taken of it." (Kennedy 1993, p. 134) However, the discovery
of propranolol supported the theory of receptors, promoted further research on it, and
changed the treatment of hypertension, angina pectoris and arrhythmias. This is
shown in current textbooks in various disciplines: pharmacology (E.g. Rang, Dale
and Ritter 1995, p.24, pp.148-170, pp.286-291, p. 295, pp. 317-319, p.433),
medicinal chemistry (E.g. Patrick 1995, pp. 94-5, pp. 102-3), physiology (E.g. Berne




Atenolol is a cardio-selective p-blocker discovered and developed by ICI. It
possesses the advantages both of propranolol and of practolol. Practolol was the first
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cardio-selective P-blocker, also discovered and developed by ICI in the mid-1960s,
but ICI withdrew it in 1975 after it was found to be toxic. Practolol was also less
potent than propranolol. Atenolol is as potent as propranolol, as cardio-selective as
practolol, without the side effects that were frequently observed in the use of
propranolol and without the serious side effects seen in the use of practolol. Atenolol
was launched in the market under the trademark of Tenormin in 1976, and became
the best selling beta-blocker in the world in the 1980s and 1990s.
Table 3.2: Major Events Related to the Discovery and Development of
Atenolol
Year Events
1964 Synthesis of practolol
1965 Pre-clinical studies of practolol, Launch of propranolol
1966 Discovery of cardio-selectivity of practolol
Clinical trials of practolol
1968 Synthesis of atenolol
1970 Launch of practolol
Pre-clinical studies of atenolol
1975 Withdrawal of practolol
1976 Launch of atenolol
3.3.2. In Search of Selectivity: From Propranolol to Atenolol
As mentioned in Section 3.2.2, ICI continued research on beta-blockers without
interruption after the discovery of propranolol. They synthesized and tested a number
of analogues of propranolol and pronethalol. (E.g. Howe et al. 1968; Crowther and
Smith 1968; Howe and Rao 1968; Howe et al. 1969; Crowther et al. 1969; Howe
1969) They also studied (3-blockers synthesized by other companies. (Dunlop and
Shanks 1968) Of these intensive and extensive studies on (3-blockers at ICI, two sets
of studies focused on a particular problem related to the local anaesthetic property of
propranolol.
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In 1965, Vaughan Williams reported that both propranolol and pronethalol are local
anaesthetics. (Vaughan Williams 1966) This raised a question whether the beneficial
effect of the drug in angina resulted from the beta-receptor blocking effect or a local
anaesthetic effect. (Shanks 1984) Researchers at ICI resolved propranolol into two
optical isomers and found that the (-)-isomer was shown to be 60-100 times more
potent than the (+)-isomer in blocking beta-receptors, whereas both propranolol and
its (+)-isomer were equally potent local anaesthetics but the (-)-isomer was less
potent in local anaesthetic activity. (Howe and Shanks 1966; Shanks 1984) The
researchers decided to begin studies with the D- (i.e. (+)-) isomer of propranolol to
determine the contribution of local anaesthetic activity to the therapeutic effect of
propranolol. (Shanks 1984)
Another approach taken by ICI to this problem was to develop a |3-blocker that was
not a local anaesthetic. (Shanks 1984) Besides propranolol, a P-blocker which was
synthesized outside the company helped the researchers' thinking. The P-blocker was
synthesized by A.A. Larcen at the Mead Johnson Pharmaceutical Company in
October 1960, though the company was not searching for a P-blocker at that time.
(Sneader 1985, p. 113; Shanks 1984) The compound was named sotalol, and, later,
found to be a p-blocker. What was important was that sotalol was devoid of local
anaesthetic activity. (Lish, Weikel and Dungan 1965; Shanks 1984) The compound
was also devoid of side effects on the central nervous system due to its hydrophilic
nature. Propranolol had this effect and could cause vivid dreams after taking it,
which was one ofmajor side effects of the drug. (Sneader 1985, p. 113; Simpson
1974) The ICI researchers synthesized sotalol and its derivatives, including its
phenoxy derivative (ICI 50232) and the acetamido derivative of ICI 50232 (ICI
50172) in the summer of 1964. ICI 50172 was found to be a P-blocker without local
anaesthetic activity like sotalol, though less potent in beta blocking than propranolol.
ICI 50172 was named practolol, and ICI decided to develop it for clinical studies in
which a comparison would be made between practolol and the D-isomer of
propranolol to determine the role ofblockade of beta-adrenergic receptors and of
local anaesthetic activity in the effectiveness of propranolol in angina and
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arrhythmias. (Shanks 1984)
The comparative studies between practolol and D-isomer ofpropranolol did not come
to fruition because unique and more interesting pharmacological properties of
practolol were unexpectedly discovered and research efforts were concentrated on
understanding of these properties. During 1965 and 1966 detailed pharmacological
studies were made in animals with practolol. In April 1966, Robin Shanks and his
colleagues at ICI almost by accident discovered that practolol blocked beta-
adrenergic receptors in the heart but not those in bronchial or vascular smooth
muscle. (Dunlop and Shanks 1968) Practolol was described as a cardio-selective
beta-adrenergic blocking drug. (Shanks 1976) This property was especially important
because the biggest problem of propranolol was its lack of selectivity in its affinity of
beta-adrenergic receptors. The beta-receptors are widely distributed in the body, and
related not only to the heart but also to the bronchi and some other organs. The most
serious problem is that beta-adrenergic receptor antagonists without the selectivity
cause the constriction of the bronchi, which can be life-threatening in patients with
asthma. This side effect was obvious in the use of propranolol, because it equally
affected both the beta-receptors on the heart and those on the bronchi. (Rand, Dale
and Ritter 1995, p. 150, pp. 166-167) Practolol blocked the beta-receptors on the heart
selectively, and was almost devoid of this side effect.6
This phenomenon was explained by the hypothesis of Lands and his colleagues of
Sterling-Winthrop Research Institute that there were two types of beta-adrenergic
receptors: Pi receptors mediating responses in the heart and p2 receptors mediating
responses in bronchial and vascular smooth muscle. (Lands et al. 1967) Practolol
blocked those receptors that Lands had classified as Pi and had little effect on p2
receptors. In subsequent studies, practolol was shown to be cardio-selective in man
(Brick et al. 1968), and was taken forward to clinical trials. The clinical trials
confirmed that practolol did not block the bronchodilator action of isoprenaline and
did not produce wheezing in asthmatic patients. (Powles, Shinebourne and Hamer
1969) An international conference on practolol was held on 5th and 6th June 1970 in
6 Practolol was not absolutely devoid of this side effect. See the Lancet, April 26, 1975, 961-962.
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London. (Lewis (ed.) 1971) Practolol (Eraldin®) was launched on the market in 1970.
(Sneader 1985, p. 114)
Practolol, however, was withdrawn from general use in 1975, because it caused
serious side effects (in the worst case, loss of eyesight) in a small number of patients
who had taken it orally for a long time. (Shanks 1984; Sneader 1985, p. 114; Editorial,
BritishMedical Journal, 14 June 1975; Cruickshank andPrichard 1987, pp.835-839)
The use of the drug was restricted to specialized hospital units after that. The drug
that eventually took over the market of practolol in 1976 was ICI-66082 (atenolol),
which had been synthesized by David Le Count in 1968, a year before the market
launch of practolol. (Fitzgerald 1977; British Patent No. 1285038) This compound,
therefore, was not searched for because of the withdrawal of practolol, but had
already been discovered in the continuous research on P-blockers in ICI, in which the
researchers had searched for a drug with both the advantages of propranolol and
those of practolol.
Practolol had two obvious drawbacks, apart from the side effect mentioned above: it
was less potent than propranolol on the heart and it also had a partial agonist activity.
(Barrett 1971; Barrett 1977; Fitzgerald 1977; Le Count 1982, p. 124) These two
drawbacks were the main targets of the research after the discovery of practolol
because the long-term toxicity of practolol was not known when the research was
conducted. (Wiseman 1971) Therefore, the demanded profiles of the next drug to
practolol were to be as potent as propranolol on the heart and to be devoid of partial
agonist activity, while it was also necessary for the drug to have less effect on the
bronchial and vascular smooth muscle (i.e. cardio-selective) and to be free of local
anaesthetic activity, like practolol. (Barrett 1977; Fitzgerald 1977; Le Count 1982, p.
119) In addition, it was required for the drug to be highly water soluble (hydrophilic)
so as not to penetrate the central nervous system and cause side effects like vivid
dreams. (Barrett 1977) To find a drug that satisfies these profiles was important not
only for improving therapies of angina and hypertension but also for understanding
the mode of action of P-blockers. All P-blockers available at that time had mixed
activities: general P-blocking activity, cardio-selective P-blocking activity, local
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anaesthetic activity and partial agonist activity (Table 3.3). Knowledge on the effects
of each activity on the body was poor. Scientists in the industry wanted to know the
contribution of each activity to the safety and efficacy of (3-blockers. They strongly
wanted a drug that had (3-blocking activity only so that they could compare its effects
with those of other (3-blockers. (Fitzgerald 1977)












Propranolol ++ - + -
Sotalol + - - -
Oxprenolol -H- - + +
Practolol + + - +
Required
Atenolol ++ + - -
(Sources) Fitzgerald (1977) and Heel et al. (1979), Partially edited by the author
The ICI research team at that time was led by Arthur M. Barrett, a pharmacologist,
and included both pharmacologists and chemists. (Fitzgerald 1977) Both sorts of
expert were required to change their approaches. The pharmacologists needed to
modify biological screening procedures so that they could identify each activity of
the examined compound. (Barrett 1977) A screening sequence with five stages was
devised. (Le Count 1982, pp. 120-126) For the chemists, it was relatively easy to
achieve potency as strong as propranolol, but it was not easy to achieve the other
demanded profiles. This was because the structural features responsible for the
presence or absence of the other properties were not obvious. First of all, in order to
achieve cardio-selectivity, the unique structure of practolol was carefully studied.
One of the chemists, Roy Hull, considered that the acidic nature of the proton in the
unique structure of practolol, -NHCOCH3, contributed to the cardio-selectivity. He
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suggested an alternative side-chain to his colleague, Le Count. (Fitzgerald 1977;
Barrett 1977) Because the original suggestion was difficult to synthesize, (Fitzgerald
1977) Le Count tried another side-chain, -CH2CONHR,7 at the same position as -
NHCOCH3 in practolol, based on Hull's hypothesis and his own thought that the NH
chain could also play a crucial role. (Le Count 1982, p. 126) The parent compound,
atenolol, was the one with H at the R position of the side-chain, -CH2CONHR (that
is, -CH2CONH2), which was synthesized through a unique, but very convenient,
method. (Le Count 1982, pp. 126-127) Within two months of its synthesis in
December 1968, the compound was found to be a cardio-selective ^-blocker, as
expected. To the researchers' surprise, however, it was found to be devoid of partial
agonist activity and also devoid of local anaesthetic activity. (Le Count 1982, p. 126;
Barrett et al. 1973; Fitzgerald 1977) Thus, the compound unexpectedly achieved all
of the targets at the same time. A number of analogues of the compounds were also
synthesized. (Le Count 1982, pp. 127-131) Many of them were cardio-selective (3-
blockers.8 However, none was closer than atenolol to the initial target. Any
additional modification led to the loss of one or more demanded profiles. For
example, a modification that enhanced the potency reduced the hydrophilic property.
(Le Count 1982, pp. 127-131) Several compounds based on other approaches were
also compared with atenolol, but none satisfied all of the initial requirements.
(Fitzgerald 1977)9 Although atenolol was not an "ideal" (3-blocker with cardio-
specificity (i.e. active on the heart only), it was at least the closest to the "ideal."
(Barrett 1977) In addition, it is said that atenolol was chosen particularly because it
was believed to be the most potent one in anti-hypertension activity. (Fitzgerald 1982,
113-114; Bilski personal communication) As mentioned in the previous section,
7 R in molecular structures represents a generalised group of atoms, which are
replaceable and to be examined with each other in order to obtain the best one.
Typically, this includes hydrogen, methyl, ethyl and other alkyl groups.
8
Ironically, a subsequent analysis with those related compounds showed that the Hull's
hypothesis was not necessarily correct. See Barrett (1977).
9 According Dr Andrew Bilski, an expert in B-blockers at AstraZeneca (formerly ICI),
there were three other candidates apart from atenolol, namely ICI 72222, ICI 78748
and ICI 89406. They had different advantages and disadvantages. For example, ICI
89406 was more cardioselective than atenolol. However, all but atenolol had partial
agonist activity, which was thought to result in less anti'hypertension activity than
atenolol. ICI 78748 had an activity to induce histamine release, which was another
reason for not being chosen. (Personal communication, May 2000)
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hypertension was the largest market for P-blockers. Thus, atenolol was chosen to be
developed as a drug.
Clinical trials confirmed the efficacy of the drug for the treatment of hypertension
and angina pectoris, its cardio-selectivity, and its lack of serious side effects,
including the one that was reported in the long-term use of practolol. (Hoffbrand
(ed.) 1977; Heel et al. 1979) Many of clinical trials included the comparison with
propranolol. (E.g. Astrum and Vallin 1974; Roy, Day and Sowton 1975; Singh et al.
1975) Atenolol was not more potent than propranolol but its cardio-selectivity, its
absence of local anaesthetic activity, and its lack of partial agonist activity were
regarded as advantages. An unexpected, additional advantage of the drug was that it
was longer acting so that it could allow once a day dosage for the treatment of the
hypertension. (Fitzgerald 1977; Heel et al. 1979) It is notable that the number of
papers on clinical trials of atenolol was much larger than that of propranolol.
Atenolol was launched in 1976 under the trademark of Tenormin. (Zeneca 1993
AnnualReport andAccounts, p. 16) An international symposium on atenolol was
held on 4th to 6th October 1976 in Nice, France. (Hoffbrand (ed.) 1977) Atenolol
became one of the world's best-selling cardiovascular drugs in the 1980s. Even in
1991, 15 years after its launch, it was amongst the top 5 selling drugs in the world
with the sales amounting to 1180 million dollars. (Scrip Yearbook 1993, p.47) The
drug, in 1993, accounted for 25% of the sales of pharmaceutical products at Zeneca,




Nicardipine is one of the drugs called calcium antagonists. It was discovered and
developed by Yamanouchi Co. Ltd. in Japan in the 1970s. When it was discovered,
the researchers at Yamanouchi did not know its mechanism of action. However,
because it showed remarkable potency in coronary and cerebral vasodilation, it was
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chosen for development. During its clinical trials, the concept of calcium antagonism
arose and provided an explanation for the action of the drug. Nicardipine was
launched in the Japanese market under the trademark ofPerdipine in 1981, and
became one of the best selling cardiovascular drugs in Japan in the 1980s.
Table 3.4: Major Events Related to the Discovery and Development of
Nicardipine
Year Events
1966 Synthesis of nifedipine (patented in 1967)
1969 Clinical trials of nifedipine in Japan (in German in 1970)
Finding of the calcium antagonist activity of nifedipine (published in 1972)
Start of research on the analogues of nifedipine at Yamanouchi
1972 Discovery of nicardipine
1974 Clinical trials of nicardipine (cerebral vasodilator) [in Japan]
1976 Launch of nifedipine (anti-angina) [in Japan]
1977 Clinical trials of nicardipine (anti-hypertension) [in Japan]
1981 Launch of nicardipine (cerebral vasodilator) [in Japan]
1982 Extension of application of nicardipine (anti-hypertension) [in Japan]
1985 Extension of application of nifedipine (anti-hypertension) [in Japan]
Suspension release tablet of nifedipine [in Japan]
1988 Suspension release tablet of nicardipine [in Japan]
3.4.2. Discovery and Development of a Calcium Antagonist in Japan
When Toichi Takenaka joined Yamanouchi Pharmaceutical after graduating from
university in 1964, he was interested in the activities of vasodilators. However,
vasodilators at that time were not highly rated as drugs for angina pectoris and
hypertension, partly because existing vasodilators such as hydralazine, dipyridamole
and cyclandelate were not very effective, and partly because the advent of |3-blockers
in the mid-1960s attracted most researchers' and physicians' attention to the new
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type of drugs. Yamanouchi also went with the tide, and eventually discovered a (3-
blocker, indenolol, in 1968. Takenaka had to stop his research on vasodilators
because he was involved in the research of the (3-blocker. However, not long after he
finished the work on the (3-blocker, he came across a new series of compounds, 1,4-
dihydropyridine derivatives. (Takenaka interview)10
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10 This interview with Dr Toichi Takenaka was conducted on 22nd January 1999.
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The compounds, called 1,4-dihydropyridine derivatives, did not originate with
Yamanouchi. Since the mid-1960s, an American company and a German company
had been studying them. In the United States, Bernard Loev and his colleagues at
SmithKline and French Laboratories were interested in 1,4-dihydropyridine
derivatives, a simple synthesizing procedure ofwhich had been discovered by A.
Hantzsch in 1882, because the pharmacological properties of this category of
compounds were not well-known even though dihydropyridines were involved in
various biochemical processes. (Loev, Ehrreich and Tedeschi 1972; Loev and Snader
1965) They studied the derivatives and found that a compound had a long-lasting
hypotensive activity in dogs when administered by injection. However, it did not
work when given orally. They synthesized a large number of compounds to find an
orally active compound. Eventually, they found one potent hypotensive compound
(SKF 24260) that was active even by the oral route, and published it in 1972. (Loev,
Ehrreich and Tedeschi 1972; Sneader 1985, pp. 143-144) They tried to develop the
compound as a drug, but gave it up later because of its toxicity. (Takenaka interview)
In Germany, F. Bossert, a chemist at Bayer AG had been studying coronary dilating
agents since 1948. He and W. Vater, a pharmacologist, found that 1,4-
dihydropyridines possessed a strong coronary dilating activity. They synthesized and
tested more than 2000 of its derivatives, and finally discovered a highly potent
coronary vasodilator (BAY a 1040) in 1966. (Bayer (Japan) 1994; Bossert and Vater
1971) The compound was orally effective. They patented this and similar compounds
in 1967 before the SKF team protected their work by patents. (Sneader 1985, p. 144)
The clinical trials of the drug started, first in Japan in 1969, then in Germany in 1970,
for the treatment of angina pectoris. This was because some Japanese medical
experts had been interested in coronary dilating agents for the treatment of angina.
The drug, named nifedipine (Adalat®), was approved in Japan as an anti-angina drug
1975, and launched in the market in 1976. In Germany, it was launched in 1975.
(Bayer (Japan) 1994; Gekkan Mikusu, Volume 24, No.14, December 1996, p. 62)
Meanwhile, Albrecht Fleckenstein at the University ofFreiburg had been studying
the mechanism of the vasodilating activity of nifedipine since 1969. He found that
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the drug was a strong calcium-ion-channel blocking agent (in short, a Ca antagonist)
and published his results in 1972. (Fleckenstein et al. 1972; Fleckenstein 1977;
Fleckenstein 1988) Vascular muscle cells contract when the intracellular calcium
concentration rises. The entry of Ca++ into cells is regulated by calcium-ion-channels
on the cell membrane. Therefore, by blocking the entry of Ca++ into vascular muscle
cells, we can stop vasoconstriction. Fleckenstein had elaborated the concept ofCa
antagonists since 1963, and nifedipine contributed to establishing the concept. He
wrote in 1988:
No doubt, the discovery of the top Ca++ antagonist nifedipine marked the
definite breakthrough of the concept of Ca++ antagonism and induced
enormous efforts by the pharmaceutical industry to expand the new Ca++
antagonistic drug family by further syntheses. (Fleckenstein 1988, 6)
In the late 1960s, Yamanouchi licensed three vasodilators from an overseas company,
though they were not 1,4-dihydropyridine derivatives. In order to test the properties
of these compounds, they had to learn the methods of biological tests on vasodilators,
because the company, which had started its own research for new drugs in 1963, did
not have sufficient skills. They learned the related techniques of experiments by
sending their researchers to domestic universities. Using the compounds and the
techniques, they obtained methods of assay for vasodilators. Although none of the
compounds turned out to be a promising drug, the technology obtained through this
experience contributed to their later work. (Takenaka interview)
Masaru Iwanami and his fellow chemists at Yamanouchi started pharmacological
studies on 1,4-dihydropiridine derivatives in order to discover a vasodilator in 1969.
(Yamanouchi 1994) They learned about the substances from information found by a
team of literature and patent investigators in the company. The original sources in
this case were the patents ofBayer and SmithKline. They synthesized a number of
the analogues. Takenaka, who had at that time been conducting the biological
screening of hundreds of compounds to find a potent vasodilator, tested these 1,4-
dihydropiridine derivatives as well. He found that one of them showed a remarkable
potency he had rarely seen before. He put it: "I didn't know the concept of calcium
antagonists at that time. But, I observed the reactions of animals given the compound,
73
and strongly felt that this was very much different from the existing vasodilators."
Takenaka, Iwanami and their colleagues decided to keep examining the compound
and its analogues. (Takenaka interview)
Although the compound was highly potent, it was less soluble in water than Bayer's
1040 or SKF 24260. This meant the compound would not work when given orally.
Therefore, the efforts of the Yamanouchi chemist team were directed to finding more
water-soluble analogues. Many approaches to getting a high water-solubility reduced
the potency of the compound. The productivity of reactions was also important. After
an enormous effort, they got a few candidates to develop as a drug. There was a
trade-off between water-solubility and potency. They selected one of the most active
compounds in their study though it had a relatively low water-solubility.
Nevertheless, even the selected compound (YC-93) had very high water-solubility
compared to existing alternatives: it was more than 100 times higher than that of
Bayer's 1040 or SKF 24260. (Iwanami et al. 1979) The selection was made in view
of the potency, bioavailability (i.e. water-solubility), duration and uniqueness of the
compound. (Iwanami et al. 1979; Takenaka interview) YC-93 was discovered in
1972 (Takenaka interview) and patented in 1974. (Iwanami et al. 1979; Japanese
Patent No. 109384; Belgian Patent No. 811324)
In pre-clinical tests with animals, YC-93 was found to be a potent cerebral and
coronary vasodilator with low toxicity. Takenaka and his colleagues also confirmed
that it was well absorbed by the oral route. (Takenaka 1974; Takenaka et al. 1976)
They seemed, however, not yet to notice that the drug had a calcium antagonistic
activity. In the paper published in 1976, they only mentioned: "The coronary
vasodilator mechanism of YC-93 seemed to be different from that of dipyridamole."
Later, they learned the concept of calcium antagonism from the literature and used
the concept effectively to persuade medical doctors to conduct clinical trials of the
drug. (Takenaka interview)
Takenaka and his colleagues decided to propose the development of the compound.
Since the company had only recently started its own research for new drugs, it did
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not have a systematic procedure to evaluate a drug development project when YC-93
was discussed.11 Masuo Murakami, the then director of the central laboratory of the
company and who had been a professor at the Research Institute of Industrial
Sciences, Osaka University before joining the company, had absolute discretion on
research policy and management. Researchers at Yamanouchi used to propose their
projects directly to him, and he decided whether to take or to drop their proposals.
Takenaka put it thus:
At the time, we used to ask the director to let us do this research, and he
used to say, "OK, go ahead." We were in such atmosphere. Research
management wasn't strict. We did what we wanted to do, and when we got
good results on it, we would propose its development. We enjoyed an
extremely high freedom about research. Later, when [famotidine] was
developed, the atmosphere was less free and there was a formal procedure
of project proposal. But, in [YC-93, nicardipine] case, we didn't have such
procedure. I briefly explained the results to the director in a research
meeting and asked, "I've got such a good compound. Let me do this."
(Interview)
Murakami immediately gave Takenaka an OK. Although Takenaka succeeded in
obtaining an organisational authorisation in this way, he heard some voices of
anxiety from the marketing side. They were anxious about the resistance of medical
doctors whom they asked to conduct clinical trials of the drug. Only several years
before, in 1967, a modern approval system for new drugs was introduced in Japan,
and this drug was the first one Yamanouchi sought to develop under this new
regulatory system. In fact, some doctors doubted the clinical value of vasodilators.
Yamanouchi's representatives and researchers faced a lot of difficulty in obtaining
such doctors' cooperation. They were trying to persuade doctors with data from
animal experiments, but it was not very easy.
Just in time, they learned of the concept of calcium antagonists from the literature on
nifedipine (Takenaka interview), which I mentioned above. Because of the similarity
between the structure of nifedipine and that ofYC-93, it was obvious that the
mechanism of action ofYC-93 could also be explained by calcium antagonism. At
11
Costs, rather than estimated sales, were the only economic factor that was taken into
consideration about R&D in the company at that time. (Takenaka interview)
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that time, nifedipine was also in its clinical trials in Japan. Furthermore, another drug
with a different chemical structure from 1,4-dihydropyridines, diltiazem, which had
been serendipitously discovered by researchers at Tanabe Pharmaceutical in the mid-
1960s and was also undergoing clinical trials at the time, was found to be a calcium
antagonist as well. (Nakajima et al. 1975; Tanabe 1994; Fleckenstein 1977;
Fleckenstein 1988) That is to say, three potent vasodilators were clinically tested in
Japan at the almost same time, in the 1970s, and during their clinical trials it became
clear that all of them were calcium antagonists, a group of drugs whose mode of
action was newly explained. This new concept attracted doctors, especially leading
doctors at universities. (Takenaka interview) Yamanouchi, the latecomer of the three,
was able to enjoy the benefit of the popularity of the concept of calcium antagonism
in academic physicians. As Takenaka put it, "Voices from outside are very important
in Japan. What opinion leaders say is crucial. ... In Japan, especially at that time,
people didn't trust any Japanese work until someone else announced it's OK."
(Interview) Probably, for leading academic physicians in Japan, Fleckenstein was
"someone else," whereas for other physicians, the leading academic doctors were the
"someone else." However, it might be worthwhile noting that people at that time did
not know whether calcium antagonists would work practically even though they had
obtained the concept. People were beginning to recognize calcium antagonism as a
new approach to the treatment of hypertension, but the clinical value of calcium
antagonists was far from established. Although many aspects of calcium antagonism
were still uncertain, the concept helped Yamanouchi's representatives persuade
doctors. Yamanouchi was able to start clinical trials ofYC-93 in 1974.
The clinical trials ofYC-93 started first as a cerebral vasodilator. There were two
reasons Yamanouchi chose this application rather than a coronary vasodilator. On the
one hand, specialists in coronary medicines at that time were doubtful about the
effectiveness of coronary vasodilators for the treatment of angina, because it was
known that the then existing vasodilators like dipyridamole dilated only the healthy
coronary artery and that this might worsen the shortage ofblood supply to the
diseased coronary artery (the "coronary steal" phenomenon). Calcium antagonists
increase blood supply to both healthy and diseased coronary arteries, but at that time
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it was not possible separately to measure each blood flow to show this. As to
cerebrovascular disorders, however, it was known that the total blood supply was
related to patients' conditions. On the other hand, the number of patients with
cerebrovascular disorders in Japan was higher than that of patients with angina at that
time. It would have taken more time and cost more to have conducted clinical trials
of the drug for the treatment of angina. (Takenaka personal communication,
December 1999)
In 1975, the drug progressed into Phase II, in which it was given to patients with
blood-flow disorder in the brain. Then, it experienced Phase III, double-blind tests
with an existing drug. Yamanouchi cleared clinical trials and applied for the approval
ofmanufacturing of the drug in 1979. The drug, named nicardipine, was approved in
1981. It was launched in the market under the trademark ofPerdipine in the same
year. (Yamanouchi 1994; Takenaka interview)
Meanwhile, the clinical trials of YC-93 as an anti-hypertensive drug also started in
1977. This was partly because its anti-hypertensive activity was confirmed in the
course of its clinical trials as a cerebral vasodilator. (Yamanouchi 1994)12 However,
there was another reason why the clinical trials as an anti-hypertensive drug came
late: the anticipated official price ofYC-93 as a cerebral vasodilator was higher than
as an anti-hypertensive drug. (Takenaka interview) That is to say, this choice of
application was made not only from a medical point of view but also from an
economic point of view. Of course, Yamanouchi did not give up the huge and
growing anti-hypertension market. After clearing another set of the clinical trials of
nicardipine for the treatment of hypertension, and after the drug was approved as a
cerebral vasodilator, Yamanouchi applied for approval of the extension of
nicardipine's application. This extension of application was approved in 1982, and
nicardipine became the first calcium antagonist approved for the treatment of anti-
hypertension. (Yamanouchi 1994) Although nifedipine had been approved as an anti¬
angina drug in 1975, it was not until 1985 that the drug became in Japan available for
12 The efficacy of calcium antagonists for the treatment of hypertension was established in the
1980s. See Kaplan (1998), p.216.
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the treatment of hypertension. (Bayer (Japan) 1994)
The dose of nicardipine tablets was originally three times daily. Later, the suspended
release tablet (twice daily) of the drug was developed especially for the treatment of
hypertension. This was approved in 1988. The injection formula for its use during a
surgical operation was also developed and approved in 1988; its water-solubility
made injection possible. Nicardipine was also launched in other countries, including
the United States, France, Italy and the United Kingdom in collaboration with
American and European companies. (Yamanouchi 1994) However, in these countries,
the applications of this drug are anti-angina and anti-hypertension like nifedipine,
rather than cerebral vasodilatation. {British National Formulary, 35, March 1998,
p.99; Bowles et al. 1981; Gelman et al. 1983; Iliopoulou, Turner and Warrington
1983; Lambert et al. 1985; Kathleen et al. 1986)
Nicardipine was very successful in the Japanese pharmaceutical market. Annual sales
in the 1980s and early 1990s were about 40 billion yen (about 200 million pounds if
one pound equals 200 yen). It was among the top 5 selling drugs in Japan from 1986
to 1990. Three years after nifedipine was approved for anti-hypertensive use and its
suspended release tablets were launched in 1985, sales of nicardipine in Japan were
surpassed by those of nifedipine. {GekkanMikusu, Volume 24, No. 14, December
1996, p. 41) In 1996, the estimated sales of nicardipine and nifedipine were 24
billion yen and 38 billion yen respectively, whereas that of atenolol, the top selling
beta-blocker even in Japan, was 11 billion yen. (Yakuji Handobukku 1997, p.268)
The official prices of nifedipine, nicardipine, propranolol and atenolol per day in
1994 were 666-1220, 626-1200, 619 -1436, 1290 yen respectively. {Yakka Yakkou
Hayamihyou 1994) Therefore, P-blockers are not always cheaper than calcium
antagonists in Japan. Yamanouchi discovered and developed another calcium
antagonist later. However, their third calcium antagonist project (YM430) was
stopped for economic reasons. Takenaka put it thus:
We quit [YM430] because of its cost rather than its technical concerns.
That's because the prices of anti-hypertensive drugs have been severely
getting lower. There are already a lot of good anti-hypertensive drugs on the
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market, and their patents have expired one after another. So, they are getting
cheaper. We would have to accept a low price in this situation. Because we
knew the drug would have needed massive production, we gave up from the
point ofview of costs. (Interview)
3.5. Discussion
3.5.1. Concepts and Compounds
Here, let us examine some of the differences and similarities between the cases of
drug discovery and development in this chapter. One of the clear differences between
the three cases is which came first, a theory or a substance. In the case of propranolol,
the hypothesis of the beta-adrenergic receptor antagonism came before the synthesis
of the compound. In the case of nicardipine, the compound came before the
explanation of its action by the theory of calcium antagonism. Atenolol was searched
for on the basis ofHull's hypothesis, though the hypothesis is not now thought to be
correct.
However, when we look at the processes of discovery closely, each of the drugs had
a prototype, namely, DCI for propranolol, practolol for atenolol and nifedipine for
nicardipine. Discoveries of all these prototypes were somewhat serendipitous, that is
to say, they were found to have unexpected properties: DCI had beta-adrenergic
blocking activity, practolol had cardio-selectivity and nifedipine had calcium ion-
channel antagonism. Moran, Black, Lands, and Fleckenstein provided the scientific
explanation of the activities of these compounds, but they were not their discoverers.
Therefore, it is wrong to describe discoveries in the pharmaceutical industry as
always theory driven.
On the other hand, it is definitely wrong to argue that theories are of no use for
discoveries in the pharmaceutical industry. On the contrary, they really help. Black's
hypothesis led ICI to the discoveries of propranolol and other (3-blockers. Land's
theory supported the efforts to discover a better cardio-selective P-blocker after
practolol. Fleckenstein's theory was nothing to do with the discovery of nicardipine,
but, as we can see in the paper by the Yamanouchi's chemists and biologists
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(Iwanami, et al. 1979), they obviously used many existing theories in their efforts to
conduct syntheses and screening of nicardipine, and probably, so did any other
researcher in the industry.
Theories and concepts are not only useful for discovering compounds but also useful
for mobilising organisational resources and creating a market. Black's hypothesis
made the research resources of ICI move toward the realisation of a practical |3-
blocker. The theory, with its evidence provided by experiments with pronethalol and
propranolol, then contributed to the establishment of their clinical market.
Fleckenstein's theory on calcium antagonists also greatly contributed to making the
markets for nifedipine and nicardipine. The contribution of a theory to drug
discovery, resource mobilization and market creation does not necessarily stem from
the correctness of the theory, as was seen in the case of atenolol.
Again, it should be noted that the discovery of a compound often provides a theory
with evidence and opportunity for further sophistication. This is seen in pronethalol
and propranolol for the theory of two types of adrenergic receptors, in practolol and
atenolol for the theory of subtypes of j3-receptors, and nifedipine and nicardipine for
the theory of calcium antagonists.
Thus, it is probably impossible to determine which comes first, a theory or a
substance, in all the cases here. Both induction and deduction are used in order to
discover a drug. However, the two cases in the UK, propranolol and atenolol, can be
regarded as relatively theory driven, whereas the case in Japan, nicardipine, can be
seen as relatively compound driven. Of course, because the British cases and the
Japanese case are classified into different types, P-blockers and calcium antagonists,
it is impossible to attribute the difference of cases simply to the difference of the
place of discovery. It is interesting to note, however, that the concept of calcium
antagonists, which came after the discovery of nifedipine or nicardipine, was devised
in Germany, a European county. Therefore, it might not be entirely wrong to argue
that this difference, between relatively theory driven and relatively substance driven,
characterized the differences in pharmaceutical innovation in this area between the
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UK (and probably other Western countries) and Japan. This could be attributed to the
greater accumulation of (Western) scientific resources. In addition, the distance
between academic research and industrial research in the medical and
pharmacological area possibly had something to do with this, because basic research
on the effects of calcium ions on muscle has been conducted in Japan for more than
50 years! (Ebashi 1988)
3.5.2. Paradigmatic and Normal-Scientific Discovery
Another issue is how different scientific and medical "worlds" are, before and after a
discovery. If they are very different, the discovery can be called a paradigmatic
discovery. If they are not so different, the discovery can be named a normal-scientific
discovery. These are based on Thomas Kuhn's terminology. (Kuhn 1970) The
discovery of propranolol seems close to a paradigmatic type, and the discovery of
atenolol seems closer to a normal-scientific type. The consequence of paradigm-
shifting discovery is destruction of an existing theory. Cannon's "sympathin E" and
"sympathin I" theory was destroyed by the receptor theory and the substances,
pronethalol and propranolol. Furthermore, his harmonious world of homeostasis has
become dubious after learning that chemical intervention in the sympathetic nervous
system might save a life. On the other hand, the discovery of atenolol did not destroy
Black's theory but reinforced it, or made it more sophisticated. ICI's search was
conducted with a relatively narrow target: to remove secondary properties of
propranolol or practolol and to improve only the primal property, beta-blocking
activity only on the heart. This property of drug is called, in technical words,
specificity or selectivity. (Le Count 1982, p. 118) Specificity refers to the ability to
hit only the target without any error, and selectivity refers to the ability to hit the
target more than error. Thus, in the normal-scientific research, the goal is less
ambitious and the area of search is narrower. Consequently, the degree of uncertainty
is relatively low.
In the case of propranolol, Black's leadership was important. He linked knowledge in
various disciplines, namely clinical medicine, physiology, pharmacology and
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chemistry together. He realised his idea by joining a pharmaceutical company,
mobilising its organisational capability and leading people towards the specific goal.
His role of connecting heterogeneous actors, factors and activities can be regarded as
that of heterogeneous engineer. Under the circumstance of high uncertainty, the
discovery of (3-blockers might not have been achieved without his leadership.
In the case of atenolol, though the scientific and technological uncertainty was
probably lower than in the case of propranolol, it was not clear whether ICI's
researchers could obtain the targeted P-blocker which had cardio-selectivity but not
local anaesthetic activity and partial agonist activity when the research was
conducted. The main task is, therefore, more specified, but it does not necessarily
mean that it was easier. Because the target was better specified, it was easier for the
company to pour massive effort into the search. A larger number of compounds were
synthesised and examined, and one of them was chosen. Its advantages over the
existing drugs were critical. Comparative studies between them had to be done to
demonstrate the advantages of the new drug.
The discovery ofnicardipine can be classified as normal-scientific, because its
discoverers knew that nifedipine, the prototype, worked. How about the discovery of
nifedipine? Its discoverers did not know why it worked when it was discovered. It
was Fleckenstein who discovered the reason. Therefore, truly scientific discovery of
nifedipine was completed by Fleckenstein's work. Which type is this? It can be
regarded as a paradigmatic discovery. Although the previous paradigm is less
obvious here than in the case of P-blocker, nifedipine provided the first example of
dihydropyridine-type calcium antagonists. (Figure 3.2) Nicardipine was one of its
modified compounds. The concept of calcium antagonists together with the
contemporary development of other calcium antagonists such as nifedipine and
diltiazem helped Yamanouchi's staff to persuade doctors.
3.5.3. Similarities between the Cases
Apart from the similarity in the interactive relationship between the theory and the
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compound, there are at least two common characteristics to be noticed between the
three cases. The first is uncertainty surrounding the research. All the discoveries
were surrounded by a large amount ofuncertainty. The application of a trial-and-
error method was inevitable, because knowledge about the relationship between a
chemical structure and activities in the body or the mechanism of each activity was
very limited. The researchers at ICI learned the cardio-selectivity of practolol by
testing. The researchers at Yamanouchi learned the anti-hypertensive activity of
nicardipine by using it in clinical trials.
The second is organisational situation. According to Black and Takenaka, the
atmosphere in which each of them worked was full of freedom and there was little
organisational resistance to their work. It might be because their organisations were
still very young. Both the ICI Pharmaceutical's laboratories at the time propranolol
and atenolol were discovered, and the Yamonouchi's laboratories at the time
nicardipine was discovered, were less than 12 years old. However, it might also be
related simply to the times: from the early 1960s to the early 1970s. To generalize
findings of this sort about pharmaceutical innovation, it is necessary to examine other
cases in other settings. In the next chapter, we will discuss the cases of discoveries of
anti-asthmatic drugs in Britain and in Japan.
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Chapter 4: Anti-Asthmatic Drugs
4.1. Introduction
In this chapter, we examine cases of the discovery and development of several anti¬
asthmatic drugs. Asthma can be roughly defined as a syndrome in which there is
recurrent reversible obstruction of the airways in response to stimuli which are not in
themselves harmful and which do not affect non-asthmatic people. Three of the anti¬
asthmatic drugs examined here, salbutamol, salmeterol and procaterol, are drugs
called (^-stimulants, which stimulate beta2-adrenergic receptors on the airway
smooth muscle and dilate the muscle. The other two, beclomethasone dipropionate
inhaler (BDP inhaler) and fluticasone propionate, are drugs called inhaled
glucocorticoids (commonly called inhaled steroids), which ease the mucosal
inflammation inside the airways. Salbutamol, salmeterol, BDP inhaler and
fluticasone propionate were discovered by researchers at Glaxo in England, led by
(Sir) David Jack and Roy Brittain. Salbutamol and salmeterol were discovered in
1966 and 1984 respectively. BDP inhaler and fluticasone propionate were originally
discovered as topical glucocorticoids in 1964 and 1981. They were "re-discovered"
as anti-asthma drugs in the late 1960s and in the mid 1980s. Procaterol was
discovered in 1974 by a research team at Otsuka Pharmaceutical in Japan, led by
Kazuyuki Nakagawa and Shiro Yoshizaki. Salbutamol (Ventolin®), salmeterol
(Serevent®), BDP inhaler (Becotide®) and fluticasone propionate (Flixotide®) were
first marketed in 1969, 1990, 1972 and 1993 respectively, and became the world best
selling drug in each area. The worldwide sales of salbutamol and BDP inhaler in
1995 were 526 million pounds and 397 million pounds respectively.
(GlaxoWellcome, Annual Report andAccounts, 1996) The sales of salmeterol in the
world in 1997 were 406 million pounds and surpassed those of salbutamol in the
same year, which were 391 million pounds. The world sales of fluticasone
propionate in 1997 were 315 million pounds and close to those ofBDP inhaler in the
same year, which were 331 million pounds. (GlaxoWellcome, Annual Report and
Accounts, 1998) Procaterol (Meptin®) was marketed in Japan in 1980 and became the
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best selling bronchodilator there in 1982. Its sales in 1996 were about 15 billion yen.
(Ycikuji Handobukku, 1997)
Table 4.1: Major Events Discussed in This Chapter
Glaxo Otsuka
Year P-stimulants Inhaled steroids [3-stimulants
1963 Research start
1966 Salbutamol discovery Research start
1969 Salbutamol launch
1972 BDP inhaler launch Research start
1974 Procaterol discovery 1
1980 Procaterol launch
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During World War II, H. Konzett at C. H. Boehringer in Ingelheim, Germany, found
that a new analogue of adrenaline had a strong bronchodilating action with fewer
side effects than adrenaline itself. (Konzett 1940a, b) Knowledge of this discovery
became generally available after the war when the US State Department was
investigating the wartime work carried out by German chemical manufacturers. The
compound, isoprenaline (isoproterenol in the US), was introduced clinically in 1951.
It was considered as the drug of choice for the relief of acute asthmatic attacks for
the next twenty years. (Sneader 1985, pp. 102-103) However, the introduction of its
aerosol form during the sixties led to a large number of deaths because of the effects
of overdose on the heart due to the lack of selectivity of isoprenaline. (Greenberg and
Pines 1967; Inman and Adelstein 1969) Another disadvantage of isoprenaline was
that it was too short acting. (Sneader 1985, p. 103; Brittain, Jack and Ritchie 1970,
p.200) Several pharmaceutical companies tried to overcome these disadvantages of
isoprenaline. In 1961, C. H. Boehringer developed a new drug called orciprenaline,
which was different from isoprenaline only in the position of a hydroxyl group in the
molecule. Like isoprenaline it was active about equally on bronchial muscle and the
heart but it was more stable in the body. Therefore it was longer acting than
isoprenaline, though it was less potent. In 1964, Mead Johnson Company in the US
discovered another adrenaline analogue, soterenol. Although soterenol was an
effective and long-acting bronchodilator, it was found to be toxic in animals and was
not marketed. (Sneader 1985, pp. 103-104; Brittain, Jack and Ritchie 1970, pp.206-
213; Jack personal communication, July 2000)
It was Glaxo that had the greatest success in solving the problem. David Jack and his
fellow researchers at Allen & Hanburys in England, which had been a subsidiary of
Glaxo since 1958 (Davenport-Hines and Slinn 1992, pp.170-172, p.198), started their
research on (3-stimulants in 1963. Their early objective was a long-acting (3-stimulant
to replace isoprenaline. Jack, who joined the company as the research director in
1961, explained his situation at that time:
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I started with 122 R&D staff after being assured by the managing director of
Allen & Hanburys and the chairman of Glaxo that the staffwould be
increased to 200 because this was the minimum needed to fmd and develop a
significant new medicine. A second assurance was that we in Allen &
Hanburys would be given at least 5 years to show ifwe would do something
useful. (Interview with Sir David Jack)1
Jack chose the area of anti-asthmatic drugs as one of the targets at his laboratories
because asthma was a very common illness but its treatment was underdeveloped at
the time. Jack put it:
[T]he secret of success in the pharmaceutical business is to find better
medicines for common illnesses. ... It's so obvious, but people forget it. I
considered asthma in 1963 because it was a badly treated common serious
illness. Isoprenaline, the most effective bronchodilator was too short-acting
and was a powerful cardiac stimulant. Theophyline, the best available orally
active bronchodilator also had use-limiting side effects. There was clearly
need for a better bronchodilator.
The other drugs which were available by 1962 were anti-inflammatory
steroids, analogues ofCortisol. And by then, prednisone, prednisolone were
available and so too, I think, would be dexamethasone and betamethasone.
These drugs were of great value in asthma because they control the
inflammation within the lungs. Unfortunately, although they were effective,
they had major systemic side effects. (Interview)
The search for a better P-stimulant was, thus, the first work the Allen & Hanburys
researchers did in the anti-asthmatic area. At an early stage in the research, Larry
Lunts, a chemist in the research team, reached the idea that inhaled isoprenaline was
short acting because it was rapidly metabolised by catechol specific mechanisms.
Catechol is a chemical group (Figure 4.2) included in isoprenaline molecules.
Therefore, he considered that non-catechol analogues of isoprenaline would be
expected to be longer acting. He replaced one of the two hydroxyl groups of the ring
by a CH2OH group. The resulting compounds are called saligenin analogues of
isoprenaline. Lunts made several saligenin analogues, side chains ofwhich were
different from each other in structure. (Lunts 1985; Jack 1996, 6) In 1966, five years
after Jack's agreement with his boss, the research team found that one of the
analogues had not only the expected longer duration of action (3-4 hours against 1
1 This interview with Sir David Jack was conducted on 26 April 1999.
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- 1.5 hour in isoprenaline), but also unexpected high selectivity for the bronchi: the
latter property meant that the compound had much less side effect on the heart,
which constituted the other major disadvantage of isoprenaline. The compound was
named salbutamol. (Hartley, et al. 1968; Brittain et al. 1968; Cullum et al. 1969; Jack
1998, p. 141) A number of clinical studies in humans confirmed the longer duration
of action and the selectivity of salbutamol in comparison with isoprenaline. (E.g.
Choo-Kang, Simpson and Grant 1969; Chatterjee and Perry 1971; Tara, Kellomaeki
and Pylaes 1971; Conolly et al. 1971; Schmann and Herxheimer 1971) Although
salbutamol was effective by mouth, the duration of action was found to be less than
when it was given by inhalation. (Simpson 1971; Minetti 1971)
The selectivity of salbutamol was strong evidence for the theory formulated by
Lands and his colleagues at Sterling Winthrop in the US that beta-adrenergic
receptors could be subdivided into betai and beta2 subtypes. There are much more
betai subtypes than beta2 in the heart, whereas there are much more beta2 subtypes
than betai in the airway. (Lands et al. 1967; Cullum et al. 1969, 150) Salbutamol was
found to be a beta2-selective stimulant. Jack wrote later: "We were naturally
disappointed that our discovery of selectivity within P-adrenergic effects had been
anticipated but were comforted by the fact that salbutamol was clearly a better drug
than any of the catecholamines." (Jack 1989, 173) Because salbutamol was beta2
selective, its short-term adverse effects were little. (Chatterjee and Perry 1971;
Minette 1971; Conolly et al. 1971) Salbutamol was marketed in 1969 and became the
most commonly used bronchodilator in the world (Sneader 1985, p. 104; Jack 1998,
p. 143; Website ofGlaxoWellcome), though controversy over the safety of the long-
term, regular use of salbutamol and other beta2-selective bronchodilators arose later.
This is discussed in Section 4.4.2 in this chapter.
Figure 4.2: Structure of Catechol
OH
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4.3. Beclomethasone Dipropionate Inhaler (BDP Inhaler)
The next project for the Allen & Hanburys' researchers after the discovery of
salbutamol was the search for an anti-inflammatory agent to ease the inflammation
inside the airways of asthma patients, which is another main cause of asthma. They
focused on glucocorticoids, a group of anti-inflammatory steroid hormones, which
are often called just "steroids." (Jack 1996, 7)
The clinical value of glucocorticoids as anti-inflammatory agents was generally
known after a report that Philip Hench at the Mayo Clinic in the US had successfully
used cortisone, one of glucocorticoids, for the treatment of rheumatoid arthritis in
1948 to 1949. (Hench et al. 1949; Sneader 1985, p. 222) Cortisone was at first
presented as a "miracle cure" because of its drastic anti-inflammatory action. As a
consequence, Hench and his colleague, Edward Kendall won the Nobel Prize in 1950.
Shortly after this, however, the reputation of cortisone began to decline partly
because it was found that cortisone also causes serious side effects due to its multiple
activities at the various parts of the body, and partly because its supply was limited
and its price was too expensive. (Le Fanu 1999, pp. 22-23) Much politics ensued
involving in rheumatologists, governments, funding organizations, pharmaceutical
companies and patients before cortisone was established as a drug. (Marks 1992;
Cantor 1992) Development of other applications, especially dermatological,
ophthalmologic and anti-asthmatic uses restored and even enhanced the usefulness of
cortisone. Many of these applications were topical uses, in which side effects were
less significant. (Le Fanu 1999, pp. 23-26) In the 1950s, several analogues of
cortisone were synthesized, aiming at enhancing potency and selectivity on
glucocorticoid receptors rather than mineralocorticoid receptors: fludrocortisone by
Squibb, prednisone and prednisolone by Schering (US), methylprednisolone by
Upjohn, triamcinolone by Lederle, dexamethasone by Merck and betamethasone by
Schering (US). The selectivity of glucocorticoids was important because their
binding with mineralocorticoid receptors causes unwanted side effects. Thus,
Dexamethasone and betamethasone, both ofwhich were marketed in the late 1950s,
were more potent and more selective than their predecessors, for example,
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prednisolone, which had been introduced in the mid-1950s. (Sneader 1985, pp.223-
226)
The application of cortisone for the treatment of asthma was reported as early as
1950. (Carey et al, 1950) However, the problem of how to reduce systemic side
effects prevented the application of cortisone and its analogues for the long-term
treatment of asthma except in severe cases. (Wilcox and Avery 1973, 85, 88)
Inhalation of corticoids had been tried since 1951 but these trials did not bring good
results even when dexamethasone, a strong glucocorticoid, was used. Systemic side
effects were observed at effective dosage levels of the drug. (Morrow Brown, Story
and George 1972, 585; Lai et al. 1972, 315; Editorial, The Lancet 1977, 2, 695) In
the 1960s, the topical application of corticoid derivatives, such as triamcinolone
acetonide (Sneddon 1976, 193) and betamethasone valerate (Williams, et al. 1964),
to skin diseases was successfully introduced. Based on these successes, around 1966,
the application of such topical anti-inflammatory steroids inside the airways by
inhalation was proposed within the Glaxo group by Wilfred Simpson at Allen &
Hanburys and by Gordon Philips and Eric Snell in Glaxo Laboratories,
independently. (Jack 1996, 7)
Glaxo had many years experience in manufacturing cortisone and its analogues.
(Davenport-Hines and Slinn 1992, pp.186-190, p.196; Elks and Phillipps 1985, pp.
176-179; Sneader 1985, p.223) Research on glucocorticoid had also been conducted
in the Glaxo group. Betamethasone valerate, one of the successful topical
glucocorticoids, was synthesized there. Following this, Glaxo researchers
synthesized a new glucocorticoid called beclomethasone dipropionate in 1964.
(Caldwell et al. 1968; Fukai 1988, pp.549-550) These experiences and the
consequent knowledge, skills, facilities and other material resources possessed,
individually and collectively, by the organization, probably played a significant role
in connecting the needs of anti-inflammatory agents in asthma treatment with the
idea ofusing topical glucocorticoids by inhalation.
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The proposal to use topical glucocorticoids by inhalation, however, posed several
questions: Would the bronchial mucosa resemble the skin in being sensitive to their
anti-inflammatory action? Would the treatment favour the spread of infection in the
lung? Would it cause all the kinds of side effects associated with glucocorticoids?
(Jack 1990, 9; Jack, interview) Anti-inflammatory activity of glucocorticoids was
(and is still) not fully understood. (Jack 1998, p. 159; Le Fanu 1999, p.28) Tests in
animals and in humans played a key role in the selection of glucocorticoids for use in
asthma. In the case of the use of glucocorticoids on the skin, there was an established
test called the McKenzie skin-blanching test (McKenzie and Stoughton 1962), which
was found to give sufficiently accurate forecasts of clinical potency because it used
humans themselves without hurting them. (Elks and Phillipps 1985, p. 176; Jack
1998, p. 159) However, it was questionable whether this was relevant to their use
inside the airways by inhalation. Despite these uncertainties, Jack and his colleagues
went ahead. They chose beclomethasone dipropionate (BDP) as an inhaled steroid,
because it was more potent than betamethasone valerate and relatively limited in
systemic activities. The topical anti-inflammatory activities were measured with the
McKenzie and Stoughton skin-blanching test, and the researchers believed that the
test also represented the activity inside the airways. The systemic activities were
measured through suppression of early-morning plasma Cortisol levels in volunteers.
The weakness of systemic activities ofBDP was later explained by its inactivation
due to oxidation in the liver during first pass metabolism. (Caldwell et al. 1968, 111-
112; Jack 1998, pp. 159-161) Then, they tested the drug in dogs. Six months of
administration ofBDP by mouth and by inhalation made the dogs develop a
condition similar to Cushing disease, in which there is too much secretion of
hydrocortisone. However, at the end of the experiment, the lungs of the dogs were
found to be normal, and infection had not been a problem. They were encouraged by
the results to proceed to human trials. (Jack 1990, 9) Clinical trials in humans
produced favourable results. (Morrow Brown, Storey and George 1972; Clark 1972;
Lai et al. 1972) Beclomethasone dipropionate inhaler was marketed in 1972 and
became one of the major treatments of chronic asthma during the 1980s and 1990s.
(Jack 1990, 9; Jack 1998, pp. 159-160)
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4.4. Salmeterol
4.4.1. Discovery and Development of Salmeterol
With the launch of salbutamol in 1969 and ofBDP inhaler in 1972, Glaxo obtained a
combination of drugs against the two major causes of asthma: constriction of the
airways and mucosal inflammation inside them. However, once the two drugs solved
the initial problems - the treatment for the two causes on a basic level - a new set of
problems on a higher level appeared.
Salbutamol had several problems. First, its duration of action, 3-4 hours is too short
to prevent worsening of asthma during the night. The level of adrenaline in the blood
drops during the night, and asthma patients often suffer severe attacks when this
happens. (Jack 1998, p. 144; Jack interview) Second, a number of P-stimulants such
as terbutaline, fenoterol and pirbuterol were marketed after salbutamol and
competition in the area became severer. Terbutaline, discovered and developed by
Astra in Sweden, was the most powerful rival. (Sneader 1985, pp. 104-105; Jack
interview) Third, a 12-year delay in its launch in the US lessened salbutamol's
competitive advantage in the new important market. (Jack 1991, 504) In addition, the
patents of salbutamol were getting close to their expiration. (Jack interview)
Jack and his colleagues tried to discover a better orally active P-stimulant during the
1970s. They also tried to find a better bronchodilator based on other physiological
mechanisms. However, they failed in both. (Jack 1998, p. 144; Jack 1991, 504; Jack
interview) Furthermore, Jack and some of his colleagues were at the time involved in
two other big projects: H2 antagonists and 5-hydroxy-tryptamine (5HT, serotonin)
related agents. (See Section 5.3. Ranitidine; Jack 1989, 182; Jack interview)
Therefore, it was in 1981, the year when a conference was held in Boston to promote
salbutamol in the US, when Jack had to think about the future ofbrochodilators, and
he "concluded that the desired drug would have to be given by inhalation if side
effects were to be avoided and would have to be much longer acting than salbutamol
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and similar P2-agonists to prevent nocturnal attacks of asthma." (Jack 1998, p. 144;
Jack 1991, 504-505)
Jack then considered how the prolongation of action might be achieved with an
inhaled P-stimulant. The target duration of action was at least 8 hours to prevent
nocturnal asthma worsening. (Jack 1998, p. 145) He considered two ways of
prolonging duration. One was to make a drug which would be more slowly absorbed
from the bronchi. The other was to make a drug which sticks firmly at its site of
action in the receptor protein and remains efficacious for a long time. He chose the
latter approach because it "was simpler and seemed more likely to work." (Jack 1991,
505) The hypothesis for achieving this was to keep the ring structure of a P-stimulant
molecule with high affinity for the adrenaline binding site in the receptor protein, and
to make a large flexible non-polar side chain to ensure selectivity of action and to
anchor the drug with the receptor protein. (Jack 1996, 10; Jack 1998, p. 145)
Jack believed that there were two types of agonism: in type 1 agonism the affected
cells were capable of responding continuously to continuing stimulation, whereas in
type 2 agonism the cells, having responded to an effective stimulus, must recover
before it can respond to another. (Jack 1977; Jack 1991, 504) He also believed that
adrenergic agonism must belong to type 1 agonism because adrenaline remains
efficacious despite being continuously present in the extra-cellular fluid. (Jack 1998,
p. 145) Although his classification of agonism seems not to have been generally used
in academic literature, it did lead him to the search for a better p-stimulant. (Jack
1991, 504)
Based on this thinking, Jack commenced the research project in 1981. However,
some of his colleagues were doubtful about the approach, because there was a large
amount of literature (E.g. Conolly et al. 1971; Jenne 1977; Greenacre, Schofield and
Conolly 1978; Plummer 1978; Harden 1983, 25) on desensitisation of P-receptors
exposed to P-stimulants for a long time and reports of tolerance to P-stimulants in
patients. (Jack 1991, 505; Jack 1998, p. 145) On the other hand, there were some
studies (Larsson, Svedmyr and Thiringer 1977; Peel and Gibson 1980; Shepherd,
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Henzel and Clark 1981) that did not find the tolerance to P-stimulants by regular use
of them. Persuading the doubtful researchers was not practical because scientific
controversy over the issue obviously existed: "The only way to settle the matter was
to find and test the desired drug." (Jack 1991, 505) Jack, as the research director,
showed his leadership by insisting that they test his hypothesis. He put it:
[Some colleagues] said, "You're wasting your time, David." ... How did I
persuade them? I told them to do it. (laugh) But then when they found that
what I was saying was not mad, it then became theirs. But at the beginning I
had to tell them to do it. (Interview)
Larry Lunts, who was the originator of salbutamol and responsible for chemistry in
the new project, decided to seek the required drug in analogues of salbutamol with
increasingly large non-polar side chain, based on Jack's hypothesis. The rates of
onset and offset of action of these analogues were measured using guinea pig
tracheal muscle. Interest in the team rose sharply when it was found that this
preparation was not easily desensitised by continuous superfusion with isoprenaline
or other P-stimulants, and that the rates of onset and offset of action of the analogues
varied considerably. These findings supported Jack's hypothesis. The researchers
who had at first doubted the idea became convinced that it would work. By
painstaking optimisation, they succeeded in finding salmeterol, a selective, very long
acting (more than 12 hours) P-stimulant with a long non-polar side chain, in 1984.
(Jack 1998, p. 146; Jack interview; Bradshaw et al. 1987; Ball et al. 1987; Brittain,
Jack and Sumner 1988; Ball et al. 1991) The potency, the duration of action and the
safety of salmeterol were confirmed in clinical trials. (Britton et al. 1992; Brogden
and Faulds 1991; Jack 1998, pp. 163-166) It was also suggested that the unusual
effectiveness of salmeterol might be due in part to its anti-inflammatory activity in
the airways. (Twentyman et al. 1990; Butchers, Vardey and Johnson 1991; Whelan
and Johnson 1992) Salmeterol was marketed in 1992. (Jack 1996, 12)
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4.4.2. Salmeterol and the (3 Stimulant Controversy
When salmeterol was marketed, there was a hostile atmosphere to regular use of (3-
stimulants. (Jack 1996, 12; Jack 1998, pp. 162-163) There had been a long lasting
controversy over regular, long-term use of P-stimulants. {Lancet editorial 1990;
Lofdahl and Svedmyr 1991; Chung 1993; Sears and Taylor 1994; Boulet 1994;
Crane et al. 1995; Ernst 1998) After the high incidence of death during the use of
isoprenaline aerosol, doubt arose over tolerance to P-stimulants during the long-term,
regular use of P-stimulants. Some researchers concluded that the mortality was due to
the side effects on the heart by overdose of isoprenaline, a nonselective P-stimulant.
(Greenberg 1967) However, other researchers thought that it might be due to the
resistance to P-stimulants which was built by their regular use. (Conolly et al. 1971;
Jenne 1977; Greenacre, Schofield and Conolly 1978; Plummer 1978; Harden 1983,
25) There were also studies which supported regular use of P-stimulants. (Larsson,
Svedmyr and Thiringer 1977; Peel and Gibson 1980; Shepherd, Henzel and Clark
1981; Harvey and Tatterfield 1982) They could not reach a consensus because
differences in test situations such as in vivo versus in vitro (Shapherd Henzel and
Clark 1981 vs. Greenacre, Schofield and Conolly 1978) and normal subjects versus
asthma patients (Holgate, Boldwin and Tatterfield 1977 vs. Harvey and Tatterfield
1982) made the controversy more complicated. However, this controversy might
have faded out had it not been for the incidence of a sharp increase of asthma
mortality in New Zealand from the mid 1970s. (Taylor and Sears 1994, 261-262)
The "epidemic" of asthma mortality since 1977 was internationally reported in the
early 1980s. (Jackson et al. 1982; Grant 1983) The medication was suspected as its
cause early on: at first, combined treatment with oral theophylline and P-stimulants,
and then P-stimulants themselves. (Grant 1983) In 1989, the first case-control study
on the relationship between the regular use of P-stimulants and asthma mortality by
researchers at Wellington School ofMedicine (New Zealand) was published. (Crane
et al. 1989) The authors claimed that use of fenoterol, a powerful P-stimulant
developed by Bohringer Ingelheim, by inhaler increased the risk of death in asthma.
This study was criticised by several groups in terms of both methodology and
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interpretation. (O'Donnell et al. 1989; Buist et al. 1989; Sacket, Shannon and
Brownman 1989; Poole, Lanes and Walker 1990) The two important points of
criticism were whether the regular use of fenoterol was the main cause of asthma
mortality or just the marker of fatal asthma, and whether the relationship with asthma
mortality was limited to fenoterol or a general problem for P-stimulants as a class.
TheWellington group conducted further case-control studies because of this
criticism, but the results supported their original arguments: it was regular use of
fenoterol that caused the epidemic in New Zealand. (Pearce et al. 1990; Grainger et
al. 1991) Other researchers also supported this and suggested that it might be due to
the very large dose and the lesser beta2 selectivity of fenoterol. (Wong et al. 1990;
Lancet editorial 1990; Lofdahl and Svedmyr 1991)
One major opposing group of the Wellington study was researchers at Bohringer
Ingelheim, the manufacturer of fenoterol, (Staudinger and Haas 1992a; Staudinger
and Haas 1992b; Schuijt and Staundinger 1995) and advisory researchers of the
company. (Buist et al. 1989; Spitzer and Buist 1990; Spitzer et al. 1992; Suissa et al.
1994) The advisory researchers conducted their own large-scale case-control studies
in Canada. (Spitzer et al. 1992; Suissa et al. 1994) Although they admitted that there
was strong correlation between the regular use of fenoterol and asthma mortality,
they claimed that fenoterol might be a marker of severe asthma because it tended to
be prescribed for that due to its high potency, and that there were no significant
differences in selectivity between fenoterol and other P-stimulants, particularly
salbutamol, but overdose of P-stimulants might cause the serious side effects.
According to them, fenoterol was prone to be overdosed because its originally
recommended dose was larger than that of salbutamol despite its relative potency in
beta stimulation. They insisted that p-stimulants were safe when they were used
properly, and that P-stimulants should be used with glucocorticoids to control
inflammation inside the airways because this could not be done by P-stimulants.
Some other researchers shared their view. (Blauw and Westendrop 1995; Wanner
1995)
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Another major opposing group of the Wellington study was Malcolm Sears and his
colleagues at University ofOtago Medical School, who claimed that although the
relationship between regular use of P-stimulants and asthma mortality was causal,
this was not limited to fenoterol alone but was potentially applicable to any other [3-
stimulant, including salbutamol and salmeterol. They insisted that asthma mortality
was not due to cardiac side effects of less selective P-stimulants but due to worsening
asthma caused by regular use of P-stimulants. (Sears et al. 1990; Sears and Taylor
1992; Sears et al. 1992; Taylor et al. 1993; Taylor and Sears 1994; Sears and Taylor
1994; Sears 1995)
The argument by Sears and his colleagues caused further debate because it claimed
that all p-stimulants should not be used regularly and that emerging longer acting p-
stimulants such as salmeterol might have the same risk as regular use of short acting
P-stimulants. Several researchers supported their view. (Crompton 1991; van
Schayck et al. 1991) On the other hand, there were also several critics, including the
Wellington group and researchers at Glaxo, of the generalisation of the results from
fenoterol to P-stimulants as a class. (Palmer and Jenkins 1991; Dahl 1991; Crane et
al. 1991; Clark 1991; Chapman Kesten and Szalai) In particular, researchers at Glaxo,
based on their post-marketing clinical studies of salmeterol, strongly opposed the
claim of the Otago group that salmeterol might exacerbate asthma. (Jenkins et al
1991; Shepherd, Jenkins and Alexander 1991; Castle et al. 1993) Sears' group,
William Inman at the Drug Safety Research Unit, which was conducting a post¬
marketing surveillance study of salmeterol, and two other groups argued that Glaxo's
study underestimated mortality of asthma related to salmeterol. (Inman 1993;
Bunney 1993; Crompton 1993; Sears and Taylor 1993) The Glaxo researchers
defended themselves. (Fuller et al. 1993) However, the guidelines on the
management of asthma issued by the British Thoracic Society in 1993 showed a
cautious attitude about regular use ofbronchodilators, especially, salmeterol. It
advised that regular use of bronchodilators should come after high dose inhaled
steroids and that long-acting bronchodilators like salmeterol should be used for more
serious cases only, because of the uncertainty about regular use of bronchodilators.
(The British Thoracic Society 1993, pp. S4-S5, pp. S10-S11, p. S18)
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There was another strand of the (3-stimulant controversy. Jeff Garnett and his
colleagues at Green Lane Hospital in Auckland, New Zealand, insisted that
increasing financial barriers to primary health care against a background of social
and economic decline were likely to have contributed to asthma morbidity and
mortality in New Zealand. They also argued that the reduction in asthma mortality in
the 1980s was mainly due to an improvement in utilisation of hospital services, and
that the further reduction in asthma mortality since 1989 would be best explained by
increase in use of inhaled steroids and by improvement in management of asthma,
that is, more careful treatment for asthma. (Garnett et al. 1995) Both the Wellington
group and the Otago group opposed this view and argued that the socio-economic
factor was not the main cause but regular use of fenoterol (or P-stimulants) was.
(Crane et al. 1995; Taylor and Wong 1995) On the contrary, there were also studies
which strongly doubted the relationship between use of P-stimulants and death from
asthma. (Mullen, Mullen and Carey 1993)
The P-stimulant controversy seemed to be fading in the late 1990s. This decline may
be partly because the "epidemic" in New Zealand ended, partly because
simultaneous use of P-stimulants and inhaled steroids provided every party involved
in the debate with a satisfying answer in practice, and partly because long-term
clinical trials of long acting P-stimulants, especially salmeterol and formoterol, did
not find exacerbation of asthma when they were used with inhaled steroids. The end
of the New Zealand "epidemic" of asthma death, in fact, led to another debate. The
Wellington group sought the cause of reduction ofmortality from the withdrawal of
fenoterol. (Pearce et al. 1995) Researchers at Bohringer Ingelheim and the advisory
researchers of the company argued that the cause was due to advances in patient
education and adequate anti-inflammatory treatment. (Schuijt and Staudinger 1995;
Ernst and Suissa 1995) As mentioned above, Garnett and his colleagues emphasized
the socio-economic factor as one of the major cause of the reduction. (Garnett et al.
1995) However, this debate was less heated. It is probable that the end of the
epidemic was less interesting for researchers than its outbreak.
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The second factor which probably contributed to the quasi-closure of the debate was
that there was a consensus over the practical problem of how to manage asthma:
simultaneous use of P-stimulants and inhaled steroids. Almost all researchers
recognised and often argued that inhaled steroid should be used to treat airway
inflammation, which causes asthma symptoms. Therefore, they would not oppose
concurrent use ofP-stimulants and inhaled steroid. In fact, most of them did promote
the treatment. (Crane et al. 1995; Lancet Editorial 1990; Staudinger and Haas 1992a;
Ernst and Suissa 1995; Sears et al. 1992; van Schayck and van Herwaarden 1993;
Rees 1991; Chung 1993; Heino 1994; Boulet 1994; Greening et al. 1994; Woolcock
et al. 1996; van der Molen 1996; Wilding et al. 1998; Jack 1998) The British
Guidelines on Asthma Management and its Japanese counterpart also adopt this
treatment. (The British Thoracic Society et al. 1997; Makino, Koshou and Miyamoto
eds. 1998, p. 69)
The third plausible factor in the decline of the controversy was the accumulated
results of the use of long acting P-stimulants. In 1994, another long-term study of
salmeterol, supported by Glaxo, showed that there was no evidence that regular use
of salmeterol contributed to asthma exacerbation, when using it with BDP. (Greening
et al. 1994) The Drug Safety Research Unit, which had initially opposed Glaxo's
results, also stated that there was no evidence that salmeterol contributed to the
deaths from asthma, after completing the study. It explained that its early
overestimation of asthma mortality in patients using salmeterol was due to the
assumption that deaths would be evenly distributed throughout the study, which was
not the case because 39 of the 73 deaths occurred in the first seven months of 25
month long study. (Mann 1994) Based on these studies, the British guidelines on
asthma management revised in 1995 and issued in 1997 showed a somewhat more
favourable attitude to salmeterol. It was recommended that low dose inhaled steroids
plus salmeterol be regarded as an alternative in step 3 treatments, while the former
guidelines placed the drug after step 4 treatments, which is for more severe asthma.
(The British Thoracic Society et al. 1997, p. S2, p. SI 1) Several studies supported the
safety of salmeterol. (Woolcock et al 1996; Wilding et al. 1997) A study on
formoterol, another long acting P-stimulant developed by Ciba-Geigy, also claimed
100
that its use with inhaled steroids improved patients' condition, (van der Molen et al.
1996) There were also studies warning that use of salmeterol might cause
subsensibility to salbutamol (Grove and Lipworth 1995), and that use of salmeterol
could delay recognition of increasing airway inflammation. (Mclvor et al. 1998)
However, the attitude to salmeterol seems to have become less hostile recently. In
1997, sales of salmeterol for the first time became more than those of salbutamol.
Despite this, it is important here to notice that the P-stimulant controversy obviously
limited the sales of salmeterol. (Ernst 1998)
4.5. Fluticasone Propionate
Although inhaled BDP was found to be an effective and generally safe treatment for
asthma, it had significant systemic side effects when used in high dosage. Because of
this and because the patents for inhaled BDP, like those of salbutamol, would expire
in less than 10 years, Jack was forced in the early 1980s to consider how it might be
replaced by a superior drug. What was required was an inhaled glucocorticoid with
more intense anti-inflammatory activity than inhaled BDP in the airways but devoid
of systemic side effects at therapeutic dosage. He consulted the Glaxo list of
potential topical glucocorticoids and chose fluticasone propionate as a candidate.
(Jack interview and personal communication) In the early 1980s, G. H. Phillipps at
the company discovered this during an unsuccessful search for a topical steroid
which did not cause skin thinning. (Dutch patent application 81 00707, 1981; US
patent 4335121, 1982; Jack personal communication) Fluticasone propionate had
been shown to be about twice as active as BDP in the McKenzie and Stoughton skin-
blanching test in humans but almost inactive after oral administration in rats and
mice. (Phillipps 1990; Jack 1998, 160; Jack personal communication)2 The
compound was later found to be similarly inactive orally in humans and the reasons
for this was attributed to the first pass hydrolysis in the liver into two inactive
fragments. This lack of oral activity was favourable for the treatment of asthma,
2 The intense skin-blanching activity was significant because it indicates tight binding of the steroid to
its receptor protein and, therefore, high topical anti-inflammatory activity. Oral inactivity in mice was
unusual because that species is extremely sensitive to glucocorticoid steroids. (Jack personal
communication)
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because part of the inhaled drug absorbed from the gut would not cause unwanted
systemic side effects. (Jack 1998, pp. 160-162; Jack personal communication)
Fluticasone propionate was thus chosen for clinical trials and shown to be twice as
active, on a weight basis, as BDP and at least as safe as BDP in asthmatic patients.
(Lundback et al. 1993; Barns et al. 1993; Holliday, Faulds and Sorkin 1994) It was
also reported that treatment with fluticasone propionate was less associated with
reduction in leg growth velocity in children than that with BDP, which implied less
systemic effects of fluticasone propionate. (Wolthers and Pederson 1993) The high
potency of fluticasone propionate was explained by its persistent binding to the
glucocorticoid receptor protein. (Hogger and Rohdewald 1994) Fluticasone
propionate was marketed in 1994 and became a very successful inhaled steroid. (Jack
1998, p. 162)
Thus, the combination of salmeterol and fluticasone propionate became a successor
to that of salbutamol and BDP. By analogy with the game of poker, Jack compared
each combination to a "full house" consisting of a selective beta2 stimulant
(equivalent to two of a kind) and a topical glucocorticoid steroid (equivalent to three
of a kind). Both are a "full house" but the former is a better one. However, this idea
was not intended from the beginning but emerged and evolved in the research and
development process. Jack put it:
Jack: And don't forget that a full house is a good hand, but is not the best
hand in poker. Similarly these combinations are unlikely to be the best hand
for asthma. Better treatments are likely to be discovered.
Hara: Did you aim at a full house?
Jack: Not at the beginning. All of this happened with increasing
understanding of the problem. One profound thing that not everybody knows
is that we think with what we know. As years go by and one "lives" with
asthma, knowledge and, with it, understanding becomes more and more,
increases and increases, and the way you think is correspondingly changed.
OK? (Interview)
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4.6. Procaterol: A Beta-Stimulant Made in Japan
Otsuka Pharmaceutical in Japan began its research on adrenergic drugs in 1971. Until
then, the company had mainly been a manufacturer of nutritional preparations for
clinical uses and over-the-counter (OTC) products. (Otsuka 1999, p.32) A little time
before the establishment of its own laboratories, the company planned to
manufacture an existing [3-blocker, which was at that time a new type of drug.
However, the supply of a key material was stopped by the parent company of the
supplier and the plan failed. When Otsuka decided to start their own research,
therefore, they chose a (3-blocker as their first target. (Miwa, interview3)
A research team at Otsuka Tokushima Laboratories led by Kazuyuki Nakagawa
started research on P-blockers in January 1972 and, one month later, succeeded in the
discovery of a P-blocker, cartelol. (Nakagawa et al. 1974; Nakagawa interview) This
was the first product of their research and was marketed in 1980. In the synthesis,
they chose pindolol, which was synthesized by a Swiss company, Sandoz, in 1964
(Saameri 1967; Hill and Turner 1969; Fukai 1988, p.232), as the lead compound.
This was because there had already been a lot of analogues of propranolol whereas
pindolol analogues seemed less exploited. (Nakagawa, interview) They tried to
replace an indole group of pindolol structure and chose a dihydrocarbostyril group,
partly because it has a proton which an indole group also has, and partly because it
has a shape as if the side chain of acetaminophen were cycled, which seemed to be as
active as acetaminophen but less toxic than it. This approach was found to be
successful, and Nakagawa and his colleagues were able to find compounds which
blocked p-receptors. (Nakagawa, interview) At least 45 derivatives were synthesized
and cartelol was chosen as a drug. (Nakagawa et al. 1974)
Beta-blockers, which attach to beta-adrenergic receptors but do nothing to them, and
P-stimulants, which also attach to the receptors and stimulate them as if they were
adrenaline, are clinically opposites but chemically very similar. This means that if
3 This interview with Dr Kazuyuki Nakagawa, the former head of chemical research, Mr. Hideyuki
Miwa, the director of research and development, and Mr Shinya Tashiro, the respiratory group leader
in the development department was conducted on 9 November 1999.
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cartelol is effective as a (3-blocker, there may be an effective [3-stimulant among its
analogues. Additionally, cartelol was found to be well distributed to the trachea. This
property was advantageous as a bronchodilator. Based on these ideas, they started the
research on P-stimulants in April 1973. Although the research was temporally
suspended because the researchers had to support the development of cartelol, it did
not take a long time for them to find a P-stimulant. The search for a P-stimulant was
relatively easy, according to Nakagawa. This was because they already had the basic
structure, a dihydrocarbostyril group, the same as cartelol, and it was the side chain
that had to be devised. (Nakagawa, interview) There were several effective (3-
stimulants at that time. Shiro Yoshizaki, the project leader, and his colleagues at
Otsuka examined these existing P-stimulants, for example isoprenaline, salbutamol,
terbutaline and isoetharine, and synthesized a series of compounds with carbostyril
and dihydrocarbostyril groups. (Yoshizaki et al. 1976; Nakagawa, interview) Despite
the interruption, they found a highly potent compound as early as February 1974.
This was the ninth compound in the research. This compound, with a carbostyril
group and an isoetharine-type side chain, was at first named OPC-2009. After the
synthesis ofOPC-2009, the researchers continued to make various derivatives partly
because there might be a better one, and partly because it was needed to ensure
sufficient patent coverage so that rival companies could not make similar compounds
to compete against Otsuka's one. By April 1974, they had synthesized about 50
compounds. About 30 of them had strong P-receptor stimulating activity, and two of
them were considered as the final candidates for development: OPC-2009 and OPC-
2030. (Nakagawa, interview; Takayanagi et al. 1977)
OPC-2009 was more active than OPC-2030, but its activity on the heart was also
stronger than that of OPC-2030. As a result of discussion among researchers and
staff in charge of development, OPC-2009 was eventually chosen. It was said that the
opinion of Akihiko Otsuka, the then Tokushima Plant Manager who also led the
laboratories, had a strong influence on the decision. Otsuka was a member of the
owner family of the company and later became its president. The reason for the
choice was that it was probably better that the efficacy was outstanding for clinical
trials and for marketing. However, this was a subtle problem. Nakagawa put it:
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It was very hard question. Ifwe had chosen OPC-2030 and had failed,
nobody would have known how different the results would have been ifwe
had chosen OPC-2009. This is because there was just one chance. ...
Japanese people then had, perhaps still have, a tendency to prefer mild drugs
with fewer side effects to very potent drugs with some side effects. Therefore,
OPC-2030 might have been successful. (Nakagawa, interview)
According to Nakagawa, there were few organizational obstacles in the development
ofOPC-2009, now renamed procaterol, because there was only one other project.
The main obstacles were more technological ones. These occurred in the
development of the tablets and the inhaler of the drug. Procaterol was easily soluble
in water and this property was convenient to make a variety of preparations.
However, because the drug was so active, it was necessary to ensure that each tablet
or puff of inhaler equally contained a specific, very small amount of drug. There
were two major technological problems there. One was to achieve this equality, and
the other was to measure the equality. They made a considerable effort to solve these
problems and were able to cope with them. In particular, the establishment of liquid
chromatography in the 1970s helped the solution of the latter problem. Another
problem was the interaction between the drug, and a very small amount ofwater or
impurities contained by diluents, packaging materials and components of inhalers.
Collaboration with suppliers of various materials was important. (Nakagawa,
interview)
The next problem in the development of procaterol was how to proceed to clinical
trials because the company had little experience in clinical trials for a new drug.
They asked Yuichi Yamamura, a professor at Osaka University and an authority on
the immunology and allergology in Japan, to be the chairman of the clinical trial
committee of procaterol. Yamamura accepted it and organized the committee. (Miwa,
interview) Otsuka's staff described this process:
Miwa: It was very important to ask Professor Yamamura to organize the
clinical trials.
Tashiro: Yes. When we asked doctors for clinical trials for the first time,
they often declined because they did not believe the drug which was made by
Otsuka, a maker of nutritional preparations. But when they found the
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organizer of the clinical trials was Professor Yamamura, they changed their
attitude and accepted us. ... Professor Yamamura also asked directly some
doctors for cooperation, saying as "Ten [patients] for you." Without this
strong leading of Professor Yamamura, it would have taken much more to
complete the clinical trials. (Interview)
Pharmacological tests of procaterol with animals started in April 1974, and showed
that procaterol was more potent, more selective and longer acting than salbutamol.
(Yabuuchi, Yamashita and Tei 1977; Himori and Tira 1977) Clinical trials began in
January 1976. Phase I, tests in healthy people, finished in June 1977. Phase II, trials
in patients, started in August 1976 and finished in November 1978. Meanwhile,
Phase III, which included double blind tests, was conducted from January 1977 to
July 1978. Here, again, salbutamol was used in comparison and procaterol was
shown to be more potent and longer acting. (Yagura et al. 1979; Shida et al. 1979)
This considerable overlapping of different phases of clinical trials was common in
Japan at that time. They applied for approval for manufacturing of the drug in
December 1978 and this was approved in October 1980. (Nakagawa, interview)
Procaterol was marketed in Japan in the same year. This drug was also tested
clinically in the US and some other countries, which supported the efficacy and
safety of the drug. (Zenetti, Rotman and Dresner 1982; Crowe, Counihan and
O'malley 1985; Siegel et al. 1985) A comparative study of procaterol and salbutamol
did not identify difference in potency and safety between the two (Crowe, Counihan
and O'malley 1985), whereas another study supported that procaterol was longer
acting (8 hours). (Siegel et al. 1985)
After its launch the marketing staff ofOtsuka had the problem of differentiating
procaterol from existing P-stimulants. Shinya Tashiro explained the strategies for its
promotion:
In the early marketing, making the characteristics of the drug clear was
essential. We regarded salbutamol as a main rival, because it was at the time
the best selling P-stimulant in Japan. First, we emphasized the higher
selectivity of procaterol. We said that the drug was more beta2 selective and
had fewer effects on the heart than existing others. Second, it was longer
acting. Because asthma fits often occur at rising in the morning, they will be
avoided if the duration of action is long enough. Another point was that the
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drug was said to have an anti-allergy activity. I heard that this was the first p-
stimulant which had such activity. Then, Professor Kazuhiko Ito at Nagoya
University suggested that this was the first one of the third generation P-
stimulants, whereas isoprenaline belonged to the first generation and
salbutamol belonged to the second generation. This was the strongest help in
the marketing. (Tashiro, interview)
Kazuhiko Ito at Nagoya University classified P-stimulants into three generations. The
first-generation drugs, including isoprenaline, were short acting and not beta2
selective. The second-generation drugs such as salbutamol were more beta2 selective
and longer acting. The third-generation drugs, in which procaterol was included, had
the strongest beta2 selectivity and the longest duration of action of the three
generations (eight hours or longer). (Kawai, Kawakatsu and Takeyama 1987) This
classification made salbutamol in the second generation sound obsolete in
comparison with procaterol in the third generation.
Another aspect of the post-marketing promotion of procaterol was the development
of a variety of administration forms. They marketed smaller tablets, granules and
syrup of the drug mainly for younger patients in October 1982. (Shiota et al 1981;
Baba et al. 1981) They also added aerosol, aerosol for children and inhalation
solution of procaterol in June 1987. (Hamada et al. 1986; Mikawa et al. 1986) As a
result, procaterol had the largest variety of preparations in p-stimulants available in
Japan. This was important because the variety of asthma patients is also high: from
babies to old people. Variety of preparation gives doctors flexibility of treatment.
Therefore, Japanese practitioners welcomed the rich variety of procaterol, according
to Tashiro. (Tashiro, interview) This development of additional forms of procaterol
also helped to maintain the sales of the drug. (Miwa, interview) In Japan, the
government have regularly revised prices of drugs and the prices in general have
been gradually decreasing. (Campbell and Ikegami 1998, p. 158) The price of
procaterol also has decreased up to almost half of the original price of nineteen years
ago. The drug had sales ofmore than 13 billion yen in 1998, but they consisted of 3.9
billion yen sales of its tablets, 1.7 billion yen of its mini tablets, 2.7 billion yen of
syrup, 4.4 billion yen of its aerosol, and so on. (Tashiro, interview)
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In fact, procaterol was such a success in the Japanese market that it outsold
salbutamol, the best selling |3-stimulant in the world. The sales of salbutamol in
Japan were about 40 % of those of procaterol. (GlaxoWellcome (Japan), internal
documents) Two reasons for this have already been mentioned. First, procaterol was
more potent and longer acting that salbutamol. Second, procaterol had a variety of
forms. It should be noticed that both doctors and patients traditionally preferred oral
medicines to inhaled medicines in Japan. Both were accustomed to the former. In
addition, the latter needed a doctor's instruction to patients about how to use inhalers.
Doctors were unwilling to do this under the notoriously busy situation described as
'three minute consultation,' according to Mike Nakayama, the product manager at
GlaxoWellcome (Japan).4 Third, in European countries and the United States,
doctors preferred salbutamol because its efficacy and safety were recognized through
its long-term use and because it was cheaper. On the contrary, under the traditional
health care system in Japan, doctors tended to prefer new drugs because they
benefited doctors and hospitals from a bigger gap between the reimbursement price
and the real price they paid and because they were usually better than older ones.
Finally, Glaxo in Japan, strategically, did not put stress on the marketing of
salbutamol, because its market size was relatively modest compared with other
products of the company. Even in the respiratory drug area, the company put more
stress on inhaled steroids. (Nakayama interview) Salmeterol has not yet been sold in
Japan at present.
4.7. Discussion
4.7.1. Normal-scientific Discovery and Reverse Salient
Compared with the discovery of propranolol discussed in the previous chapter, the
discovery of salbutamol and that of inhaled BDP can be regarded as a normal-
scientific discovery rather than a paradigmatic discovery. Isoprenaline, a non¬
selective P-stimulant which had actually been used as a bronchodilator, and
prednisolone and other glucocorticoids which had actually been used for the
4 This interview withMrMike Nakayama was conducted on 24 March 2000.
108
treatment of asthma, were already in use. Neither discovery contradicted any existing
major theory. Major problems in research on them were clear: enhancement of the
potency, improvement of the selectivity, and extension of the duration of activity.
Selectivity in P-stimulants and glucocorticoids is very important because this leads to
reduction in side effects. Beta stimulants mimic adrenaline and glucocorticoids
mimic Cortisol. Both adrenaline receptors and glucocorticoid receptors are widely
distributed in the body. Non-selective or poorly selective drugs will act on all
receptors of the same kind in the body and cause various responses of the body. This
is one of the major causes of side effects of these drugs. In the case of
glucocorticoids, in addition, some of them significantly act on mineralocorticoid
receptors as well. Duration of activity is also very important, because patients cannot
have a sound sleep and wake up feeling good if duration of activity is not long
enough. In particular, asthma tends to worsen during the night and its morning fits
may be fatal.
Research on anti-asthmatic drugs at Glaxo headed for these specific problems in
existing drugs. Isoprenaline, the commonly used P-stimulant before salbutamol,
lacked bronchial selectivity and was short acting. Prednisolone, the commonly used
glucocorticoid before BDP, was also lacking selectivity and was only orally effective.
Its use for asthmatic treatment, therefore, caused considerable systemic effects. Thus,
lack of the selectivity and shortage of the duration can be regarded as the "reverse
salients" of P-stimulants. A reverse salient in technological change is a component in
the technological system that has fallen behind or is out of phase with the others,
according to Thomas Hughes, the proponent of the notion. Scientists and engineers
concentrate on the correction of reverse salients. When a reverse salient cannot be
corrected within the context of an existing system, the problem becomes a radical
one, the solution ofwhich may bring a new and competing system. (Hughes 1987,
p.73-75; Hughes 1983, p. 79) Occurrence of systemic side effects was the reverse
salient of glucocorticoids for asthmatic treatment. In addition, P-stimulants and
glucocorticoids deal with different causes of asthma. The former works by dilation of
the bronchial muscle. The latter is involved in control of inflammation ofmucosa
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inside the airways. When we regard the asthma therapy as a technological system,
the progress in fl-stimulants possibly causes reverse salients in glucocorticoids.
These reverse salients were obvious for researchers at Glaxo, who were working on
this therapeutic area. They could easily turn the reverse salients into critical problems
(Hughes 1983, p. 80), though this does not mean that their solution was easy.
Researchers at Glaxo, eventually, coped with those critical problems, as we can see
in the case studies. They first tried to find a longer acting (3-stimulant and, as a result,
they found salbutamol, which is not only longer acting but also, unexpectedly,
bronchi selective. Then, they turned their attention to glucocorticoids, because
another cause of asthma had to be controlled. They solved the problem of selectivity
by using an existing topical glucocorticoid, BDP, by inhalation, not by discovering a
selective glucocorticoid. This solution is justified by a view that the site-specific
delivery is important because all cells probably have the same glucocorticoid
receptors. (Taylor and Shaw 1993; Utiger 1993) This was more than the modification
of an existing drug in the same approach. This was innovative in finding a new
approach to the use of glucocorticoids for asthma and also in finding a new
application of topical glucocorticoids. After the development ofBDP inhaler, they
turned their attention to P-stimulants again. The reverse salient this time was also
extension of duration. Salbutamol, after all, did not get rid of the reverse salient
completely. More than 8 hours long duration was necessary. What is important here
is that this reverse salient became critical because rival companies had developed
longer acting P-stimulants such as procaterol. Here, it is obvious that reverse salient
is not only a technical phenomenon but also a social one. In the area of
glucocorticoids, Glaxo continued to search for a safer steroid. As a result, they found
fluticasone propionate, which is claimed to be safer because it is orally inactive. Thus,
these drugs can be seen as a result of Glaxo's struggle with the reverse salients. The
motive of this struggle can be seen in Jack's words:
Jack: I asked myself. What is wrong with salbutamol? Answer: nothing
except that it is too short active. Then, I was trying to make a longer acting
one. It's simple. Similarly, that is why I chose fluticasone propionate.
Because I perceived the patents on beclomethasone dipropionate disappear,
what would we do? What do we need? What is wrong with beclomethasone
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dipropionate? It was not selectively acting. We should make more selectively
acting, something better. That is fluticasone. So, why? What made me think
of this was, in one word, necessity. I had to. It was necessary.
Hara: Necessary from the medical reason?
Jack: Medical, but double, in order to keep my organization solvent. So,
never mind the medical, but by the way, the only way to keep it solvent is to
satisfy the medical problem. (Interview)
Thus, the normal-scientific discovery of drugs seems to be conducted as the
correction of reverse salients within the context of an existing system, ifwe adopt
Hughes' terminology. Once a reverse salient is corrected, another will appear. As a
result, a series of discoveries, such as salbutamol, BDP inhaler, salmeterol and
fluticasone propionate, emerge. Evolutionary economists would describe this as a
technological trajectory. (Dosi 1982; Nelson and Winter 1977) These characteristics
seem to be consistent with Kuhn's analogy, normal science as puzzle-solving. (Kuhn
1970, pp.35-42) However, the case ofBDP inhaler was somewhat different from the
other cases in adopting a different "rule" (Kuhn 1970, pp.38-39), that is to say, a
combination of topical steroids as compounds and inhalation as the way of
administration.
4.7.2. Social Process in the Shaping of Drugs
In the cases of anti-asthmatic drugs, as in other cases, the process of discovery and
development involved considerable uncertainty. Mechanisms of interaction of a drug
and the body were so complex that researchers did not understand them fully. As a
result of this uncertainty, there were scientific controversies: for example, whether or
not beta-adrenergic receptors are desensitised by long time exposure to P-stimulants;
whether or not the regular use of P-stimulants increases asthma mortality; and
whether or not socio-economic factors such as financial barriers to primary care was
a major cause of the "epidemic" of asthma mortality in New Zealand. The market for
drugs also has uncertainty. In the case of procaterol, this uncertainty raised some
problems: for example, which is better, a very effective drug with some but tolerable
side effects or a less effective drug with fewer side effects? These controversies and
problems were not solved by examining nature alone. It was social process that
solved them. Sometimes, powerful leadership brought a closure. When David Jack
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began the search for a longer acting P-stimulant, he did not persuade doubtful fellow
researchers but told them to do it. When Otsuka's staff discussed the choice of drug
for development, it was the voice of Akihiko Otsuka that was crucial. On the other
hand, a subtler, longer lasting process toward a closure occurred when there was no
single powerful authority. The P-stimulant controversy has been virtually closed
partly because the "epidemic" of asthma mortality waned, partly because there was a
consensus that the combination of P-stimulants and glucocorticoids should be
adopted in the management of asthma from the therapeutic point of view, and partly
because the safety of long-acting P-stimulants such as salmeterol became widely
accepted as they were clinically used for quite a long time. Thus, the wane of
interests, the emergence of a practical consensus, induction by test and induction by
use collectively brought a closure to the controversy. It should be noted that the
properties of p-stimulants were not truly known by these. (Cf. MacKenzie 1996,
pp.257-258)
4.7.3. Substances in the Shaping of Drugs
In the previous chapter, we discussed the role of theories and that of substance in
pharmaceutical innovation. The provisional conclusion was that it is impossible to
determine which comes first, a theory or a substance. The cases in this chapter
support this conclusion. The research that produced salbutamol in 1966 was based on
the receptor theory, for example. However, the researchers did not know the concept
of subtypes of P-receptors, which were published in 1967 by Lands and his
colleagues. (Lands et al. 1967) Salbutamol, later found to be a beta2 selective
stimulant, supported Lands' theory. David Jack, in my interview, mentioned his three
gurus. Two of them were human: R.P. Stephenson and D.E. Koshland, Jr., both of
whom contributed to progress of receptor theory. (Stephenson 1956: Strange and
Koshland 1976) However, the third guru Jack mentioned was non-human:
salbutamol. This raises an important question: can people learn from substances?
Salbutamol, of course, does not speak. Mediated by social processes, the properties
of salbutamol were measured, interpreted and understood. However, salbutamol is,
of course, not purely socially constructed. Salbutamol has something imperative
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within it, something foreign to human society within it. Because of this, researchers
can learn something from substances, given the existence of society which provides
them with theories, equipment, salaries and so on.
4.7.4. Making Differences
Because procaterol was a product of the normal-scientific discovery, there were
some similar drugs when it was developed. Therefore, it was necessary for Otsuka
staff to make its differences from the others clear in order to sell it successfully. The
differences had to be conceptually expressed and empirically demonstrated.
Kazuhiko Ito's classification of (3-stimulants generations was especially helpful in
the marketing, because it made existing drugs sound obsolete. Results of comparative
clinical trials were fully made use of in the marketing. These are understandable
because a normal-scientific discovery has, by definition, at least an exemplar and
maybe some similar discoveries, whereas a paradigmatic discovery has no exemplar
and must be distinguishable. Therefore, the efforts to point up differences from other
drugs are probably more critical in the development and marketing of drugs coming
from normal-scientific discoveries than in those from paradigmatic ones. Thus, when
we look not only at discovery but also at development and marketing, we may also
be able to identify different types of innovation in the pharmaceutical industry.
In the next chapter, we examine the cases ofH2 antagonists, drugs for the treatment
of peptic ulcers. The cases consist of a paradigmatic discovery, cimetidine, and two
normal-scientific discoveries, ranitidine and famotidine. We will examine their
development and marketing processes as well in order to identify the types of
innovation in the pharmaceutical industry.
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Chapter 5: Histamine H2 Antagonists
5.1. Introduction
Histamine H2 antagonists are a group of drugs which are used for the treatment of
peptic (both duodenal and gastric) ulcer. One of the main causes of peptic ulcer is
believed to be an excessive secretion of acid in the stomach, due to various factors
such as stress and doses of aspirin. (Another main cause is now believed to be
Helicobacterpylori, a kind of bacteria discovered in 1983, which destroys the
mucous membrane of the stomach). Unlike previous drugs which just neutralised the
gastric acid, histamine H2 antagonists reduce dramatically the amount of acid
secreted in the stomach. Histamine H2 antagonists inhibit histamine, one of the
important chemical transmitters in the body, from fitting into the receptors called
histamine H2 receptors, which play an essential role in the acid secretion in the
stomach. Histamine H2 antagonists were discovered by (Sir) James Black and his
colleagues at the British subsidiary of SmithKline and French (now SmithKline and
Beecham) in the early 1970s. Though the first marketed histamine H2 antagonist was
cimetidine (Tagamet®) made by SmithKline and French, it had two precursors called
burimamide and metiamide, both ofwhich were also discovered in the same
company by Black and colleagues. The second histamine H2 antagonist to be
marketed was ranitidine (Zantac®) discovered by (Sir) David Jack and his colleagues
at Glaxo (now GlaxoWellcome). And the third was famotidine (Gaster®, Pepcid®)
discovered by Isao Yanagisawa and his colleagues at Yamanouchi in Japan. These
histamine H2 antagonists brought a major breakthrough to the area. First,
therapeutically, they have eliminated the need for surgery for the treatment of peptic
ulcer. The disease has been increasingly treated by physicians rather than by
surgeons since the advent of these drugs. Second, they were extremely successful in
the market. Cimetidine and ranitidine were two of the top-selling drugs in the world,
and famotidine was one of the top-selling drugs in Japan and also considerably
successful in other countries. Each of them has provided each company with
enormous profit and contributed to the company's further investment in R&D and
other operations. In this chapter, we look at these histamine H2 antagonists.
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Table 5.1: Major Events Discussed in This Chapter














5.2. Burimamide to Cimetidine
5.2.1. Introduction
James Black applied the same approach to the discovery of histamine H2 antagonists
as to his discovery of P-blockers, that is, he started from a natural occurring molecule,
and then modified its structure to enhance the selectivity and stability to a particular
type of receptors. The natural molecule this time was histamine, whilst for P-blockers
it was adrenaline. Although the idea was quite simple, its realization was not at all
easy. It took Black and his colleagues six years to discover the first H2 antagonist,
burimamide, in 1970. However, burimamide had a decisive flaw which prevented its
practical use as a drug. They modified it and discovered metiamide in 1971. Though
metiamide was free from the problem which burimamide had, it had undesirable side
effects. They modified it further and eventually succeeded in the synthesis of
cimetidine in 1972. Cimetidine finished clinical trials successfully and was marketed
in the UK in 1976 and in the US in 1977. (Duncan and Parsons 1980) In the early
1980s, it became the top-selling drug in the world. (Ganellin 1985, p. 115)
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5.2.2. Discovery of the Histamine H2 Antagonist
For a long time, the relationships between histamine, gastrin and gastric secretion
were poorly understood. Gastrin as the gastric secretion stimulant was first reported
by J.S. Edkins in 1906, when he derived it from an extract of the stomach. (Edkins
1906) Histamine was discovered by H. Dale and P.P. Laidlaw in 1910. (Dale and
Laidlaw 1910; Sneader 1985, pp. 165-166) Gastric secretion stimulants were found in
many kinds of extracts of other tissues later. (Koch, Luckhardt and Keeton 1920; Ivy
1930) Because at that time it was known that histamine stimulates acid secretion
(Koch, Luckhardt and Keeton 1920; Popielski 1920) and it exists in many tissues
(Abel and Kubota 1919), some researchers concluded that histamine and gastrin were
identical. (Rothlin and Gundlach 1921; Sacks, Ivy, Burgess and Vandolah 1932;
Gavin, McHenry and Wilson 1933) However, in the mid 1930s, researchers at
McGill University, Canada, claimed that gastrin and histamine were different
substances. (Babkin 1934; Komarov 1938; Mcintosh 1938) S.A. Komarov repeated
the Edkins' experiment more systematically and showed that even histamine-ffee
extract of the stomach could cause the secretion of gastric acid whereas histamine-
free extracts of other tissues could not. (Komarov 1938) Moreover, F.C. Mcintosh
compared the increase of histamine caused by injection of histamine with that caused
by stimulation of the vagus nerve, the widely distributed nerve, and suggested that
histamine functioned as a "local hormone" working indirectly for the acid secretion
rather than as a "true hormone" (that should have been "gastrin") working directly.
(Mcintosh 1938) Thus, they showed that gastrin was different from histamine and
suggested that gastrin might work more directly in the gastric secretion and be more
important than histamine. Since then, many efforts had been made to unveil the new
hormone, gastrin. (E.g. Uvnas 1943; Harper 1946; Jorpes, Jailing and Mutt 1952)
However, the controversy continued until gastrin was identified chemically. For
example, C. F. Code discussed on gastrin as below:
"Gastrin" then, may be simply another histamine releaser. Study ofwhether
this action is confined to the release of histamine in the gastric mucosa or
whether it is shared by other tissues is hampered by the lack of a ready source
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ofpurified "gastrin" and, apparently, by the difficulty of preparing it so that it
will be free of histamine. (Code 1956)
At last, in 1964 gastrin was isolated (Gregory and Tracy 1964) and its chemical
structure, a polypeptide hormone, was identified subsequently. (Gregory, et al. 1964)
Then, "[m]any researchers turned their attention to seeking specific inhibitors of
gastrin-induced acid secretion". (Ganellin 1982, p.4)1 This was represented by the
statement below about gastric secretion in a physiology textbook published in 1968:
Histamine and gastrin deserve some special consideration, histamine
because it has for such a long time been involved in theories of gastric
secretion as well as other activities, and gastrin because it is now firmly
established as playing a major role in gastric activity and also is the first
gastrointestinal hormone whose chemical nature has been determined.
The role of histamine as a physiological agent in gastric secretion can still
not be regarded as either proved or disproved. (Davson and Eggleton eds.
1968, p.619)
Similarly, L.R. Johnson in his paper in 1971, "Control of Gastric Secretion: No
Room for Histamine?" argued that "histamine may have nothing to do with the direct
stimulation of acid secretion". (Johnson 1971)
This view was reinforced by the fact that existing antihistamine drugs at the time
could not stop acid secretion (Ganellin 1982, pp.2-3; Patrick 1995, p.283; Sneader
1985, p. 170),2 though they could stop other body responses caused by histamine,
particularly allergic symptoms like urticaria and hay fever. (Sneader 1985, pp. 167-
168; Ganellin 1982, p. 2) In addition, in the 1950s M. I. Glossman and his colleagues
at University of Illinois College ofMedicine, supported by Eli Lilly, examined
gastric acid-secretion inhibitory activity of various histamine analogues, but no
effective inhibitor was discovered. (Glossman, Robertson and Rosiere 1952; Ganellin
1985, pp. 99-100) Therefore, the idea of using histamine antagonists as the way of
inhibiting acid secretion was generally regarded as "played out." (Ganellin 1982, p.4)
1
However, there seemed to exist some researchers who kept believing that histamine was
significant in the gastric secretion. (E.g. Code 1965)
2 There was also a concerted effort by researchers at Eli Lilly in the 1950s to find an antagonist of
histamine-stimulated acid secretion. (Ganellin 1982, p.4)
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For example, when Glaxo started its research programme for anti-acid drugs in 1968,
they first did it by searching for an anti-gastrin compound.3
James Black described the atmosphere at the time:
... suddenly, [in 1938], we had the discovery of gastrin. Everybody went
alive. And they were able to show its structure and they synthesised it.... we
now have up until 1938 everybody saying histamine, after 1938 everybody
saying gastrin. So when the anti-histamine drug didn't stop acid secretion, it
was said that that was because acid was stimulated by gastrin. Now that is
why no one was looking for a histamine antagonist because they didn't think
histamine was involved. (Interview)4
Why then did Black follow a different way? Two reasons have been put forward.
One is his experience of adrenaline receptors. Black had succeeded in finding beta-
adrenergic receptor antagonists before joining SmithKline and French. (See Chapter
3) His familiarity with two types of adrenaline receptors led him to the analogy of the
histamine receptors. (Duncan and Parsons 1980, 620; Black interview) The other is
previous research on histamine by other scientists. Conventional antihistamines
failed not only to inhibit the acid secretion in the stomach but also to block the
dilation of blood vessels and some other actions caused by histamine. Therefore, in
1948, B. Folkow, K. Heager and G. Kahlson speculated that there might be two types
of receptors sensitive to histamine. (Folkow, Heager and Kahlson 1948)5 These two
reasons led Black, the newly appointed Head ofBiological Research of the British
laboratories of SmithKline and French (UK), to propose a research programme on
the unidentified second histamine receptor in 1964. (Duncan and Parsons 1980, 620)
The research programme began in September 1964 with the expectation that it would
be over by Christmas. It consisted ofBlack and M.E. Parsons as pharmacologists,
W.A.M. Duncan as a biochemist and G. J. Durant as a chemist. As they found the
3 Interviews with Sir David Jack and with Ms Angela Palmer. See footnote 13.
4 This interview with Sir James Black was conducted on 3rd March 1999.
5
Later, but before the SmithKline and French team identify the histamine H2 antagonist, Ash and
Schild proposed in 1966 that the actions of histamine blocked by conventional antihistamine
drugs should be defined as histamine Hi receptors and that other actions not blocked by the
antihistamines should be mediated by other receptors, or non-Hi receptors, with results of further
investigations on the actions of histamine by their own and others. (Ash and Schild 1966;
Ganellin 1982, pp.2-3; Duncan and Parsons 1980, 620)
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programme unexpectedly difficult, J.C. Emmett and C.R. Ganellin joined in the team
in 1965 and 1966 respectively (Duncan and Parsons 1980), in order to reinforce the
chemistry part.
Because there was only a hypothesis, they started to modify histamine itself. Many
different approaches were tried, including a straightforward analogy with P-blockers,
to fuse a benzene ring and an imidazole ring together. But all of these early trials did
not work. (Ganellin 1982, pp.5-6) Numerous failures raised doubts about the
hypothesis. Only the results that showed the different stimulating effect on the
different receptor sites between 2-methylhistamine and 4-methylhistamine,
implicating the two types of receptors, encouraged them to continue. However, this
did not lead to the discovery of selective antagonists. (Ganellin 1982, p.7) In the first
four years, about 200 compounds were synthesised and tested with no success.
Meanwhile, Parsons found that the assay they had been using was not able to detect
partial agonists. Partial agonists are the compounds which have both characteristics
as agonists and antagonists. He suggested a new assay able to find even partial
agonists. (Duncan and Parsons 1980) They re-examined some of the compounds
synthesised earlier, which had some potential from the theoretical point of view.
(Ganellin 1982, p.7) By this screening, they found one compound showing a weak
blocking activity. This had been synthesised by Durant in 1964, the very first year of
the research programme! (Duncan and Parsons 1980)6 It was not detected in the first
screening because it was a partial agonist. The compound, N°- guanylhistamine
(SK&F 71448) became the lead compound for the next stage. (Ganellin 1982;
Duncan and Parsons 1980)
Before they discoveredN°- guanylhistamine, they had also found a compound7
which inhibited the acid secretion. However, its activity was not by antagonism at the
histamine H2 receptors but by another mechanism. There was strong pressure both
within the research team and from the company to develop it, and eventually some
diverted effort along this track was made temporarily. However, Black succeeded in
6
Historically, this compound was first synthesised in 1928, but was reported to be devoid of
interesting physiological activity. (Ganellin 1985, p.102)
7
a -methyl histidine 3,4-dichlorobenzene sulphonate
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reminding the team members that they were not interesting in an antisecretory
compound per se, but in a competitive non-Hi receptor antagonist. (Duncan and
Parsons 1980) Black put it:
I was looking for a histamine antagonist. I was not looking for something
which would inhibit acid secretion. ... This particular compound inhibited
acid secretion. And then I was put under the great pressures to develop this
as an anti-acid secretory compound. And I was able to show that it was the
salt of dichlorobenzene sulphonate which was doing the inhibition, and
there is nothing to do with histamine at all. And so, "Go away! Don't follow
this." (Interview)
Black's reputation was important for the survival of the project. He himself
observed:
[The company] would have to have really good reasons, if you understand,
for cutting me off. But they had a problem. Because I had by this time, what
you might call, a track record. (Interview)
After the discovery ofN°- guanylhistamine, the research team made many of its
analogues. One of them, SK&F 91486, which was synthesised in 1968, had a longer
side chain and showed a stronger antagonist action though it was still a partial
agonist. This made the research team more confident. (Duncan and Parsons 1980)
The organisational pressure, however, increased more and more. The 1967 annual
report of SmithKline and French announced that they " began to concentrate [their]
efforts on a smaller number of research areas and to give these areas more intensive
study." (SmithKline and French, Annual Report 1967, p.7) Several research
programmes in progress were mentioned there but Black's project was not. Duncan
and Parsons described the situation very well:
The parent company in the United States had had a major reorganisation of
its research activities, and questions were being raised about the relevance
of the research program in the British laboratories. This probing led to the
resolve by the British workers that the survival of the U. K. Research
Institute within the SK&F organisation required that it make a major
discovery and that it should do it soon. Duncan was now Research Director
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and it was decided that of the various research programs being worked on in
Welwyn, the histamine-receptor antagonist program was the one most likely
to fulfill this requirement and therefore, that we should concentrate all our
available resources on making it happen. This inevitably produced trauma
within the Research Institute, and it is very considerably to the credit of all
our colleagues that they cooperated in this policy even though it inevitably
led to the contraction, or annihilation, of their own favorite programs. These
were not happy time... (Duncan and Parsons 1980, 621)
The UK research team invented the term "H2", in order to emphasise the difference
of their objectives from those of their counterpart in the United States and of other
companies which were looking for anti-secretory compounds. (Duncan and Parsons
1980, 621-622)8 It can be said they set their domain not in the specific disease but in
the specific approach, at least partly because of organisational reasons as regards
their relationship with the US parent company.
In 1969, SK&F 91581, a thiourea analogue of SK&F 91486, was found not to act as
a partial agonist, even though its activity as an antagonist was weaker than SK&F
91486. Further lengthening of the side chain of SK&F 91581 led to the discovery in
1970 of burimamide, which showed much stronger antagonist activity without
stimulant activity. In total, about 700 compounds had been synthesised and tested
before this discovery. (Duncan and Parsons 1980, 622; Ganellin 1982, pp.14-16)9
Burimamide demonstrated that there are histamine H2 receptors and particular
compounds that can antagonise the activity of the receptors. Confidence and morale
in the research team became very high. (Duncan and Parsons 1980, 622) However,
burimamide was not active enough to be given orally. This meant that it could not be
considered as a drug candidate. (Ganellin 1982, p. 16) Further modification was
necessary to find a practical candidate, but Black and Duncan decided that they
should undertake single-dose experiments of burimamide in humans to confirm the
transferability of the animal pharmacology to humans and that they should publish
8 Black did not like "H2" very much as the name of the receptor. In fact, there were people who
read the title of the SK&F team's first paper as a new "hydrogen receptor" antagonist! (Black
personal communication, October 1999)About the chemical modification from histamine to burimamide, see Ganellin (1985, pp. 102-
106) and Patrick (1995).
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their data as early as possible. (Duncan and Parsons 1980, 622) The experiments
were conducted in 197110 and confirmed that burimamide inhibited acid secretion in
humans as well as in animals. These findings were very important because they
showed a key role of histamine in the gastric secretion which had been controversial
for a long time. The results were published in Nature in 1972, only a year after the
Johnson's "No Room for Histamine" paper. According to Duncan and Parsons
(1980), this very early publication came from the intention to encourage other
scientists to confirm their findings and to extend the research in the area. It can be
imagined that this also affected the valuation of this research by the management of
the parent company.
After the discovery of burimamide, various modifications were examined
systematically to increase potency. Based on an elegant, rational thinking of
chemistry, sulphur was introduced in the side chain by Ganellin. (Black personal
communication, October 1999) This, together with the introduction of CH3 in the
ring system, made the compound about ten times more potent. This compound was
synthesised in 1971 and named metiamide. (Black et al. 1974; Ganellin 1982, pp. 16-
23; Ganellin 1985, pp. 106-111; Duncan and Parsons 1980, 623; Patrick 1995,
pp.294-298) Because it was effective even by oral administration, they believed that
they had at last achieved their objective, a drug! Top priority was given to scaling-up
of the synthesis. The team was now expanded and about 150 scientists came to be
involved in metiamide and other aspects ofH2 receptors. In March 1972, Duncan,
Black and one of their American colleagues visited the Food and Drug
Administration (FDA) in the United States to talk about burimamide and metiamide,
which was the first of several meetings between SK&F and the FDA on the matter.
In June 1972, an application was made to the Committee on Safety ofMedicines
(CSM) in the UK for a clinical trials certificate for metiamide and this was granted in
April 1973. (Duncan and Parsons 1980, 623) The first international symposium on
histamine H2 receptor antagonist was held in London in October 1973.11
10 The first volunteers were Duncan and Ganellin. (Duncan and Parsons 1980, 622)
11 In the welcome speech in the symposium, Duncan stated that in the drug industry potential new
drugs were usually not discussed at such an early stage, that for various reasons nevertheless he
decided the early disclosure of data and that one of the reasons was to improve its development.
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However, metiamide was not free from flaws. Even as early as March 1972, the
research team regarded the presence of a thiourea group in the molecule as a
potential disadvantage and started an effort to replace it with another structure. The
pre-clinical development found that metiamide produced a granulocytopenia, a
shortage of the normal number of granular leucocytes in the blood, in some dogs, and
some other side effects in rats and dogs. These effects were judged to be acceptable
therapeutically when both merits and demerits of metiamide were taken into account.
(Duncan and Parsons 1980, 623) However, of 700 patients treated with metiamide in
the clinical trials, a few cases of granulocytopenia were reported. (Ganellin 1982,
p.23) Because of these, the CSM recommended the suspension of the UK clinical
trial certificates in June 1974. The FDA also took a similar action. The company had
some meetings with the FDA and the CSM. In the UK the clinical trial certificate for
metiamide was re-granted but for use only in seriously ill patients. (Duncan and
Parsons 1980, 624) Duncan and Parsons described how this matter, together with
Black's resignation in 1973 to accept the chair of pharmacology at University
College, London, depressed the research team. (Duncan and Parsons 1980, 624)
They had already started work on modifying the structure ofmetiamide in March
1972, and eventually found that its nitroguanidine analogue and cyanoguanidine
analogue were as potent as metiamide even without the thiourea group, which was
regarded as the cause of the side effects ofmetiamide. The cyanoguanidine analogue
was more potent and chosen as a successor ofmetiamide. This is cimetidine
(Brimbelcombe, et al. 1975; Ganellin 1981; Ganellin 1982, pp.23-27; Ganellin 1985,
pp. 111-114; Patrick 1995, p.281), which was synthesised in 1972. (Ganellin 1982,
p.33) It gradually became clear that cimetidine did not have the major side effect of
metiamide. In 1974, cimetidine was administrated to a patient who had
agranulocytosis, serious granulocytopenia, caused by metiamide. The substitution of
cimetidine for metiamide led to a rapid recovery from agranulocytosis. This was
evidence that cimetidine is free from this side effect. (Duncan and Parsons 1980,
624) After that, the development of cimetidine progressed rapidly. The drug was first
(Duncan 1973) But, again, the symposium was also regarded as held at least partly because of the
politics in the organisation, academic and medical society. The social role of these kinds of
symposia in medical sciences is discussed by (Thagard 1999, pp.91-92, pp. 185-198)
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marketed in the UK in 1976, in the US in 1977 and in over 100 countries by 1979
under the trademark Tagamet. (Ganellin 1982, p.33)
SmithKline and French intensively promoted cimetidine worldwide. In the statement
of the chief executive officer in the 1976 annual report, the then chairman, Robert
Dee, stated, "[w]e will devote a major share of our resources —people and money—
to make 'Tagamet' available to patients throughout the world in 1977. ... The
effective worldwide marketing of 'Tagamet' is a top priority." (SmithKline
Corporation, Annual Report 1976, p.3) The most important thing was to inform the
medical market about the drug. They held the Second International Symposium on
Histamine H2-Receptor Antagonists in London in October 1976. (SmithKline
Corporation, AnnualReport 1976, p.9) Face-to-face promotion was also conducted.
The following extract from the 1976 annual report shows it:
Because of the uniqueness of the H2-Antagonist concept, our sales
representatives will be informing the world's physicians of a new method of
treating gastrointestinal disorders. To prepare our people to do this, we have
developed an intensive and comprehensive instruction program. The
program includes training in the safety and efficacy profile of the compound,
and also instruction in the concept of biochemical receptors and antagonists,
which underlies the mode of action of'Tagamet.' (SmithKline Corporation,
AnnualReport 1976, p. 9)
The following extract from the 1977 Annual Report of SmithKline Corporation
shows how the company prepared the worldwide market introduction of cimetidine:
... parallel strategic programs were implemented to assure that we had
adequate chemical supplies and pharmaceutical production facilities, and the
marketing capability to introduce the product effectively to the medical
professions. Production facilities were expanded in the United Kingdom,
Germany, France, Puerto Rico and a number of other countries. Sales forces
were increased in several international markets, including Spain, Germany
and Italy. (SmithKline Corporation, AnnualReport 1977, p.4)
The development from histamine, through burimamide and metiamide, to cimetidine
has been regarded as one of the best examples of "the rational approach" (Sneader
1985, p.171; Patrick 1995, 281) of drug discovery. This also has changed the view of
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the role of histamine in the gastric secretion. It can be seen clearly when we compare
the following statement in a recent textbook with that in 1968 cited above:
Histamine is a major physiological mediator ofHC1 secretion. Cimetidine, a
specific antagonist ofH2 receptors, blocks a large portion of acid secretion
elicited by any known secretagogue. ... Gastrin is not as potent a direct
stimulant of parietal cells as acetylcholine or histamine. The physiological
response to elevated levels of gastrin in the blood is greatly attenuated by
cimetidine. Thus a major component of the physiological response to gastrin
may result from gastrin-stimulated release of histamine. (Beme and Levy
eds. 1996. pp.466-467)
Black won a Nobel Prize in 1988 for his achievement in the discoveries of [3-blockers
and histamine H2 antagonists.
5.3. Ranitidine
5.3.1. Introduction
In 1968, David Jack, who was then research and development director at Allen and
Hanburys, set up a research team for a gastrin antagonist, after he has successfully
achieved the discovery of salbutamol and BDP inhaler. (See Chapter 4) The team
leaders were Roy Brittain (pharmacology) and Barry Price (chemistry). They
changed their target to histamine H2 antagonists when burimamide appeared. They
eventually discovered a new potent H2 antagonist, ranitidine, in 1976. Ranitidine is a
member of a new chemical class ofH2 antagonists in which the imidazole ring in
burimamide, metiamide and cimetidine molecules is replaced by a furan ring
carrying a basic substituent. Ranitidine was found to be more potent and more
selective than cimetidine. Because of these superior characteristics as a drug and
Glaxo's intensive global marketing efforts, it steadily displaced cimetidine after it
was marketed in 1981 and became the world top selling drug by 1988.
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5.3.2. Shaping a World Best Selling Drug
Jack and his colleagues first considered the possibility of an improved treatment for
peptic ulcer in 1968. (Jack personal communication, February 2000; Glaxo internal
documents) Originally, this research team was directed towards the discovery of an
antigastrin compound. (Glaxo internal documents; Jack interview; Palmer
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interview) This was found to be a very difficult task because gastrin is a relatively
large peptide hormone whose cellular receptors were ill-defined. (Jack personal
communication) The project was about to be axed after it had been unsuccessful for
almost four years. (Palmer interview) In 1972, the research objective was abruptly
changed to a new histamine H2 antagonist when Black's work on histamine H2
receptors was made public. Jack explained:
Roy Brittain and I attended a lecture by James Black in Hatfield Polytechnic
in which he revealed that burimamide, a simple derivative of histamine,
inhibits not only histamine-induced acid secretion in animals and man but
also that which follows ingestion of food. These results established beyond
doubt the physiological role of histamine in acid secretion and gave our
chemists a much easier starting point than gastrin analogues for their project.
At that time, large molecules such as gastrin were "bad news" for medicinal
chemists because their chemistry and biology were more difficult and less
well understood than that of small mediators like histamine. (Interview)
The SmithKline and French researchers probably believed that the imidazole ring, as
in histamine or an alternative basic aromatic ring system was essential in a potent
histamine H2 antagonist. This is evident in cimetidine and related compounds in the
contents of their patent on H2 antagonists. (British Patent 1421792) The first
objective of the Glaxo research team was, therefore, to find a potent H2 antagonist
that does not contain such a ring system, rather than to find a more selective drug.
(Jack interview and personal communication) Their starting point in 1972 was
burimamide and later cimetidine. Jack put it:
By 1976, we were looking for a drug as good as cimetidine. What we found
was a better one. Ranitidine proved to be about 5 times more active than
12 The interview with Sir David Jack was conducted on 27th April 1999. The interview with Dr
John Wood and Ms Angela Palmer at GlaxoWellcome was conducted on 9th April 1999.
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cimetidine as a histamine H2 antagonist and to be more selectively acting
because, unlike that drug, it does not inhibit cytochrome P450 processing
enzymes in the liver or antagonise the actions of testosterone in man. We
were very lucky to achieve this outcome because we were unaware of these
shortcomings of cimetidine when ranitidine was first synthesised.
(Interview)
The Glaxo team struggled unsuccessfully for nearly four years to circumvent the
SK&F patents by replacing the imidazole ring by a variety of non-basic aromatic
systems. (Jack personal communication) The breakthrough came in 1976 when John
Clithelow, a senior medicinal chemist, having made some poorly active furan
analogues of potent H2 antagonists, remembered that furan can be converted into a
tertiary amine by a specific chemical procedure. The resultant compound retains the
furan structure but it has a basic group outside the furan ring system. (Jack personal
communication)
The conversion was first carried out on the furan analogue ofmetiamide and yielded
a modestly potent H2 antagonist. Next came the dimethylaminomethyl furan
analogue of cimetidine. It was found to be less active than cimetidine and to be toxic
in animals. After a few modifications were tried in the side chain, the one that
contains an unusual nitro-ethene grouping was found to be more active and less toxic
than cimetidine. This was synthesised in 1976, named ranitidine. (Jack personal
communication; Technical booklet published by Glaxo Group Research titled Ulcers,
p. 12) However, because ranitidine was a poorly soluble solid, it was replaced in the
development programme by ranitidine hydrochloride in 1977.13 Following extensive
toxicity tests in animals, clinical trials of ranitidine started in 1978. Its efficacy and
safety was confirmed in clinical trials. It was marketed in the UK in 1981, in the US
in 1983, under the trademark of "Zantac." (Jack personal communication; Brittain,
Jack and Price 1981; Brittain and Jack 1983; Glaxo internal documents; Bradshaw et
al. 1979; British Patent 1565966) Further research found that the furan ring system of
ranitidine could be replaced by other base-substituted aromatic structure to yield a
variety of potent, long-acting H2-antagonists but none was found to be superior to
13 For convenience, hereafter I will refer to the compound simply as ranitidine instead of
ranitidine hydrochloride.
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ranitidine. (Jack personal communication; Brittain and Jack 1983, 74; Brittain, Jack
and Price 1981, 311-312; Palmer interview)
Because they could obviously witness the success of cimetidine, it is easy to
speculate that Glaxo was less uncertain and more confident about the success of
ranitidine, which was gradually found to be better than cimetidine. This led the
company to undertake the large investment in manufacturing and marketing. This
also led the then quite "Commonwealth" oriented company to become a really
international company operating in many countries including other European
countries, the United States and Japan. Documents published by the company
described the situation:
All available resources were swung behind the new compound. In the
process, Glaxo began to break new ground in almost every department.
Clinical trails were wider in scope and completed far more quickly than had
ever been the case before. ... Marketing was approached in a totally new
way, with co-promotion and licensing deals to achieve rapid penetration of
markets. ... At the same time, greater-than-ever investment in production
resources helped to meet the demand as it rose. In summary, Zantac was
developed and brought to market in a single, worldwide programme, rather
than locally and piecemeal as had always been the case in the past. (Glaxo
1987, p.10)
Angela Palmer, who had worked closely with the research team, also described it:
Ranitidine was first made chemically in 1976. Ranitidine hydrochloride ...
was made in mid 1977. And large-scale production in a production plant at
Montrose was commenced in October 1980. And certainly, a large amount
of effort was put into the development. The company realised it's a good
drug at the very early stage. (Interview)
John Wood, who had worked on the clinical trials since 1983, explained the
internationalisation as follows:
We were a small-medium sized Commonwealth-English company. And we
had a new product. We wanted to internationalise. Our chairman at the time,
Sir Paul Girolami, decided this company needed to be internationalised, so
we had to take a new drug, Zantac, and set up new companies in other
countries, for example, America. ... Zantac was the opportunity. It was the
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new drug we would take into new countries. Now, I think that ifwe hadn't
had Zantac, [we] might have been less encouraged to move other countries.
(Interview)
In the course of this all-out and worldwide development of the drug, the approach
that was taken was so-called "development-in-parallel." This approach was based on
the idea that every month lost between synthesis and sales was potential revenue lost.
(Glaxo 1987, p. 11) This represents their confidence in the success of the drug in the
market. Roy Brittain, the research director at Ware since 1983, stated, "Had we done
our test strictly one after the other we could have lost a year or more in development
time." (Glaxo 1987, p. 11)
Richard Blythe, the secondary production controller at Glaxo Pharmaceuticals stated:
We got going on production facilities before the clinical trails or even the
animal trials were finished. If you wait until trials are over, you're eating all
the time into your patent life. (Glaxo 1987, p. 11)
The significance of communications between functions was emphasised. John
Padfield, the then pharmacy director at Glaxo Group Research, put it:
We had to understand what was going on in development, of course. We
had to talk constantly with the marketing people to discover what they
wanted in terms of presentation, dosage forms, likely shelf lives and so on.
We also had to understand the needs of the production people. (Glaxo 1987,
P-12)
All these efforts toward the worldwide, simultaneous development were based on the
thought that market success would not just happen, but had to be planned. (Sir) Paul
Giolami, the Group chief executive at the time, stated later:
[Zantac] did not just come out. It was made here in every respect — a whole
team work, research, development. (Glaxo 1994, p. 8)
Giolami also stated elsewhere, stressing the marketing function:
Marketing has made that product as much as our research laboratories. For
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instance, in the United States where we had hardly started and in Germany
and Japan where we were very small, we had to achieve two contradictory
things: Make the most ofZantac and yet not hold back the development of
our own company. That's when we came up with the idea of a co-marketing
arrangement. We had the imagination and flexibility to hire a marketing
team from a major company. (Glaxo 1987, p. 10)
The co-marketing arrangement was to promote the product jointly with marketing
partners in other countries. Its rationale was explained to be that any dilution of
income would be offset by faster market penetration. The partners were Menarini in
Italy, Cancan in Germany, Fournier in France, Hoffmann-La-Roche in the US and
Sankyo in Japan. Glaxo also had its own marketing subsidiaries in these countries
though their strength in each market was varied. (Glaxo 1987, p. 17) These
subsidiaries and the local partners in the same countries jointly promoted the drug.
Even in the subsidiaries, local autonomy seemed to be regarded as important. John
Wood put it:
I think the most important thing, this is a really important thing, is that our
entire company was built on a human network of devolution, or
decentralization. ... In this case, they were not told what to do. They were
given the product, and they were allowed quite a lot of freedom to do
differently in different countries. ... The bosses of countries hired their
people. ... Giolami's view was that the local people know best. (Interview)
The key role ofmarketing was shown by another activity, namely, persuading
medical professionals. David Richards, the then medical director at Glaxo Group
Research, was reported to say:
By conducting clinical trials in all the main potential markets, we were able
to create demand for the product among the opinion leaders before we
actually launched. (Glaxo 1987, p. 11)
Comparisons with cimetidine were fully utilised in the persuasion. It is easy to
imagine that this tactic worked very well to take the existing market from cimetidine.
John Wood put it:
We've done a whole series of trials to compare ourselves with Tagamet.
And we wrote many papers, to describe findings. And we were very
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fortunate because SmithKline had chosen a wrong dose. It's the dose which
was not giving them the maximum effect. So we could use the dose of
Zantac which gave a higher effect, both in ulcer healing and in maintenance.
We had many chances to show that were repeated in other countries, and we
showed that the lack of sexual side-effects, we showed that at high doses the
side-effects got even worse with Tagamet. (Interview)
Wood also explained how they could take advantage of ranitidine's superior efficacy
and duration to provide more convenient dosage compared with cimetidine:
Tagamet was being given four times a day. ... Two pills at the bedtime to
help you with acid over night. Five pills throughout a day. When we
introduced Zantac, it was two pills, one in the morning, one at night. And
then we did a whole series of big trials. And we made it converted to one
pill a day, twice as big, at night, which worked just as well. ... And Tagamet
tried to do that. They moved to 400mg twice a day which was not as good as
their original dose, but more convenient. Then they moved to 800mg once a
day, which was like a horse pill, and in that stage they were failing and
losing. They had a big market share but we were taking more and more
market share, as people learned the benefits of the product. (Interview)
Also Glaxo's internal documents stated:
Zantac was marketed with the promotional messages, "Fast, Simple, Safe"
which doctors interpreted as Faster, Simpler and Safer than Tagamet,
although no such direct comparison was permitted in promotion14
There were also many papers by medical doctors in which ranitidine and cimetidine
were compared and the superiority of ranitidine was reported. (Dowschke, Lux and
Dowschke 1979; Zeldis, Friedman, Isselbagher 1983; Strum 1983)
The application of the drug was expanded. In 1984, ranitidine was reported to have
superior results in maintenance treatment, that is, a smaller chance of relapse when it
is taken continuously. (Gough et al. 1984; Silvis 1985; Glaxo 1987, p. 11) This can be
accepted if the side effects of a drug are low enough. This maintenance treatment
was used as the most important concept for competition with cimetidine. It is
14 In response to it, SmithKline and French promoted Tagamet as being "Tried and Trusted",
according to the same document. On the promotion battle between Zantac and Tagamet, see also
Angelmar and Pinson (1991), pp.7-8, pp.10-12, and Exhibit 19-23.
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reported that Glaxo set out to persuade doctors that ulcers needed long-term,
probably lifelong, maintenance treatment. (Angelmar and Pinson 1991, p.11 and
Exhibit 22)
Many kinds of administration forms have also been developed. Wood put it:
We did a lot of different pharmaceutical forms, so, normal tablets, larger
tablets, effervescent tablets, injections, soft gel capsules, and syrup, and
those,.... finally, we got permission in the US to move it over the counter so
that you didn't need to get doctor's prescription, you are just going to a shop
in the US, a pharmacy shop or supermarket or garage and buy some Zantac.
That's the lowest strength. And by that stage we had treated two hundred
and forty million people. (Interview)
These developments after the first product launch were quite intensely promoted by
the company. Wood, again:
I think it's fair to say that the company started off investing more and more
and more as we went along. And I've worked on this drug for 16 years, and
I never had any restriction on the amount ofmoney I could spend. Now, in
other words, I wanted to do this trial, that trial, that trial, [and they said] just
"do it." So I was never, ever [constrained], (Interview)
As a result of these marketing efforts, ranitidine overtook Tagamet sales on an
annual basis and became the highest selling drug in the world in 1986. In 1988, its
sales worldwide exceeded 1 billion pounds and its sales in the US exceeded 1 billion
dollars. (Glaxo internal documents)
5.4. Famotidine
5.4.1. Introduction
Famotidine was the third marketed histamine H2 antagonist, which was developed by
Yamanouchi, a Japanese pharmaceutical company. Famotidine is said to be much
more active than cimetidine. The imidazole ring of cimetidine is replaced with a 2-
guanidinothiazole ring and the side chain is also changed to contain a
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sulfonylamidine group. (Patrick 1995, p.309) This work was be done by Isao
Yanagisawa and his colleague at Yamanouchi's Central Research Laboratories.
Famotidine was launched on the market in Japan in 1985 (Yanagisawa 1994, p. 167),
in the US in collaboration with Merck in 1986 (Angelmar and Pinson 1991, p.12),
and in about 80 countries by 1994. It has been the best selling histamine FL
antagonist in Japan since 1988. (Gekkan Mikusu, Volume 24, No. 14, December 1996,
p.48) It was reported that famotidine in Japan enjoyed twice the sales of either
ranitidine or cimetidine, but in the world its share was only about a third of that of
ranitidine in 1993 and 1994. (Scrip Yearbook, 1995 Volume 1, p. 129)
5.4.2. Making the Top Histamine H2 Antagonist in Japan
A group of researchers ofYamanouchi began the search for anti-peptic-ulcer drugs
in the mid-1970s. (Yanagisawa 1994, p. 162) They had studied the application of
prostaglandins until then. One possible application area for them was anti-gastric-
ulcer. Their interest moved into the area, and began to look at other substances as
well. Therefore, at the beginning, their search did not focus on histamine FL
antagonists. Rather, their field of searching included broad types of anti-acid
substances, including prostaglandins, histamine FL antagonists, and other substances.
(Yanagisawa interview)15 The chemical synthesis and biological screening began in
August 1976, after the investigation of patents and literature. (Yanagisawa personal
communication, September 1999) The research team consisted of four chemists, two
pharmacologists, two assistants, and two researchers dedicated to the investigation of
literature and patents, according to Yanagisawa. (Interview) Three lead compounds
were chosen: one was discovered by Yamanouchi's researchers; the other was the
compound originated from Schering; and the third was cimetidine, which was
marketed and highlighted in the same year. (Interview) Because two of them were
not H2 antagonists, the pharmacological evaluation was done by both anti-acid
activity and anti-histamine activity. (Yanagisawa 1994, p. 162) The superiority of
cimetidine was found in the course of the research in terms of potency and safety and
it became the final lead compound. (Interview) They succeeded in replacing the
15 The interview with Dr Isao Yanagisawa was conducted on 22nd January 1999.
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cyanoguanidine part of the cimetidine molecule with cyano amidine and carbamoyl
amidine parts.16 (Yanagisawa, Hirata and Ishii 1984) Subsequently, they found that
the compound containing the carbamoyl amidine had a histamine H2 antagonist
activity which is as strong as cimetidine. They also intended replacement of the
imidazole ring of cimetidine, tried many kinds of rings, and discovered that the
compounds with a 2-guanidinothiazole ring showed very strong H2 antagonist
activities. Eventually, they discovered that the compound that was the product of a
combination of these two modifications was most active among all of the tested
compounds. (Yanagisawa, Hirata and Ishii 1984; Yanagisawa 1989; Yanagisawa
1994) However, this compound was not stable enough to be industrialised. This
instability was thought to be due to the carbamoyl amidine part and its replacement
was considered. Because they had already tried many kinds of amidine derivatives,
and the carbamoyl amidine derivative had been the best of all, the idea for further
improvement almost ran out. A suggestion of the then director of the research
laboratories to try sulfamoyl, which is slightly different from calbamoyl, opened the
way to a solution. Yanagisawa was suspicious of the idea because sulfamoyl amidine
derivative was supposed to be unstable as well and difficult to synthesise.
Furthermore, the compound was not known in the previous literature. However, his
team succeeded in the synthesis of the compound, and found that it was stable
despite Yanagisawa's anticipation. (Yanagisawa 1994, pp. 165-166) This compound
is famotidine (Yanagisawa, Hirata and Ishii 1987; Yanagisawa 1989, pp.208-210;
Belgian Patent 882071, 1980), which was reported to be about 30 to 40 times more
potent than cimetidine in vivo. (Takagi, Takeda and Maeno 1982; Friedman 1987)
424 compounds had been synthesised and screened before they reached famotidine.
(Interview) After the toxicological and pharmacological characteristics were
confirmed to be satisfactory in the pre-clinical studies, the clinical trials of
famotidine was started in 1980. The efficacy and safety of the drug were confirmed
and it obtained an approval for manufacturing in January 1985. There seemed to be
no significant problems after the synthesis to the launch, including scaling-up and
organisational obstacles, despite difficult production conditions and modest
15 Amidines were chosen because of their similarity to guanidines in terms of the chemical
structure. (Yanagisawa 1989, pp. 203-206)
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estimation of market size, according to Yanagisawa. (Interview) International
development was made by Merck (US), and it was marketed in the US in 1986 and in
other about 80 countries by 1994. (Yanagisawa 1994)
Famotidine rapidly took the market from cimetidine and ranitidine in Japan. In 1986,
its sales exceeded that of ranitidine, and in 1988 it superseded cimetidine as the
highest selling histamine H2 antagonist in Japan. {GekkanMikusu, Volume 24, No. 14,
December 1996, p.48) In 1993-4, its share in the Japanese market was about twice
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greater than either that of ranitidine or that of cimetidine. The success of famotidine
in the Japanese market has been explained from several points. Firstly, it was
reported to be much more potent than cimetidine. This meant fewer doses, which are
convenient for the patients and doctors who want to control their patients' dosing.
Secondly, it has been seen as having fewer side effects than cimetidine. It is said that
these two points have been thoroughly emphasised by Yamanouchi's representatives.
These are similar to the marketing tactics Glaxo adopted against cimetidine. Thirdly,
the price of famotidine was set higher than that of cimetidine. {Gekkan Mikusu,
Volume 24, No. 14, December 1996, p.48)18 This is beneficial for the company, given
the quantity sold. Furthermore, unlike ordinary commodities, prescribed drugs can be
sold in higher quantities despite being more expensive than rival products. In Japan,
though the official prices, which are used at the reimbursement from the various
health insurance programmes, are set under the fee schedule scheme, the real prices
applied to the trading between hospitals and pharmaceutical companies are often
lower than the official ones. The margin between the two prices (yakka saeki)
constitutes a significant part of hospitals' and clinics' revenues. (Campbell and
Ikegami 1998, p. 148) Therefore, higher price can be welcomed by doctors and can
result in the more frequent prescription. This has seemed to be the case in famotidine
17 Market shares of famotidine, ranitidine and cimetidine in the Japanese anti-ulcer drugs in 1994
were reported to be 21%, 10% and 10% respectively. The total share of these three histamine H2
antagonists was only 42% in Japan, whereas in the world their total comes to 58% in 1994. (Scrip
Yearbook, 1995 Volume 1, p. 129) This was because many kinds of traditional anti-ulcer drugs
were still commonly used in the Japanese anti-ulcer drug market.
18 Prices of pharmaceutical drugs in Japan are set by the Central Social Insurance Medical Care
Council (Chuikyou), an advisory committee to the Minister of Health and Welfare under the
national fee schedule {shinryo hoshu) scheme. This scheme is universal and virtually compulsory
in Japan. (Campbell and Ikegami 1999, pp.16-19, pp.145-150)
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compared with cimetidine, that is to say, the higher official price of famotidine has
seemed to stimulate doctors' preference for the drug. (GekkanMikusu, Volume 24,
No. 14, December 1996, p.48) These three factors can explain the advantage of
famotidine over cimetidine, but not over ranitidine. One possible reason why
famotidine has surpassed ranitidine in the Japanese market share is the difference of
sales forces. Yamanouchi regarded famotidine as the most important product to
promote, while Nippon Glaxo, the main Japanese subsidiary of Glaxo, did not have
such a large sales force, and Sankyo, the co-marketing partner ofGlaxo in terms of
ranitidine, had several other important drugs at the time to promote, which included
their own products, and could not concentrate sales efforts only on ranitidine.
{GekkanMikusu, Volume 24, No. 14, December 1996, p.49)
The last point is interesting because it can also explain why famotidine could not be
very successful in overseas markets.19 The overseas marketing of famotidine was
conducted by Merck (US), but the world's largest pharmaceutical company also
seemed to be unable to concentrate its promotional resources on famotidine because
of internal competition with other, more profitable, drugs introduced around the same
time. (Angelmar and Pinson 1991, p. 12)
A few other factors have been reported to contribute to the success of famotidine in
the Japanese market. One of them is that it was emphasised in promotion that
famotidine reinforced a protection factor in the stomach mucous membrane. {Gekkan
Mikusu, Volume 24, No. 14, December 1996, p.49) This activity was identified by
using a new instrument, namely, an ultrathin endoscope. (Daneshmend et al. 1989)
Another is that it has had an injection formula as well from the beginning of its
market launch, which has been welcomed by hospitals. Furthermore, because of
frequent additions in application, dosage and form, the company has had many
opportunities to meet doctors and explain the drug to them. {GekkanMikusu, Volume
24, No. 14, December 1996, p.49) Thus, famotidine has been the top selling
19 Worldwide market shares of famotidine, ranitidine and cimetidine in anti-ulcer drugs in 1994
were reported to be 12%, 35% and 11% respectively. Market share of each in the US was 11%,
48%, 14% respectively and in the Europe 7%, 40%, 8% respectively in the same year. (Scrip
Yearbook, 1995 Volume 1, p. 129)
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histamine H2 antagonist in Japan, but has had smaller sales than ranitidine in the
world.
5.5. Discussion
5.5.1. Paradigmatic Innovation and Modification-based Innovation
The discovery of cimetidine (including burimamide and metiamide as its prototypes)
is a paradigmatic discovery, whereas that of ranitidine or famotidine is a normal-
scientific discovery. (See Section 3.5.2.) The discovery of cimetidine changed the
theory of gastric acid secretion radically. A general belief that the key relevant
substance in gastric acid secretion was gastrin was replaced by another that it is
histamine. People now believe that there are two different subtypes of histamine
receptors after the discovery of cimetidine. The discovery also changed the treatment
for peptic ulcer. After the advent of cimetidine, peptic ulcer seems to be the
jurisdiction of physicians, not that of surgeons as before. In contrast, the discovery of
ranitidine and of famotidine did not change the theory and therapy established by the
discovery of cimetidine, but supported and promoted them.
This difference reflected the level and characteristics ofuncertainty surrounding the
process of discovery and development of these drugs. In the case of cimetidine,
scientific, technological and business uncertainties were extremely high.
Scientifically, histamine had been discounted as a key to the physiology of gastric
acid secretion. Technologically, there was no exemplary compound that inhibited the
acid secretion by antagonising histamine receptors. Even the way of assay to find
such activity was not known. From the business point of view, it was considered
doubtful that medical practitioners would accept such drugs even if the companies
fortunately succeeded in their discovery.
This high uncertainty accompanying paradigmatic discovery created distinguishable
profiles in the other aspects of innovation, especially in the organisation and in the
market. In the organisation, the research team at SmithKline & French faced much
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severer organisational resistance than its counterparts at Glaxo and Yamanouchi.
Even within the research team, it is reported that there was significant suspicion
about the possibility of such a drug. The parent company was about to axe the project
when there had been no outputs for years. In those circumstances, it was the
charismatic leadership of James Black that kept the project alive. Because of his
outstanding achievements in the work on P-blockers at ICI, and his strong
enthusiasm about new histamine receptors, the research team was prevented from
deviation from histamine antagonists and the company did not dare to scrap the
project. It was probably fortunate for them that the research site was geographically
distant from the head office of the company so that they could have autonomy to
some extent. The British subsidiary had to think about its own survival in the
company group and its members might have shared the senses of crisis and unity.
Therefore, the British company succeeded in concentrating its resources on the
histamine H2 antagonist project after 1968 when they found SK&F 91486, a weak
antagonist of histamine H2 receptors. In order to persuade people inside and outside
the company, they invented the concept of histamine H2 receptors and hurried to
make the results public when they discovered burimamide, though it was hopeless as
a pharmaceutical drug.
In contrast, in the cases of ranitidine and famotidine, at least, scientific and
technological uncertainties were lower than in cimetidine. The existence of histamine
H2 receptors had already been known. The researchers at Glaxo and Yamanouchi had
exemplary compounds including burimamide, metiamide and cimetidine, though
some of their properties were as yet unknown. They had also exemplary methods of
assay. They knew a significant part of the problems their precursors had faced. Their
companies were probably more supportive than SmithKline and French in the US,
though the eventual size of the market seemed to be unclear at that time.
However, the research teams in Glaxo and Yamanouchi faced different problems
from those their counterpart in SmithKline and French did. They had to make
something different and better in practice. The Glaxo team started from burimamide
and the Yamanouchi team started from cimetidine, but both groups had to
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circumvent the patents of SmithKline and French if they wanted to enjoy their
income fully. Each of them also had to make a drug which is at least as good as
cimetidine, but with some additional advantages over cimetidine to promote its drug
effectively. Yamanouchi also had to circumvent Glaxo's patents and find further
additional advantage over ranitidine. Therefore, what they had to do was only
modification, but modification was not at all easy because there were not only
natural restrictions but also social restrictions.
In addition, because it was obvious that the delay of the launch meant loss of the
income, Glaxo and Yamanouchi had to develop their own histamine H2 antagonists
very efficiently. This was achieved by doing different tasks in parallel20 (Glaxo 1987,
p.l 1; Glaxo internal documents; Interview with plant managers at Yamanouchi21),
which was apparently similar to the concurrent engineering in the machine industry
but different from it in that neither production specialists nor marketing specialists
took part in the drug design process.22
In the promotion, differences between the previous product(s) and theirs had to be
emphasised. Secondary advantages such as smaller dosage, longer duration, lack of
minor side effects, variety of forms and additional activities were emphasised. In the
ranitidine case, an important additional activity was the maintenance treatment, while
in the case of famotidine, it was the protection of the mucous membrane. They used
academic papers as evidence for their claims. In the famotidine case, new
experimental instruments helped to identify an additional activity. These efforts of
persuasion were directed outside of the company, mainly, to doctors.
Because both Glaxo and Yamanouchi were mainly domestic companies at the time,
they had to ally themselves with overseas companies. This turned out to have both
advantages and disadvantages. If the choice of partner was right, the co-marketing
could exploit the market very rapidly. Glaxo was very successful in most countries
20 SmithKline and French also adopted the parallel approach in the development of metiamide
and cimetidine, as we saw in Section 5.2.2.
21 The interview with plant managers at Yamanouchi was conducted on 17th September 1996.
22 On the concurrent engineering, see Clark and Fujimoto (1991), pp.211-217.
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because of this. However, if they chose a "busy" partner, this did not work.
Yamanouchi chose Merck as an overseas partner and could not enjoy a large share
outside Japan. Glaxo chose Sankyo as a Japanese partner and could not obtain a large
part of the Japanese market. The national health care system seemed to support the
exceptional success of famotidine in Japan. Because of its higher price, that is,
because of higher opportunity to gain margin under the system, doctors probably
preferred to prescribe it.
In sum, the innovation process of cimetidine was characterised by high scientific and
technological uncertainty, stronger organisational resistance, the powerful leadership
of the project leader, a new concept that changed theory and therapy, and an
exemplary role of the compound. In contrast, the innovation process of ranitidine and
famotidine was characterised by lower scientific and technological uncertainty, the
social restriction on modification, the organisational pressure of efficiency, the
systematic and intensive efforts in development, and the creation of differences from
existing rivals. From these we can identify two types of innovation in the
pharmaceutical industry. The first type is represented by the case of cimetidine and I
name it paradigmatic innovation, not only because it is based on paradigmatic
discovery but also because every aspect of the innovation process is paradigmatic.
The second type is represented by the cases of ranitidine and famotidine. This is
named modification-based innovation rather than normal-scientific innovation,
because socially acceptable and distinguishable modification is regarded as the most
important element in this type of innovation, whereas its normal-scientific aspect in
discovery is less important in the whole process of innovation.
These two types of innovation do not necessarily link to the business performance.
Ranitidine was more successful in business than cimetidine, though the former is a
modification-based innovation and the latter is a paradigmatic innovation.
Famotidine was not so successful as ranitidine in the world, though it was also a
modification-based innovation. However, it was most successful of the three
histamine H2 antagonists in Japan.
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5.5.2. Rational Drug Discovery?
Although cimetidine was popularly regarded as discovered by a rational approach, it
does not seem the case when we look at the process closely. It seems true that a
rational and theoretical approach was adopted in various parts of the process, but trial
and error also played a significant role. This seems the same as in the cases of
ranitidine and famotidine.23 In other words, in these discoveries, new knowledge
obviously came from not only existing knowledge that the researchers possessed, but
also from interactions of compounds and organisms. We cannot attribute the
processes only to social process or cognitive process. We must take nature into
account as well.24 This also has another important implication for the innovation
study. In the linear model of innovation, it is assumed that development follows
research. However, as revealed in the case ofmetiamide and cimetidine, in the
pharmaceutical industry, as well as other industries, some problems arise in the stage
of development, and they sometimes force the project to go back to the research
stage again. This reversal from development to research is probably not very
apparent because the drugs that failed in the development process are thrown away
before the market launch, and their relationship with their successors is unlikely to be
clear for outsiders. Unexpected interaction between compounds and organisms often
causes problems which may induce the reversal from development to research.
23 In burimamide case, about 700 compounds, in ranitidine, hundreds of compounds (Palmer
interview), and in famotidine, more than 400 compounds were synthesised.
24 The discovery ofHelicobacterpylori in the stomach is another example which reminds us of a
essential part that nature plays in the knowledge creation. See Thagard (1999), pp.39-83.
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Chapter 6: LHRH Analogues
6.1. Introduction
The drugs that we examine in this chapter are called luteinising hormone releasing
hormone (LHRH) analogues, which are used for the treatment of prostate and breast
cancer, endometriosis and some other sex-hormone-dependent diseases. LHRH is a
hormone secreted from the hypothalamus in the brain, and it stimulates the secretion
of luteinising hormone (LH) from the pituitary gland. LH, in turn, stimulates the
secretion of testosterone from the testes in males, or stimulates oestrogen production,
ovulation and the development of the corpus luteum in females. Therefore, LHRH is
a hormone that fundamentally regulates growth and activities of the gonads, so its
analogues can be used for the treatment ofvarious diseases in sex organs or the
control of reproduction in human and other animals. The two LHRH analogues that
we examine in detail here are leuprorelin acetate (hereinafter, leuprorelin) developed
by an alliance between Takeda in Japan and Abbott in the US, and goserelin
developed by ICI Pharmaceuticals (now AstraZeneca) in the UK. They are the most
successful LHRH analogues on the market in the world. Leuprorelin was synthesised
in 1973 by a group of scientists at Takeda led by Masahiko Fujino. Goserelin was
discovered in 1976 by Anand Dutta and Barry Furr at ICI Pharmaceuticals. However,
what made these drugs highly successful in the market was the development of their
depot preparations, which can release the drugs very slowly within the body. Frank
Hutchinson and Barry Furr at ICI Pharmaceuticals achieved the development of the
depot preparation1 for goserelin in 1981. Yasuaki Ogawa and his colleagues at
Takeda developed the equivalent for leuprorelin in 1984. Leuprorelin was first
marketed with a preparation for daily injection in the United States in 1985. Then its
depot preparation was launched in the US in 1989 and in Japan in 1992. Goserelin
was marketed as its depot preparation from the start. It was launched first in the UK
in 1987, then in the US in 1990 and in Japan in 1991.
1 The word "formulation" in place of "preparation" is often used among the experts in the area.
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Fig 6.1 Compounds Discussed in This Chapter
^Underlines show replacement.
a) LHRH
amino acids: pGly - His -Trp - Ser -Tyr - Gly - Leu - Arg - Pro - Gly - NH2
position: 1 23 456 7 89 10
b) TAP-031
pGly - His -Trp - Ser -Tyr - Gly - Leu - Arg - Pro - NHCH.CH,
c) Leuprorelin
pGly - His -Trp - Ser -Tyr - P-Leu - Leu - Arg - Pro - NHCHXEU
d) Triprorelin
pGly - His -Trp - Ser -Tyr - D-Trp - Leu - Arg - Pro - Gly - NH2
e) Goserelin
pGly - His -Trp - Ser -Tyr - D-Ser(Bu') - Leu - Arg - Pro - azaGlv - NH2
f) Buserelin
pGly - His -Trp - Ser -Tyr - D-Ser(BuV Leu - Arg - Pro - NHCtLCH^
Table 6.1: Major Events Related to the Discovery and Development of LHRH
Analogues
Year Leuprorelin Goserelin
1960 Discovery ofLRF (LHRH)
midl960s Basic research start (Abbott) Basic research start (ICI)
1971 Research start (Takeda)
Discovery ofLHRH structure
1972 TAP-31 discovered
1973 Discovery of leuprorelin
1975-6 Discovery of paradoxical effects
1976 Discovery of goserelin
1979 Depot preparation research
start
1981 Depot preparation research
start
Depot preparation developed
1984 Depot preparation developed
1985 Launch in the US (daily
injection)
1987 Launch in the UK
1989 Launch in the US (depot
preparation)
1990 Launch in the US
1991 Launch in Japan
1992 Launch in Japan
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6.2. Discovery of LHRH
The idea that the brain has an influence on the reproductive system via the pituitary
gland was suggested in the 1930s. Since then, a number of scientists had done
anatomical and physiological studies on the cerebral regulation of hormone secretion
from the pituitary gland. (Harris, Reed and Fawcett 1966; Harris 1972; Schally et al.
1968; Burgus and Guillemin 1970) Geoffrey Harris in England was one of the
leading researchers in this area. In 1947, he and J. D. Green proposed that this
regulatory system worked by means of a humoral relay through the tiny vessels that
linked the hypothalamus in the brain with the pituitary gland. (Green and Harris
1947) This idea was not immediately accepted. (Wade 1978, 210) For example,
Thomson and Zuckerman (1953) claimed that the vessels that Harris had reported did
not form the pathway of chemical transmitters. Harris argued back that Zuckerman's
experiment had flaws. (Harris 1955, pp. 87-88) However, to convince others of his
idea, Harris had to find the substance, which was secreted from the hypothalamus
and stimulated the release of hormones such as luteinising hormone (LH). Not only
Harris but also some other researchers in the world, including Samuel McCann,
Roger Guillemin and Andrew Schally in the United States, addressed this problem.
(Harris, Reed and Fawcett 1966; Harris 1972; Schally et al. 1968; Burgus and
Guillemin 1970; Wade 1978, 210-211)
In 1960, McCann's research team in Pennsylvania reported that extracts of a part of
the hypothalamus stimulated the secretion ofLH from the pituitary gland in rats.
They suggested the existence of an LH-releasing factor in the hypothalamus.
(McCann, Taleisnik and Friedman 1960; McCann 1962) At about the same time,
Harris's team independently found that extracts of a part of the hypothalamus caused
ovulation when infused into the pituitary gland in rabbits. They concluded that the
hypothalamus contained a specific substance which stimulated the release of the
gonadotrophic hormone such as LH. (Campbell, Feuer, Garcia and Harris 1961;
Harris, Reed and Fawcett 1966, 268) Guillemin's team confirmed these results in
1961 by using extracts of rat and sheep hypothalamus. (Guillemin 1964; Harris, Reed
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and Fawcett 1966, 268) The LH-releasing factor was speculated to be polypeptide
from its properties as early as 1962. (McCann 1962; Guillemin 1964)
There was keen competition between McCann, Harris, Guillemin, Schally and Karl
Folkers for isolation and molecular characterisation of the LH-releasing factor.
(Wade 1978, 302-303; Wade 1981, pp. 183-226) In particular, Guillemin and Schally
concentrated their efforts on obtaining the molecular structure of the LH-releasing
factor, whereas Harris and McCann also paid attention to physiological aspects of the
substance. (Wade 1978, 358; Harris andNaftolin 1970; Latour and Woolgar 1986,
pp.117-119) Guillemin and Schally had already engaged in severe competition for
the structure of another hypothalamic hormone called thyrotropin-releasing factor
(TRF; or thyrotropin-releasing hormone, TRH) from around 1962 to 1969, before
they began to pour their full energy into the investigation on the structure of the LH-
releasing factor.2 (Latour and Woolgar 1986, pp. 105-150; Wade 1978; Guillemin
1978; Schally 1978) In the previous competition over TRF (H), Guillemin and
Schally redefined the name of the game in discovery of hypothalamic hormones.
Discovery of a hormone was redefined as the identification of its molecular structure
by using methods acceptable to peer scientists. To find a substance having an activity
or to speculate its molecular structure without recognised methods became
insufficient to constitute discovery of a hormone. This new rule was essential to the
practical use of these hormones in therapy, because natural supply of these hormones
was very limited (only 250 micrograms ofLH releasing factor from 160,000 pig
hypothalami3) and so they had to be synthesized. What was also important was that
this new definition of discovery changed the financial requirement for participating
in the competition for discovery. It became necessary for each research team to buy
expensive, sophisticated analytical equipment and obtain millions of animal
hypothalami in order to compete effectively. (Latour and Woolgar 1986, pp. 118-124,
pp. 134-143) It should be noted that it was unclear at that time whether the substance
really existed or not, whether it was a polypeptide or not, and whether it was an
2 Guillemin and Schally "independently" determined the structure of TRF(H) in 1969. Both of them
won the Nobel Prize in Physiology or Medicine in 1977 in recognition of their contribution to
research on hypothalamic hormones.
3 Wade (1981), p. 205
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unknown substance or not. (Latour and Woolgar 1986, pp. 116-117) Therefore, it
was very risky to invest huge amounts ofmoney into this competition for the
molecular structure. Probably, the uncertainty about the search of the structure of
LHRH was considerably reduced after the identification of the structure ofTRF (H),
but this did not happen until 1969. Fortunately for Guillemin and Schally, both of
them managed to obtain huge financial support from organisations such as the
National Institute of Health or the Veteran Administration, although this support
considerably increased the pressure on them to hasten the research. (Wade 1978,
221; Wade 1981, p.197; Latour and Woolgar 1986, p.139) Because of these factors,
Gullemin's and Schally's groups managed to take the lead in the competition for the
structure ofLHRH over the other groups, even though they began to concentrate on
LHRH as late as 1969. Of course, they and their collaborators were creative and
skilful researchers. However, Guillemin and Schally might not have caught up with
the other groups without the combination of the more demanding definition of
hormone identification and characterisation they had established, their research
priority, their risk-taking attitude to the high uncertainty in the area and their
financial resources. (Wade 1981, p. 199. pp. 220-224)
In 1971, Schally's team finally reported the molecular structure of the LH-releasing
factor in pigs. Two Japanese chemists, Hisayuki Matsuo and Yoshihiko Baba, and a
Japanese physiologist, Akira Arimura, crucially contributed to the discovery. (Wade
1981, pp. 204-214) It was a decapeptide, that is, it consisted of ten amino acids. (Fig.
6.1a) (Matsuo et al. 1971) LHRH, which had been Schally's terminology (Schally et
al. 1968), became widely accepted as the name of the substance. Soon after that,
Guillemin's team confirmed an identical structure ofLHRH in sheep. (Burgus et al.
1972; Amoss et al. 1971) It is reported that shortage of the LH-releasing factor
delayed Roger Burgus, Guillemin's chemist collaborator, in his efforts to determine
the structure of the substance. (Wade 1978, 302) Harris's team was also said to be
close to discovering the structure at that time. (Harris 1972, xiv; Gregory 1971, p.21;
Furr interview4) It was not only analytical chemistry but also synthetic chemistry that
contributed to the discovery of the structure ofLHRH. Synthesizing the replica of a
4 The interview with Dr Barry Furr, one of the discoverers of goserelin at ICI Pharmaceuticals
Division (now AstraZeneca), was conducted on 21st July 1999.
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speculated substance and then examining its biological activities was a major tool to
reveal or confirm the molecular structure of the substance. (Latour and Woolgar
1986, p. 144; Wade 1981, p.212) Schally's group succeeded in the synthesis of
LHRH, too, in 1971. (Matsuo, Arimura, Nair and Schally 1971; Schally et al. 1971b)
The research team ofKarl Folkers, who was a former collaborator of Schally's in his
TRH project, also succeeded in synthesizing LHRH and confirming its biological
activity, soon after Schally's announcement of the LHRH structure. (Sievertsson et al.
1971)
Because LHRH was supposed to regulate the reproductive system, several
pharmaceutical companies recognized its medical and commercial potential early on.
Two companies were involved in the discovery ofLHRH. In England, ICI's
Pharmaceuticals Division was in collaboration with Harris. (Harris 1972, xii-xiv;
Gregory 1971) In the United States, Wilfrid White at Abbott Laboratories
collaborated with Schally in research on both follicle stimulating hormone-releasing
hormone (FSH-RH) and LHRH.5 (Schally et al. 1968, 537-538, 548-550; Schally et
al. 1971a) In addition, researchers at Hoechst in Germany independently succeeded
in synthesizing LHRH only three months after the first announcement of its structure.
(Geiger et al. 1971)
6.3. Synthetic LHRH Analogues: an Overview
Even before the structure ofLHRH was announced, analogues ofLHRH as well as
LHRH itself began to be synthesized and examined by various research groups,
including the groups involved in the competition for the structure ofLHRH, in order
to confirm the structure. (Monahan et al. 1972; Chang et al. 1972; Schally et al.
1972; Geiger et al. 1972; Fujino et al. 1972a; Yanaihara et al. 1972) The early
purpose of the synthesis ofLHRH analogues was to understand the structure-activity
relationship for the hormone and to create a synthetic antagonist of LH-release
(Schally et al. 1972, 366; Vale et al. 1972, 933; Monahan, Amoss, Anderson and
Vale 1973, 4616, 4619), rather than to find a more potent agonist. This was because
5 The two hypothalamic hormones were found to be identical later. (Schally et al. 1971a; Matsuo et al.
1971; SchaOy, Arimura and Kastin 1973, 344; Besser and Mortimer 1974, 176)
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antagonists of LH-release were thought to be useful for contraception, whereas
LHRH itself could be used as a pro-fertility drug. (Besser and Mortimer 1974, 178)
However, when several analogues were found to be more potent than LHRH in these
efforts, their clinical potential as pro-fertility agents began to gather more attention.
In 1972, Masahiko Fujino at the Central Research Division of Takeda Chemical
Industries found that an analogue with modification at position 10 ofLHRH
molecule (Fig. 6. lb) was five times more potent than LHRH. (Fujino et al. 1972b) In
the next year, Michael Monahan and his colleagues at the Salk Institute, where
Guillemin was leading the research, reported that several analogues with
modification with D-amino acids (optical isomers) at position 6 had several times
higher potency than LHRH. (Monahan, Amoss, Anderson and Vale 1973) In 1974,
Fujino and his colleagues found that several analogues with modification at both
position 6 and position 10 of the molecule was up to about a hundred times as potent
as the original substance. One of these was leuprorelin (Fig. 6.1c), the story ofwhich
we examine in detail in the following section. (Fujino et al. 1974a; Fujino et al.
1974b; Rippel et al. 1975) Schally's group reported similar results around the same
time. (Coy et al. 1974; Vilchez-Martinez et al. 1974) Coy and Schally (1978)
estimated that about 700 analogues ofLHRH had been synthesized by 1978. Among
them were included four analogues marketed later: leuprorelin synthesized and
developed by an alliance of Takeda and Abbott, triptorelin by Schally's group (Coy
et al. 1975), goserelin by ICI (Dutta, Furr, Giles and Valcaccia 1978) and buserelin
by Hoechst (Sandow, von Rechenberg, Jerzabek and Stoll 1978). (Fig. 6. ld-f) All but
triptorelin are analogues modified at both position 6 and position 10 of the LHRH
molecule.
These highly active analogues ofLHRH, so-called "super-active" agonists were at
first thought to be useful for stimulating fertility. However, when these compounds
(including synthetic LHRH) were tested in laboratories and hospitals in the mid-
1970s, it was found that they had a paradoxical effect: their repeated administration
did not stimulate but eventually inhibited reproductive function in animals and
humans. (Oshima et al. 1975; Corbin and Beattie 1975; Banik and Givner 1975;
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Rippel and Johnson 1976; Happ et al. 1978) This was speculated to be due to the
phenomenon of "desensitisation" or "down-regulation" of the physiological
processes responsible for LHRH release. (Hsueh, Dufau and Catt 1977; Belchetz et
al. 1978; Rivier, Rivier and Vale 1978, 2303; Sandow 1983, 571-575; Furr and
Woodburn 1988, 535) This discovery of the paradoxical effect led researchers to
alternative applications: including treatment for breast cancer (Johnson et al. 1976),
contraception (Beattie and Corbin 1977), treatment for prostate cancer (Redding and
Schally 1981; Warner, Santen, Demers and Max 1981), treatment for idiopathic
precocious puberty (Crowley et al. 1981), treatment for endometriosis (Meldrum et al.
1982), treatment for uterine fibroids (Filicori et al. 1983) and some other applications
(Corbin 1982; Sandow 1983; Waxman 1984; Cutler et al. 1985; Furr and Woodburn
1988). These applications became much more important than the short-term pro-
fertility use, which had originally been regarded as the main application. It should be
noted that the development of these various applications was simultaneously
conducted by different research groups with different analogues. We examine the
development of applications of two analogues, leuprorelin and goserelin, in detail in
the following sections. However, other analogues also contributed to the
development of their various clinical applications. These include buserelin (Jacobi
and Wenderoth 1982; Faure et al. 1982; Waxman et al. 1983a, b [treatment for
prostate cancer]; Klijn and de Jong 1982 [treatment for breast cancer]; Lemay and
Quesnel 1982 [treatment for endometriosis]; Labrie et al. 1984 [combination therapy
of prostate cancer with antiandrogens]; Maheux et al. 1984 [treatment for fibroids]),
triptorelin (Redding and Schally 1981; Tolis et al. 1982 [treatment for prostate
cancer]; Redding and Schally 1983 [treatment for breast cancer]) and D-Trp6- Pro9-
NEt-LHRH synthesized and developed by the Salk Institute (Rivier, Rivier and Vale
1978 [contraception]; Crowley et al. 1981 [treatment for idiopathic precocious
puberty]; Meldrum et al. 1982 [treatment for endometriosis]; Filicori et al. 1983
[treatment for fibroids]; Comite et al. 1986 [treatment for central precocious
puberty]).
Another important aspect in the development ofLHRH analogues was the
development of novel preparations (or formulations). Although "super-active"
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LHRH analogues were longer acting than LHRH itself, it was necessary that they
were given daily in order to obtain the long-term paradoxical effect. Oral
administration did not produce a clinically effective activity. Therefore, daily
injection was the first preparation, by which leuprorelin was approved by the Food
and Drug Administration in the USA. Because of the lack of convenience of this
preparation in particular in countries where self-injection was not generally allowed,
various other preparations were developed. The second preparation was a nasal spray
preparation developed by Hoechst for buserelin. As the third preparation, ICI
developed a biodegradable, sustained-release preparation in the early 1980s, which is
described in detail in Section 6.5. (Furr and Woodburn 1988, 536) The fourth
preparation was the one using biodegradable injectable microcapsules, adopted by
Syntex for their LHRH analogue called nafarelin (Sanders et al. 1984), Schally's
group for triptorelin (Reddings, Schally, Tice and Meyers 1984) and Takeda for
leuprorelin (Ogawa, Okada, Heya and Shimamoto 1989). These biodegradable
preparations were different from each other in composition and/or in production
methods. All of these new preparations greatly contributed to the diffusion of these
medicines. It should be noted that they were also developed by various research
groups. However, due to limitation of space, in the following sections, we look
closely only at the processes of discovery, development of application and
development of preparation, in two highly successful LHRH analogues, leuprorelin
and goserelin.
6.4. Leuprorelin
Leuprorelin (leuprolide, in the US) is the first marketed LHRH analogue, discovered
and developed by the alliance of Takeda Chemical Industries in Japan and Abbott
Laboratories in the US. It was synthesized by a research team led by Masahiko
Fujino at Takeda. Fujino, around 1965, studied synthesis of peptides under D. N.
Ward, one of Guillemin's co-workers, at the University of Texas. Fujino witnessed
the keen competition between Guillemin and Schally over TRH there and was
interested in hypothalamic hormones such as TRH and LHRH. He described the
situation:
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At that time, it was still very hard to synthesize peptides. If you had been able
then to combine five amino acids, you would have been able to get a PhD. ...
It was suggested to me [by a Japanese professor] that I do characterization
and synthesis ofTRF at Texas, but when I went there, it hadn't been isolated
yet. So I couldn't do that. Instead, I worked on LH, luteinising hormone,
there.
[Guillemin, Schally and McCann] were really fighting each other. ... I saw
them spending enormous amounts ofmoney. I saw a ceiling of the laboratory
removed to set up huge columns for chromatography for the isolation [of the
hypothalamic hormones], I saw a number of excellent researchers really
seriously working on the substances, and thought that something unusual
must be going on. I felt that something extraordinary would happen when the
substances were identified. I was really impressed. (Fujino interview6)
After Fujino came back to Japan, he was involved in the research on the synthesis of
adrenocorticotrophic hormone (ACTH) and gastrin derivatives for a while. (Fujino
interview; Takeda 1983, p. 753) When the isolation and characterisation of TRH was
announced in 1969, he started research on the synthesis of TRH, because he had been
interested in it since his stay in Texas. The objective was to find a simple and
economical way of synthesizing TRH. His team succeeded in synthesizing TRH on a
large scale in 1974, and it was marketed in 1978. (Fujino 1992, p. 2; Fujino
interview; Takeda 1983, p.743, pp. 1006-1007) This experience gave Fujino
confidence in peptide research. He said:
What I thought first was that [TRH] would become a drug if I could produce
it at the level of kilograms. Because the substance was very active, we didn't
need more. At that time, you could announce that you had made it if you
could make only a few milligrams of it. ... So, when I succeeded in making
TRH in kilograms, my confidence grew. I was convinced that I could make
drugs from peptides. (Interview)
Meanwhile, Abbott proposed to Takeda that they collaborate in research on
hypothalamic hormones in October 1970. Abbott had been in particular interested in
LHRH and its analogues. As mentioned above, the company had helped Schally's
group to identify the molecular structure ofLHRH. The company chose Takeda as its
partner because Abbott's research staff including Wilfred White knew that Fujino
6 The interview with Dr Masahiko Fujino was conducted on 28th January 1999.
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and his colleagues at Takeda did good work on the synthesis of peptides. Fujino also
knew White's work in the area. Takeda accepted the proposal and they made a
contract of research collaboration in August 1971. Shortly before that, the molecular
structure ofLHRH had been announced. The two companies at first agreed that
Takeda would do the synthesis ofLHRH analogues and Abbott would do biological
tests of them. Although Takeda had an excellent ability in synthetic chemistry, it did
not have the in vitro assay for the hormone. However, each company learned the
other's skill and later began to do both synthesis and biological tests. They
exchanged information and material, but otherwise, worked quite independently.
(Takeda 1983, 743; Fujino 1992, p.3; Fujino interview; Kuwashima 1996. p. 119;
Arnold et al. 1974)
Fujino's team started the synthesis ofLHRH analogues around the end of 1971. The
initial objective was to get a fertility stimulant. The methods they had developed for
the synthesis ofTRH were partly applied to this work and made it efficient. At first,
replacement of every position of amino acid was tried. (Fujino et al. 1972a; Fujino
1992, p. 4) However, the results were disappointing. All the early analogues were
much less potent than LHRH. Then they tried the replacement ofglycineamide (Gly-
NH2) at position 10 with various alkylamines, which have a similar size to
glycineamide. Fujino focused on position 10 because it was speculated that an
enzyme destroyed the LHRH molecule at that position. Fortunately for him, the
method his team was using for the synthesis, the liquid-phase method, was suitable
for this replacement, whereas the more commonly used solid-phase method was not.
(Fujino interview) Fujino had chosen the liquid-phase method because he had
regarded it as better in producing a large quantity of peptide fragments, though there
had been different opinions about the value of these methods at that time. (Fujino
personal communication, August 2000) Among them, an analogue (TAP-031), which
was replaced by ethylamide, showed high potency, 5 times as potent as LHRH in the
ovulation-inducing assay. (Fujino 1992, pp. 4-5; Fujino et al. 1972b; Fujino et al.
1973a; Fujino et al. 1973b; Rippel et al. 1973) This was the most potent LHRH
analogue at that time and indicated to others that the replacement at position 10 was
effective in enhancing the potency ofLHRH analogues. TAP-031 was marketed later
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as a fertility stimulant for cattle, but failed to be a drug for humans because its
administration for this purpose, the frequent injection, was not practicable. (Fujino
1992, p. 5; Fujino interview; Takeda 1983, pp. 1035-1036)
Fujino and his colleagues then tried replacement of amino acids at other positions,
while keeping the modification of position 10. Fujino noticed glycine at position 6.
He explained the reason:
I noticed it because only glycine has no side chain. So, I thought that this was
probably essential for the molecule to be bent. ... When we replaced it with
another amino acid, the activity disappeared. I thought this was due to the
bend of the molecule. So, I tried D-amino acids rather than ordinary L-amino
acids to change the bend at position 6. Then, the activity remarkably
increased. I've got it, I thought. (Interview)
Two episodes showing the serendipitous aspect of this discovery were also reported.
First, when a young researcher was told by Fujino to link an ethylamide to position
10, he did it wrongly to position 9, but the resultant peptide showed a high potency.
This made Fujino notice the replacement of position 10. Second, another young
researcher simply replaced an amino acid at position 6 with another, and the resultant
LHRH analogue showed an astonishing activity. However, other skilled researchers
failed to reproduce the experiment. Fujino did not ignore this happening. He made
the researcher check every amino acid he had used. Then, it was found that the amino
acid used at position 6 was not an L-amino acid but a racemic amino acid, which is a
mixture of two optical isomers, an L-amino acid and its D counterpart. A racemic
amino acid is the crude product of amino acid synthesis. The young researcher used
the crude synthetic amino acid, which should have been divided into the two isomers.
However, this event turned Fujino's attention to the bend at position 6. (Ogawa and
Fujino 1994, pp. 176-177)
As mentioned in Section 6.3, Monahan at the Salk Institute independently found that
the replacement of glycine at position 6 with a D-amino acid produced a several
times more potent LHRH analogue. (Monahan, Amoss, Anderson and Vale 1973)
However, when Fujino and his colleague combined the replacement at position 6
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with the replacement at position 10, they obtained 50 to 80 times more potent
analogues in ovulation-inducing activity in rats. (Fujino et al. 1974a; Fujino et al.
1974b; Fujino 1992, pp.5-6) The activity of these analogues was not so remarkable in
vitro, at most several times. Fujino explained the difference between in vivo and in
vitro:
You cannot know how strong the activity is, in vitro. You can know only
whether the activity is strong. In vitro, the activity did not appear so strong.
But in animals, it showed an outstanding activity. This is because its action
lasted [in animals], ...In vitro, you measure only one release. So, you cannot
know [its whole activity], (Interview)
Among the several analogues substituted at position 6 and position 10, the most
potent one, [D-Leu6, des-Gly-NFb10, Pro-ethylamide9]-LHRH (TAP-144, leuprorelin),
was chosen for the clinical development, aiming at the induction of ovulation in
infertile women. (Fujino et al. 1974b; Rippel et al. 1975; Fujino 1992, p.6)7 In the
end, they synthesized about 150 LHRH analogues to obtain this one. (Fujino 1992,
p.4)
However, in the process of pre-clinical studies, researchers at Abbott noticed the
paradoxical effect of "super-active" agonists, mentioned in Section 6.3. When they
gave a large dose of leuprorelin continuously to rats to examine its long-term toxicity,
they found that it inhibited ovarian and uterine growth and that it caused atrophy of
some sex organs such as the uterus and the epididymis. (Rippel and Johnson 1976;
Fujino interview) Several similar observations were reported outside the company at
the time. (Oshima et al. 1975; Corbin and Beattie 1975; Banik and Givner 1975)
Knowing that the drug acted as if it were an antagonist in the long term, they began
to look for alternative applications such as the treatment of sex hormone-related
cancer. It was still possible to develop the drug as an ovulation-inducing drug.
However, from the point of view of clinical usefulness and profitability, anti-cancer
application became the priority. (Kuwashima 1996, p. 121) It had been known that
the growth of breast cancer and that of prostate cancer were dependent on the level of
7 [D-Ala6, des-Gly-NH210, Pro-ethylamide9]-LHRH was about as potent as leuprorelin, but the latter
was better from the viewpoint of production. (Fujino personal communication, August 2000)
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sex hormones in the blood. (E.g. Jensen et al. 1971; McGuire, Chamness, Costlow
and Shepherd 1974 [on breast cancer]; Huggins, Stevens and Hodges 1941; Byar
1973 [on prostate cancer]) Because the drug could ultimately reduce the level, the
researchers thought to use it for the treatment of breast cancer first. They confirmed
that the drug led to mammary tumour regression in rats. (Johnson, Seely, White and
DeSombre 1976) However, Fujino pointed out uncertainty in this area:
It was not clear. At that time, it was said that too much steroid [sex] hormone
caused breast cancer, but it didn't show up when measured. Also, patients of
prostate cancer weren't necessarily rich in the male hormone. Anyway we
tried. When we tried [leuprorelin], it surely worked in animals. ... So, there
must be a relationship [between sex hormones and cancer]. But this isn't very
clear even now, though it has become somewhat clearer after the advent of
the inhibitory "super-agonists." (Interview)
The clinical trials of leuprorelin for the treatment of breast cancer failed to show very
good results. (Harvey et al. 1981) Fujino claimed that this was due to contextual
reasons rather than the efficacy of the drug itself.8
Because surgical treatment was known to be quite effective in breast cancer,
the drug was only able to be tested in patients with severe cancer who could
not be treated by other means. It was because no one knew whether the drug
was really effective in advance. No early-stage patient was willing to be
given such a drug. I thought it was natural that the drug failed to show
efficacy because it was given to the patients for whom no drug would work.
(Interview)
Another target was prostate cancer, which was a very common cancer in the US and
in European countries. There was no very effective treatment for this cancer in the
advanced stage. Surgical castration was effective but often caused psychological
trauma. Oestrogen therapy was also effective but with considerable side effects.
(Gittes 1991, 241-242) Therefore, the potential market seemed to be promising. The
development of leuprorelin for this use was first conducted by TAP Pharmaceuticals,
a joint venture between Takeda and Abbott, in the US, where there were a large
number of patients with the disease. (Takeda 1983, p.743; Fujino 1992, p.8;
8
Leuprorelin succeeded in obtaining an approval by the Japanese regulator for the treatment of pre¬
menopausal breast cancer in 1996, four years after its marketing for the treatment of prostate cancer in
the country. (Takeda internal document)
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Kuwashima 1996, p.122) Kunio Takeda, the then senior vice president of TAP
Pharmaceuticals and a member of the Takeda family, championed the development
of the drug. (Fujino interview) The drug for this application was then tested in
animals (Warner, Santen, Demers and Max 1981) and in patients (E.g. Warner et al.
1982; Vance and Smith 1984; Santen et al. 1984; Smith et al. 1985). Comparative
clinical trials with surgical castration or oestrogen therapy were also conducted.
(Warner et al. 1983; The Leuprolide Study Group 1984; Winfield and Trachtenberg
1984) The drug went through clinical trials successfully and obtained an approval for
the treatment of prostate cancer from the FDA in the US in 1985. It was marketed
under the trade name "Lupron®" in the country. As mentioned in Section 6.3, the
drug was at first given by daily injection, presupposing self-injection. (Fujino 1992, p.
8)
However, the development of leuprorelin in Japan was slower. First, there were
fewer patients with prostate cancer in Japan. (Fujino interview) Second, because self-
injection was not usually permitted in Japan, daily injection was difficult in practice
there. (Yamanaka, Makino, Kumasaka and Shida 1984, 558; Fujino interview) Third,
as a result of these, there was a strong suspicion about marketability of the drug in
Japan amongst the management and the marketing division of Takada. Fujino
described the situation:
In Japan, prostate cancer was not common at all. So, nobody thought of
[leuprorelin] seriously. They said, "This would not sell even 200 million yen
at best." Only Konishi-san [the then president of the company] stood by us,
saying that this should be developed in Japan as well. But the others
disregarded the drug, which is now the best selling drug in Takeda. ... I think
if Konishi-san had not supported it, it might have been abandoned. So, its
development in Japan was late. ... In Japan, self-injection wasn't permitted
except insulin. So, they said, "Daily injection can't sell in Japan. Who wants
to go to the doctor everyday?" (Interview)
In this situation, researchers at Takeda sought a more convenient preparation. In the
middle to late 1970s, Yasuaki Ogawa and his colleagues at the Pharmaceutics
Laboratories of Takeda tried several preparations of leuprorelin such as a nasal spray,
but failed to obtain stable absorption. Then, they turned back to injection, but this
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time, they thought of a slow-release preparation by putting the drug into
biodegradable microcapsules, so that the patient would need only one injection in a
month, for example. Since the mid-1970s, a number of studies on using
biodegradable materials for making slow-release preparation had been reported.
However, most previous applications were for steroids, which were insoluble in
water, and with tiny sticks of biodegradable polymer rather than microcapsules.
Therefore, it was a difficult challenge for them to find out how to enclose the
hydrophilic peptide in particles of hydrophobic biodegradable polymer with an even
distribution. They chose a co-polymer of lactic acids and glycolic acids (PLGA), as
the biodegradable material. Around 1975, Ogawa had heard of this material from Tai
Matsuzawa, who was a senior researcher of the Pharmaceutics Laboratories and in
the US at that time. (Ogawa interview9) Matsuzawa, one of the earliest experts in
biological pharmaceutics in Japan, was sending new concepts and information
related to the area, including bio-availability (BA) and drug delivery systems (DDS),
from the United State to Japan. PLGA was part of that. This material was then well
known as biodegradable and used in the United States, but the ratio ofmixture was
varied and needed optimisation. (Matsuzawa interview10)
The first task for Ogawa's team was to obtain the polymer. This was not easy.
Ogawa put it in detail:
I asked various chemical companies in Japan for the polymer, but they said
they didn't know about such material and didn't produce it. Then, I wrote to
the American Company that had published a book about the material, asking
for it. They said they could supply it, but the price was ten thousand dollars
per 100 grams of the polymer. ... That was too expensive. So we gave up the
idea ofbuying it and decided to make it, based on the patents. Because our
company had a polymer group in the chemicals division, I went there first
and asked. The man I asked was one ofmy peers employed in the same year
and gave me an OK. However, when the plan went up to a higher rank,
another man gave me a ring, asking, "How much do you want?" When I said,
"Ten or twenty kilograms at most in a year," he said, "You should know that
you need at least a ton if you want to order a chemical product. We can't do
9 The interview with Dr Yasuaki Ogawa, who developed the depot preparation of leuprorelin, and Mr
Kouji Sonoi, who was involved in the clinical development of leuprorelin, was conducted on 27th
January 1999.
10 The interview with Dr Tai Matsuzawa was conducted on 8th February 1999.
158
business on such a small scale. I don't know what your friend said, but we
can't help you."
Then, we tried to synthesize the polymer by ourselves. But, it was impossible
for us to make it, referring only to the patents. So, there was nothing left for
us but to look for a chemical company who could make the polymer for us.
... Fortunately, Wako Pure Chemical Industries in Osaka, which was
producing cellulose polymers for pharmaceutical uses, took it seriously and
sent a researcher to our laboratories. The researcher happened to be a two
year junior ofmine in the same course at the same university. ... The
company agreed to synthesize the polymer for us, and we were able to start
the research at last. That was in 1980 or 1981. (Interview)
Ogawa's team at Takeda and researchers at Wako made a joint effort to obtain a
suitable polymer for the purpose. First, they developed a method of polymerisation
without using a heavy metal catalyst. This was because they were unable to get the
material necessary for the conventional method using a heavy metal catalyst. At the
same time, the new method was better than the conventional one because the former
was free from contamination of the heavy metal. Next, they tried to optimise the
average molecular weight and the ratio of the mixture of lactic acid and glycolic acid.
They synthesized 7 or 8 polymers with different ratios ofmixture and examined their
biodegrading and drug releasing properties. The best ratio of lactic acid/glycolic acid
for a month-long release was found to be 75/25. This work was completed in 1984.
(Ogawa and Toguchi 1991, 22; Ogawa 1999)
In parallel with the development of the polymer, Ogawa and his colleagues also
developed the method for producing microcapsules. First, they tried the method
called the phase separation method, which Syntex patented for a LHRH analogue
preparation in 1982. However, they did not have a powerful mixer and when they
tried it with their less powerful one, they could not obtain proper microcapsules.
Ogawa, an expert of emulsion research, next tried another method called the in-water
drying method, which produced microcapsules from a threefold, water/oil/water
emulsion of the drug. This method produced good microcapsules though the rate of
capture of the drug was only 5%. By differentiating the viscosity of the inside water
solution including the drug and the outside water solution and by doing the process
under a very low temperature, they managed to improve the rate of capture up to
more than 95% by the end of 1984. Luckily again for them, this method was later
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found to be more suitable for mass production than the phase separation method used
by Syntex and Schally's group, because it did not need an organic solvent, which
was potentially dangerous and difficult to remove completely from the product.
(Ogawa and Toguchi 1991, 20-21, 23; Ogawa interview; Ogawa, Okada, Heya and
Shimamoto 1989)
The sustained-release preparations, or the depot preparations, ofLHRH analogues,
like the one developed by Ogawa's team, were also being developed by other groups,
including ICI, Syntex and Schally's group around the same time. These groups were
keenly competing with each other. All the mentioned groups adopted PLGA as the
matrix material and all but the ICI group adopted microcapsules as the form.
(Sanders et al. 1984; Redding, Schally, Tice and Meyers 1984; Hutchinson and Furr
1985) Takeda was not always the top runner. Ogawa wrote:
I have experienced two serious shocks, which nearly made me quit the work.
The first shock was the encounter with Syntex patent. ... Their idea was the
same as ours, and we were far behind. We just managed to produce
microcapsules on a small scale. Although I was deeply disappointed, my boss
encouraged me to catch up with them before commercialisation. The second
one was when I saw Dr Sanders' paper in the Journal ofPharmaceutical
Sciences and Prof Schally's one in Proceedings of the National Academy of
Sciences in October 1984.1 supposed, at first, that they were in clinical trials,
and my shock then was even bigger than the first one. However, when I
collected more information about them, I found that both were using the same
method, which was originally created by Southern Research Institute, and
neither had yet been tried clinically. I was convinced that I could catch up
with them before commercialisation because I knew that their method had
problems. (Ogawa and Toguchi 1991, 23)
By using a different method, Ogawa's group was able to avoid existing patents and
file their own patent. (Japanese Patent Tokkai 62-201816)
The next problem that Ogawa's team faced was to obtain the support of other
divisions and the management of the company. Because the preparation was
unfamiliar to everyone, there was a strong doubt within the organisation about
whether the regulator and doctors would accept it. Ogawa put it:
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When I proposed this, 99% of people in the development division looked
suspicious. "What price are you proposing to the government?" "How can
doctors control the treatment?" "Do you think doctors will be willing to leave
their patients alone for a month?" Most opinions were like that. Only one, the
then director of the development division, Dr Takahashi supported us.
Without him, this project might have been discarded. More accurately, only
Dr Takahashi and Mr Konishi, the then president, said that this was very
interesting. Of course, people in the research division, including Dr Morita,
the then head of the division, supported us. But the rest in our company said
that it would be hard to market such a drug. (Interview)
In 1984, the clinical development of the depot preparation managed to become a
project, and was given a codename TAP-144-SR. At the beginning, its priority was
still very low. However, when the company asked its allied overseas companies in
the US and Europe which of its projects they found most interesting, all answers
included TAP-144-SR. TAP Pharmaceuticals, which was about to launch the daily
injection preparation of leuprorelin promptly announced that they would also
develop the depot preparation in the US. Soon after that, European partners also
decided to develop it in European countries. This movement enhanced the priority of
its development in Japan. (Ogawa interview; Ogawa 1999)
In 1985, the depot preparation proceeded to clinical trials in Japan. However, there
was another difficulty there. Kouji Sonoi, a manager at the Pharmaceutical
Development Division of Takeda, said, "Doctors in Japan at first regarded the drug
as out of the question. ... They were unfamiliar with the concept of a one-month-
long acting drug." (Interview) Ogawa added, "It was also difficult to make the
protocol for the clinical trials, because the drug was an unprecedented one." The
protocol of clinical trials is usually made through discussion with a manufacturer of a
new drug and doctors who conduct its trials. However, in the case of leuprorelin,
doctors had no experience in clinical trials of this kind of drug. Here, it was fortunate
for Takeda that the drug had already been marketed in the US with the preparation
for daily injection, and that the clinical trials of its depot preparation also were more
advanced in the US than in Japan. The experience in the US helped in the making of
the protocol and reduced the anxiety of doctors about its efficacy and safety. (Ogawa
and Sonoi, interview) The efficacy and the safety of the depot preparation were
shown in clinical trials in various countries. (E.g. Sharifi, Soloway and the
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Leuprolide Study Group 1990; O'Brien and Hibberd 1990; Giraud 1990; Akaza et al.
1990; BischofF and German Leuprorelin Study Group 1990; Niijima et al. 1990;
Rizzo et al. 1990; Aso et al. 1991)
There was a problem in the manufacturing of the drug, too: how to make sure of its
germ-freeness. This was an essential task to pass the inspection of regulators.
Because the drug was a peptide and contained in the delicate microcapsules, the
easiest way, heating, was not available. Therefore, Takeda's engineers decided to
make all the production processes germ-free. It was an extremely troublesome effort
to construct the germ-freeness of all processes. They achieved this by showing that
every element such as equipment and material was germ-free. It is reported that more
than 1,000 documents were produced to validate the germ-freeness of each element
of the production process. (Toguchi, Ogawa, Okada and Yamamoto 1991, 407;
Ogawa and Fujino 1994, p. 189; Ogawa interview)
The depot preparation of leuprorelin was first marketed in the US, France and Italy in
1989. The launch in Germany and the UK followed. In 1992, it was launched in
Japan, as Leuplin®. (Ogawa 1999; Ogawa and Fujino 1994, p. 190) Meanwhile, other
applications, such as the treatment for endometriosis, precocious puberty and uterine
fibroids, were also clinically studied (E.g. Dlugi, Miller, Knittle and Lupron Study
Group 1990; Lee, Page and The Leuprolide Study Group 1989; Parker and Lee 1989;
Friedman et al. 1991). These were approved by regulators later. (Ogawa 1999;
Takeda internal documents) The sales of leuprorelin worldwide in 1994 were 425
million dollars. (Rickwood and Southworth 1995, p.119)
The success of the depot preparation of leuprorelin brought organisational power to
pharmaceutics researchers, the researchers working on pharmaceutical system such
as preparation and dosage forms, in Takeda. Ogawa explained it:
Before, pharmaceutics researchers were regarded as only blenders.
Preparation was not necessarily regarded as a research area in the research
division. [Since the success of the depot preparation] everyone has
recognized that preparation is a research area. The company founded the
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DDS Research Laboratories. They also built a new building for the
Pharmaceutics Laboratories. (Interview)
The drug also enhanced the significance of pharmaceutics amongst academics and
bureaucrats in Japan. Ogawa put it:
I think that this was a major cause, though not the only cause, which made the
concept of drug delivery system important in the Japanese society of
pharmaceutical sciences. Leuplin is now ... recognized by academics as
textbook stuff. Another thing is that the Ministry ofHealth and Welfare has
recognized these products, maybe because [Leuplin] worked very well. They
gave us quite a reasonable price for the drug. (Interview)
Sonoi added that the depot preparation of leuprorelin by injection contributed to
establishing an advantageous differentiation of the product from the most significant
rival product, goserelin, which adopted a different form of depot preparation and was
marketed a little earlier than the leuprorelin depot preparation. (Sonoi interview)
6.5. Goserelin
The Pharmaceuticals Division of Imperial Chemical Industries (ICI) had a research
tradition in sex hormone-related medicines for humans and animals. (Sneader 1985,
pp. 198-199; Furr interview) Tamoxifen citrate (Nolvadex®) was one of the products
from this tradition. The drug, discovered by ArthurWalpole and his colleagues, was
an effective anti-oestrogen and marketed for the treatment ofbreast cancer in 1973.
(Sneader 1985, p.199; Kennedy 1993, pp.133-134, p.175) Walpole was also in
collaboration with Geoffrey Harris at Oxford on research on LHRH from 1966. (Furr
1991; see Section 6.2) Barry Furr, one of the key researchers who discovered
goserelin, described their position in the area at that time:
ICI Pharmaceuticals worked with Harris, trying to isolate that factor. And at
the time that Schally and Guillemin described their deca-peptide, ICI had
three possible structures for LHRH. One ofwhich was the same, two of
which were different. So we were very close behind Schally and Guillemin.
And this work was done by Arthur Walpole, Geoffrey Harris and an
outstanding peptide/protein chemist called Harry Gregory. (Interview)
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Furr succeeded Walpole in some of his responsibility in the reproductive biology unit
at ICI's Pharmaceuticals Division in the mid-1970s. By that time, a number of
research groups in the world had begun to synthesize and examine LHRH analogues
to find a drug. ICI's team also started the search for effective LHRH analogues for
pro-fertility and anti-cancer uses. Furr put it:
Initially, we were looking for agents that were the same as LHRH but more
potent and more stable, and our concept was that we could use these to
stimulate reproduction. At the same time, we were looking for LHRH
antagonists, and our view was that these would inhibit reproduction. And
these were the ones that we believed to be useful in breast and prostate cancer
and in sex hormone-dependent gynaecological conditions. So we had a
concept that: LHRH agonists would be pro-fertility, and then LHRH
antagonists would inhibit fertility. That was the overall view. (Interview)
Based on the information that replacement of amino acids at position 6 and at
position 10 was important for obtaining the potency and the stability ofLHRH
analogues, Anand Dutta and his fellow chemists at ICI tried not only D-amino acids,
as others were doing, but also a-aza-amino acids, whose derivatives were rather
unexploited. This was because they thought that both types of amino acids were
more resistant to peptide-destroying enzymes (Dutta and Morley 1975; Dutta and
Giles 1976; Dutta, Furr and Hutchinson 1993, 11-12) Furr described the situation:
When LHRH agonists were being developed, there was a recognition that
they were rapidly broken down in blood and tissues by enzymes, and they
were cleaved between positions 6 and 7, and 9 and 10. ...
We tried primarily D-amino acids and aza-amino acids. And we tried then in
various positions, we tried two azas, one aza in 6 and one in 10, we tried D-
amino acid in 6 and aza in 10, and that was the combination that gave us the
best results in terms of intrinsic potency, potency at the level of the pituitary
gland and also stability from attack by the enzymes. (Interview)
ICI researchers also had to work outside the patents of other companies. However,
this was not the starting point of their research. Again, Furr's explanation:
We chose to put an aza-glycine in, which gave us, we believe, a better quality
product. So there was an element of avoidance although at the time we were
doing it, there was a lot of overlap, because other people were working at the
164
same time. So we weren't always sure what other people were doing. It only
became clear later. (Interview)
The ICI research team thus synthesized more than a hundred analogues. Among them
the one that showed best total performance in terms of efficacy and duration of
action was chosen to be developed in 1976.11 This was goserelin, which substituted a
D-amino acid, D-Serine (Bul), at position 6 and azaglycine at position 10 (fig. 6.1e).
Goserelin showed 100 times higher ovulation-inducing activity in rats. (British
Patent 1524747; Dutta, Furr, Giles and Valcaccia 1978; Dutta et al. 1978; Dutta, Furr,
Giles and Morley 1976; Dutta, Furr and Giles 1979a; Dutta Furr and Giles 1979b;
Dutta, Furr and Hutchinson 1993, 11-13; Furr 1998, 118; Furr interview)
When Furr and his colleagues examined goserelin, they encountered the paradoxical
effect ofLHRH analogues, as other researchers working on them did. (Dutta, Furr
and Hutchinson 1993,13-15; Furr 1998, 119) Furr described it:
We realized this was not a paradox but a well-known effect, which was
described by physiologists as desensitisation of tissue, by pharmacologists as
tachyphylaxis, and then by molecular biologists and by biochemists as
receptor down-regulation, which was describing the mechanism of action. So
it was a well-appreciated phenomenon. But because endocrinologists rather
than pharmacologists worked on it, it was initially a surprise... (Interview)
When Furr noticed the paradoxical effect, he switched the target ofgoserelin to the
one for LHRH antagonists, the treatment of sex hormone-dependent diseases such as
breast cancer and prostate cancer. (Dutta, Furr and Hutchinson 1993, 15; Furr 1998,
119; Furr interview) The use for stimulating fertility was not impossible, but it
required practitioners to administer the drug every 90 minutes. Furr thought that this
could not be a major use. (Furr interview) Therefore, Furr and his colleagues
investigated the possibility of using the drug for the treatment of breast cancer, which
they were familiar with through the prior development of tamoxifen. They tested the
drug in rats and found that it had an anti-tumour activity against a certain kind of
mammary tumour. (Nicholson and Maynard 1979; Furr and Nicholson 1982)
11 According to Dr Furr, easiness of synthesis on a large scale may have been also taken into
consideration. (Furr personal communication, July 2000)
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However, there was a concern about the strategic positioning of goserelin when they
already had tamoxifen citrate, an effective drug for the treatment of breast cancer.
Furr put it:
One of the problems I had ... was that we also had Nolvadex [tamoxifen],
which was very good in breast cancer, and that was an orally available drug
with a reasonable side effect profile. So, I was not clear how we could
develop Zoladex [goserelin] to be commercially successful as a daily
injection in breast cancer, when we had a good competitor, which was
Nolvadex. It was in the same company but even if it had been in another
company it would still have been a difficult competitor, to argue a case.
(Interview)
Furr and his colleagues changed the primary target of goserelin to the treatment for
advanced prostate cancer, which had a few alternative treatments such as surgical
castration and oestrogen administration but all were not without problems, as
mentioned above. (See Section 6.4.) They did not give up its use for the treatment of
breast cancer, but the priority was put on the treatment of prostate cancer. (Furr
interview) Clinical Studies of goserelin for the treatment of prostate cancer started in
the early 1980s. Three early studies with about 10 patients claimed the efficacy of the
drug in the treatment. (Allen et al. 1983; Walker et al. 1983; Ahmed et al. 1983)
Another report claimed that the drug failed to show a long-term efficacy in the
treatment of 15 patients. (Kerle, Williams, Ware and Bloom 1984) However, later
studies with the depot preparation of goserelin did not support this report. The failure
was interpreted as probably due to the variation of patients, based on a study with 29
patients (Grant et al. 1986, 542), or perhaps due to insufficient dosage and less than
ideal preparation form, based on a study with 27 patients. (Murphy et al. 1987) Trials
with a larger number of patients did not demonstrate the therapeutic failure again.
(Debruyne et al. 1988; Peeling 1989; Soloway et al. 1991)
Meanwhile, a depot preparation of goserelin was developed. Although daily injection
could be used and was used in the early studies, it was thought that the preparation
would limit the acceptance of medical practitioners and reduce patient compliance
with the treatment. They began to investigate alternative ways of administration of
the drug. Nasal administration was examined, but they found that it was not suitable
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because the absorption rate was low and too variable. The next preparation
considered was a depot preparation with a biodegradable material. (Dutta, Furr and
Hutchinson 1993, 15) Here, Furr's human network contributed to the solution. He
explained it:
I had some very good fortune with Zoladex in that I had worked with a
formulation scientist, called Frank Hutchinson, and we together developed
slow release formulations of prostaglandins for dogs. ... So I said, one day, to
Frank, "We have an LHRH agonist, which is a peptide, and we need to
deliver this as a monthly depot so that we don't have to give daily injection.
And ideally, we want something that's biodegradable so that there will be no
depot left at the end of the month. It's no good having to cut pieces of plastic
out of a patient. Can you do it?" And he had the concept that he could by
using polymers of lactic acid and glycolic acid. So, he said he could do it, and
a lot of people said, "This would be impossible because how can you
encapsulate a biodegradable peptide in a biodegradable matrix and expect to
get activity?" But he had all sorts of reasons why he could do it. And he did it.
And I tested the materials he made and they worked. (Interview)
Suspicion was not only about feasibility of such preparation but also about the
absence of immune rejection response to the used material. (Furr 1998, 119)
However, Hutchinson began to attack the target in 1979. (Furr interview) In the
development process, a serendipitous event saved the project. Furr talked about the
episode:
[The preparation] seemed to work for a very short period, ... a period of
about a week. But we couldn't ... get longer periods of action. Then, I went
on holiday, and the person who was collecting the samples continued to
collect them for a much longer period than we normally did. And when I
came back, I analysed the results. What had happened was that we got our
usual seven-days worth of activity, then we lost activity for between seven
and twenty days, and then the activity returned. Frank Hutchinson then
realized, when he saw these data, that there were two phases of release of the
drug. ... He realized there was a diffusional phase of release, followed by a
degradation phase of release. So, then he could change the characteristics of
the polymer of lactide and glycolide to overlap diffusion and degradation, and
then you got a smooth release of the drug. So, it was a bit of good fortune that
I'd gone on holiday, because we might not have realised that there was a
secondary phase, because normally we stopped the experiment when we lost
the activity. (Interview)
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The first depot preparation of an LHRH analogue, a tiny rod ofPLGA matrix
containing the drug for implanting, was thus developed in 1981. (Furr 1998, 119;
Dutta, Furr and Hutchinson 1993, 15-21; Hutchinson and Furr 1985)
Soon, clinical trials of the depot preparation ofgoserelin started. In them the drug
was compared with existing endocrinological treatments, surgical castration,
oestrogen therapy and even the daily injection of the same drug. It was shown that
the preparation was as effective as surgical castration and oestrogen, safer than
oestrogen, and more effective than the daily injection ofgoserelin. (Grant et al. 1986;
Van Cangh, Opsomer and Wese 1986; Namer et al. 1986; Murphy et al. 1987;
Emtage et al. 1987; Peeling 1989; Soloway et al. 1991)
There were several problems to be solved in the process of clinical development.
Firstly, ICI workers had to explain the mode of action to the medical and regulatory
authorities because they expected that goserelin would have a stimulatory effect but
it had an inhibitory effect. (Furr interview) Secondly, "super-active" LHRH
analogues in fact had an acute stimulatory effect, often called the "flare-up"
phenomenon. (Waxman et al. 1985) They were able to demonstrate that this
phenomenon was not serious to patients unless they had an imminent risk of spinal
collapse. (Furr interview; Grant et al. 1986, 542; Murphy et al. 1987, 189; Beacock et
al. 1987, 440-441; Chrisp and Goa 1991, p.281) This phenomenon was observed in
every "super-active" LHRH analogue, and it was proposed that the combination
therapy with anti-androgens could avoid the exacerbation of symptoms caused by the
phenomenon. (Labrie et al. 1984; Klign, De Voogt, Schroder and De Jong 1985;
Gittes 1991, 242) Some other side effects also had to be explained and shown to be
practically insignificant. Thirdly, establishment of its production was a very difficult
task. The production of the peptide on a large scale with a high degree of quality and
stability was another unprecedented achievement and required a lot of skills and
effort. (Furr interview) These problems were resolved by organisational integration,
in particular, through a multi-disciplinary team, consisting of chemists, biologists,
pharmacists, pharmacologists, toxicologists, production managers and project
coordinators. (Furr interview)
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Goserelin was first launched in the UK in 1987 for the treatment of prostate cancer
under the trade name "Zoladex®." It was then marketed in the US in 1990 and in
Japan in 1991. Meanwhile, applications for the treatment of pre-menopausal breast
cancer, endometriosis and fibroids were also clinically developed (Williams et al.
1986; Zeneca 1999a [breast cancer]; Shaw and Zoladex Endometriosis Study Team
1992; Candiani et al. 1990; Zeneca 1999b [endometriosis and fibroids]). Goserelin
was launched in the UK for endometriosis and breast cancer in 1992 and for fibroids
in 1996. (Furr personal communication, July 2000) The sales ofgoserelin worldwide
were estimated to be 321 million dollars in 1994. (Rickwood and Southworth 1995,
P 119)
6.6. Discussion
6.6.1. Uncertainty Surrounding Drugs
When we look through the case ofLHRH analogues described above, we can see
clearly how much and how different kinds ofuncertainty there have been in the
discovery and development of the drugs. Firstly, there was uncertainty about the
molecular structure ofLHRH. Secondly, there was uncertainty about how to improve
potency and stability by modifying the structure of LHRH. Discussion about these
two kinds ofuncertainty seems to have been closed since the late 1970s. Thirdly,
there has been uncertainty about how to use LHRH analogues. Fourthly, intertwined
with this, there has been uncertainty about the mode of action ofLHRH and its
analogues. These two types ofuncertainty were more observable in these drugs than
in others in the previous chapters because they had the paradoxical effects, that is to
say, the opposite effects to what were originally expected. The uncertainty about the
action mechanism and the application opportunity is still high and open to discussion.
It is important to note that the uncertainty has also been socially conditioned. For
example, the pharmaceutical companies had to explore the mode of action of their
drugs before they could explain the paradoxical effects.
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There was also uncertainty related to the clinical development ofLHRH analogues.
Failures in their clinical trials clearly show us various aspects of the uncertainty
around clinical trials. In the case of leuprorelin, the drug showed efficacy in rats with
mammary tumours, but failed to show the same level of efficacy in patients with
breast cancer. This may be due to the differences between rats and humans. It may be
due to the differences of the stage ofprogress of the disease. Other explanations are
also possible. In the case of goserelin, one of its clinical trials failed to show the
long-term efficacy in prostate cancer, although the others showed that. This may be
due to the shortage of its dosage. It may be due to the form ofpreparation. It may be
due to the variation of the patients. Again, there are a lot of other possible
explanations. Therefore, various factors, including the characteristics of the tests (E.g.
in vitro or in vivo), the characteristics of the subject (E.g. rats or humans, males or
females, early stage patients or advanced stage patients), the variety of the subject,
the dosage of the drug and the form of the drug, consisted of the uncertainty around
clinical trials. It should be noted, again, that these factors are also social ones.
Availability of subjects, availability of types of the drugs and acceptability of
experimental methods are all socially conditioned.
There was also uncertainty related to the manufacturing of the drugs. We can find
various aspects of this uncertainty in the development of the depot preparation of
leuprorelin. Difference between production in the laboratory and that in the plant was
revealed. Supply of the material was also found to be uncertain. Patents by others
limited the development. Tacit knowledge played an important role, because
Takeda's researchers failed to reproduce the polymer from the patents only, but the
polymer maker that helped the company managed to do that. Availability of
equipment also limited the development of production methods. The optimisation of
polymer and the improvement ofmicrocapsules were achieved through a trial-and-
error method. The validation of germ-freeness of the production process was made
through a step-by-step way. All of these constituted the uncertainty surrounding
manufacturing. It is obvious that they are socially conditioned. For example, a small
quantity of organic solvent used in laboratories was not a problem, but a large
quantity of it for commercial production would have required a special building,
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special equipment and special expertise to control it, under regulations. This would
have cost a lot and become a serious problem for the pharmaceutical company. This
enhanced the company's preference for the method without organic solvent to the
one using it. Therefore, the difference between production in laboratories and in
plants was not only a "technical" issue but also a social issue.
Finally, there was a class of uncertainty which was more obviously social. One was
organisational uncertainty. The leuprorelin researchers at Takeda faced suspicion
amongst the management and the other divisions. But for the support of the then
president, the product would have been discarded. The goserelin researchers faced a
strategic problem when they considered the application for the treatment of breast
cancer because they already had another potent drug in the same therapeutic area.
There was also market uncertainty. The companies had to explain to the medical
authorities and the regulatory authorities how their drugs worked, how effective they
were and how safe they were. This market uncertainty was also the major source of
the organisational uncertainty.
6.6.2. Types of Innovation
In the previous chapter, we identified two types of innovation in the pharmaceutical
industry: paradigmatic innovation and modification-based innovation. The former
was characterised by very high uncertainty, people's unfamiliarity with the drug and
their suspicion, the necessity of strong leadership and the exemplary role of the drug.
The latter was characterised by moderate scientific and technological uncertainty, the
social restriction ofmodification, the importance of organisational integration and
systematic resource mobilization, and the necessity of the construction of differences.
The innovation ofLHRH analogues described in this chapter appears to be closer to
paradigmatic innovation. There was high uncertainty as discussed above. People
inside the organisation and outside were at first unfamiliar with the drugs and
showed their suspicion. Strong leadership was needed. However, the exemplary role
of the drug was not very clear. Various LHRH analogues were simultaneously
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developed by different organisations. Leuprorelin was the first LHRH analogue with
modifications at position 6 and 10. Goserelin was the first LHRH analogue with the
depot preparation. Both played an exemplary role in a particular aspect among the
class of drugs, but neither was an absolute exemplar. Various competing LHRH
analogues affected the shaping process of each other. In such a situation, the
construction of differences, one of the major characteristics of modification-based
innovation, was important. Thus, various LHRH analogues collectively made a
paradigm and were at the same time differentiated from each other. It can be said that
in the case ofLHRH analogues, paradigmatic innovation and modification-based
innovation were mixed. This implies that the distinction between paradigmatic
innovation and modification-based innovation is not a matter of a dichotomy but a
matter of degree.
6.6.3. Competition and Innovation
In the case ofLHRH analogues, it is noticeable that keen competition was observed
throughout the innovation process: in the discovery ofLHRH, in the synthesis of
LHRH analogues, in the development of clinical applications, in the development of
preparations and in clinical trials. Several groups in the US, Europe and Japan always
participated in each stage of the competition, though there were a few cases of
entrance and exit. On the one hand, this competition cost each player. It limited the
potential range of choice in technology for each through a patent war. Patients for
clinical trials are also limited. For example, it was reported that the introduction of
the depot preparations ofLHRH was delayed because of this limitation. (Waxman
and Saini 1991, 419) However, on the other hand, the competition benefited the
players. Each of them obtained information and ideas from the others through patents
and papers. In addition, their efforts collectively educated medical professionals,
patients and regulatory authorities so that these people could accept this class of
drugs easily. It is difficult to say whether the beneficial aspects of the competition
overwhelmed the costs for each player. However, it can be said that the competition
accelerated the innovation process ofLHRH analogues as a whole.
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6.6.4 Cultural Factors in Innovation
It does not seem that there are remarkable differences between the case of leuprorelin
and that ofgoserelin. However, it is doubtful whether Takeda would have succeeded
in developing leuprorelin without its alliance with Abbott and the development of the
drug in the US conducted by the alliance. As described, researchers at Abbott once
collaborated with Schally. They possessed the in vitro assay, which Takeda did not
have at that time, for LHRH and its analogues. This and probably some more
technologies and skills were transferred from Abbott to Takeda, though some were
also transferred from Takeda to Abbott. It was researchers at Abbott who discovered
the paradoxical effects of leuprorelin and proposed the alternative application for the
treatment of breast cancer and prostate cancer. It can be said that these are indicating
the gap in quality and quantity of scientific expertises between the US and Japan at
that time.
It was also said that without the precedent development of the drug in the US by
TAP Pharmaceuticals, the joint venture between Takeda and Abbott, it would have
been more difficult to develop it in Japan. There was difference in the number of
patients with prostate cancer between the US and Japan. There was also difference in
regulation between the two countries. For example, self-injection was permitted in
the US but not in Japan. However, it seems difficult to attribute the delay of the
development of leuprorelin to these only. The evaluation of the drug amongst
managers, medical practitioners, patients and regulators in Japan seemed to be
influenced significantly by the evaluation in the US. Probably, these people in Japan
were more cautious with something uncertain than their American counterparts. It is
likely that this risk-aversion of people in Japan also contributed to the delay of the
development of leuprorelin in Japan, compared with the US and European countries.
In the next chapter, we examine three more cases of drug discovery and development
in Japan in detail to confirm the different types of pharmaceutical innovation, which
arose in this and previous chapters.
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Chapter 7: Three Case Studies of Pharmaceutical
Innovation in Japan
7.1. Introduction
In this chapter, we examine three cases of drug discovery and development, which
took place in Japan, in order to confirm the existence of different types of drug
innovation and to understand the properties of each. The first case is that of
mevastatin, the first, exemplary drug among a class of drugs called HMG-CoA
reductase inhibitors. Although this drug itselfwas not brought to market, it provides
us with a rare case of paradigmatic innovation in Japan. The second case is cefotiam,
a cephalosporin antibiotic, which can be regarded as a modification-based innovation.
The third is the case of tamsulosin, a drug called an a ic-blocker which is used for
the treatment of urination disorder accompanying benign prostate hypertrophy. This
drug is chemically one of the drugs called a -blockers, which had not been
unfamiliar to experts, but it was the first one used for urination disorder. This drug,
therefore, can be regarded as a modification-based innovation as a compound, but
can be regarded as a paradigmatic innovation as a therapy. In each case, the detailed
process of innovation inside the company is examined.
7.2. Mevastatin
7.2.1. Introduction
The drugs called HMG-CoA reductase inhibitors, including lovastatin, pravastatin
and simvastatin, are used for the treatment of hypercholesterolemia.
Hypercholesterolemia refers to the presence of abnormally large amount of
cholesterol, especially LDL-cholesterol, in the circulating blood, and it may cause
such diseases as arteriosclerosis and coronary heart disease. HMG-CoA reductase is
the rate-limiting enzyme in the synthesis of cholesterol in the body. HMG-CoA
reductase inhibitors antagonize the action of the enzyme and reduce the amount of
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LDL-cholesterol in the blood. HMG-CoA reductase inhibitors appeared on the
market in the late 1980s and have been remarkably successful. The sales of lovastatin
(Mevacor®) and pravastatin (Mevalotin®) were estimated to be 1.3 and 1.6 billion
dollars, respectively, in 1993. (Scrip Yearbook 1995, Vol. 1, p. 102) Simvastatin
(Zocor®) is more successful. Its worldwide sales had surpassed those of lovastatin by
1994 and amounted to 3.6 billion dollars in 1997. Simvastatin was probably the top
selling drug in the world in the late 1990s. (Yakugyo Jihou 1999, p.131)
Lovastatin, pravastatin and simvastatin are all analogues of a drug, mevastatin (ML-
236B; compactin), which was the first HMG-CoA reductase inhibitor discovered by
Akira Endo at Sankyo Co. in Japan in 1973. However, the development of
mevastatin was ceased in 1980. Meanwhile, Merck Co. (US) obtained experimental
data and samples ofmevastatin from Sankyo, discovered lovastatin in 1978, and
marketed it in 1987. Merck also chemically synthesized simvastatin from lovastatin,
and launched it in 1988. Sankyo re-examined analogues ofmevastatin just after
giving up the development ofmevastatin, and decided to develop pravastatin, which
had been already discovered by Sankyo's researchers in 1979. Pravastatin was
launched in the market in 1989. In contrast with the enormous success of these
analogue drugs, the story of the discovery and development of mevastatin, the
prototype drug, was full of hardships. Although mevastatin failed to be a drug, its
discoverer, Endo still believes that mevastatin could also have been as successful as
its analogues if it had been marketed.
7.2.2. Mevastatin
Akira Endo was a senior researcher at the Fermentation Research Laboratories in
Sankyo, the dedicated laboratories for the discovery of useful substances from
microbes, when he started research on anti-cholesterol drugs in 1971. Before that,
from 1966 to 1968, he had stayed in New York to study the biochemistry of
phospholipid and cholesterol. (Endo interview1; Endo 2000) At that time, scientists
were close to understanding the synthesizing process of cholesterol in the body
1 The interview with Dr Akira Endo was conducted on 5th November 1999.
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(Bloch 1965) and had identified HMG-CoA reductase as the enzyme that plays a
central role in controlling the process. (Bucher, Overath and Lynen 1960; Siperstein
and Fagan 1966; Siperstein 1970; Dietschy, Jean and Wilson 1970) The relationship
between the amount of cholesterol in the blood and the frequency of coronary heart
disease was also well known (the Framingham study). (Emerson Thomas et al. 1966;
Dawber and Kannel 1966) People in the United States had become very conscious
about the amount of fat ,in their diet because a great number of people there died of
heart diseases, though this had not necessarily been the case in Japan yet at that time.
However, there was no truly effective and safe anti-cholesterol drug even in the US.
At first, Endo's interest was in the biochemistry of phospholipid and cholesterol, but
later he became interested in the discovery of an anti-cholesterol drug, after learning
about cholesterol-related diseases. (Endo interview)
Table 7.1: Major Events Discussed in This Section
Year Events
1971 Research Started
1973 Discovery ofMevastatin by Endo (Sankyo)
1974 Turndown ofMevastatin by the Central Research Laboratories
1976 Discovery ofMevastatin's Effectiveness in Hens
Organisational Authorisation for Pre-clinical Study ofMevastatin
1977 Controversy on the Safety ofMevastatin in Sankyo
1978 Clinical Trials ofMevastatin by Yamamoto
Organisational Authorisation for Clinical Development ofMevastatin
Discovery of Lovastatin (Merck)
1979 Discovery ofPravastatin (Sankyo)
1980 Suspension of the Development ofMevastatin
1981 Organisational Authorisation for Development ofPravastatin
1984 Clinical Trials ofPravastatin Started
1987 Launch ofLovastatin (Merck)
1988 Launch of Simvastatin (Merck)
1989 Launch ofPravastatin (Sankyo)
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Figure 7.1: HMG-CoA Reductase Inhibitors discussed in This Section
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After coming back to Japan in autumn 1968, Endo was involved in research on
antibiotics for a while. Simultaneously, he studied the literature on cholesterol to find
a way to the discovery of an anti-cholesterol drug. Three approaches were considered
for lowering the amount of cholesterol in the blood: blocking the intestinal
absorption of cholesterol from the diet, inhibiting the synthesis of cholesterol in the
body, and promoting its excretion. (Kuwashima 1998, p.461; Endo 1992, 1570)
Inhibiting the biosynthesis seemed most effective of the three alternatives because
biosynthesis was regarded as contributing most to the amount of cholesterol.
(Siperstein 1970) Furthermore, he learned from the literature that the activity of
HMG-CoA reductase is closely related to the overall rate of cholesterol synthesis.
(Endo 1992; Siperstein and Fagan 1966; Siperstein 1970; Dietschy, Jean and Wilson
1970) By autumn 1970, he was convinced that he could reduce the amount of
cholesterol in the blood if he could inhibit the activity ofHMG-CoA reductase in
some way. (Endo 1999) At the time, however, his idea was only a hypothesis without
any "hard" evidence.
Endo, subsequently, decided to search for a substance able to inhibit HMG-CoA
reductase from microbes, rather than from chemical syntheses. This choice was
based on his interests and expertise. He was familiar with and interested in microbes,
especially moulds and fungi, from his childhood in a farm family. He studied them at
the Department of Agriculture, Touhoku University, and continued researching them
to find useful substances for medicine and agriculture after he joined Sankyo.
(Endo interview; Endo 1999) He also speculated that some microbes would produce
HMG-CoA reductase inhibitors as a weapon to fight against other microbes that
required sterols like cholesterol for growth. (Endo 1992, 1570) Since 1969, he had
been at the Fermentation Research Laboratories, which was newly established to
reinforce the search for antibiotics and other drugs from microbes. About 80
researchers at the laboratories were involved in the search for antibiotics. A half of
the rest, about 10 researchers including Endo, was seeking drugs like various enzyme
inhibitors. Therefore, he was in a position which was organizationally suited to him
searching for HMG-CoA reductase inhibitors from microbes. (Endo interview;
Kuwashima 1998, pp.460-461)
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Endo, with Masao Kuroda, devised an assay system using rat liver enzymes to
identify inhibitors of biosynthesis of cholesterol. A more specific assay system,
which could detect only HMG-CoA reductase inhibitors by using [14C] HMG-CoA,
was also available, but it was too expensive to use for screening thousands of
samples. The method they chose was less focused: it could not distinguish the
inhibition ofHMG-CoA reductase from any other inhibition in the early stages of the
cholesterol synthetic pathway. (Endo 1992, 1570) However, the method was less
expensive and so they could afford it. To obtain further savings, they improved the
existing assay system and achieved 20 times to 40 times higher efficiency. (Endo
2000; Kuwashima 1998)
In April 1971, Endo and Kuroda began the screening of samples extracted from
various microbes. For over 2 years, approximately 6,000 microbial strains were
tested for their ability to inhibit cholesterol synthesis. As the result of the screening,
two strains of moulds were found to produce active substances. One -was Pythium
ultimum, which produces citrinin, a substance known as a mycotoxin. However, they
gave up the development of citrinin as an HMG-CoA reductase inhibitor because it
was too toxic. (Endo interview; Endo 1992, 1570) The other was a strain of
Penicillium citrinum, which produces mevastatin (formerly called ML-236B or
compactin), ML-236A and ML-236C. Neither ML-236A nor ML-236C was so active
as mevastatin. Mevastatin was discovered in July 1973 and its structure was
determined by a combination of spectroscopic, chemical, and X-ray crystallographic
methods three months later. (Endo, Kuroda and Tsujita 1976; Endo 1992, 1570)
Later it was also identified that mevastatin is an HMG-CoA reductase inhibitor.
(Endo, Kuroda and Tanzawa 1976) It took Endo more than two years, and came as
he was reaching the limits of his patience:
I was prepared to give up this approach ifwe were unable to gain a feeling of
hit for two years. The feeling is that we will likely hit a target ifwe keep
trying a little more. Without such readiness in mind, a search of drugs tends
to get bogged down. This is unlike a lottery, which must includes prizes. [In a
search of drug,] no one knows if there is a prize. ... It is like a battle, in which
we have the limited variety of and the limited number of forces. Ifwe have
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no prospects ofvictory after a two-year-long battle, we should retreat. (Endo
interview)
In early 1974, Endo's team handed over mevastatin to the in vivo assay team at the
Central Research Laboratories, where efficacy and safety of drugs are preliminarily
tested in animals. (Endo 1992, 1573; Kuwashima 1998, 462) Mevastatin cleared
acute safety tests, but, unexpectedly, it was found in March 1974 that the substance
did not lower plasma cholesterol in rats. Rats were the predominantly used animals
in the first stage of in vivo tests. Other animals such as rabbits, dogs and monkeys
were occasionally used, but only after tests in rats because they were more expensive
than rats. Rats were the first living "filter" for screening out inappropriate substances.
Mevastatin was screened out there. (Endo interview; Endo 1992; Kuwashima 1998,
463)
Endo did not give up. Mevastatin was the product of his hard work for almost three
years. Furthermore, he was not convinced that ineffectiveness in rats truly indicated
ineffectiveness in humans. He and his team members decided to conduct in vivo tests
by themselves. (Endo interview; Kuwashima 1998, 463) At the time, he belonged to
the non-antibiotic research groups at the Fermentation Research Laboratories. This
research institute was still a young organization and, in particular, the non-antibiotic
research groups there were regarded as groups of "play," which were not expected to
bring immediate products to the company. Therefore, his research proposal about
anti-cholesterol drugs was readily approved when he submitted it to the director in
April 1974. (Endo interview) Endo and his colleagues gave mevastatin to rats by
injection and tried the substance in mice instead of rats, but failed to obtain any good
results. The only hope was that the substance reduced the amount of cholesterol in
the blood when they administrated it to the disease-model rats (that is, the rats
artificially made hypercholesterolemia). (Endo 1987; Endo 1992, 1574) They also
conjectured that the cholesterol inhibiting action ofmevastatin could be antagonism
against HMG-CoA reductase because of the structural similarity between an HMG-
CoA molecule and a mevastatin molecule. This mechanism of action was in principle
very suitable for a drug. (Endo interview; Endo 1992, 1571) However, their work
continued for two years without good results. (Endo interview)
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In the meantime, Endo learned of the work by Goldstein and Brown which showed
that the activity ofHMG-CoA reductase is suppressed by a particular class of
lipoprotein known as LDL and that HMG-CoA reductase in cells from patients with
familial hyper-cholesterolemia (FH) is not suppressed by LDL. Goldstein and Brown
proposed the existence ofLDL receptors and the deficiency of them in FH patients.
(Brown, Dana and Goldstein 1973; Brown and Goldstein 1974)2 Their studies of
cholesterol metabolism strongly helped Endo's study in both experimental
techniques and in the general idea of developing HMG-CoA reductase inhibitors.
(Endo 1992, 1572) Endo wrote to Goldstein in October 1975. Endo's work interested
Goldstein. Goldstein agreed with Endo's idea that mevastatin might work in disease
cells. He also proposed to Endo that they conduct joint research. Endo acquired cells
from FH patients from the United States and tested mevastatin in the cells and other
mammalian cells by using the techniques Goldstein and Brown developed. As a
result, he confirmed that mevastatin strongly inhibited synthesis of cholesterol in
(cultured) human and other mammalian cells. (Endo 1992, 1572; Endo 1987; Endo
1991)
In early 1976, Endo decided that he should change the animals used in the
experiments from rats to other animals with high levels ofHMG-CoA reductase in
their livers. When he happened to talk with a senior researcher at the Central
Research Laboratories, who was doing the toxicity tests of agricultural chemicals
with hens, he asked the researcher to try mevastatin in the hens that had been used in
other experiments and were going to be killed. Endo thought hens were appropriate
for trying mevastatin since the eggs they lay every day are rich in cholesterol.
Because the talk between Endo and the researcher was an informal one in a bar, the
idea was realized without any organizational resistance. Endo has speculated that the
tests in hens might not have been realized if they had been formally proposed to the
Central Research Laboratories, which had turned mevastatin down two years before.
(Endo interview) The tests were conducted in spring 1976. Endo and his colleagues
found that the amount of cholesterol in the hens was reduced by as much as 50%.
2 Goldstein and Brown won the Nobel Prize in 1985 for these achievements.
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Because hens are not mammals, the data were not acceptable for drug development.
However, the remarkable results in hens opened up an opportunity to conduct tests in
dogs and monkeys. (Endo interview; Endo 1992, 1574) When they administrated
mevastatin to dogs, the amount of cholesterol in the blood was reduced by 45%.
Mevastatin also showed remarkable potency in monkeys. (Tsujita et al. 1979; Kuroda
et al. 1979) Thus, Endo was convinced that mevastatin would be effective in humans
even though it has no effect in rodents such as rats and mice. (Endo interview; Endo
1992, 1575) Sankyo decided to develop mevastatin as a drug in August 1976. It was
also decided that the project would be a joint undertaking between the Fermentation
Research Laboratories, the Central Research Laboratories and the Laboratory Animal
Science and Testing Center, with Endo becoming the project leader. (Endo
interview) Until then, Endo had experienced a lot of criticism in the company. He put
it thus:
There were a lot of [unpleasant] experiences. Some people said to me, for
example, "Stop such research." Others said, "You waste young people,"
because I used several young researchers. Especially, our efforts probably
made some people in the Central Research Laboratories irritated. You know,
they were not happy, because they had turned [mevastatin] down but I tackled
it persistently. ... At that time, the Central Research Laboratories was the
centre of the drug development. Our Lab was only peripheral. (Interview)
An approach by Merck, the American pharmaceutical giant, to Sankyo about
research collaboration on mevastatin possibly enhanced the value of the substance in
the eyes of senior research managers at Sankyo. The patent of mevastatin was
publicized in Belgium and Japan in December 1975. Having learned of this
substance from the patents, Merck Sharp & Dohme Research Laboratories proposed
some joint research to Sankyo on mevastatin in the spring of 1976. The two
companies made a disclosure agreement, and Sankyo sent the related data,
experimental methods and a sample ofmevastatin to Merck. (Endo interview; Endo
1994; Endo 1987) Although Merck did not give an immediate positive valuation to
mevastatin at that time (Endo 1994, 125), the company's approach drew the attention
of the senior research managers at Sankyo to the substance.
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Formal pre-clinical tests started in January 1977. In toxicological tests in rats,
another problem arose in the spring of 1977. Toxicologists at the Laboratory Animal
Science and Testing Center found tiny, unfamiliar crystals within the liver cells of
the rats that were given a massive amount ofmevastatin. They were very concerned
about this phenomenon because mevastatin would be given to patients for a very
long time. A subtle debate was held between Endo and the toxicologists. At that time,
it was impossible for them to analyse the crystals directly. Using a variety of indirect
evidence, Endo argued that the crystals were cholesterol ester, which should be
resoluble. (Endo Interview; Endo 2000; Endo 1994, 124-125) The toxicologists and
pathologists at the Laboratory Animal Science and Testing Center did not easily
agree with him. Endo described the subtle character of the debate:
When [the toxicologists] doubted the safety of a substance, its project would
usually be abandoned. I have witnessed a lot of such cases. However, [the
toxicologists] didn't used to say "no." It was because they didn't want to take
the responsibility of stopping the project. They didn't want to incur our ill
will. So, they asked us how we thought about the unfavourable results of their
tests, instead of saying "no" straightforwardly. We answered it, but they were
not convinced of our answer. We offered another answer, and so on. They
just waited for us to give up the substance. This is a very Japanese way, isn't
it? (Interview)
Endo also put it thus:
It is a matter of course that unfamiliar phenomena are observed when we test
an unfamiliar substance. [The crystal] was an example of such phenomena.
Whether they can develop a unique drug or not is dependent on how they deal
with such phenomena. I analysed the crystal and identified it as cholesterol.
Even though I explained the phenomena logically, even though I showed
evidence to the pathologists and toxicologists, they were not convinced. ...
The story would have been completely different if there had been a precedent.
If a company in America, Britain or elsewhere outside Japan had found the
same thing and had insisted it's OK, there might have been no problem.
(Interview)
About the same time, a group of chemists at the Central Research Laboratories was
conducting synthesis of analogues ofmevastatin. (Sato et al. 1979) They also tested
biologically one of them, RWX-163 (R-163), without informing Endo's team. The
first presentation about RWX-163 (R-163) in the company was given on 22 and 23
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June 1977. In December 1977, the promoters ofRWX-163 (R-163) insisted that the
compound did not produce any crystals in liver cells of rats. They also claimed that it
reduced the amount of cholesterol in rats. The proposal to replace mevastatin with
RWX-163 (R-163) was discussed at the project-coordinating meeting on 10 January
1978. Unfortunately for Endo's team, Kou Arima, the then director of the
Fermentation Research Laboratories and a main supporter ofmevastatin project in
the company, was absent from the meeting. The proposal won the consensus of the
major members and was to be finally approved by Arima, who was also the director
of the Central Research Laboratories. It was very hard for him to ignore the
• • • 3
consensus at the meeting without convincing reason. Mevastatin was thus about to
be turned down again. (Endo interview and personal communication) 4 However,
Endo and Arima did not give up mevastatin. Endo explained the reasons.
The compound had only two hundred times less potency than mevastatin.
This means patients would have to take it two hundred times more than
mevastatin at a dose. Such a compound can't become a drug. However, for
the chemists at the Central Research Laboratories, this was an opportunity for
taking an initiative. Moreover, this was favourable for the pathologists and
toxicologists at the Laboratory Animal Science and Testing Center because
there would be no problem in their jurisdiction. Their interests coincided here.
This resulted in one versus two. And, you know, it was the pathologists who
were regarded as responsible finally for the safety of a substance. Therefore,
if they didn't say "yes," a substance compound couldn't be a drug.
(Interview)
Endo and Arima tried to find a way outside the company to save mevastatin from
being dumped. Before then, in the autumn of 1977, Akira Yamamoto at the Osaka
University Hospital had asked Endo for mevastatin to try it in one of his patients with
serious familial hypercholesterolemia (FH). Yamamoto had come to know Endo
through Endo's paper on the work of Goldstein and Brown. Yamamoto proposed that
he would take the initiative with the tests. This was a genuinely attractive proposal
for Endo. Soon after the project-coordinating meeting on 10 January 1978, Endo
3 Arima was somewhat regarded as an outsider in the research laboratories because he had worked at
other department for a long time before he became the director. (Endo personal communication, April
2000)
4 It should be noted that experimental results about mevastatin was presented in academic societies in
1977 but responses of scientists were not very favourable. Goldstein's team and Yamamoto's team
were rare exceptions. (Endo 1987, 652; Endo 1994, 125)
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went to see Yamamoto and arranged the tests. In Sankyo, only Endo and Arima
knew of this plan.5 The tests began on 2 February 1978. Arima later let the head of
toxicology at Sankyo know about the plan of the tests. This caused turmoil within the
organisation. However, there was no way for others in the company to stop the tests,
because the doctor took the initiative. Doctors, especially ones belonging to
universities, had great power over pharmaceutical companies at the time in Japan. At
the next project-coordinating meeting on 9 February 1978, the direction shown at the
last meeting was reversed and the development ofmevastatin was approved. (Endo
interview and personal communication)
The tests of mevastatin by Yamamoto's team at first did not show very good results.
The amount of cholesterol in the blood was reduced but less than expected.
Furthermore, side effects such as muscular weakness were observed. The tests were
ceased. However, Yamamoto was intuitively convinced that mevastatin should work
when he listened to the patient's neck and found that "vascular bruit (noise)" was
impressively reduced after the use of the drug. The side effect was regarded as due to
an overdose of the drug. In addition, the patients had a particular kind of
hypercholesterolemia, called homozygous FH. Although his professor told him to
give up the drug, he tried it again with alterations in dosages and targets. (Yamamoto
1999, 78) Yamamoto treated 9 other patients with primary hypercholesterolemia with
lower dosage of mevastatin. These tests produced remarkable results. (Yamamoto,
Sudo and Endo 1980; Endo 1992, 1575; Endo 1994, 125) In May 1978, the
development of mevastatin was formally authorized at the corporate meeting of
Sankyo head quarter. In November of the year, formal clinical trials (Phase I) began.
However, Endo left Sankyo and moved to Tokyo Noko University in December 1978.
(Endo 2000)
In the summer of 1979, clinical trials of mevastatin proceeded to Phase II and the
drug was administrated to many patients with serious hypercholesterolemia by over
5 Before the tests in Japan, Endo had planned the similar attempt in the US, based on a proposal of
Goldstein to try mevastatin in his patients with serious FH in May 1977. However, this attempt was
not realized because of the lack of sufficient safety tests and objection of a domestic medical authority.
(Endo interview; Endo 1991, 721)
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10 groups in Japan. The results showed that mevastatin was effective for all kinds of
hypercholesterolemia except homozygous FH. Some of the results of clinical trials
were presented at the International Symposium on Drugs Affecting Lipid
Metabolism in June 1980. (Endo 1994, 126) However, most of these clinical trials
were suddenly suspended soon after that symposium, because of the report that
mevastatin showed toxic effects in some dogs at high doses in a long-term toxicity
study. (Endo 1992, 1575) Endo criticised the study thus:
[The tests] committed three errors. First, doses were too much. About 1000
times higher doses than the effective doses in man were given to the dogs.
Second, a long-term toxicity study usually lasts for a year. However, in this
case, it was extended to two years because there had been nothing wrong
after 39-week-long administration. I can't understand why they made such a
decision. ... Third, it was a matter of course that toxicity was observed. But
the dose was 1000 times higher. They should have analysed the phenomenon
logically, because there was nothing wrong in 50 times higher doses. Any
drug would show toxicity if it was taken to the amount of 1000 times higher
than ordinary doses. Therefore, such tests are total nonsense. (Interview)6
When Endo was at the company, he insisted that the long-term toxicity tests should
be done with 50 times higher than the effective doses in human.7 However, his
insistence was not accepted. The much higher doses were adopted together with
lower doses. It was because even the highest doses had not produced serious toxic
effects in the middle-term toxicity tests conducted before. There was also an opinion
that toxicity tests should be conducted with doses high enough to produce some toxic
effects. (Endo 1991, 721) Endo generalized the problem here thus:
If there had been an exemplar, it would have been all right. If an American
company or a company elsewhere had done [a long-term toxicity study] with
only 50 times higher doses, the Japanese company would have done with 50
times higher. But there was no such exemplar. [Mevastatin] was very safe.
They thought that's OK because they didn't find toxic effects in the sub-acute
toxicity tests [with the same amount of doses]. So easy. Their thinking wasn't
based on theories. Very intuitive. I think this is a Japanese way of thinking.
They are not good at thinking logically and analytically. (Interview)
6 About the details of the doses of the tests, see Endo (1992), 1575 and Endo (1994), 126.
7 Even the doses Endo had insisted at that time were later found to be 250 times higher than the
ordinarily effective doses. (Endo correspondence)
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Although the results of the test might have been different if they had chosen lower
doses and a shorter period of time, which was a practical option at the first trial, these
sorts of experiment cannot be redone. Even if the second trial had showed that
mevastatin had been safe, doubts among people could not have been wiped out
completely. (Endo 1991, 721-722) As a result, Sankyo virtually ceased the
development of mavastatin in the summer of 1980. Sankyo mentions this incident
just briefly in its official story ofmevastatin and pravastatin: "[pravastatin] was
selected because of its advantage in the balance of efficacy and safety." (Sankyo,
1996, 10) Although mevastatin failed to be a drug, it was used in some medical
studies even after that. In August 1981, Hiroshi Mabuchi and his colleagues at
Kanazawa University reported effectiveness of mevastatin in 7 patients with FH.
(Mabuchi et al. 1981) The team also reported in March 1983 that mevastatin was
very effective in combination with another drug for the treatment ofFH without any
side effects. (Mabuchi et al. 1983) Yamamoto's team confirmed these results. These
studies appeared to greatly accelerate the development ofHMG-CoA reductase
inhibitors in the 1980s. (Endo 1992,1576; Brown and Goldstein 1981, 516)
Mevastatin provided "hard" evidence to support theories of cholesterol synthesis in
the body. Brown and Goldstein acknowledged the contribution of mevastatin in the
editorial of a major medical journal as following:
Many hurdles must be overcome before compactin [mevastatin] and
mevinolin [lovastatin] can be accepted as a "penicillin" for
hypercholesterolemia. ... Yet, the studies with the parent compounds
compactin and mevinolin have established a general principle: interference
with cholesterol synthesis can trigger an increase in LDL receptors, thereby
reducing LDL levels in plasma without depleting vital body stores of
cholesterol. This is indeed encouraging news. (Brown and Goldstein 1981,
517)
7.2.3. Lovastatin, Simvastatin and Pravastatin: The Offspring
7.2.3.1. Discovery and Development of Lovastatin and Simvastatin by Merck
Merck obtained a sample of mevastatin and unpublished data related to it from
Sankyo under a disclosure agreement in July 1976. According to Endo, researchers at
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Merck appeared to be disappointed because of the poor results in rats. However, after
Sankyo provided them with new data for dogs in October 1976, Merck became more
interested in the research ofmevastatin. In April 1977, Merck asked Sankyo for
additional samples ofmevastatin for tests. Endo taught researchers at Merck methods
for experiments in dogs. By October 1978, researchers at Merck had reproduced the
same experimental results as Sankyo's ones. (Endo 1994, 125; Endo 1992, 1576)
However, the contract between Merck and Sankyo included a clause about
maintaining secrecy, but did not include one about prohibiting Merck from
conducting improved inventions for a fixed period. (Endo interview) Rather, the
contract included a following clause:
It is understood that no patent right or license is hereby granted to either party
by this agreement and that the disclosure of proprietary information and
materials shall not result in any obligation to grant either party any rights in
and to the subject matter of the party. (Endo 2000)
Researchers at Merck began their own screening tests and discovered lovastatin from
a strain ofmould in November 1978. (Alberts et al. 1980; Alberts 1988; Endo 1994,
125)8 It is reported that clinical trials of lovastatin were once interrupted because of
the suspension of the development ofmevastatin. However, Merck gradually
resumed the clinical trials after the studies by Yamamoto and by Mabuchi which
indicated the effectiveness of mevastatin for the treatment ofFH. (Endo 2000; Endo
1994, 126-127) As to the survival of the project, the fact that the then president of the
Merck Sharp and Dohme Research Laboratories, P. Roy Vagelos was a famous
researcher in the biochemistry of lipids and cholesterol should be noted here.
(Galambos and Sewell 1995, 125; Endo 2000) Lovastatin cleared clinical trials and
was approved by the FDA in the autumn of 1987. (Hoeg et al. 1986; The Lovastatin
Study Group II 1986; Havel et al. 1987; Grundy 1988, 25) In the course of clinical
trials of lovastatin, the detailed action mechanism ofHMG-CoA reductase inhibitors
8 Endo independently discovered lovastatin from another mould in early 1979 and named it monacolin
K. (Endo 1979; Brown and Goldstein 1981, 516) The application for patents of Monacolin K by Endo
was before that of lovastatin, but because of the difference of principle in the US patent law and its
counterparts of the most countries in the world including Japan (priority on invention versus priority
on application), the patent of lovastatin became valid in the US only and the patent of monacolin K,
which was handed over to Sankyo by Endo, became valid in the rest of the world. Therefore, Merck
did not market lovastatin in Japan but did simvastatin later. (Endo 2000; Endo 1987, 652)
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was explained. (Bilheimer et al. 1983; Grundy 1988) Side effects which occurred in
animal tests at very high dosage levels were also successfully explained and did not
inhibit the project. (MacDonald et al. 1988) In the early 1980s, Merck synthesized
simvastatin by modifying lovastatin chemically. (Hoffman et al. 1986) The company
developed it in parallel with lovastatin. In 1988, Merck marketed simvastatin, which
became the second HMG-CoA reductase inhibitor marketed. (Todd and Goa 1990,
586-587)
7.2.3.2. Discovery and Development of Pravastatin by Sankyo
In parallel with the development ofmevastatin, researchers at Sankyo had searched
for a better HMG-CoA reductase inhibitor by screening natural substances and
synthesized compounds. This work linked with the investigation of the mechanism,
activities and the structure-activity relationship ofmevastatin. That is, in order to
understand mevastatin, it was necessary to examine related substances and
compounds as well. Masao Kuroda, who was one of main researchers involved in the
HMG-CoA reductase inhibitor project at the Fermentation Research Laboratories,
described this process thus:
In real laboratories, things don't proceed so neatly as "We have established
the assay system. Now, let's begin the screening with it." In reality, we are
building an assay system with trials and errors. (Interview)9
One of the substances discovered to be active in these efforts was pravastatin. This
substance was first found in 1979 when Sankyo researchers examined the
metabolites in the urine of dogs that were given mevastatin. (Kuroda interview;
Serizawa et al. 1983a, 604; Sankyo 1996, 10) Although the substance was found to be
active when it was first discovered, the researchers could not identify its chemical
structure because the quantity was too small. Because it was a metabolite, the
researchers speculated that it should be a hydroxyl derivative of mevastatin. They
tried to produce it by chemical modification and microbial transformation. The latter
approach was found to be more efficient. Then, they matched the physical chemistry
9 Interview with Dr Masao Kuroda was conducted on 24th March 2000.
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properties of the substance thus produced with those of the metabolite and at last
identified the structure of the substance named pravastatin. It was in fact a hydroxyl
derivative ofmevastatin. Establishment of large-scale production was also essential
for them to conduct various pre-clinical tests and clinical trials. However, pravastatin
did not become the candidate for the development immediately after the discovery
but many other substances were examined as well. (Kuroda interview; Kuroda 1994,
76-77; Serizawa et al. 1983a; Serizawa et al. 1983b; Serizawa et al. 1983c; Serizawa
etal. 1983 d)
Soon after the failure of the development ofmevastatin in the summer of 1980,
Sankyo's researchers began reviewing "hundreds of' these analogues ofmevastatin.
(Kuroda interview; Kuwashima 1998, 463) The standard of potency was mevastatin.
The new candidate substance had to be better than mevastatin. Pravastatin was the
survivor of the screening. Kuroda described the situation at that time thus:
The problem was that we were the first to develop an HMG-CoA reductase
inhibitor in the world. In such case, there were objections and scepticism that
such mechanism of action would not result in a drug. It was our pride as the
first research team who discovered such kind of compounds that persistently
led us to the development ofpravastatin. (Interview)
Despite some voices of suspicion within the company, Sankyo decided to develop
pravastatin in 1981. (Kuroda personal communication, April 2000; Kuwashima
1998) Sankyo stated that the choice was made because of stronger effectiveness and
less toxicity. (Sankyo 1996, 10) The company attributed these advantages to the
tissue-selectivity (that is, the ability to inhibit cholesterol synthesis selectively in
livers and intestines) of pravastatin. (Tsujita et al. 1986; Koga et al. 1990; Sankyo
1996, 10; Tsujita 1993, 627-629) Researchers at Sankyo also made a considerable
effort to develop a more efficient microbiological production method of pravastatin
and succeeded in obtaining one using a strain of an Australian microbe. (Serizawa et
al. 1983a; Serizawa et al. 1983c; Matsuoka et al. 1989; Sankyo 1996, 10) Clinical
trials of pravastatin in Japan started in February 1984. Pravastatin cleared clinical
trials rapidly with good results, (Nakaya et al. 1987; Mabuchi et al. 1987; Kuroda
1994, 82-83) and was approved for manufacturing by the Ministry ofHealth and
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Welfare and marketed in Japan in 1989. It also went through clinical trials in the US
and European countries and obtained favourable results. (Hunninghake et al. 1990;
Hoogerbrugge et al. 1990) By 1996, it was being sold in 69 countries. (Kuwashima
1998)
The remarkable successes of these three analogues of mevastatin, namely, lovastatin,
simvastatin and pravastatin, in the market were already stated in the introduction of
this section. There are three other HMG-CoA reductase inhibitors marketed today,
which are also highly successful in the market: atorvastatin (Lipitor®) marketed by
(R) •
Warner and Lambert, cerivastatin (Lipobay ) marketed by Bayer, and fluvastatin
(R) •
(Lescol ) marketed by Novartis. Although these three compounds share the key




Cefotiam is an antibiotic synthesized and developed by Takeda Chemical Industries
in Japan. This drug is classified into a subgroup of antibiotics called cephalosporins.
Cephalosporins are analogues of cephalosporin C, originated in Italy but identified
and investigated in the UK. Cephalosporins have the similar chemical structure to
penicillins: both subgroups of antibiotics possess the structure called P-lactam.
Therefore, they are also broadly called p-lactam antibiotics together with some other
antibiotics with the same structure. Cefotiam was synthesized in 1974 (Takeda 1983,
p. 743) and launched in Japan in 1981. Cefotiam is classified as one of so-called
second-generation cephalosporins, which have broader spectrum of activity than
first-generation ones, but in general lesser antibacterial activity against Gram-
negative bacteria than third-generation ones. (Webber and Wheeler 1982, p. 377;
Donowitz and Mandell 1988, 490) However, this does not mean the second-
generation cephalosporins became obsolete after the advent of third-generation ones.
This is because doctors do not always use the third-generation cephalosporins for
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fear ofmaking bacteria resistant to antibiotics. In Japan, the increase of antibiotic-
resistant bacteria has been a major medical problem since the 1980s. (Hiramatsu
1999, 114) Narrower spectrum of activity has an advantage of preventing a broad
range of bacteria from becoming antibiotic-resistant unnecessarily. (Silver and
Bostian 1993, 378) Therefore, cefotiam has been sold very well in Japan even after
the advent of third-generation cephalosporins. Its sales in Japan were estimated to be
about 22 billion yen (about 110 million pounds) in 1998. It was the second best
selling antibiotic for injection use in Japan. (Yakuji Handobukku 1999)
Table 7.2: Major Events Discussed in This Section
Year Events
1945 Discovery ofCephalosporium acremonium
1953 Discovery ofCephalosporin C
1962 Synthesis of the first marketed cephalosporin, cephalothin
1971 Start of the cephalosporin project at Takeda
1974 Synthesis of SCE-785 and SCE-963
1975 Stop of the development of SCE-785; Start of the development of SCE-963
1976 Start of the clinical trials of SCE-963 (cefotiam)
1980 Approval for manufacturing of cefotiam
1981 Market launch of cefotiam
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Figure 7.2: Cephalosporins Discussed in This Section
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7.3.2. Discovery and Early Progress of Cephalosporins
Giuseppe Brotzu, a professor at the Institute ofHygiene of Cagliari in Italy
conjectured that self-purification of seawater might be partly due to microbial
antagonism. In 1945, he sampled seawater near a local sewage outfall and discovered
a species ofmould, Cephalosporium acremonium, which produced a substance
having a wider antibacterial activity than penicillin. He published his finding in a
pamphlet in 1948, which had only a small circulation. This attracted little attention in
the country. He then sent a copy to his friend in London, Blyth Brooke and suggested
that English researchers should take up the work to isolate the active substances,
which would be beyond his resources. Based on the suggestion of the Medical
Research Council, Brook wrote to (Sir) Howard Florey at the SirWilliam Dunn
School ofPathology at Oxford. Florey gladly agreed to take up further investigation.
Brotzu sent a culture of his mould to Florey in September 1948. (Abraham and Loder
1972, pp.3-5; Selwyn 1980, pp. 39-40)
At Oxford, Edward Abraham and H. S. Burton found an antibiotic, named
cephalosporin P, from the organic solvent extract of the Brotzu's culture by 1949, but
this had only a narrow spectrum of antibacterial activity. In August 1949, they found
another substance from the culture fluids. The substance, which was hydrophilic and
had a broader spectrum of activity as described by Brotzu, was at first named
cephalosporin N. This was later renamed penicillin N because it had the same
nucleus of molecular structure as penicillin. In the process of isolating cephalosporin
N, Abraham and G. G. F. Newton found the third antibiotic as a contaminant from
crude cephalosporin N preparations in 1953. This substance, named cephalosporin C,
was found to have similar range of activity to cephalosporin N but be much less
active. However, this new antibiotic had some unique properties such as non-toxicity,
stability and, in particular, resistance to penicillinase, a class of enzymes produced by
bacteria. These enzymes destroy penicillins including cephalosporin N. (Newton and
Abraham 1955; Newton and Abraham 1956; Abraham and Loder 1972, pp. 5-7;
Sneader 1985, pp. 316-317)
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The production of cephalosporin C in quantity was difficult at the time. The Oxford
researchers helped the Medical Research Council's Antibiotic Research Station to
produce the substance on a larger scale. The National Research Development
Corporation (NRDC) secured patents related to the production of Cephalosporin C.
(Abraham and Loder 1972, pp. 7-9; Selwyn 1980, p. 46) The Antibiotic Research
Station had been founded to avoid repeating the situation that had arisen when
British companies had to pay large royalties to produce penicillin by deep
fermentation processes, which were developed in the US. NRDC had been
established in 1949 to exploit discoveries made in Britain, which had, again, not been
achieved in the case of penicillin. (Sneader 1985, pp. 316-317) NRDC asked all
British pharmaceutical companies having fermentation facilities to help the
production of cephalosporin C, but only Glaxo showed serious interest. In 1956,
NRDC began to organize meetings between Glaxo and the researchers at Oxford and
the Antibiotic Research Station. By 1957, lOOmg of cephalosporin had been
produced by Glaxo, some ofwhich contributed to the work to confirm the chemical
structure of the substance. (Abraham and Loder 1972, p. 10)
Several foreign companies contacted NRDC and signed licensing agreements related
to cephalosporin C with the corporation: Squibb and Eli Lilly in the US in 1959;
Merck, Pfizer, SmithKline and French (all in the US), Ciba (Switzerland) and
Farmitalia (Italy) in 1960; and Fujisawa in Japan in 1961. However, the possibility of
developing cephalosporin C itself as a drug in practice disappeared when methicillin,
a potent semi-synthetic penicillin, showed resistance to penicillinase in 1960.
(Abraham and Loder 1972, p. 10) Fortunately, the patient research on cephalosporins
at Oxford, which was supported by the accumulation of intellectual and material
assets obtained from their research on penicillin since the mid 1930s, provided
cephalosporins with a future. By 1960, the researchers at Oxford had identified the
chemical structure of cephalosporin C (Abraham and Newton 1961; Hodgkin and
Maslen 1961), and found that 7-aminocephalosporanic acid (7-ACA), which could
be obtained in small amounts from cephalosporin C by using a particular method,
was a rich source of derivatives that had much higher potency than cephalosporin C.
(Loder, Newton and Abraham 1961; Abraham and Loder 1972, p. 9, pp.11-15;
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Selwyn 1980, p. 46) This meant, in principle, that it should be possible to produce a
lot of potent semi-synthetic cephalosporins from 7-ACA in the same way as semi¬
synthetic penicillins were then being obtained from 6-aminopenicillamic acid.
(Sneader 1985, p.318) The critical problem to exploit the commercial potential of
cephalosporins was to discover a method for producing 7-ACA on a large scale.
(Abraham and Loder 1972, pp. 10-11)
In 1960, Robert Morin and his colleagues at the Lilly Research Laboratories devised
a more efficient procedure of converting cephalosporin C into 7-ACA. (Morin et al.
1962; Abraham and Loder 1972, p. 11; Selwyn 1980, p. 47) By that time, both Eli
Lilly and Glaxo had achieved large-scale production of cephalosporin C by
fermentation. Thus, 7-ACA became available in larger quantity, and a number of
derivatives were synthesized and examined in search ofpotent antibiotics. At Eli
Lilly, Robert Chauvette and his colleagues prepared a series of 7-ACA derivatives,
and cephalothin was selected for clinical trials from them. (Chauvette et al. 1962)
This was marketed in 1964 and became the first marketed cephalosporin. (Griffith
and Black 1964; Selwyn 1980, p.47) Shortly after that, Glaxo also succeeded in
making a marketable semi-synthetic cephalosporin, cephaloridine, which was
marketed in 1964. (Muggleton, O'Callaghan and Stevens 1964; Selwyn 1980, p.47)
Both cephalothin and cephaloridine were claimed to have a broader spectrum of
activity than penicillins, to be active against some penicillin-resistant bacteria, and to
be free from serious side effects. Safety to patients with penicillin allergy was also
reported. (Griffith and Black 1964; Muggleton and O'Callaghan 1967) Eli Lilly, then,
synthesized the first orally active cephalosporin, cephaloglycin, by adopting the same
side-chain as ampicillin, a semi-synthetic penicillin developed by Beecham a little
earlier. Shortly later, however, this drug was replaced by a better-absorbed oral
cephalosporin named cephalexin, which was synthesized independently by Eli Lilly
and Glaxo and marketed in 1967. (Wick 1967; Newall 1985, p.215; Selwyn 1980, p.
47; Sneader 1985, pp.318-319) In 1970, Chauvette and his colleagues at Eli Lilly
developed a new chemical process for converting penicillin into cephalexin. This
production process could be applied to other cephalosporins, and made the
production of7-ACA more efficient. (Chauvette et al. 1971; Selwyn 1980, p.47) By
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1971, several cephalosporins with similar properties became clinically available,
including cefazolin (Fujisawa), cephapirin (Bristol), and cephacetrile (Ciba-Geigy).
(Hewitt 1973; Numata 1981, p. 19) These cephalosporins were later called first-
generation cephalosporins, which were more active against Gram-positive bacteria
such as staphylococci and streptococci (non-resistant ones), but less active10 against
Gram-negative bacteria such as E. coli, Klebsiellia and Pr. mirabilis, than second-
generation cephalosporins such as cefamandol, cefaclor (Eli Lilly) and cefuroxime
(Glaxo), which were marketed since around 1972. (Donowitz and Mandell 1988;
Numata 1981, pp.41-45) Cefotiam developed by Takeda was one of the second-
generation cephalosporins. When they started research on cephalosporins in 1970,
first-generation cephalosporins were their exemplars and targets to be superseded in
the search for a new drug. (Numata 1981, p. 20)
7.3.3. Takeda's Start of Research on Cephalosporin
Takeda Chemical Industries is one of the oldest pharmaceutical companies in Japan,
and also has decades of history of pharmaceutical research, including prodrugs of
vitamin Bi (Arinamin®) which had been major products of the company for a long
time. (Morita 2000, pp. 173-175) In the 1960s and 1970s, antibiotics became the
leading drugs which brought substantial profits into pharmaceutical companies in
Japan. (Nihon Yakusi Gakkai 1995, pp. 119-123) In this area, however, Takeda did
not have competitive products until the end of the 1960s. In 1967 Takeda started
research on semi-synthetic penicillin and succeeded in synthesizing sulbenicillin
disodium by 1968, which was marketed in 1973 (Lilacillin®). (Takeda 1983, pp. 755-
756) The company also started preliminary research on cephalosporins in 1967. In
order to discover a new cephalosporin, however, they had to establish the supply of
7-ACA, which was not generally available. In November 1970, Takeda agreed with
Ciba-Geigy about cooperation on cephalosporin research. Under this agreement,
Takeda started intensive research on cephalosporins with 7-ACA supplied by Ciba-
Geigy in 1971. Results of the research would be shared between both companies.
(Takeda 1983, p.743, p.764) Takeda also started research on production of
10
First-generation cephalosporins were in general more active against Gram-negative bacteria than
penicillins. (Hewett 1973, S314)
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cephalosporin C in 1970. This research resulted in the invention of a new production
process of deacetylcephalosporin C (DCPC) in 1973, which was later found to be
able to be used as an alternative material for production of cephalosporins. (Takeda
1983, p.765) The sales force of Takeda, however, could not just wait for the birth of
their new cephalosporin. Immediately after the agreement with Ciba-Geigy, Takeda
developed a new production process for cephalexin, and marketed its generic product
in 1973 under the process patent system in Japan.11 In addition, Takeda and Ciba-
Geigy cooperated on clinical trials and marketing ofCiba's cephalosporin,
cephacetrile, in Japan. This was marketed in Japan in 1978. (Takeda 1983, p.818)
The earliest attempt at synthesizing a new cephalosporin at Takeda was conducted by
the research group that had created sulbenicillin disodium, a semi-synthetic penicillin.
In May 1970, they began to synthesize new cephalosporins on a small scale, having
the agreement with Ciba-Geigy in prospect. They found that one of them, SCE-20,
which had the same side chain as sulbenicillin disodium, had an activity against a
particular group of Gram-negative bacteria called Pseudomonas aeruginosa.12 This
interested the researchers because existing antibiotics were hardly active against
these bacteria. In 1971, with a supply of 7-ACA from Ciba-Geigy, they synthesized
further analogues of SCE-20, and found that two of them, SCE-120 and SCE-129,
were much more active against the bacteria than SCE-20 though they were not very
active against other bacteria. Although there was doubt about its marketability,
Takeda decided to develop SCE-129 in 1973 because of its unique activity against
Pseudomonas aeruginosa. Researchers at Ciba-Geigy and academic specialists in
infectious disease supported Takeda's decision. (Takeda 1983, p.971; Numata 1981,
pp. 11-16) SCE-129 was named cefsulodin and launched in 1981 (Takesulin®). From
the beginning, however, it was obvious that this would not cover the needs of the
sales division of the company, because of the narrow range of antibacterial activity
of the drug. They needed a cephalosporin with a much broader range of activity.
11
Japan's patent system was reformed to be the product patent system in 1976. See Howells and
Neary(1995), pp. 145-149.
12 Pseudomonas aeruginosa are typical opportunistic pathogen and can cause various infectious
diseases, including sepsis, osteomyelitis, airways infection, and urinary tract infection, particularly in
patients who do not have a normal level of immunity. They are resistant to commonly used antiseptics
and antibiotics and may cause hospital infection.
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(Hiramatsu interview13) Although these early attempts did not earn much income, it
should be noted that they earned trust from Ciba-Geigy and ensured further supply of
7-ACA, which helped further cephalosporin research at Takeda. (Takeda 1983, p.
971) The research group that produced cefsulodin did not belong to the Central
Research Division, but to the Manufacturing Division. They were somewhat
peripheral as researchers in Takeda. (Numata interview) The search for a broader
cephalosporin, which the company truly needed, was conducted by the "mainstream"
of Takeda's research division. (Takeda 1983, p. 973)
7.3.4. Discovery of Cefotiam
Takeda charged the First Chemical Research Department at the Central Research
Division led by Katsura Morita with doing research to discover a new cephalosporin
in 1971. Morita described this project as "a life-betting gambling" for the company
and for himself. The project was created by strategic needs of the company, and the
project team had to achieve the goal though they had no experience in synthesizing
cephalosporins. If they failed, they would have had to take responsibility for the
failure, and the company would have lost out in the Japanese antibiotic market.
(Morita interview14; Morita 2000, pp. 207-208) Two of the staff of the Investigation
Department also participated in the project team. They investigated almost all related
patents and literature, and mapped the situation of cephalosporin research in the
world, including chemical structures and antibacterial properties of all
cephalosporins available. Pessimistic opinions arose in the team, when they looked at
the chart. (Morita interview: Morita 2000, pp. 208-209) Morita persuaded his team
members:
I said, "There were only several thousand compounds. Despite this, no
existing cephalosporin had stronger activity [against Gram-positive bacteria]
than penicillins. In addition, penicillins were cheaper than cephalosporins. So,
we can catch up [with leading companies]. Moreover, penicillin has only one
13 The interview with Dr Mitsuo Numata, who was the leader of the key research group in the
synthesis of cefotiam, Dr Kenji Okonogi, who was involved in the biological study on cefotiam and
other antibiotics, and Mr Nobuyoshi Hiramatsu, who was involved in the development of antibiotics
at Takeda, was conducted on 26th January 1999.
14 This interview with Dr Katsura Morita was conducted on 8th February 1999.
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place to be modified. But cephalosporin has two places. That means hundreds
of thousands of compounds in principle can be synthesized. Not the level of
several thousand. So, we have a chance." (Interview)
Morita succeeded in persuading his members. He also faced the question ofwhich
approach to adopt, random searching or rational searching. He thought about his
available resources and chose the latter. He put it:
It was a divergence whether was better: to make as many compounds as
possible without thinking until coming across a hit, like blind shooting; or to
make a working hypothesis first, then begin to synthesize compounds based
on the hypothesis. I was afraid we would not tolerate the former choice. I
thought we should make a hypothesis about why cephalosporins were active,
what kind of mechanism killed bacteria, and what structure should be
designed. The hypothesis had to be unique which others did not share. I
thought we should make such a hypothesis by ourselves. My staff agreed with
me. (Interview)
The hypothesis was made based on knowledge in organic chemistry in the related
area (E.g. Sweet and Dahl 1970) and investigation of structure-activity relationship
of existing cephalosporins. Morita and his colleagues conjectured that an "active
hydrogen" in the side chain at 7 position of a cephalosporin molecule (figure 7.3)
was linked with antibacterial activity of the drug by enhancing the chemical
reactivity of the molecule to the cell-wall-making enzyme ofbacteria. (Morita et al.
1980, pp. 17-18; Morita 2000, p. 209-212; Morita interview) Not all team members
were fully convinced of the hypothesis. A few researchers did not adhere to the
hypothesis. (Morita interview) It is still unclear if the hypothesis is correct. (Numata
interview) Most researchers were, however, convinced that they would work with
this hypothesis. Based on this hypothesis, they considered putting a particular atomic
group called P-ketoacid into the side chain in order to produce an "active hydrogen"
(figure 7.4). This structure was chosen because it was unique and not enclosed by
patents of other companies. (Numata 1981, p.22: Morita et al. 1980, p. 17; Numata
interview) However, it was clear that this was a very hard task because P-ketoacid
was very unstable. (Morita 2000, pp.212-213; Numata 1981 p.26)
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R is called 7 position side chain.
Y is called 3 position side chain.
(H) shows an "active hydrogen."
Generic Name R Y Company




















Figure 7.4: Target Compounds with the p-Ketoacid Side Chain
R and Y are variable chemical groups.









Morita thought that this project had to be done in at most three years. (Morita 2000,
p.208) Morita organized five dedicated research groups. This was an exceptionally
concentrated deployment of research force. Three of them were charged with
chemical synthesis. One was in charge ofpharmacological study. The other one was
in charge of supply of P-ketoacids. (Morita interview; Numata interview) Morita
mixed "lay researchers," that is, researchers who had not been specialized in the area,
into the research groups. Morita put it:
"Cephalosporins are more expensive than penicillins." "Cephalosporins are
less active than penicillins." People who were familiar with antibiotics and
penicillins tended to say such words to me. I did not want those people in my
project team. I preferred ignorant people without such prejudice. Ignorant
people can act boldly, take drastic measures and find something unexpected.
... Indeed, after all, they did produce excellent results. (Interview)
Mitsuo Numata, the leader of the winning research group in this project was one of
the "lay researchers." He also share the opinion with Morita:
[A success point is] that [Morita] did not use specialists only, but mixed lay
people with specialists. ... If the team members had been specialists only,
their view would have been much narrower. The team needed someone with
foolishness enough to challenge what specialists believed to be impossible.
Of course, lay people only would not have produced any better results.
Mixture was important. (Interview)
There was keen competition between the research groups. Numata, one of the group
leaders, and Kenji Okonogi, who conducted biological study of the compounds
synthesized by all research groups, described the situation at that time merrily:
Hara: Was there exchange of information between the research groups?
Numata: No. Rarely. Because we were fighting each other (laugh). Members
of each group spoke ill of other groups at Okonogi's laboratory. He was a
good listener.
Okonogi: Yes. I can confess it now. To be honest, it was a very hard job to
be fair to every group (laugh).
Numata: I asked him, for example, not to give this information to Dr Ochiai
(laugh). All of us had a strong sense of rivalry. However, Morita had an
ability to control this situation. (Interview)
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Morita made careful efforts to control conflicts inside his research organization. He
described an example of his efforts:
I did not become a co-author of papers produced by the researchers in my
department after I became the Head. I even declined to be mentioned in
acknowledgements. ... If I had allowed them to put my name into their
papers, I could not have promoted competition in my organization. If I had
become a co-author of one research group, I would have had to become a co¬
author of another research group, in order to be neutral between them. But if I
had done this, it would have made me look indifferent and somewhat
irresponsible. (Interview)
In the first year of the project, SCE-150, which did not include P-ketoacids in the
structure, was synthesized by one of the research group. Although SCE-150 was as
potent as the most potent cephalosporin available at that time, Morita gave up its
development because he believed that it would become obsolete before it appeared
on the market several years later. (Morita interview)
The research group led by Numata succeeded in putting P-ketoacids into
cephalosporin molecules at the 7 position side chain and synthesized many
compounds. Most of them showed only disappointing activity. However, when they
introduced an atom group called methyl-thio-methyl to the P-ketoacid side chain, the
resultant compound showed fairly high potency. (Numata et al. 1978a, b; Numata
1981, pp. 25-26; Morita et al. 1983, p. 19) This result encouraged them to make
further analogues of this compound. Serendipitous discovery occurred in this process.
When they tried to combine another related atom group called thiocyanate with the
side chain, the nuclear magnetic resonance analyser in their laboratories was broken.
Because of this, the compound was left for a week. After the machine was repaired, a
young researcher of the group analysed the compound and found that it was different
from what they expected. They examined the unknown compound and found that the
atomic group at the end of the side chain had become a cyclic structure. Moreover,
this new compound possessed a remarkable antibacterial activity, which was stronger
than any existing cephalosporin, particularly against Gram-negative bacteria. This
showed the way to what they were looking for. When they used thiourea, another
related chemical group, in place of thiocyanate, the similar reaction, namely
204
"cyclization" occurred immediately and produced a cephalosporin with a unique side
chain called 2-aminothiazol-4-ylacetyl in good yields (Figure 7.5). They then made
an effort to optimise another side chain at 3 position. The consequent cephalosporin,
codenamed SCE-785 (figure 7.2), satisfied the requirements for a competitive
cephalosporin in the future market. Takeda decided to develop SCE-785 in July 1974,
five months after its synthesis. (Numata et al. 1978c, 1262-1263; Numata 1981, pp.
27-30; Morita et al. 1983, p. 19; Takeda 1983, p. 973; Numata interview) The unique
structure of SCE-785, 2-aminothiazol-4-yl, later became a standard component
structure: most third-generation cephalosporins developed later adopted it. (Takeda
1983, p. 973; Webber and Wheeler 1982, p. 379, pp. 389-390)
Figure 7.5: The "Cyclization" of the (3-Ketoacid Side Chain Resulting in
Formation of 2-Aminothiazol-4-ylacetyl Side Chain
SCE-785 was pre-clinically tested for about a year. Its efficacy was confirmed.






bladder of rabbits to which a lot of SCE-785 was administrated. This was believed to
be due to the low solubility of the compound in water. Morita insisted the
continuation of its development because results in humans might be different from
those in rabbits, but toxicologists at Takeda argued that they should wait for a better
drug. (Morita 2000, p. 214; Morita interview) SCE-785 proceeded to clinical trials
with healthy volunteers, but one of them showed side effects. This was also believed
to be due to the low solubility of the compound in water. (Numata interview; Takeda
1983, p. 973) Thus, the development of SCE-785 was stopped in December 1975.
(Takeda 1983, p. 973)
Along with the development of SCE-785, the search for a better cephalosporin was
continued in Morita's department. This time, Morita concentrated researchers' efforts
on improvement of 2-aminothiazol-4-ylacetyl cephalosporins, that is to say,
analogues of SCE-785. (Morita 2000, p.213; Morita interview) At this stage, he
made Numata's group open their information to other researchers in order to promote
competition among them. (Morita interview) Numata was transferred to the
manufacturing division to help development of the production process of SCE-785.
(Numata interview) At Morita's department, further efforts were made to optimise
the side chain at 3 position. Okonogi, who was involved in assaying of these
compounds, described how busy he was at that time, to deal with the compounds
synthesized one after another:
We examined about 30 compounds a week. We divided them into two
sessions. It took three days to assay compounds: plant bacteria on the first
day; put compounds into the culture next day; then observe results on the
third day. By that time, our company had adopted a five-day working
week. ...So we had two sessions: Monday to Wednesday and Wednesday to
Friday. We continued this for weeks. (Interview)
As a result, one hundred and fifty four compounds were synthesized. When the
development of SCE-785 was stopped, several compounds having higher solubility
in water were chosen from the newly synthesized compounds. After detail
examination of these compounds, Takeda decided to develop one of them, SCE-963,
in place of SCE-785 in December 1975. This compound, named cefotiam (figure 7.2),
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also had a broad range of activity and was in particular more active against some of
Gram-negative bacteria than existing antibiotics at that time. Cefotiam quickly
passed through pre-clinical tests and proceeded into clinical trials in August 1976.
(Takeda 1983, p. 973-974; Numata et al. 1978c; Morita et al. 1983, pp. 19-20;
Tsuchiya et al. 1978)
7.3.5. Development of Cefotiam
Development of an efficient production process for cephalosporins proceeded
concurrently with chemical syntheses and biological studies of the compounds.
(Takeda 1983, p. 973) Production costs of cephalosporins had been a critical problem
for the commercialisation of the drugs. Penicillins were much cheaper than
cephalosporins at that time, and this produced obstacles to research and development
of cephalosporins. Morita faced such criticism when he led the cephalosporin project
at Takeda. He put it:
One ofmy senior colleagues asked me, "Morita, I heard you began to
research cephalosporins. But, do you know prices of penicillins and
cephalosporins?" I said, "I don't know exactly, but cephalosporins seem
expensive." He said, "10 times expensive. I mean, costs of raw materials. In
addition, penicillins are fast in fermentation. Moreover, it is easy to extract
penicillins into butanol, but cephalosporins are hydrophilic and insoluble in
butanol. How could you succeed?" (Interview)
In order to reduce costs of cephalosporins, Takeda had made efforts early on in their
cephalosporin research. As I mentioned above, they developed a new production
process of deacetylcephalosporin C (DCPC) in 1973. They then invented a new route
to produce semi-synthetic cephalosporins such as cefotiam from DCPC in good
yields and on a large scale. This reduced production costs to an acceptable level.
(Takeda 1983, p.974; Tsushima et al. 1979) It should be noted, however, that this
problem of costs of cephalosporins was also related to patents secured by other
companies. Numata explained it:
At that time, only members of the syndicate [organized by NRDC] could use
[the raw material, 7-ACA], ... When we thought about methods of its
207
production, we found more patents protected them. So, only DCPC enabled
us to circumvent those patents. ... So, we at first made DCPC and use it as
raw material of cephalosporins. Later, those patents expired one by one, and
it became more economical to use 7-ACA available on the market than to use
DCPC made by us. (Numata interview)
Takeda also had to design a unique preparation to make cefotiam suitable for
practical use. Because of the production route of cefotiam and in order to maintain
stability of the compound, the company decided to market cefotiam as a salt with two
moles of hydrochloric acid. When this salt alone was dissolved in water, however,
the solution was too acidic to be appropriate in clinical use. Therefore, they prepared
sodium carbonate with the drug to neutralise the acid. Then, they reduced the
pressure of phials containing the preparation to control carbon dioxide generated
when water was added into the phial. To produce the phial, they also had to develop
new equipment for packaging. (Takeda 1983, p. 974) Fortunately for them, however,
the good solubility of the prescription was highly appreciated by medical
practitioners including doctors and nurses, according to Nobuyoshi Hiramatsu, who
was involved in the marketing of cefotiam. (Interview) This is because medical
practitioners often face cases in which they have to administer an antibiotic to
patients immediately. (Numata personal communication, June 2000)
Clinical trials of cefotiam went ahead smoothly. In February 1977, cefotiam
proceeded to Phase II. Its double-blind trials with cefazolin, a highly potent first-
generation cephalosporin developed in Japan, were conducted from November 1977.
The results of these Phase III trials were presented at the annual conference of the
Japan Society of Chemotherapy in June 1978. Efficacy and safety of cefotiam were
supported there. (Shimizu, Kumada and Okuzumi 1979; Various papers in
Chemotherapy, Volume 27, Supplement 3, April 1979) Based on these data, Takeda
and its development partner Ciba-Geigy (Japan) obtained approval for manufacturing
cefotiam from the Ministry ofHealth and Welfare in 1980. Takeda launched
cefotiam under the trademark Pansponn in February 1981. (Takeda 1983, p. 974)
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Cefotiam was also marketed in several foreign countries including Germany, but its
sales abroad were limited.15
Two institutional factors contributed to the relatively rapid development of cefotiam
in Japan. First, because antibiotics were used for the cure of acute diseases, its long-
term side effects were regarded as less important than those of drugs for chronic
diseases such as hypertension and hypercholesterolemia. Rather, the regulatory body
sought to approve any better antibiotic as soon as possible. (Hiramatsu interview)
Second, there was a well-organized society of specialist doctors in the chemotherapy
area in Japan. This society, the Japan Society of Chemotherapy was practice-oriented
rather than basic-research-oriented: it focused on evaluation of drugs rather than
research about infectious diseases. (The Japan Society of Chemotherapy, website16)
This society had its own routine to manage clinical trials. When pharmaceutical
companies asked the society to do clinical trials, it organized and arranged them.
Then, the clinical trials proceeded steadily under the initiative of the society. This
system strongly promoted development of antibiotics in Japan. (Hiramatsu interview)
Cefotiam was profitable because it was more active against bacteria than existing
drugs at that time. This was not only because the drug was sold better than other
drugs, but also because its price was fixed at higher level than other drugs by the
regulatory body. In Japan, the official price of a drug is fixed in comparison with
those of other equivalent drugs or most similar drugs if there is no equivalent drug.
Because cefotiam was almost double as active as existing drugs, it succeeded in
gaining the same price as others in only a half quantity. In other words, it won almost
double price per gram, compared with existing drugs. (Hiramatsu interview)
15 It was said that Ciba-Geigy gave up its launch in Switzerland because of its small sales prospects. In
the US, its launch was not fulfilled because the delay of obtaining an approval from the regulatory






Tamsulosin is a drug that is a remedy for the urination disorder accompanying
benign prostatic hypertrophy. (Japanese Patent WO 95/02419, 1995) It was
discovered by a research team led by Toichi Takenaka in 1980 at first as a potential
anti-hypertension drug. However, its new application in the urological area of the
drug was later recognised and it was clinically developed in this area. In addition, the
drug was developed at first in its racemic mixture (Yamanouchi 1994; Takenaka, et
al. 1995), that is to say, in a 50:50 mixture of two stereoisomers that have a mirror-
image relationship. A racemic mixture is symbolized as (±), while each of the
stereoisomers is expressed as (+) or (-). It was later switched to be the single (-)-
isomer only. Tamsulosin (Harnal®) was marketed in Japan in 1993 (Yamanouchi
1994), in European countries in 1995 and in the US in 1997. (Takenaka interview)17
It had sales in Japan of about 150 million pounds and its overseas sales were about
50 million pounds in 1997. (Nihon Sougou Kenkyusyo 1998, p. 274)
Table: 7.3: Major Events Discussed in This Section
Year Events
1976 Research Started
1980 Discovery ofYM12617 (a racemic mixture of tamsulosin)
1982 Organisational Authorisation
1983 Clinical Trials Started
1986 Switch to the Single (-) Isomers (tamsulosin)
1993 Launch in Japan
17 The interview with Dr Toichi Takenaka was conducted on 22 January 1999.
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7.4.2. Synthesis of Tamsulosin
Benign prostatic hypertrophy (BPH) often arises when men age. It causes some
difficulties in urination such as retarded urination, frequent urination and residual
urine. It is said that a fifth ofmen over 55 years old suffer from the disease.
(Yamanouchi 1994) Although it is not a fatal disease, it seriously damages the
quality of life of the patients. BPH had previously been treated by traditional Chinese
medicine or hormone preparations. Surgery was the only treatment that was more
effective. Furthermore, most patients were unwilling to go to urogenital clinics,
partly because of the negative images of the clinics, especially in Japan, and partly
because the disease was not fatal. (Takenaka interview) It was common for sufferers
to buy over-the-counter (OTC) drugs based on traditional Chinese medicine to
relieve the difficulty.
Tamsulosin was not synthesized at first as a drug for the treatment of the urination
disorder. Researchers at Yamanouchi had been involved in research on a and /3
adrenergic receptors since 1965. As outcomes of this research, they discovered a /3 -
blocker for the treatment of heart diseases and hypertension, indenolol in 1968, a j3 -
stimulant for the treatment of asthma, formoterol in 1972, and an a j3 -blocker for
the treatment of hypertension, amosulalol in 1976. (Yamanouchi 1994; Takenaka, et
al. 1995) The discovery of tamsulosin stemmed from the research on amosulalol.18
From the research on differences in the receptor selectivity ofvarious a j3 -blockers,
researchers found the (+)-isomer of amosulalol to be more potent in blocking a i
receptors, a subtype of a receptors, and the (-)-isomer to be more potent in blocking
j3 i receptors, a subtype of j3 receptors. They synthesized the derivatives of
amosulalol to obtain more-potent a \ blockerswithout j3 i blocking activity. They
found that sulfamoylphenethylamines constituted a structurally new type of potent a
i blockers. YM-12617 (the racemic mixture of tamsulosin), synthesized in 1980, was
found to be the most potent compound of all (Takenaka, et al. 1984; Takenaka, et al.
18 The research on tamsulosin was a continuation of the research on amosulalol. Therefore, it is almost
impossible to identify the starting point on the research of tamsulosin. In this paper, I will defme the
starting point as being 1976, just after the discovery of amosulalol. See Fukai (1995), p.489.
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1995) and became a candidate to be developed. (Figure 7.6) Therefore, tamsulosin
was synthesized as an a \ blocker, without a specific application of the compound.
Toichi Takenaka explained why he turned his attention to a i blockers:
I was interested in a receptors, because at that time a new theory emerged
that there were two subtypes of a receptors, namely, a \ receptors and a 2
receptors. Then, I was keen to know what kinds of roles each subtype played.
So, we examined their distribution and related properties. I remained in this
area of research because ofmy intellectual curiosity, and expected to lead
studies and experiments, such as one on which subtypes govern the prostate
and the urethra, to academic publication. (Interview)
The synthesis of the compound, in other words the modification from amosulalol to
the compound, was said to have been done quite rationally and relatively smoothly.
Takenaka put it thus:
The drug design went smoothly, because the lead compound was our own and
we had experience of amosulalol. And in our own research, we had been
involved in research on the sympathetic nerve system for a long time, since
around 1965. So, we had already, in our company, developed concepts,
methods for experiments and whatever related to the drug. (Interview)
7.4.3. Discovery of the Application
At first, a i blockers were considered for use in treating anti-hypertension. However,
Yamanouchi had already developed indenolol, nicardipine (Ca++ blocker) and
amosulalol as anti-hypertension drugs and intra-company competition between these
drugs existed. Therefore, the researchers started a search for an application of the
new a \ blocker. (Yamanouchi 1994)
The research team turned their attention to the area ofurology. There were at least
three reasons for this. First, they considered the research ofRaz and Caine (1972)
suggesting that a receptors played a predominant role in urethral contraction,
though they had not identified which subtype of a receptors was related to the
activity. (Yamanouchi 1994; Takenaka, et al. 1995) This led Takenaka and his
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colleagues to conduct their own investigation of the distribution of the subtypes, as
described in his statement above. Takenaka's connection with a urologist was the
turning point of his work. He put it thus:
An unexpected enquiry about whether our company was dealing in a classic
a blocker came from a urologist friend ofmine when we were doing the
research. ... Because I couldn't understand why he was interested in such a
drug, I went to ask him. Then, I found that he wanted to try the drug to
improve his patients' urination because the Israeli [Raz and Caine's] research
said it could do this. ... I answered him that I couldn't provide any
immediately but that I would likely be able to provide the drug soon.
Therefore, just at that time, the lead compound, the concept and the idea of its
application came together. (Interview)
Secondly, the area ofurology had not been well-developed as a market for the
pharmaceutical industry. The competition was not considered to be fierce and a good
business opportunity was expected there. Thirdly, Yamanouchi staff had established
a connection with urologists through the development and marketing of an antibiotic
for urinary tract infection. The area was a new and strategically important market for
them. They were able to hear urologists' views and exchange information with them
through their medical representatives. (Takenaka interview)
The research team found that the receptors that mediate contraction of the smooth
muscle in the lower urinary tract and prostate gland of the rabbit are a i receptors.
(Honda, Miyata-Osawa and Takenaka 1985; Takenaka, et al. 1995) Their subsequent
study, in collaboration with urologists at the University of Tokyo, showed that the
human urinary bladder base and prostatic urethra are also mediated by a i receptors.
(Kunisawa, et al. 1985)19 This opened the way to applying YM-12617 to the
treatment ofurination disorder accompanying BPH.
19 The collaboration with the university was a key to the unprecedented research because animal
experiments did not guarantee the same results in human beings and because the company could not
do experiments with human tissues on its own, according to Takenaka (Interview).
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7.4.4. Acquisition of the Internal Authorisation
Yamanouchi decided in 1982 to develop YM-12617 as a drug for the treatment of
urination disorder accompanying BPH. There were several other similar candidate
compounds, but YM-12617 was chosen because it was believed that its overall
record in potency, pharmacokinetic properties and costs was best of all.
The acquisition of approval, from the company management, for the development of
YM-12617 was the most crucial barrier facing the research team on the path to
turning their discovery into an innovation.20 The management was full of doubts
about the marketability of the drug.21 First, there was a doubt as to whether BPH
could really be considered to be a disease. Secondly, this drug would reduce the
necessity of surgery for the treatment ofBPH.22 There were questions about whether
the drug would be accepted by practitioners and how it would coexist with surgery.
There was also the problem of how high a price should be set to balance the
anticipated decrease in doctors' income from surgery.23 Thirdly, there was a problem
of estimating the potential market size for this drug, because many patients ofBPH at
the time were unwilling to go to urogenital clinics.
The connection and communication with urologists played an essential role in
sweeping away these concerns. Takenaka, the project leader, had an interest in
medical needs and actively investigated this with the marketing staff. They found
that a group ofurologists at Gunma University had been doing studies on BPH for a
long time in a village in Gunma Prefecture. This data provided Takenaka's team with
a valuable basis for estimating the number of potential patients. Market information
20 This paragraph is based on the interview with Dr Takenaka.
21 The procedure for decision making had already been institutionalised in Yamanouchi in the 1980s.
First, a research group leader would propose the development of the drug to the assessment meeting
inside R&D. Then, if the proposal were approved by the assessment meeting, it would be proposed in
the management meeting. The decision of the management meeting would be final. (Takenaka
interview)
22 This is a common problem in the cases of histamine H2 antagonists and of anti-prostate cancer drugs.
See Chapter 5 and 6 of this thesis.
23 A higher drug price implies a higher income for doctors in the conventional Japanese health care
system. This is because of the margin between the official price and the amount actually paid to
purchase the chug. See Section 5.4.2 of this thesis.
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obtained from urologists like this enabled Takenaka to prepare evidence good
enough to persuade the management. (Takenaka interview)
Economic reviews were conducted systematically by the company even after the
approval for development had been given by the management. An expert department
of the company assessed the project at least three times: before Phase I, before Phase
III and before the application for governmental approval. They estimated the market
size and sales, development and production investments and operational costs. It was
their policy to proceed as fast as possible when the results were good. Therefore, the
economic review had a significant influence on the speed of development. (Takenaka
interview) Because the company had at first estimated the number of patients for the
drug as being 50,000, the priority of the project was not very high until 1985. By an
improvement in the technology used in the medical check-up of the disorder, the
estimated number of the patients was corrected to being 150,000. After that, the
priority of the project rose greatly. (Nihon Sougou Kenkyusyo 1998)
7.4.5. Technological Changes in the Development Process
In 1983, Yamanouchi started clinical trials of the drug, following its pre-clinical tests
which had started in the previous year. (Nihon Sougou Kenkyusyo 1998) There was
no practical problem in Phase I and Phase II. However, it was known that YM-12617
was a racemic mixture and that only its (-)-isomer was clinically active. An
American consultant of Yamanouchi suggested to the company that the racemic
property of the drug might become a significant problem in marketing in the United
States and European countries.24 The company knew that the single isomers of the
drug would be at most twice as active as its racemic mixture and that it would cost a
lot to produce the single isomers, together with the loss of time and money that they
had already spent for the clinical trials ofYM-12617. Nevertheless, the company
decided "with tears" to switch the drug to the single (-)-isomers because they wanted
to use the drug strategically as a decisive step for the company's globalisation. They
24 There was also the same opinion in academia from the viewpoint of drug safety and Yamanouchi
was aware of this. (Takenaka, et al. 1995, 778; Ariens 1984)
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re-started the clinical trials of the (-)-isomers ofYM-12617, now named tamsulosin,
from Phase I in 1986. (Takenaka Interview)25
Another problem was the control of a minor side effect. Although tamsulosin was
selective to the receptors at the prostate and the urethra, it also had a weak influence
on blood pressure. This can cause orthostatic hypotension, dizziness felt on standing
up. In order to avoid this disorder, the Takenaka group, at first, tried to increase
gradually the dosage of the drug so that the body could get accustomed to it. This
method was, however, very bothersome for doctors and patients. Therefore, they
considered making a sustained release preparation of the drug to avoid the side effect.
They succeeded in realizing this and achieving an oral, once-a-day administration in
1986. (Takenaka interview; Fukai 1995, p.489; Yamanouchi 1994; Takenaka, et al.
1995) This was also commercially important. Takenaka put it thus:
We chose a sustained release preparation for the drug and this was another
key factor in the success. This was done intentionally. We considered the
business aspect very much at that stage. We had many talks with doctors and
heard them say, "Sustained release is better," "Yes, this is good," and
comments like that. (Interview)
Commercial consideration was also seen in Yamanouchi's efforts to establish an
economical large-scale production system for the drug. They considered the
abandonment of the other isomers, namely, (+)-isomers, to be a waste. They
succeeded in the recycling of the isomers to turn them into (-)-isomers and reduced
the production costs enough for them to be acceptable. (Takenaka interview)
7.4.6. Clinical Trials and Promotion
In the clinical trials of tamsulosin, the cooperative attitudes of doctors toward the
trials were important. For example, doctors could use placebos in the clinical trials.
But, it was, and it has probably been, extremely difficult for them to use placebos in
clinical trials, under the practice of informed consent, in Japan. However, a
25 The establishment of an economical, large-scale synthetic procedure was also reported to promote
the switch. (Fukai 1995, p.489)
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comparison with placebos is the most convincing way of showing the efficacy and
safety of a drug. Yamanouchi succeeded in obtaining doctors' cooperation to use
placebos in Phase II and Phase III of the clinical trials of the drug. They also
succeeded in obtaining doctors' agreement to conduct more-detailed dosage response
tests. Moreover, they persuaded doctors to apply the US guidelines, which were
stricter than the Japanese counterparts, to the trials. With the cooperation of doctors,
they achieved a high quality of clinical trials, which confirmed the efficacy and
safety of the drug. (Takenaka interview; Kawabe, et al. 1990)26
The market was shaped partly by the company and partly by other actors in Japanese
society. Takenaka put it thus in my interview with him:
Takenaka: Social needs in the treatment ofBPH changed and influenced [the
development of the drug] positively. More men went to urogenital clinics.
Doctors wrote about the urination disorder in newspapers, and people
recognized it.
Hara: As a disease?
Takenaka: Yes, luckily. We promoted it intentionally to some extent, but
there was a limit to what we could. After all, society did it. And the concept
ofQOL [quality of life] penetrated deeply in the society. You wake up
frequently at night for urination, so you can't have a good sleep, and this is a
bad quality of life. We need a drug to improve the situation. It was the time
such thoughts emerged.
Scientific and technological progress also affected the progress of the development
and sales of the drug. In 1987, subtypes of a \ receptors were pharmacologically
found and named a iA receptors and a ib receptors. (Morrow and Creese 1987;
Minneman, Han and Abel 1988) Lepor, et al. (1993) showed that the a i receptors
which mediate the contraction of the prostatic smooth muscle are the a ia subtype.
Later, by using molecular biology, three subtypes of a i receptors were found to
exist, re-named a ]a receptors, a ^ receptors and a ic receptors. (Schwinn, et al.
1990; Lomasney, et al. 1991) Price, et al. (1993), using techniques of molecular
biology, identified that the a \ receptors which predominantly exist in the prostate
26 The size and the format of clinical trials of tamsulosin were praised by both editors of the Journal of
Urology. (Wein 1990; Lepor 1990)
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are the a ic receptors (which encode for the pharmacological a iA receptors).27
Several studies showed that the affinity of tamsulosin to the pharmacological a iA
receptors and the cloned a ic receptors is greater than that to the a ib receptors.
(Abrams, et al. 1995) These studies showed that tamsulosin is selective in the
prostate because of its high affinity to the a Jc receptors (or, the pharmacological a
ia receptors). According to Takenaka, "this completed the scientific concept of the
drug." (Interview) He described how this worked in the marketing of the drug:
The influence [of the concept of the a ia blocker] was enormous. In
particular, when the word "selectivity" appeared, I could announce that I had
discovered a selective drug. It was a scientific achievement. I could write
many papers on it and become famous. This made the marketing of the drug
very easy. "How is it different from existing drugs?" "Doctor, this is a iA
selective." "What's aiA?" "Well, you don't know? a ia is the one that is
widespread in the prostate." "A-ha! So it works on BPH." Like that. We
could give a very simple explanation. (Interview)
Tamsulosin was launched in Japan in August 1993 under the trade name ofHarnal.
As I already mentioned, it was also launched in the US and European countries later.
The drug was exclusively developed by Yamanouchi. There were approaches from
several companies about co-development but Yamanouchi declined them all. (Nihon
Sougou Kenkyusyo 1998) The experience of the international development of the
drug was a crucial step for the globalisation of the company28. (Interview) To my
question ofwhat was the most important factor in the success, Takenaka mentioned
leadership and teamwork and emphasized the role of the experience of success in
them. (Takenaka interview; Nihon Sougou Kenkyusyo 1998) He put it thus:
While I had been researching receptors, I had also made several drugs from
the research. Some of them succeeded commercially, others not. But when I
researched something, I made a drug from the research and led it to the
market. I did Pulsan, then I did Perdipine, and then Lowgan, and this Harnal.
27 The pharmacological classification of a, receptors and their molecular biological classification had
not been consistent until recently. (Forray, et al. 1994; Kirby and Pool 1997)
28 Yamanouchi has a bitter experience of the co-marketing of famotidine. See Section 5.4.
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Then Hypoca.291 materialized and commercialised research as drugs, so the
management looked at me positively.
... After all, to be trusted is important. If you are trusted, you can do things as
you like, to some extent. Then, you can take some risks. It's important to
have experience of success. People who have experience of success can do
something radical. (Interview)
7.5. Discussion
7.5.1. Types of Innovation
The innovation process of mevastatin clearly demonstrates the properties of the
paradigmatic innovation discussed in the previous chapters. There had been no
exemplary drug before mevastatin. It was this compound that played an exemplary
role later. Although there had been a theory on the biosynthesis of cholesterol in the
body before mevastatin, the compound demonstrated the idea of lowering the
cholesterol level in the blood by inhibiting HMG-CoA reductase and showed what
this kind of compound could achieve. Because of this novelty, scientific and
technological uncertainty was very high. There was little knowledge about how to
obtain the target compound. Endo bet on microbes. It was fortunate for him that a
microbe did produce such a substance. Endo and Kuroda had to design an assay
system to identify the substance. Even after the discovery of the substance, they had
to discover how to demonstrate its efficacy in animals, because its initial tests with
rats failed to show this. Organisational resistance based on unfamiliarity with the
concept of the compound arose in the company Endo was working for. The project
was almost axed again and again. Each time it happened, Endo had to take defensive
actions. In particular, he mobilised academics including Goldstein and Yamamoto as
a source of power. Without Endo's strong leadership, the project would have been
axed. Although this compound itselfwas indeed abandoned after Endo's departure,
its several analogues were developed by different companies and each of them
achieved great success.
29 Pulsan®, Perdipine®, Lowgan® and Hypoca® are the trade names of indenolol, nicardipine,
amosulalol and barnidipine, respectively.
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In contrast, in the case of cefotiam, scientific and technological uncertainty was not
so high as in that of mevastatin, because there were several exemplars, that is, the
"first generation" cephalosporins. What the Takeda researchers had to do was to
modify the molecular structure of the exemplars in order to obtain a significantly
better one. However, existing patents, access to raw material and the room for
improvement limited the opportunity for modification. Morita, the project leader,
organised a number of researchers to achieve the task systematically, though he also
added an element of competition to the process. The company made organisational
efforts to make the drug competitive in various aspects: efficacy, range of target
bacteria, safety, production costs, and convenient preparations. In each aspect, the
construction of its differences from existing cephalosporins without harming its
competitiveness was essential. Therefore, in the aspect of production costs, the
covering of differences was the task, because from the beginning its production
process was forced to be different due to the patents of other companies. Thus, the
case of cefotiam clearly demonstrates the properties of modification-based
innovation.
The case of tamsulosin was ambivalent. The compound itselfwas not so novel as in
paradigmatic innovation, because a-blockers were well-known compounds. It had
exemplars as compounds. Therefore, uncertainty in synthesis was not very high.
However, the drug has novelty in its application, that is, the treatment for urination
disorder accompanying BPH. Social uncertainty was high because people inside and
outside the organisation were doubtful about the practicality of the idea of using an
a-blocker as a drug for the treatment ofurination disorder. Takenaka defended the
project from this suspicion by providing evidence, including the potential market size
of the drug, by himself. The company promoted the drug by using the concept of aic-
blockage, which explains its selectivity in the prostate. In this process of shaping a
new application, the linkage with doctors in the urological area was in particular
important. They provided Takenaka and his company with the idea, the evidence and
the concept. However, without the heterogeneous engineering conducted by
Takenaka and his colleagues, the idea might not have succeeded. Thus, the case of
tamsulosin has some properties of paradigmatic innovation and some properties of
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modification-based innovation. This ambiguity can be attributed to its novelty in
application and the familiarity with its molecular structure. Therefore, I propose to
regard this as belonging to another type of innovation and name the type the
application innovation.
7.5.2. Interpretative Flexibility and Organisational Authorisation
The cases in this chapter reveal how a pharmaceutical company is not a monolithic
organisation. On the contrary, in the company there are divergences of opinions
among researchers, between researchers and toxicologists, between researchers and
marketing staff, and between researchers and the management. In the case of
mevastatin, there was interpretative flexibility30 about the efficacy and safety of
mevastatin, with Endo and researchers at the Central Research Laboratories, and
Endo and toxicologists at the company, having different views. The researchers on
the Central Research Laboratories thought that the drug did not work because it did
not lower the plasma cholesterol level in rats, whereas Endo thought that the drug
failed to show its efficacy because the animal tests was not appropriate. The
toxicologists believed that mevastatin was not safe enough because they observed
unknown deposits in the liver cells of the rats given a large amount of the drug,
whereas Endo believed that it was safe because the deposits were resoluble
cholesterol ester. About the toxicity study that led to the suspension of the
development of mevastatin, the company considered that mevastatin was not safe
enough because the long-term tests demonstrated its potential toxicity, whereas Endo
considered that mevastatin was safe because the tests had flaws in the choice of
dosage. In the case of cefotiam, there was also interpretative flexibility about the
safety of SCE-785, the prototype of the compound. Morita thought that the
compound should be examined in humans because humans were not the same as the
rabbits which showed its toxicity, whereas toxicologists thought that it should be
abandoned because the activity of the drug in rabbits probably represented its activity
in humans. In addition, there were other kinds of divergence of opinions in the cases
in this chapter. In the case of cefotiam, there were doubts about the possibility of
30 On interpretative flexibility, see Section 2.1.2. of this thesis.
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further improvement of cephalosporins and about the profitability of the new
cephalosporin among the people inside the company. In the case of tamsulosin, there
were also doubts within the company about marketability and profitability.
It was the task of the project leader to obtain organisational authorisation despite the
existence of these divergences and doubts within the company. Various resources
were mobilised for this. In the case ofmevastatin, the hens that were informally
obtained from other laboratories and the linkage with an external medical academic
played an important role in obtaining organisational authorisation. In the case of
tamsulosin, the track record of the project leader, the linkage with external medical
academics and doctors, and the social awareness of the quality of life were
significant in the shaping of organisational authorisation. In the case of cefotiam,
although the project team obtained organisational authorisation from the beginning,
they had to demonstrate the feasibility and profitability of the compound in order to
sweep away doubts within the company. In order to achieve this, their organisational
capability was crucial. Thus, obtaining organisational authorisation was a very
important aspect in any type of innovation, and various elements including social
networks, non-human entities and organisational activities were mobilised for
achieving this.
7.5.3. Culture, Social Structure arid Innovation
The three cases of the Japanese pharmaceutical innovation described in this chapter
show the influence of structural and cultural factors on the innovation process of
pharmaceuticals. The case of mevastatin shows the importance of consensus in the
Japanese organisation. The project-coordinating meeting played a decisive role, and
the project could not go ahead without the agreement of toxicologists and
pathologists. It also demonstrates the power of clinicians, particularly those at
universities, in Japan. But for the offer of clinical trials from Yamamoto at Osaka
University, the project ofmevastatin would have been axed earlier. The case of
cefotiam, the existence of a special society of clinicians, namely the Japan Society of
Chemotherapy was highlighted. This well-organised society facilitated the
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development of antibiotics in Japan. In the case of tamsulosin, the unwillingness of
Japanese people to go to urogenital clinics and the difficulty of the practice of
informed consent in Japan were indicated. Although the extent to which each of
these cultural and structural factors affects the innovation process of pharmaceuticals
seems to be varied, it is clear that these factors increase the complexity of innovation
process in the pharmaceutical industry.
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Chapter 8: Conclusion
In the previous chapters, we examined more than ten British and Japanese drug
innovations in four different therapeutic areas: namely, cardiovascular diseases,
bronchial asthma, peptic ulcer and prostate cancer. In addition, we also investigated
three more cases ofpharmaceutical innovation in Japan. The processes of these
innovations may appear to be linear ifwe look only at their formal aspects. However,
close examination of the processes reveals that this is not the case. They were not
linear but much more complex. They included various properties: diversity,
serendipity, interpretative flexibility, interactions between various human actors and
between human and non-human actors, corporative strategy, leadership,
heterogeneous engineering, organizational resistance, reverse salients, controversy,
selection, regulation, market estimation, cost reduction, persuasion, promotion,
rhetoric, politics, social acceptance, and so on. Scientific knowledge, technical
knowledge, managerial knowledge, knowledge about organisation, economic
knowledge, knowledge about clinical practice, knowledge about markets, knowledge
about regulation and knowledge about society in general were newly combined or
created in the process of transforming a chemical into a drug. At the same time, a lot
ofmaterials were constructed: compounds, assay systems, disease model animals,
scientific equipment, production equipment, plants, packages, specialised inhalers,
and so on. Various institutions were also established: project teams, project
evaluation boards, clinical study groups, regulations, guidelines, and so on. Thus, the
shaping process of a drug is a co-creation ofmaterials, knowledge and institutions.
Although numerous lessons may be extracted from the cases this study includes, I
highlight three major findings here: the shaping process of drugs, the different types
of pharmaceutical innovation and the features of Japanese pharmaceutical innovation.
In the rest of this concluding chapter, I will first describe the shaping process of
prescribed drugs in a more specific way than the description above but in a more
general way than in each case study. I will then propose three different types of drug
innovation, which emerged from the case studies. Each of the types has different
profiles in its shaping process. Next, I will examine differences between the UK and
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Japan in pharmaceutical innovation. Finally, I will discuss some theoretical and
practical implications of this study.
8.1. The Shaping Process of a Drug1
A prescribed drug is shaped by various factors, as mentioned above. Although the
shaping process is complex, it is not chaotic. This is because shaping technology is
an activity in which people pursue certainty in an uncertain world. (Munakata 1989)
This purpose cannot be completely achieved, but gives the shaping process of
technology some distinguishable profiles. We can distinguish four aspects of the
shaping process of a drug. Each aspect can be characterised and distinguished by the
main activities and the main actors it includes. The aspects of the shaping process of
a drug consist of the shaping of the compound, the shaping of the application, the
shaping of organisational authorisation and the shaping of the market. In this section,
we will see what kinds of activity and actor play what kinds of role in each aspect of
the shaping process of a drug. At the same time, we will examine how the objects of
the process, the compound, the application, organisational authorisation and the
market, are shaped.
8.1.1. The Shaping of the Compound
The first aspect of the shaping process of a drug is the shaping of the compound. The
compound here refers to the material aspect of a drug. The core of the compound is a
chemical believed to have a profile of biological activities of clinical use. Therefore,
this aspect includes the process of drug discovery and biological and clinical tests.
However, the compound here also includes later modification of the molecular
structure, preparation (formulation) for its practical use and any other materials used
for its practical use. Several actors and factors play a significant role in this aspect.
Let us examine them one by one.
1 As discussed in Section 2.1.4,1 use the words "the shaping of technology" rather than "the
social shaping of technology" in order to withdraw the apriori priority of the social.
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First, in the shaping of the compound, the primary player is the leader of the research
project, whose interest and expertise orients the direction of and limits the range of
the search for the compound. James Black's interest and expertise in beta-blocker
and H2 antagonists, David Jack's in anti-asthma drugs, Masahiko Fujino's and Barry
Furr's in LHRH analogues, Akira Endo's in HMG-CoA reductase inhibitors, Toichi
Takenaka's in receptor-based drugs, and Katsura Morita's in cephalosporins were the
driving forces of their research projects, which eventually led to the discovery of
drugs.
Second, the knowledge and skills of the research team and the company also limit the
area of research. As we saw in Chapter 2, drug discovery means the discovery of the
"fact" that a chemical has a biological activity that can be clinically useful. Therefore,
cooperation between chemists and biologists is essential. Their different expertise
may also guide the research in a specific direction. Glaxo's intellectual assets in
steroids, Takeda's and ICI's in peptide synthesis, Sankyo's fermentation,
Yamanouchi's in adrenergic receptor-based drugs and Takeda's in antibiotics,
embodied in fellow researchers and supporting staff, probably facilitated research in
specific areas. However, the shaping activity of a compound also contributed to the
accumulation of these intellectual assets. It was seen in the pairs of innovation in the
same organization, such as propranolol and atenolol, salbutamol and salmeterol, BDP
and fluticasone propionate, and mevastatin and pravastatin. Thus, the intellectual
capability of the organisation in biology, chemistry and relevant scientific disciplines
is an important factor.
Third, the material conditions of the research team and the company constrain the
research. This is closely related to the intellectual assets described above. Intellectual
assets are always accompanied by specific non-human entities: for example, assay
systems, model animals and special experiment equipment. These entities also seem
to make some research areas easy but others hard to accomplish. For example, Glaxo
had patented steroids when Jack looked for anti-inflammatory substances, and that
probably significantly affected his choice and eventually resulted in the development
of inhaled steroids. In contrast, mice used in tests may have prevented mevastatin
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and its analogues from becoming a drug, because it showed the ineffectiveness of the
series of drugs in lowering the level of cholesterol. In addition to Endo's obsession
with the substance, however, hens, then dogs and monkeys, helped Endo to overturn
the previous belief about mevastatin's ineffectiveness. Of course, strictly speaking,
these animals did not intend to prove or disprove the belief and it was people who
believed or disbelieved the proof,2 but without them mevastatin and its analogues
may have been discarded in practice.
Fourth, linkage with the frontiers of relevant science and technology outside the
organization is also important. Researchers can obtain new knowledge or improve
their existing expertise from an external network. In particular, in Japanese cases
such as the discoveries of leuprorelin and mevastatin, links with state-of-the-art
science in the US played a crucial role: providing the leading researchers with
specific research interests. In contrast, in British cases, their intellectual sources
seemed to be more domestic. Some key researchers including Black and Furr had
worked as academic researchers before they joined pharmaceutical companies. The
range of the external network, however, is relatively narrower in this aspect than in
others: normally, it does not include clinicians and engineers. Special science and
technology disciplines seemed to be particularly influential. Knowledge transfers
were normally conducted through literature probably because researchers possessed
the relevant tacit knowledge and understood and speculated about others' work.
However, when a research organisation does not possess the relevant tacit knowledge,
sending people to or collaborating with other organisations having the knowledge is
necessary. (Collins 1992, pp. 51-78) This is observed in the case of nicardipine in
which researchers were sent to universities to learn necessary techniques for
experiments and in the case of leuprorelin in which the research team was in
collaboration with another company in order to develop the biodegradable polymer
for its depot preparation.
Fifth, the strategy of the company sometimes affects the properties of the compound.
In the case of cefotiam, Takeda's strategy to enter the cephalosporin market was the
2 Relevant discussion here is found in MacKenzie (1996a, pp. 13-16) and Collins and Yearley (1992).
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starting point of research. In the case of ranitidine and famotidine, Glaxo and
Yamanouchi were looking for anti-peptic ulcer drugs when Black discovered H2-
antagonists. Their previous strategic choice of the therapeutic area probably
encouraged the Glaxo and Yamanouchi researchers to conduct their own research on
H2-antagonists. In the case of tamsulosin, Yamanouchi strategically wanted the drug
to be internationally competitive. Regulatory bodies, in particular those of American
and European countries, preferred purer compounds as drugs. Therefore, they chose
to switch from the racemic mixture of the drug to the single isomers that were
effective, even though they had to spend a lot ofmoney and time over the change.
Sixth, market needs also sometimes affect the properties of the compound. Here, the
notion of reverse salients (Hughes 1983, pp.79-105) seems to be useful. The search
for anti-cholesterol drugs resulting in the discovery of mevastatin was driven by
Endo's recognition of potential market needs. In the case of anti-asthmatic drugs in
Glaxo, two approaches, bronchial dilation and anti-inflammation, were adopted for
the treatment of bronchial asthma. When bronchial dilation was achieved by
salbutamol, anti-inflammation became the reverse salient. When it was solved by
BDP, the short duration of action of salbutamol became the reverse salient because
other companies launched longer acting bronchodilators. Then, salmeterol eliminated
the reverse salient. Fluticasone propionate resolved the reverse salient ofBDP,
namely moderate potency. It is important to notice that these reverse salients
emerged not only when relevant technologies or therapies advanced but also when
rival companies launched competing products. This role of competition should be
added to the discussion of reverse salients. Perceived potential demand also explains
why LHRH analogues such as leuprorelin and goserelin appeared on the market as
their depot preparation. The inconvenience of daily injection urged the Takeda and
ICI researchers to develop more convenient forms of the drugs. A similar example is
also seen in the case of the development of preparation of cefotiam.
Seventh, the regulatory systems significantly affect the properties of the compound,
though their influence is not always clearly observed. However, it is obvious that the
level of acceptable toxicity and efficacy of the compound are defined by the
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regulation. The quality and purity of the compound are also controlled by the
regulation. For example, tamsulosin was switched late on in its R&D process from
being a racemic mixture to being the single isomer. This was because the regulators,
especially American and European ones, preferred purer compounds. In the case of
leuprorelin, it was in practice impossible for Takeda to sell the drug for daily
injection because the Japanese regulator did not permit self-injection. This
encouraged the development of the depot preparation of the drug.
Eighth, competitors have an influence on the shaping of the compound. Their patents
limit the range of possible compounds. When researchers at Glaxo or Yamanouchi
tried to modify the molecular structure of an existing compound in order to discover
a new H2 antagonist, they had to avoid infringing patents of SmithKline & French.
This led them to the somewhat unique molecular structures of ranitidine and
famotidine. LHRH analogues and their preparations were different because the
latecomers had to avoid existing patents of rivals. On the other hand, competitors
also have a positive influence. Their patents and other publications may help the
search for a new drug. The work of researchers at SmithKline & French Laboratories
gave a concept ofH2-antagonist to researchers at other companies including Glaxo
and Yamanouchi. A similar intellectual spill-over between rivals was also seen in the
case ofLHRH analogues.
Ninth, serendipity sometimes plays an important role. For example, cardio-selective
(3-blockers, the paradoxical effect ofLHRH analogues, two phases of release of
goserelin depot preparation and the cyclisation of the side chain of cephalosporins
were all serendipitously discovered. This implies the role of non-human entities in
the shaping of the compound. Although serendipity includes cognitive and social
activities as well, without the independent activities of non-human entities it would
not have happened. The shaping of the compound is a complex process in which not
only human actors but also non-human entities play an active role.
Tenth, production costs may also affect the choice of the compound. As is suggested
in the case of leuprorelin, production costs seem to be taken into consideration in the
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choice of the compound, when there is more than one compound with similar
properties.
8.1.2. The Shaping of the Application
The second aspect of the shaping process of a drug is the shaping of the application.
This is, in other words, the shaping process of the meanings of the compound in
practice. The compound often has various biological activities. The same hormone or
neurotransmitter often plays various roles in the body because their receptors at
different places cause different reactions. For example, (3 adrenergic receptors not
only dilate bronchi but also increase heart rate when they are stimulated by
adrenaline. This is also the case in drugs mimicking the activity of naturally
occurring hormones and neurotransmitters. That is to say, the compound often has
plural potential activities.
The first two factors that limit the application of a compound stem from properties of
the compound itself, in other words what the compound can do, and therapeutic
needs, that is, what people need. This is why an Hi-antagonist cannot become an
anti-peptic ulcer drug though it is used for the treatment of hay fever. This is also
why p2-blockers, which are of little clinical use, have not appeared on the market.
Normally, these two factors, the range of activities of the compound and the range of
therapeutic needs, narrow down the application of the compound to only one or one
main and a few relevant applications. In some cases, however, more than one
potential application may exist.
When these plural potential applications are unrelated to each other and one of them
is clinically used, the others may cause side effects. For example, isoprenaline dilates
the bronchi but at the same time increases the heart rate, which is dangerous for
patients with heart failure. In such cases, the ambiguity of the compound is normally
what should be eliminated. This should be done in the shaping of the compound.
Drugs with selectivity such as P2-stimulants and Pi-blockers were results of
ambiguity reduction. However, when side effects of this sort are of little harm and
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can be controlled, the ambiguity may be retained and the application of the
compound is selected for various reasons. Such cases are not common, but
tamsulosin is one. LHRH analogues are another example. In these cases, we can
explore the shaping process of the application.
The third factor related to the shaping of the application, which was seen in the cases
ofLHRH analogues, is the cognitive ability of the project leader and other
researchers to explore the potential applications of the compound. Researchers
working on LHRH analogues at first thought that the main application of the drugs
was fertility promotion. However, when they came across the "paradoxical effect" of
LHRH analogues, the researchers turned their attention to sex hormone dependent
diseases such as breast cancer and prostate cancer. This was possible because they
had broad knowledge about potential therapeutic areas. They had planned the
development of both agonists and antagonists ofLHRH early on and had
accumulated relevant knowledge about the potential therapeutic areas before their
encounter with the paradoxical effect. Thus, the broad knowledge of researchers in
therapeutic areas is an important factor in the shaping of the application. In other
words, the intellectual capability of organisation across a range of therapeutic areas
conditions the search for applications.
The fourth factor is an external network; in particular amongst clinicians from whom
the researchers collect information about how to use the drug. In the case of
tamsulosin, the key researcher heard of the possible new application of a blockers
from a urologist. Without the linkage between the drug researcher and the clinician,
such information would not have been transferred to the drug researcher and
tamsulosin might not have appeared as a drug for the treatment of the urination
disorder. Therefore, network linking to clinicians, who play an equivalent role to the
"lead users" (von Hippel 1988), is important for the shaping of the application. The
fifth factor is the competitor. As with the shaping of the compound, the behaviour of
competitors has a spill-over effect. In the case ofLHRH analogues, their makers
entered the same therapeutic areas one after another.
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The sixth factor is the size of the potential market of the drug. In the case of
tamsulosin, if its market for urination disorder had been regarded as being much
smaller than its hypertension market, Yamanouchi would have chosen the application
for anti-hypertension rather than for the treatment ofurination disorder. In the cases
ofLHRH analogues, Takeda, Abbott and ICI recognised that the prostate cancer area
would be a more promising market for their drugs than other areas such as
contraception and the treatment ofgynaecological disorders because they thought
that there was no stronger competitor in the former area. It should be noticed that the
potential market is not just what exists but what is recognised as being able to be
shaped. The recognition of the potential market probably overlaps with the shaping
of the real market. In other words, the recognition of the potential market is a mental
simulation of the shaping of the real market. Researchers' speculation about how
much they will be able to expand the market is reflected in their recognition of the
size of the potential market, which in turn affects the shaping of the application. The
shaping of the real market will be discussed below.
8.1.3. The Shaping of Organisational Authorisation
The shaping of organisational authorisation means the persuasion of people inside
the company, in particular the management. In the cases in this study, we can see that
even people in the same organisation may resist to the development of a new drug
when the concept of the drug is novel and unfamiliar to them. The background of this
is the conflict between groups within a company over its limited resources. The
clinical development of a drug costs a huge amount, as described in Chapter 2, and
its failure seriously damages the financial situation of the company. The shaping of
organisational authorisation can be regarded as the "micro" political aspect of the
drug. In fact, in many cases, including nicardipine, salmeterol, burimamide,
leuprorelin, mevastatin, tamsulosin and cefotiam, organisational resistance or
criticism was observed. It was necessary for the researchers to obtain organisational
authorisation. Without it they could not have realised the development of their drugs.
Several factors play an important role in the shaping of organisational authorisation.
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The primary player is the project leader. Endo had to gather evidence for the efficacy
ofmevastatin by himself after other researchers who had conducted the preliminary
animal tests had denied it. He also had to arrange its clinical trials to reverse the
decision of the company to abandon the development of the drug. Takenaka also had
to provide the management with evidence for the marketability and profitability of
tamsulosin. It was reported that researchers at SmithKline and French Laboratories in
England also had to make a lot of effort to prevent the American parent company
from cutting the project off. To convince people within the company, not only
evidence but also the track record of the project leader was important. Black had
such a reputation. Takenaka in the case of tamsulosin was trusted by the management
because he had had several successful achievements in the past including the R&D of
nicardipine. The position and power of the project leader in the company are also
important. Jack in the case of salmeterol was the director of research and
development at Glaxo at that time, and he could tell people to work on the drug
instead of persuading them persistently. In the cases of leuprorelin and cefotiam, the
project leaders succeeded in obtaining the support of the top management of the
company.
The management is the counter player. The decision of "go or no-go" by the
management (Kuwashima 1998; Pisano 1997, p.97) is the ultimate element in
shaping organizational authorization. Unless they recognise the significance of the
project, the discovery of a drug will not lead to an innovation. In the case of
leuprorelin, Shinbei Konishi, the then president of Takeda, and Kunio Takeda, the
then vice president of TAP Pharmaceuticals and a member of the Takeda family,
supported the development of the drug in Japan and the US. Also, in the case of
cefotiam, the then top management of Takeda backed the project in a somewhat top-
down manner. In the case of nicardipine, Masuo Murakami, the then director of the
central laboratory of Yamanouchi and a powerful figure in the company, gave
Takenaka his approval. Jack, the head of research and development at Glaxo, himself
actively led the projects of the anti-asthma drugs.
234
Thirdly, evidence for the future of a drug, such as the properties of the compound,
estimation ofmarketability and profitability, and the distinguishable concept of the
drug, is important. In other words, it is significant how well the compound and its
application are depicted as a future drug. The drug's properties, which relate to
efficacy and safety, are particularly important. If they are not good, the drug may
have to be discarded in the development process or may be rejected by regulatory
bodies. Even if successfully launched, it may have to be withdrawn or may earn little
income. Estimation ofmarketability and profitability is a simulation of the shaping of
the market. The potential size ofmarket, the expected situation of competition and
the estimated price of the drug are important in the decision making. In many cases,
however, it was indicated that the forecasting of these parameters was extremely
difficult in practice. This is understandable when we consider that uncertainty is very
high in the pharmaceutical industry and it takes several years from the decision to the
market launch. Therefore, these parameters are perhaps important but unlikely to be
decisive. Rather, the concepts of drugs like "H2," "ai selective" and "third
generation" may be more convincing than the uncertain estimation of sales and
profits. However, if the R&D assessment system is strictly institutionalised as is seen
in the case of tamsulosin, the estimation of sales and profits is more critical and
conditions the behaviours ofproponents, opponents and decision makers. Internal
workers involved in the estimation of market are likely to gain more power in this
case.
Fourthly, linkage with external experts, in particular clinicians, sometimes plays an
important role in supplying evidence. In the case ofmevastatin, Endo used his
network amongst worldwide researchers including Goldstein and Brown and
domestic clinicians including Akira Yamamoto at Osaka University Hospital in order
to enhance the credibility of his argument. Yamamoto's active proposal for clinical
trials of the drug overturned the previous trends of opinion within the company.
Takenaka and his colleagues used the data they obtained from clinicians at
universities in order to prepare convincing evidence of the marketability and
profitability of tamsulosin.
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Fifth, corporate strategy affects the decision of go or no-go. Glaxo had a strategic
interest in the anti-asthma area because of its potential size of market. Both Glaxo
and Yamanouchi regarded anti-peptic ulcer area as strategically important. Takeda
aimed at the establishment of its domain in the cephalosporin antibiotics area.
Strategy thus promoted the projects of anti-asthma drugs and ranitidine in Glaxo,
famotidine in Yamanouchi and cefotiam in Takeda. If the companies had had a
strategy focusing on other therapeutic areas, the progress of the projects might have
been delayed. In fact, in the cases of leuprorelin and goserelin, it was said that the
projects were not given very high priority at first, though it is uncertain how much
this affected the lead time from their discovery to market launch.
Sixth, organisational capability in recognising the value of new drugs is also
important. Researchers of other groups and people belonging to divisions of clinical
development, finance, production, marketing and sales may become opponents of the
project. Their understanding of the concept of the new drug and their insights into
pharmaceutical business significantly affect to what extent the project will face
organisational resistance. The newer the concept of the drug is, the more difficulty
people other than its researchers have in understanding it. The organisational
resistance in the case of cimetidine seemed to be much more than that in the case of
ranitidine or famotidine.
Seventh, changes in social values seem to have an influence on the decision making.
For example, the rise in awareness of the quality of life in Japanese society possibly
affected the approval of tamsulosin by the Yamanouchi management. The recent
emergence of "lifestyle drugs," which improve the quality of life and alleviate the
physical disorders of old age, including Viagra®, Prozac®, and HMG-CoA
reductase inhibitors ("Losing the drugs war," Financial Times, April 13 1999) may
reflect the similar worldwide change in social values. This change is now more
obvious than before, and the projects working on this kind of drug find it easier to
obtain organisational authorisation today. It is said that pharmaceutical companies
are particularly sensitive to negative public response. (Clarke and Montini 1993, 54)
It is possible that they will abandon their research in a particular area if the general
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public criticises it, as was seen in the case of genetic modified crops. ("Monsanto
drops GM 'terminator'," The Guardian, 5 October 1999)
8.1.4. The Shaping of the Market
The fourth and final aspect of the shaping process of a drug is the shaping of the
market. This includes clinical trials, approval of regulatory bodies and marketing.
More heterogeneous actors, particularly outside the company, are involved in this
aspect than in others. This can be regarded as the "macro" social aspect of the drug.
It is this aspect that is most closely investigated by other sociological works on drug
development. (See Chapter 2.) In this section, we will examine what kinds of actor
are generally involved in the shaping process of the market of a drug, though there
arc probably more relevant actors in specific cases. (E.g. Clarke and Montini 1993)
The first actor is the company, which defines the target market of the drug and tries
to seize it. The definition of the target market has been mainly conducted in the
shaping of the application and in the shaping of organisational authorisation.
However, the company can redefine it in the process of shaping markets, including
clinical trials and marketing. The ability of the company to identify the potential
market restricts the range of their real market. This is a strategic as well as a
cognitive issue. They have to decide their therapeutic and geographic domains. They
also have to forecast the future of their business conditions and their own position.
Their organisational capability also limits their future market. Unless they can secure
sufficient money, production capability, cooperation of clinicians and patients,
necessary sales force, expertise in legal and regulatory affairs, and management
ability to organise these heterogeneous functions, the shaping of the market is
unlikely to be achieved. Glaxo in the case of ranitidine most remarkably
demonstrated their organisational capability to achieve the quick shaping of its
worldwide market. Process development capability (Pisano 1997) is one of the key
factors.
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The second actor is the regulator, which officially approves the manufacturing and
marketing of the drug within its jurisdiction. This is, in other words, the social
authorization of the drug, and an analogue of the organizational authorization of the
drug seen in the company. Of course, the values and criteria are probably different
between the two. The safety, quality, efficacy and cost-effectiveness ("Clinical
watchdog rejects anti-flu drug for NHS," Financial Times, October 1 1999) of the
drug should be more important for the regulator than marketability and profitability,
which is essential for the company. However, in practice, the difference is probably
much less than it appears, because without the regulatory approval the drug cannot
be marketed, and the value and criteria of the regulators are likely to be reflected in
the management decision of the company. It is obvious that there is no market if the
regulator does not approve the drug. As was seen in the case of pronethalol in
Chapter 3, the prescribing restriction of the drug ruled by the regulator seriously
limits the size of its market. As we saw in the case of practolol in the same chapter,
the regulator may limit the market of a drug later on. In addition, the regulator in
Japan determines the price of the drug, as mentioned in the case of leuprorelin and
famotidine. This also affects the size of the market in terms of value.
The third actor is the doctor, who conducts clinical trials and prescribes the drug after
its launch. Doctors directly constitute the drug market. Therefore, their evaluation of
the drug is crucial for the establishment and expansion of its market. The leading
clinicians in the therapeutic area of the drug play a particularly important role. Their
support and collaboration are essential in the clinical trials. They often have interests
in clinical trials and in the publication of results. The collaboration between the
company and the doctors often results in the high quality of clinical trials, which in
turn enhances the value of the drug amongst doctors and government officials. The
opinions of leading clinicians on the drug also affect its valuation. In particular, in
the highly hierarchical medical society in Japan (Campbell and Ikegami 1998, p.67),
leading clinicians at universities have a very strong influence over the other doctors.
This was typically observed in the case of procaterol.
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Two activities are especially important to involve doctors in the shaping of the
market of drugs: clinical trials and promotion. Clinical trials are very important to
secure support from both doctors and regulators. They are the core evidence of
efficacy and safety, and have a crucial influence on the evaluation of the drug.
Leading clinicians learn the properties of the drug while they conduct its clinical
trials. They in turn transfer their evaluation to practitioners, regulators and other
people who are concerned with the drug. Thus, clinical trials are not only scientific
experiments but also the process of shaping the market. However, as many scholars
indicate (Marks 1997; Abraham 1995; Epstein 1996; Richards 1988; Bodewitz,
Buurma and de Vries 1987), the results of clinical trials are not free from controversy,
which affects the market of the drug. The occurrence of such controversy was
observed in the cases of (3 stimulants and LHRH analogues. The settlement of these
controversies was not achieved by "crucial" clinical trials but resolved by the
redefinition of the problem or the accumulation of experience (both tests and uses)
among medical society over a considerable time. Major players in such controversies
are also clinicians.
After the launch of the drug, doctors who prescribe the drug, in other words, who can
make their patients use it, directly constitute its market. As long as the cost of the
drug is reimbursed by medical insurance systems, therapeutic properties of the drug
rather than its cost normally affect their choice. New drug concepts such as "(3
stimulants," "Ca antagonists," "H2 antagonists," "super-agonist," "HMG-CoA
reductase inhibitors" and " a ic blockers" attract doctors' interests. Drug properties
labelled as "new generation," "more selective," "longer acting," "safer" and so on
also appeal to them. The latter was seen in the cases of latecomer drugs such as
procaterol, ranitidine, famotidine and cefotiam. Ease of use can also become a good
reason for choice. Depot preparations ofLHRH analogues demonstrate this.
Therefore, the shaping of the compound and its application strongly affects the
shaping of the market. At the same time, however, it is also important for the
company to inform and convince doctors that the drug has these advantageous
characteristics. The means of promotion normally consist of clinical trials, academic
papers, symposia, conferences, advertisements and visits by medical representatives.
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Promotion based on scientific evidence is particularly important in this industry. In
addition, the financial opportunity for doctors is important. If doctors suffer a
significant decrease of income because of the substitution of the drug for the existing
treatment, the drug is unlikely to be accepted by them. This can be seen in the cases
of tamsulosin and LHRH analogues.
The fourth actor is academics who create knowledge, skills and artefacts related to
the drug research and development. They are supporting the properties and concepts
of the drug and results of clinical trials, which is the evidence of usefulness of the
drug and the basis ofmarketability and profitability. They may, therefore, construct
and destroy the market of the drug at any time. For example, a new technique using
biotechnology identified subtypes of a i receptors, which explained the mode of
action of tamsulosin and promoted its marketing. In contrast, as in a case study
provided by Richards (1988), "randomised, controlled, double-blinded" clinical trials
at the Mayo Clinic destroyed the market of vitamin C as an anti-cancer drug.
The fifth actor is the rival company having a competitive product in the same
therapeutic area. There are both advantageous and disadvantageous effects in the
shaping of the market. The advantageous effect was seen in the cases ofLHRH
analogues and nicardipine. The simultaneous clinical development of the same type
of drug by different companies facilitated learning of doctors and regulators about
the drugs. The disadvantageous effect is more obvious. Patients are limited in
number, so companies must divide the market. Competition also affects the price of
the dmg, though its effect on the price seems to be complicated because of the
regulation.
The sixth to eighth actors are patients, their families and carers, and activists. The
number of patients who give their informed consent to clinical trials is essential for
the company to develop the drug. This factor seems to explain partially the delay of
the development of leuprorelin in Japan. In the case of drugs for the treatment of
diseases that are not very serious, it is essential for the company to make patients
aware of the diseases. In the tamsulosin case, it was necessary to make the BPH
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patients visit clinics. Articles and lectures by opinion leaders, the advice of family
doctors and advertisements by the company contributed to making the patients aware
of the disorder and conveyed the idea that the disorder could be and should be cured
by going to hospital. Patients, together with their families, carers and activists, may
actively request the development and marketing of particular drugs, as was seen in
the case studies of anti-AIDS agents and thalidomide. (Epstein 1996; Timmermans
and Leiter 2000; see also Clarke and Montini 1993)
The ninth actor is the compound. The compound was defined as the chemical
believed to have biological activities of clinical use. (See Sections 8.1.1. and 2.2.3.)
Without the compound, of course, there is no market for the drug. However, because
this is based on belief, the properties of the compound are not absolutely stable. It is
possible that the efficacy and safety of the compound described earlier may become
problematic in the process of clinical trials and practical uses. For example, safety of
practolol became doubtful when the reports about its side effects appeared. The drug
lost the market. When the safety ofmevastatin became problematic, the company
gave up its development rather than tried to re-establish the belief of its safety. Thus,
mevastatin failed in the shaping of the market.
8.1.5. Interaction between the Different Aspects of the Shaping
I described four aspects of the shaping of a drug above. In each aspect, various actors,
factors and activities are involved. Real shaping processes of drugs are probably
much more complex and different from case to case. Although my description of the
shaping process of drugs is not exhaustive, we can learn several important things
from the examination of the factors discussed in this thesis.
First, several actors and factors are involved in each aspect of the shaping of a drug.
Some intend to participate in the shaping process of the drug, whereas others
participate without intention or awareness. Different actors sometimes give different
meanings to the same drug. For example, for Endo, the project leader, mevastatin
was a safe drug with a remarkable anti-cholesterol activity while for toxicologists at
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Sankyo it was a drug with high uncertainty in regards to safety, and for some
researchers at the Central Research Laboratories, it was something invented out of
their labs. (See Section 7.2) As proponents of the SCOT (see Section 2.1.2) argue,
such interpretative flexibility results in a diversity of candidate drugs (RWX-163, for
example, in the mevastatin case); the closure mechanism is indeed a social, political
process (networking among external specialists in the case). Second, however, not
just human actors but also non-human entities play a role in each aspect, as advocates
ofANT (see Section 2.1.3) insist. Actors are not naked. (Strum and Latour 1987
[1999]) Without non-human entities, human actors cannot shape drugs though non-
humans alone, of course, cannot shape them, either: hence they constitute
"heterogeneous" networks. Various material entities, including compounds (see
Section 4.7.3), animals (e.g. mice and hens in the development of mevastatin),
human bodies (e.g. the unexpected side effect of practrol), scientific instruments (e.g.
ultrathin endoscopes in the case of famotidine) and production equipments (e.g.
mixers in the case of leuprorelin depot) restrict or facilitate the shaping process.
Although they never determine the process by themselves, their influences are
indispensable. This may be described as the material imperative. Third, actors are not
isolated from each other or from the wider context, including other actors not
mentioned here. Actors interact with each other in the process of drug shaping. This
interactive relationship between various actors in innovation process is consistent
with the key argument of the social shaping of technology. (MacKenzie and
Wajcman 1999, 3-27; Williams and Edge 1996, 867) Many actors observed in case
studies here are those that were mentioned in other sociological studies in the
biomedical and pharmaceutical area. (See Section 2.2.4.3) Fourth, relevant actors
seem to become more external, more heterogeneous and more institutional in the
shaping of the market than in the shaping of organisational authorisation, in the
shaping of organisational authorisation than in the shaping of the application, and in
the shaping of the application than in the shaping of the compound. This appears to
be consistent with the argument of technology studies that technology is more
heterogeneous and a more diverse range of institutions than science. (See Section
2.1.5.) However, this does not mean that external and institutional factors have no
influence on the aspects of the shaping of the compound and of the application.
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Rather, their influence seems to be more indirect and more likely to be mediated by
the researchers' cognition in these aspects than in the shaping of the market.
Fifth, the most important finding here is that the four aspects of shaping of a drug
interact with each other. The compound limits the shaping of the application. The
compound and its proposed application are key factors for the project leader to
persuade management. Therefore, they limit the shaping of organisational
authorisation. They are also key factors for the company to apply for approval of the
regulator and to promote the drug amongst doctors. So, they also limit the shaping of
the market. The shaping of the application can be regarded as the cognitive
simulation of the shaping of the real market. As was seen in the case of tamsulosin
(Section 7. 4), unless the potentially profitable application is recognised by
pharmaceutical companies, the market of drugs will not be exploited. The
organisational authorisation of the compound conditions the shaping of its market.
Without organisational authorisation, it is obvious that the compound cannot become
a drug, as we can see in the case ofmevastatin.
There are also influences in the opposite direction. The application sometimes affects
the shaping of compound. For example, in their use for the treatment of prostate
cancer, LHRH analogues should be given to patients every day to obtain the
paradoxical effect. For this, depot preparation had to be developed. Organisational
authorisation, in which the marketability and profitability of the drug are discussed,
limits the choice of the compound and its application by researchers. It is unlikely
that they will choose a drug or an application which seems to be unmarketable and
unprofitable. Yamanouchi, for example, gave up the development of their latest
calcium antagonist, because they doubted its competitiveness and profitability, given
the relatively low prices of anti-hypertension drugs. (See Section 3.4) The market
also affects all aspects of the shaping of a drug. The market restricts the decision of
management as to whether they authorise the development of the drug. If the
possibility of the successful shaping of the market seems to be slim, the project of the
drug will probably fail to obtain approval by management. The needs of the market,
therefore, have an influence on the shaping of the compound and its application.
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Market needs basically restrict the range of the search for applications. Two things,
however, should be noticed: first, the market is not clear at all in advance; second,
the market is not what exists in advance but what is constructed. This can be said of
most cases in this study. Therefore, on the one hand, the cognitive abilities, insights
and visions of research leaders and management mediate the influences from the
market to the shaping of the compound, the application and the organisational
authorisation. On the other hand, the practical ability of the company to achieve the
shaping of the market also modifies these influences, though other contingent factors
such as regulation, medical sciences and social movement also intervene in the real
shaping process of the market. The constructed nature of market is in accordance
with the discussion by SST authors. (Williams and Edge 1996, 877)
Thus, the four aspects of the shaping process of a drug are interactive. They are not
sequential but overlapping and co-evolving. The interactive relationships include not
only explicit and observable ones but also implicit and cognitive ones. Because
human actors speculate about the results of their activities, speculated results
sometimes play a role in the shaping process. This anticipative behaviour of actors
involved in innovation process such as scientists and companies are consistent with
the arguments ofWebster (1991, pp.48-50, p.59) and McKelvey (1996, p.226).
Market constituencies including doctors, patients and regulators are also likely to
accept drugs they believe to be scientifically reasonable and technologically reliable
in terms of efficacy and safety. Therefore, it can be said that each of the four aspects
is reflected in all the others through the anticipative ability of relevant human actors.
The four aspects are also inter-dependent. If one aspect becomes unstable, all the
others also become unstable. For example, if the safety of the compound becomes
problematic, its application, its organisational authorisation and its market also
become questionable. If the market of a class of drugs dwindles, a new compound of
the class for the conventional application is unlikely to appear. Even if it happened to
appear, the management would probably axe the project. In sum, a drug emerges
only when all its four aspects are successfully shaped and being shaped. The
compound, the application, the organisational authorisation and the market
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collectively support drug innovation. Figure 8.1 schematises the interactive
relationships between the four aspects.
Figure 8.1: Interactions between the Four Aspects of Drug Shaping
The Shaping of the
Compound £





The Shaping of the
Organisational Authorisation £
The Shaping of the
Market
It should be noted that the inter-reflection is neither perfect nor exclusive. There are
always contingencies and actual results of any action are not exactly the same as
anticipated ones. They are inter-dependent but not self-contained. It is possible for us
to regard them as a network consisting of various actors, factors and activities
including: the project leader, various specialists, material resources of the
organisation, external network linking industrial researchers with academic scientists
and clinicians, the management, the cooperative strategy, the organisational
capability, market needs, market size, regulators, doctors, competitors, patients,
families and carers, activists, journals, conferences, protocols, dossiers for approval,
concepts of drugs, and so on. New factors can enter the network at any time and
transform or even dissolve it. Relevant non-human entities may change the network
without intention. Humans can intentionally transform or scrap the network. Humans
also alter the network without or against their intention. Thus, the shaping process of
a drug is a networking activity, which is like the one that actor-network theorists
describe. (See Section 2.1.3.) It includes both the "social" and the "material." It can
be altered. This transformation of the networks surrounding drug development
processes also seems to share a lot of points with the discussion of dynamic
networking related to vaccine development by Galambos and Sewell (1995).
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Finally, it should be noted that the products of the shaping process of a drug are not
only the drug but also various sub-products. For example, paradigmatic drug
innovations like that of propranolol and cimetidine changed the theory of the relevant
receptors. In other words, the shaping process of these drugs produced a theory.
Science plays a role in the shaping of a drug and vice versa. Potent J3 stimulants
caused controversy with regard to their safety and guidelines for their use were set up.
Regulations condition the shaping of a drug and vice versa. Glaxo earned a huge
income from the marketing of ranitidine and became one of the giant pharmaceutical
companies in the world. Pharmaceutical companies create drugs and vice versa. In
addition to them, a lot of actors, factors and activities are produced from the shaping
process of a drug: experimental materials, experimental methods, the cognitive
ability of researchers, the cognitive ability of the management, knowledge about a
new therapeutic area, a new linkage with external specialists, a new strategy, a
reputation of the company among doctors, patients and investors, and so on. As I
mentioned at the beginning of this chapter, the process of shaping a drug is also a
process of co-creating materials, knowledge and institutions.
Thus, the shaping process of drugs is not linear. The linear model of innovation has
been mainly criticised for three points. First, there are two-way flows of knowledge
between science and technology. (E.g. Faulkner and Senker 1995, pp. 206-211)
Second, there are also two-way influences between science and technology on the
one hand, and the economy and markets on the other. (E.g. Klein 1985) Third,
heterogeneous actors are involved in these interactive relationships. (E.g. McKelvey
1996; Pinch and Bijker 1987) Our findings here, that is to say, the interactive
relationship between the four aspects of drug shaping process, are consistent with
these three criticisms of the linear model. The shaping process of the drug seems to
be better described by the "pinball" model (Webster 1991, p. 47) than by the linear
model. Our "pinball" is, however, different from the normal one: first, there are
many, various "balls" (elements of drug technology), which are simultaneously
bouncing offmany, various "pins" (shapers of drug technology); second, the "balls"
can combine together and split; third, the "pins" are movable; fourth, some "pins"
(human "pins") have their intentions but others not; fifth, there is no strict distinction
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between "balls" and "pins"; sixth, there is no external player and it is human "pins"
that bring "balls"; seventh, some "pins" may exit and others may enter. It might be
more like football with many, sticky balls, which is played in a rain forest! Anyway,
the most important point here is that our research demonstrates that this non-linearity
and interactivity of the innovation process is applicable even in the pharmaceutical
industry, contrary to traditional view held by both practitioners and academics. (See
Section 2.1.6). The innovation process is not linear even in the pharmaceutical area.
8.2. Types of Pharmaceutical Innovation
When we compare the shaping processes of various drugs described in this study, we
can find differences between them. In some cases, the concept of a new drug has no
exemplar. Most people inside and outside the organisation are unfamiliar with the
concept and wary of it. Therefore, the project leader and co-workers must first
persuade people in their company to obtain organisational authorisation. Then if the
company decides to develop it, they must persuade outside people such as doctors
and regulators. In other cases, the concept of a new drug has an exemplar and few
people are suspicious about it. However, there might be another kind of suspicion
amongst people in the company: concerning its profitability. Doctors and regulators
may fail to find any advantage over the existing drugs of a similar kind. Therefore,
the researchers seek to create advantageous characteristics, which are enough to
differentiate their drug from others. The company promotes the characteristics
amongst doctors and regulators. Thus, the difference in familiarity with the concept
of a drug induces distinct patterns as to the shaping of drugs.
We can divide the situation of the shaping of drugs into three types in terms of
familiarity: the case in which both the compound and its application are unfamiliar;
the case in which the compound is familiar but its application is unfamiliar; and the
case in which both of them are familiar.3 Corresponding with this classification, we
3 The application in this classification does not mean the therapeutic area itself but the idea of
using a compound for the treatment of a specific therapeutic area. For example, in the case of
cimetidine, people knew peptic ulcer and wanted an effective drug for it, but no one in advance
knew a class of drugs such as cimetidine could be used for the treatment of peptic ulcer.
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can identify three types of innovation in the pharmaceutical industry. I name them
paradigmatic innovation, application innovation and modification-based innovation,
respectively, as in Table 8.1. We examine the characteristics of each of them one by
one.
Table 8.1: Three Types of Pharmaceutical Innovation
Type of Innovation Compound Application Examples (relevant chapters)
Paradigmatic
innovation
Unfamiliar Unfamiliar Propranolol (Ch. 3) British
Salbutamol (Ch. 4) British
Cimetidine (Ch. 5) British
Leuprorelin (Ch. 6) Japanese-American
Goserelin depot (Ch. 6) British
Mevastatin (Ch. 7) Japanese
Application innovation Familiar Unfamiliar BDP (Ch. 4) British
Tamsulosin (Ch. 7) Japanese
Modification-based
innovation
Familiar Familiar Atenolol (Ch. 3) British
Nicardipine (Ch. 3) Japanese
Salmeterol (Ch. 4) British
Fluticasone propionate (Ch. 4) British
Procaterol (Ch. 4) Japanese
Ranitidine (Ch. 5) British
Famotidine (Ch. 5) Japanese
Cefotiam (Ch. 7) Japanese
8.2.1. Paradigmatic Innovation
The first type is paradigmatic innovation, in which neither the compound nor the
application is familiar before being shaped. Because the concept of the drug does not
have an exemplar but itself constitutes one, we name the innovation that involves
such a drug paradigmatic innovation. This is, of course, the analogy of Kuhn's
terminology. (Kuhn 1970) Propranolol, salbutamol, cimetidine, leuprorelin, the depot
preparation ofgoserelin and mevastatin can be classified into this type. Following
their appearance, drugs with similar molecular structure and the same mode of action
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were developed. Several characteristics of paradigmatic innovation can be extracted
from the case studies of these drugs.
First, the level ofuncertainty is very high. All kinds ofuncertainty are involved:
scientific, technological, business and regulatory uncertainties. In the case of
burimamide, metiamide and cimetidine, the existence ofH2 receptors and their
effects on gastric acid secretion was unknown when the search for the compound was
conducted. The assay system to identify such a compound was not fully established,
either. It was also unclear whether the practitioners would accept such a drug in place
of the surgical treatment. In the case of pronethalol and propranolol, the receptor
theory was not widely believed when they were looking for drugs based on it. In the
case ofmevastatin, the existence ofHMG-CoA reductase inhibitor was uncertain.
The safety ofmevastatin was also uncertain. In the cases of leuprorelin and goserelin,
their paradoxical effect was unknown. It was also uncertain whether doctors and
regulators would accept these drugs.
Second, because of very high uncertainty, the level of doubt about the drug is also
very high among people both inside and outside of the company. To shape
organisational authorisation, the project leader must persuade the management and
other relevant staff in the company. Strong, dauntless leadership is necessary. Endo,
for example, did not give up when he faced negative responses from inside the
company. He found a way out of adverse circumstances by himself or with help from
outside the company. Black did not make a compromise with the idea of developing
a drug which was not the ^-antagonist he had been looking for. His track record and
reputation contributed to keep the project alive. Such organisational resistance to
innovation and the need of strong leadership seem to be conformable to Donald
Schon's argument on the product champion (Schon 1963). However, leaders in drug
innovation are probably more properly named project champions than product
champions because they have to be active before any product is invented. In addition
to the leadership, the clear profiles of the drug are important. In particular, the basic
properties of the drug, namely clear efficacy and acceptable safety are essential.
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Third, the project leaders and co-workers must do heterogeneous engineering (Law
1987, pp. 113-116) to connect up heterogeneous actors, factors and activities in order
to achieve the shaping of the compound, the application and organisational
authorisation. Endo and his co-workers devised an assay system by themselves,
procured animals for experiments, established the linkage with top world scientists in
the field and arranged the preliminary clinical trials. The shaping of the market also
requires heterogeneous engineering, which is often conducted organisationally. For
example, to shape a market for goserelin, ICI's workers developed its depot
preparation, supported its clinical trials, demonstrated its advantages over the
surgical treatment or other kinds of drugs, explained its mode of action, showed that
the "flare-up" phenomenon was not serious, established its production process,
obtained approvals for marketing from regulators of various countries, set up its
marketing and distributing organisations in these countries and informed doctors
about how to use its unique preparation. To achieve this, they had to link a huge
number of heterogeneous actors, factors and activities with each other. Thus, the
process of paradigmatic innovation can be regarded as the shaping of a new network
for innovation.4
Fourth, paradigmatic innovation transforms major factors including science, therapy
and business. The discovery of pronethalol and propranolol destroyed the then
dominant "sympathin" theory and established the receptor theory as a paradigm. The
discovery of salbutamol demonstrated the subtypes of adrenergic (3 receptors. The
discovery of burimamide, metiamide and cimetidine also evidenced the existence of
H2 receptors. LHRH analogues led to the discovery of the paradoxical effect and
contributed to the relevant research. Mevastatin also played a role in providing
evidence of the theory of cholesterol regulation in the body, which had been
advanced by Joseph Goldstein and Michael Brown. Thus, paradigmatic innovation
transforms scientific theories. It also changes therapies. Cimetidine transformed the
main stream of the treatment for peptic ulcer from surgery to internal medicine.
LURH analogues also created a new alternative for the treatment of prostate cancer.
41 think that the concept of network here is essentially the same as actor-network (See Section 2.1.3)
and that of Galambos and Sewell (1995). At least, the similarity among them is more important for us
than the differences.
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Mevastatin made the high level of cholesterol in the blood a therapeutic area that
could be treated by drugs. This transformation in science and therapy in turn changes
business in the pharmaceutical industry in terms of the research strategy, the
approaches and targets of research projects, the organisation and approaches of
marketing and the conditions of competition.
8.2.2. Application Innovation
The second type is application innovation, in which the profile of the compound is
familiar but its application is not. Because it is the application of the drug that is
innovative, we name this type application innovation. BDP as inhaled steroid for the
treatment ofbronchial asthma and tamsulosin for the treatment ofurination disorder
are examples. These drugs are or can be used in other areas. BDP is used in the
dermatological area. Tamsulosin can be developed as a drug for the treatment of
hypertension. However, companies developed new applications for strategic reason.
There are several characteristics of application innovation.
First, the level ofuncertainty is still high, especially in the shaping of the application,
organisational authorisation and the market. On the shaping of the application, in the
case ofBDP, there were various doubts: about efficacy, fear of causing infection and
side effects. On organisational authorisation, in the case of tamsulosin, the
management had a suspicion about whether the urination disorder would be regarded
as a disease, whether doctors would accept the drug, whether patients would go to
urogenital clinics to receive such a treatment, and whether the government would
give it a price good enough to be accepted by doctors. On the shaping of the market,
it is likely to be the case that doctors and regulators are at first doubtful about the
advantage of the new drug. It is mainly because the mode of action is unfamiliar to
them in this type of innovation. This was seen in the case of tamsulosin, in which
doctors initially asked the difference of the drug from others. The answer the
company provided was that it was "aic selective" and the <xic receptors are
concentrated in the prostate.
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Second, high uncertainty causes suspicion among people in application innovation,
as in paradigmatic innovation. Persuasion of these people is important here, too. It is
the role of the project leader to obtain organisational authorisation. Evidence of
feasibility, marketability and profitability is necessary. Jack, the leader of the BDP
project, conducted animal experiments and demonstrated that BDP would work as an
inhaled glucocorticoid. Takenaka, the project leader of tamsulosin, himself actively
investigated the medical needs for the drug with the marketing staff and obtained
convincing data about the potential size ofmarket. For the successful shaping of the
market, it is essential that the clinical trials of the drug demonstrate its high efficacy
and acceptable safety in the proposed therapeutic area. In addition to this, the
company must actively promote the drug. Takenaka and his colleagues mobilised the
aic receptors, which had been just discovered by using biotechnology, to establish
the concept of tamsulosin and promote the drug.
Third, heterogeneous engineering is necessary to shape a new application,
organisational authorisation and the market. For example, a broad range of different
actors, factors and activities had to be connected with each other to accomplish the
shaping of these aspects of tamsulosin: the project leader, doctors, local knowledge
in medical practice, linkage with doctors, academic physiologists, concepts for the
justification of the new application, corporate biologists, toxicologists, an assay
system, experimental animals, academic clinicians, epidemic studies, marketing staff,
market estimation, the track record of the project leader, the management, the
consultant, the regulatory body, chemical engineers, techniques for the separation of
isomers, pharmaceutics experts, development of a new preparation for the reduction
of side effects, development of an economical production system, clinical trials,
collaborative attitude of clinicians, patients, patient education, the change in social
needs, a new technique ofmolecular biology to identify the generic characteristics of
receptor subtypes, promotion activities, and so on. In the application innovation, a
network including a new set of clinicians is created.
Fourth, application innovation also significantly transforms relevant factors,
especially therapy and market. BDP introduced inhaled steroids into the treatment for
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bronchial asthma. Tamsulosin created a new market for the medicinal treatment of
the urination disorder accompanying benign prostatic hypertrophy. They also
changed the business of the companies. With the introduction ofBDP, Glaxo
obtained full coverage of the treatment for bronchial asthma. The respiratory area
became one of the major business areas ofGlaxo. Yamanouchi also established its
network in the area of urology with tamsulosin.
8.2.3. Modification-based Innovation
If both the profiles of the compound and its application are familiar to relevant
people, the innovation of the drug is classified into the third type. We name it
modification-based innovation, because profiles of the drug can be seen as
modification of those of an exemplary drug. Its examples include atenolol,
nicardipine, procaterol, salmeterol, fluticasone propionate, ranitidine, famotidine and
cefotiam. However, modification-based innovation is not the same as the incremental
innovation, which is often discussed in literature on innovation. The incremental
innovation is characterised by bit-by-bit, cumulative improvement, particularly in
components of the technological system. This does not include major change in
organisational competences and often assumes that its purpose is in efficiency and
cost reduction. (Abernathy and Utterback 1978; Tushman and Anderson 1986;
Henderson and Clark 1990) Modification-based innovation is not a bit-by-bit kind of
innovation. It takes about ten years to develop even a modified drug. It is normally
chosen from hundreds of similar compounds, which are secured by patents. In this
situation, bit-by-bit improvement is unlikely to happen. It is also difficult to identify
components of the product in the pharmaceutical industry as is seen in assembled
products. There may not be a need for major change in skills, abilities and
knowledge in the organisation when the company already has experience in
developing the same kind of drug, as in the case of atenolol, but it is not the case
when the company first develops a modified drug, the exemplar ofwhich was
developed by another company. The cases of nicardipine, procaterol, ranitidine,
famotidine and cefotiam illustrated the latter situation. Therefore, it also seems to be
difficult to apply the distinction between competence-destroying discontinuities and
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competence-enhancing discontinuities with its original meaning (Tushman and
Anderson 1986) to the pharmaceutical innovation. Finally, modification-based
pharmaceutical innovation pursues neither efficient production nor cost reduction.
Rather, it is fundamentally product innovation. It may cause radical change in the
production process. Thus, modification-based innovation is not the same as the
incremental innovation. It is perhaps closer to the original notion of normal science
(Kuhn 1970) than the incremental innovation. Modification-based innovation is
based on past scientific achievement and existing therapeutic approaches and does
not challenge them. However, this does not mean either that modification-based
innovation is not an organisational challenge, or that it is devoid of radical process
change.
Modification-based innovation has several characteristics. First, the level of
uncertainty is generally lower than in paradigmatic innovation or application
innovation especially in terms of feasibility. However, business uncertainty still
remains. Existing patents have to be circumvented. In addition, the condition of
competition and the valuation by the regulator are uncertain. Therefore, suspicion
about the patentability, marketability and profitability of the drug may arise. In the
case of cefotiam, there was a doubt within the company that it was too late to enter
the area. Whether the company can develop a drug having a distinct advantage over
existing drugs is essential for successful marketing and regulatory application. In
other words, the construction of differences is crucial in modification-based
innovation. Secondary properties such as selectivity, duration of action and
convenient forms of dosage are important, in addition to sufficient efficacy and
safety. The cases of atenolol, procaterol and ranitidine well demonstrate this
characteristic.
Second, because the main uncertainty springs from business conditions, the decision
of the management plays a key role. The strategic, top-down approach is often
adopted in modification-based innovation. In this approach, systematic and intensive
mobilisation of resources in the organisation is carried out. Clinical trials, production
process development, the development of preparations, and the establishment of the
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marketing and distributing system are often conducted simultaneously. This is
because the speed of development is crucial: rival companies also see the same
business opportunity. The keys to the accomplishment of fast development are
organisational capability and organisational integration. The case of ranitidine and
that of cefotiam well illustrate such an organisational effort.
Third, heterogeneous engineering of the construction of differences is an important
activity in modification-based innovation. As we discussed above, the company often
conducts a considerable part of this activity in a systematic and organisational way.
In this effort, various kinds of factors including new concepts such as "cardio-
selectivity," "longer-acting" and "the third generation p stimulants," close
relationship with leading clinicians, more convenient forms, a richer variety of forms,
papers on comparative clinical trials, instruments and techniques ofmeasurement and
analysis to demonstrate the differences between the new drug and existing ones,
catch phrases like "Fast, Simple, Safe," users' needs and cost performance are
mobilised, as was seen in the cases classified in this type of innovation. For this,
relevant actors and their activities have to be linked with each other. If the company
has the experience in the development of a drug in the same area, for the most part
the network used for this heterogeneous engineering is probably an existing one.
How much the company can exploit the network for the shaping of the drug is the
main question in modification-based innovation. But if the company does not have
the experience, the construction of quite a new network will be required.
Fourth, influences ofmodification-based innovation on relevant factors are in general
more limited than with other types of innovation. Modification-based innovation
does not challenge existing paradigms of science and therapy. Rather, it maintains
them. However, it may transform market structure and conditions to a great extent.
The drugs produced by modification-based innovations often supersede existing
drugs including the paradigmatic original, as was demonstrated in the cases of
ranitidine and famotidine. Thus, modification-based innovation may provide the
company with more money than paradigmatic innovation. This income changes the
organisation and the strategy of the company. It also provides resources for further
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research and development. Therefore, modification-based innovation may transform
not only the market but also the company.
In sum, we can distinguish three types of pharmaceutical innovation classified in
terms of familiarity with the concept of a drug, namely paradigmatic innovation,
application innovation and modification-based innovation. This implies that the
pattern of the shaping of a drug is neither the same nor thoroughly different. This
means that the shaping process of a drug is manageable and that the way of its
management is not "the one best way." It should be noted that any type is not in
particular linked with market success. Ranitidine seemed to be more successful on
the market than cimetidine, though it was a modification-based innovation. But this
is not the case for every modification-based innovation. In the next section, we will
examine the differences between Japanese cases and British cases in terms of the
types of innovation.
8.3. Distinctive Features of Japanese Pharmaceutical Innovation
When we look at Table 8.1 from the viewpoint of Japanese - British comparison, we
find that most cases of Japanese pharmaceutical innovation belong to modification-
based innovation rather than paradigmatic innovation whereas its British counterparts
are distributed in a better-balanced way. This is not due to my choice of cases. Other
researchers also indicate the same point with using a larger amount of samples.
(Hawkins and Reich 1992) On the contrary, I chose mevastatin because it is a rare
paradigmatic innovation in Japan. Leuprorelin may also be an exception. However,
leuprorelin is probably better regarded as a half-Japanese and halfAmerican
innovation, because it is unlikely that the drug would have been shaped successfully
without the contribution ofworkers at Abbott and TAP Pharmaceuticals in the
United States. Mevastatin was not completed as an innovation because it was
discarded halfway through the development. Thus, there is no case in our study that
can be seen as an unconditional example of paradigmatic innovation shaped in Japan.
This is consistent with the view that is generally held about Japanese pharmaceutical
innovation. (Kneller 1999, p. 422; Odagiri and Goto 1996, p. 246; Reich 1990, 134)
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It is probable that some historical, structural and cultural factors are related to the
tendency of Japanese pharmaceutical industries towards modification-based
innovation. In this section, we discuss the factors that are probably related to this
tendency, in order to deepen our understanding of the shaping process of a drug. The
case studies of the two "almost" paradigmatic innovations involving Japanese
companies, namely leuprorelin and mevastatin, are particularly useful to identify
such factors.
8.3.1. Level of Science and Technology
As a latecomer amongst industrial countries, Japan has a history of importing
scientific knowledge and technology from Western countries. (Odagiri and Goto
1996) Although Japan has made some unique contributions to the progress of science
and technology in the pharmaceutical area, it seems that the Japanese level of science
and technology in the area was considerably lower than its British and American
counterparts at least until the 1970s, the period when most of the drugs examined in
this study were discovered. Many Japanese industrial researchers in this study,
including Fujino and Matsuzawa in the case of leuprorelin and Endo in the case of
mevastatin, studied in the United States. Their experience there led them to the
research resulting in the discovery and development of the drugs. All other concepts
of the drugs in this study, namely P blockers, Ca antagonists, p2 stimulants, H2
antagonists and cephalosporin antibiotics came from British, German or American
scientists. Although aic antagonists seemed to be first named by Yamanouchi's
researchers, it was overseas scientists who discovered ajc receptors. These examples
indicate that the level of the scientific basis in the pharmaceutical area in Japan was
in general lower than such countries as the UK, the US and Germany. This was the
case not only in the academia but also in the industry. It was only after 1960 that
most large Japanese pharmaceutical companies began to establish their full-scale
research laboratories to discover new drugs. (Nihon Yakushi Gakkai 1995, p. 123)
Scientific knowledge and technology was not sufficiently accumulated within
pharmaceutical companies in the 1970s. They had to send their researchers to foreign
and domestic universities to obtain necessary knowledge and skills. An example of
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technology transfer from domestic universities to pharmaceutical companies can be
seen in the case of nicardipine, in which the techniques for experiments were
transferred. Thus, the insufficient level of science and technology in the
pharmaceutical area in Japan may be one of the factors explaining the lack of
paradigmatic innovation in the country.
8.3.2. Collectiveness of the Organisation
Consensus, interdependence, group-based, overlapping, intensive communication
and the sharing of information and knowledge are the concepts that are often used to
characterise the Japanese corporate organisation. (Porter, Takeuchi and Sakakibara
2000, pp. 69-76; Fruin 1992, pp. 301-320; Nonaka and Takeuchi 1995, pp.75-83,
pp. 198-199; Clark and Fujimoto 1991, pp.215-228) These characteristics can be
expressed with one word: collectiveness. Collectiveness of the organisation probably
contributes to the integration of resources in the organisation but may enhance the
level of organisational resistance to unfamiliar ideas and uncertain plans. In the case
ofmevastatin, Endo, the project leader, faced strong organisational resistance, which
almost killed the project, again and again. Unfamiliarity with the concept of the
HMG-CoA reductase inhibitor, uncertainty as to its efficacy and safety and the lack
of an exemplary drug of the same kind seemed to amplify the doubt among people in
the company. The pharmacologists who conducted the tests with rats and the
toxicologists who found the unknown crystals in rat cells tried to turn the project
down, rather than trying to find an explanation or solution to let it continue. It was
Endo's tenacious attitude and the power of academic clinicians that saved the project.
The lack of an exemplar also caused doubts within the company in the case of
leuprorelin, and became one of the reasons for the delay of its development in Japan.
Organisational resistance was observed in other cases of the pharmaceutical
innovation in Japan, including nicardipine, tamsulosin and cefotiam. In the case of
tamsulosin, the track record of Takenaka, the project leader, contributed to the
shaping of organisational authorisation. In other cases, a powerful member of the
management backed the project so that it could survive. Thus, the collectiveness of
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the Japanese organisation may be another factor that hinders the shaping of the
paradigmatic innovation and application innovation in particular.
8.3.3. Exclusiveness of the Market
It is said that the pharmaceutical industry in Japan was nurtured and promoted
through a highly regulated market with government-set prices and that health policy
served as implicit industrial policy. (Reich 1990, 125) The National Health Insurance,
fully established by 1961, promoted the expansion of the Japanese pharmaceutical
market in the 1970s. (Reich 1990, 130) The Japanese government has allowed
doctors not only to prescribe drugs but also to dispense them. In the obligatory health
insurance system, doctors are paid through the fee-for-service reimbursement that is
based on the fee schedule lists set by the government. The prescriptions dispensed by
doctors are reimbursed to doctors' clinics or hospitals. The margin between the
purchase price and the reimbursement price set by the government, called "yakka
saeki" which is estimated to amount to a quarter of the total sum paid by insurance
for pharmaceuticals, has constituted an important source of income and profits to
doctors' clinics and hospitals. Therefore, Japanese doctors have had a strong
tendency to prescribe drugs in excess ofwhat is needed. (Reich 1990, 130-132; Low,
Nakayama and Yoshioka 1999, pp.175-176; Campbell and Ikegami 1998, p.148;
Odagiri and Goto 1996, p.244; Howells and Neary 1995, p.236) This also has
contributed to the expansion of the Japanese pharmaceutical market. Nowadays, the
Japanese pharmaceutical market is the second largest in the world. (Reich 1990, 124;
Kneller 1999, p. 411) This large market has enabled Japanese pharmaceutical
companies to rely almost on domestic sales alone. Health policy was more
advantageous for domestic companies than foreign companies. For example, clinical
trials for drug approval had to be conducted in Japan on native people. (Reich 1990,
129) General industrial policies also contributed to the growth of Japanese
pharmaceutical companies. Japan restricted investment by foreign companies until
the mid 1970s. Until then, the Japanese pharmaceutical market was secured for
domestic pharmaceutical companies. (Reich 1990, 133) Patent policy in Japan before
1976 protected only the process technology of drugs, that is to say, if you changed
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the method of the production process, you could obtain a patent even if the product
was the same. (Reich 1990, 134; Howells and Neary 1995; pp. 145-149) Thus, the
mixture of industrial policy and health policy in Japan has contributed to the growth
of the Japanese pharmaceutical market and the almost exclusive exploitation of the
market by domestic companies.
The close relationship between doctors and pharmaceutical companies has also
limited the access of foreign companies to the Japanese pharmaceutical market.
(Odagiri and Goto 1996, 246; Low, Nakayama and Yoshioka 1999, p. 176)
Pharmaceutical companies in Japan regard their relationship with doctors as
particularly important because doctors have almost decisive power in the choice of
drugs and because doctors have substantial power over the national health policy.
However, doctors were more powerful in the 1960s and 1970s than at present, and
pharmaceutical companies at the time regarded them as if they were "kings." (Low,
Nakayama and Yoshioka 1999, pp.175-176, pp. 178-180; Reich 1990, 132; Campbell
and Ikegami 1998, pp.27-29, pp.31-32, pp. 129-131; Howell and Neary 1995, pp.28-
29, pp.54-55) This power relationship between doctors and companies explains why
Endo was able to reverse the trend of opinion within the company by mobilising a
doctor's offer of a clinical trial ofmevastatin. To establish a good relationship with
such a powerful actor, pharmaceutical companies in Japan have made a lot of effort
by deploying a large number of representatives. (Odagiri and Goto 1996, 246) This
has functioned as an entry barrier for foreign companies.
It is said that the relationship between the government and pharmaceutical companies
has been more ambivalent. The pharmaceutical industry is not a major political
power-base in Japan. (Howells and Neary 1995, p.55) The pharmaceutical industry
is not under the jurisdiction of the Ministry of International Trade and Industry
(M3TI) but under the Ministry ofHealth and Welfare (MHW). The former has
characteristics as a promoter of industry, but the latter is essentially a regulatory
body even though it has some promoting functions as well. (Howells and Neary 1995,
p. 191, pp.239-240, p.251) Thus, on the one hand, the MHW looks powerful and has
seemingly had no hesitation in imposing drug price cuts and other policies on the
260
industry. (Howells and Neary 1995, p. 237, p.249) On the other hand, however, the
close links between the MHW and pharmaceutical companies are often mentioned.
(Howells and Neary 1995, p. 139) As was revealed in the scandal ofGreen Cross, one
of the large pharmaceutical companies in Japan, many retired senior bureaucrats of
the MHW seem to have joined the pharmaceutical industry. (Low, Nakayama and
Yoshioka 1999, pp. 176-177; Reich 1990, 137) Pharmaceutical companies have
provided senior bureaucrats with longer job opportunities. These ex-bureaucrats
probably play an important role as mediators between the industry and the MHW.
Thus, formally, the relationship between the government and pharmaceutical
companies in Japan appears to be of an arm-length kind, but informally it may be
closer.
The mixture of health and industrial policies, the relationship between doctors and
pharmaceutical companies, and the relationship between the MHW and the
companies have constructed a large, closed market in Japan. This closed market has
provided Japanese pharmaceutical companies with opportunity for earning
satisfactory profits. However, at the same time, it may have prevented the companies
from paying attention to overseas markets5. (Reich 1990, 128) This may in turn have
reduced the incentives to discover and develop internationally competitive drugs
with unique concepts and higher uncertainty. Instead, modification-based innovation
is probably preferable as long as it is marketable and profitable in the domestic
market. That is to say, the closed and protected market in Japan limited the vision of
domestic pharmaceutical companies to less uncertain opportunities to earn profits. In
other words, the bounded vision (Fransman 1990, p.3, p.286) of pharmaceutical
companies is directed to modification-based innovation by structural factors
including health policy, industrial policy, the relationship between doctors and
companies, and that between the regulator and companies.
Several other institutional factors also seemed to promote modification-based
innovation in Japan. Pharmaceutical price policy was one of them. Since 1981, the
5 This constitutes a clear contrast with British pharmaceutical companies, which had to face
international competition early on because the UK market was not secured for them but open for
foreign companies. (Owen 1999, p.371; Owen 1994)
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MHW has reduced the reimbursement price of drugs. (Campbell and Ikegami 1998,
p. 158) This has had an unintended impact on innovation-seeking activity in the
pharmaceutical industry. Doctors responded to the price cuts by shifting their
prescription patterns to products with higher profit margins, that is, new drugs. This
stimulated pharmaceutical companies to introduce new drugs frequently. However,
these new drugs did not have to be truly innovative drugs. (Reich 1990, 137) It is
only since 1989 that the MHW has distinguished between innovative drugs called
"picashiyi' and less innovative drugs called "zoroshirT and has promoted the former.
(Howells and Neary 1995, p. 126) Until then, the approval policy and price policy
had unintentionally promoted modification-based innovation rather than
paradigmatic innovation.
In sum, these factors, namely the level of relevant science and technology, the
collectiveness of the Japanese organisation and the exclusiveness of the Japanese
pharmaceutical market, probably contributed to the Japanese companies' tendency
towards modification-based innovation. However, because these factors themselves
have been historically and socially shaped, they will not last forever. This means
some paradigmatic innovations may emerge from Japan. But it cannot be shaped by
the effort of pharmaceutical companies alone. Many relevant factors mentioned
above also have to be changed. And this will need enormous effort by many people
in Japan.
8.4. Concluding Remarks
8.4.1. The Shaping Process of Drugs Is Not Linear
The conclusion of this study is that the pharmaceutical innovation process is not
linear. The linear model of technological change is not applicable even to the
pharmaceutical industry, contrary to the common views ofboth practitioners and
academics. Drug innovations happen neither from science, via technology, to market,
nor from social needs, via science and technology, to market. The process of
pharmaceutical innovation is interactive and multilateral. Numerous actors, entities
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and their relationships are involved in the process. Even within a pharmaceutical
company, there are many actors whose views and interests are different. Drugs are
shaped by interaction among various actors, factors and activities. The four aspects
of the shaping process of drugs, namely the shaping of the compound, of the
application, of organisational authorisation and of the market, are interactive, inter-
reflective and co-evolving. The compound, its application, its organisational
authorisation and its market are shaped together and together constitute a drug. They
are also interdependent: if one of them is dissolved, then the rest will also become
unstable and dissolved. The shaping process of drugs also transforms relevant actors,
factors and activities, including science, technology, artefacts, organisations, human
relationships, organisational relationships and market. The shaping of drugs is,
therefore, the co-creation ofmaterials, knowledge and institutions. Thus, three major
points of the criticism of the linear model - the interaction between science and
technology, the interaction between science/technology and economy/market, and
the involvement ofheterogeneous actors in the interactions - are indeed applicable to
pharmaceutical innovation. The linear model has lost its last bastion!
This non-linearity of drug shaping process has several practical implications. In order
to promote innovation in the pharmaceutical industry, financial and material support
in research must help but is not sufficient. The shaping of drugs consists not only of
research but also of development, in-house politics and market creation. For example,
creating opportunities for communication between drug researchers and clinicians in
various therapeutic areas in terms of drug development, between the management of
pharmaceutical companies and external scientific and medical experts and patients in
terms of drug assessment, and between companies, regulators, doctors, academics,
patients and general public in terms of drug marketing are all ways which would
probably be effective in stimulating innovation. An integrative approach, which
includes all aspects of drug shaping and pays attention to not only economic but also
"social"6 means of promotion, is necessary. Without intervening in the "social" side
of the shaping process of drugs, innovation-promoting campaigns in the
pharmaceutical industry will be less efficient and less effective.
6 With regard to the term "social" here, see Section 2.3.4.
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Although innovation process is not linear, either in the pharmaceutical industry or in
other industries, there are several differences. For example, with regard to the
comparison with other industries, such as automobiles and electronics which are
sometimes characterised by incremental innovations, the innovation process in
pharmaceuticals seems to be more strongly linked with science and with regulation.
External sources of scientific knowledge more directly take part in the shaping
process of technology. This is consistent with the argument ofFaulkner and Senker
(1995, pp.208-209), which compared knowledge flows from universities into
companies in three "high-tech" areas, biotechnology, engineering ceramics and
parallel computing. Regulation is often paid little attention in the innovation model
(e.g. Klein 1985), but it is an essential factor in any aspect of drug shaping. Thus,
these are two distinctive features of the innovation model in pharmaceuticals
compared with other industries.
8.4.2. Both Human Actors and Non-human Entities Are Essential
It should be noted that non-human entities play an indispensable, but not decisive,
role in the shaping process of drugs. This research basically supports the key claim of
actor-network theory that technology is a heterogeneous network. (See Section 2.1.3)
Neither people alone nor things alone can shape drugs. Although this sounds obvious,
it should be emphasized because it reminds us of the material imperative, that is to
say, the fact that non-humans strongly restrict all our activities, though their
restriction is not deterministic. This suggests, for example, that the distribution of
physical resources (e.g. scientific apparatus, or disease-model animals) in an
economy affects the shaping of drugs. It also implies that the material infrastructure,
including stable energy, good materials, excellent production equipment and efficient
logistic means, also influences the performance of drug innovation. In particular, it
was seen in our case studies that the level of such industries as scientific instruments
and production equipment is essential for the shaping of not only compounds but also
their organisational status (in terms of acceptable production costs) and market (as
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regards demonstrating their efficacy and safety). It should be also noted that the
shaping process of drugs itself produces new material imperatives.
8.4.3. There Are Different Types of Drug Innovation
The shaping processes of different drugs are neither the same nor completely
different. We found three distinguishable patterns in terms of the relative level of
uncertainty of each aspect. In paradigmatic innovation, uncertainty is high in all
aspects. In application innovation, uncertainty is high in all aspects except the
compound. In modification-based innovation, uncertainty is high in the shaping of
organisation authorisation and that of the market. These three types of drug
innovation have different characteristics in the shaping process. Paradigmatic
innovation is characterised by strong resistance within the organisation and suspicion
outside the organisation. Therefore, it needs strong leadership to accomplish
innovation. Leaders also have to combine heterogeneous factors inside and outside
the organisation to construct all aspects of the drug. In application innovation,
linkage with clinicians in the new application area is particularly important in order
to identify new applications of known compounds. Strong leadership can be also
required to overcome considerable resistance inside and outside the company against
the unfamiliar use of a familiar compound. The construction of a new network in the
new therapeutic area is also needed. In the modification-based area, though
uncertainty in the creation of the compound and its application is not so high, there is
uncertainty in patentability, marketability and profitability of the new drug.
Therefore, the creation of differences is the key task. It also requires swift
development, because the opportunity cost due to delay is clearer. An organisational
capability to conduct systematic and intensive development is needed. There are also
differences in the degree of impact of innovation on relevant actors, entities and
factors among the different types of innovation. The impact of innovation is most
significant in paradigmatic innovation and least significant in modification-based
innovation.
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With regard to the relationship between the types of innovation and the four aspects
shaping drugs, in paradigmatic innovation, all aspects of the drug shaping are
important: in the shaping of the compound and its application, the fusion of external
and internal knowledge is particularly significant; in the shaping of organisational
authorisation and the market, persuading people about the efficacy and safety is the
key task. In application innovation, the shaping of application is obviously essential.
Linkage with external knowledge, in particular communication with clinicians in
various areas is important. In terms of the shaping of organisational authorisation and
the market, it is necessary to persuade people of the efficacy of the new application.
In modification-based innovation, in the shaping of the compound, avoiding the
patents of other companies is one major problem. Constructing differences from
existing drugs is another. In the shaping of organisational authorisation, persuading
the management of its marketability and profitability is critical. In the shaping of the
market, persuading customers and regulators of the differences of the drug is
necessary. Thus, different kinds of innovation have differences in the order of
emphasis on the four aspects of shaping drugs and require different activities in each
aspect.
It seems difficult, and perhaps unwise in terms of risk "portfolio," for a drug
company to pursue exclusively any one of the types of drug innovation, given that
there is keen competition between companies in the same therapeutic areas and that it
takes about ten years to develop a drug. In addition, although the three types of
innovation possess differences in drug shaping process, they also have similarities,
for example, relevant actors, entities and activities and their interactive relationships.
Therefore, the management of drug innovation for each innovation seems not to be
completely mutually exclusive. Nevertheless, there seems to be different points of
emphasis in the management of different types of drug innovation. To promote
paradigmatic innovation, the reduction of organisational and regulatory resistance is
needed. However, this resistance is necessary to protect the company and society
from the undesirable results that might come from the development of inappropriate
drugs. Proper assessment of projects is required. For this, it seems effective to
encourage communication between various external scientific and medical experts,
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and the management and the regulator. The management and the regulator should be
also aware of the constructed nature of scientific knowledge. Even though dominant
scientific knowledge is inconsistent with the concept of a new drug, it can be
possible that existing scientific knowledge has flaws. To promote application
innovation, the communication between corporate researchers and clinicians in
various therapeutic areas seems important. The communications between researchers
in different areas and between researchers and marketing staff in various therapeutic
areas also seem to be helpful. In order to promote modification-based innovation,
building the integrated organisation is crucial so that the development of drug can be
swiftly achieved. Communication with medical practitioners and patients may be
helpful to identify the needs for improvement.
In sum, the shaping processes of drugs are neither identical nor radically different.
There are three types of innovation, namely, paradigmatic innovation, application
innovation and modification-based innovation. Each innovation has different
characteristics in the shaping process of drugs, and so the shaping process of drugs
should be managed somewhat differently, according to the type of innovation.
8.4.4. Drug Innovation in Japan: Historical, Cultural and Structural Factors
As discussed in Section 8.3, when we compare the Japanese cases with the British
cases, the proportion of modification-based innovation seems to be higher in Japan
than in the UK. Historical, cultural and structural factors, namely the relatively lower
level of science and technology in the biomedical area in Japan, the "collectiveness"
of Japanese organisations and the exclusiveness of the Japanese pharmaceutical
market seem to contribute to this orientation of Japanese companies toward
modification-based innovation. That is to say, these features of the Japanese context
in which drug innovations take place seem to be more favourable for modification-
based innovation than for paradigmatic innovation. These contextual features of
Japanese pharmaceutical innovation are not always shared with other industries in
Japan. The levels of science and technology vary between different fields ofR&D.
The structure and the openness of market also seem to vary between different
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industries. However, the collectiveness of organisations seems to be common in
Japan, although its effects on innovation may be different between industries. In the
industries in which their scientific base is relatively stable, market needs are better
articulated and incremental innovations are dominant. In these industries, such as the
automobile industry and the electronics industry, consensus-based, collective
organisation is probably favourable for innovation. However, in the pharmaceutical
industry, such organisation may be inappropriate to particular types of innovation,
namely, paradigmatic innovation and application innovation because unfamiliar ideas
cannot be easily accepted by all relevant actors in the organisation.
Thus, the comparison between Japanese and British pharmaceutical innovation
shows that historically, culturally and structurally formed factors, for example, the
level of science and technology, properties of organisations, and properties of
markets, affect the pattern of drug shaping process. It supports the arguments of the
social shaping of technology that historical and structural context should not be
ignored in understanding technological change. (See Section 2.1.4) These influences
from contextual factors are less obvious than influences from directly involved actors
such as researchers, managements, doctors and regulators. This implies that in order
to understand the process of technological change we should take into account not
only observable actors, factors and activities in each individual innovation process,
but also hidden factors characterising the context in which innovations take place. In
terms of research methods, comparative studies of innovation between different
historical, structural and cultural contexts are necessary to understand innovation
process fully.
From the practical point of view, the involvement of historical, cultural and structural
factors in drug innovation process suggests that broader transformations of society
may be required in order to change the pattern of innovation. For example, to
promote paradigmatic innovation in Japan, it may be necessary to transform its
scientific and technological culture, organisational culture and market structure.
Relevant scientific and technological jobs in Japan should be made more attractive
for young people and foreign people with ability. The research infrastructure should
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be improved, and flows of knowledge between public sector researches and
industries should be promoted. Heterogeneity and heterodoxy in organisation should
be allowed. Unfamiliar things should be tried rather than being avoided. The market
should be open wide to foreign companies and the competition among them should
be encouraged so that Japanese companies can have larger incentive to paradigmatic
innovation. It is obvious that these transformations require more than the effort of
pharmaceutical companies alone. Scientists, engineers, educators, managers,
investors, doctors, regulators, policy planners, citizens, patients, their carers and
family members should each play their role. In other words, everybody is, indeed, to
some extent involved in the shaping process of a drug. Ifwe want better medicines,
we should be aware of this, think about our roles and play the roles.
8.4.5. Reflexive Remarks
As the final remarks of the thesis, I would like to note several things. I have learnt
about the research process in the course of this study. First, I have learnt that there is
a kind of "snow-ball effect" in acquiring access to interviewees. That is to say, if I
can obtain an agreement about interviewing from a person or company ofgreat
repute, it becomes easier for me to get another agreement. There are two routes for
obtaining contacts: the personal route from one person to another and the formal
route from companies' spokespersons through their management to their researchers
and staff. In taking either route, I mentioned my track record in interviews when I
asked for another interview, which seemed to help me acquire an agreement. In the
company-route case, spokespersons also seemed interested in which companies were
included in my list of interviewees. Interestingly, it seemed to me that building the
list of interviewees by the personal-route was more difficult in Japan than in the
United Kingdom. In Japan, the formal, company-route seemed easier. This might
suggest the cultural properties of both countries: more individualistic British society
and more institutional (corporative) Japanese society. Second, despite the snow-ball
effect, I could not achieve access to the full range of researchers and staff related to
each case. Companies did not always allow me to meet people who I wanted to
interview with. This can cause the exclusion of diverse views of the drug shaping
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process. I tried to minimise the potential biases due to this exclusion by using written
evidence by different authors. In fact, I am afraid that not all interviewees feel happy
about my story, which are different from theirs because of different evidence. When I
showed my early draft of each case to relevant interviewees, some of them expressed
specific disagreements with my account. Therefore, my story is not the same as the
interviewee's story. Since my methodology ran the risk of generating a "great man"
view of innovation, it is to some degree reassuring that at least some "great men"
were unhappy with my account. However, my thesis does rely greatly upon
interviews of key researchers and there still remains room for a richer account due to
the fact. Thirdly, it was found that follow-up communication with interviewees was
very important to acquire additional information to understand the case processes of
shaping drugs. In the course of reconstruction of cases, it was usual for me to come
across questions which had not come to mind in the interview. Therefore, I have
learnt that it is important to ask interviewees to allow follow-up communication after
interviewing. Fourthly, there was a potential tension between the author and
interviewees and relevant companies over the contents of the story of drug shaping.
As mentioned above, some interviewees and companies seemed uncomfortable with
my account. However, fortunately, all interviewees were generous enough to tolerate
my different views. It should be noticed, however, that there is a risk of the rejection
of cooperation by interviewees and companies if the interviewer fails to obtain their
trust. Therefore, I have learnt that it is essential for the interviewer to be sincere and
careful enough to obtain the trust of interviewees. Fifthly, I have learnt that it is
extremely difficult to obtain internal documents on drug discovery and development,
such as the notebooks and letters of researchers and the minutes of company
meetings. In some cases, I did ask interviewees for such documents, but they
declined my request because of the reason of confidentiality. I have to admit that this
limitation ofmy feasible data collection restricted the kind of analysis that I could do
For example, it was difficult to conduct a full analysis in terms of the sociology of
scientific knowledge with the available data. However, I also confirmed that
scientific papers are useful sources of information about the shaping of drugs.
Although we should be careful about the non-constructivist style of these papers,
they sometimes show controversies, as was seen in Chapter 4. Given the extremely
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difficult situation in obtaining internal documents about drug R&D, contents of
specialist scientific papers should be examined carefully in order to find traces of
"social" aspects of drug shaping. Knowing these things about the research process
especially in the area of the pharmaceutical industry, I would be able to build up
evidence more efficiently with less trials and errors.
The other remarks are about questions that remain. First, how general are the
findings of this study? Are the four aspects of drug shaping and the three types of
drug innovation applicable to other drug innovations? Are they applicable to newer
drug innovations, which are based on biotechnology? Are the types of innovation
size-dependent? When taking the division of labour, for example, between large
pharmaceutical companies and small and medium sized biotech companies into
consideration, how do the models of innovation change? I conjecture that
modification-based innovation may be size-dependent in the sense of being easier in
large companies because the uncertainty in R&D is relatively low and integrated and
speedy mobilisation of resources for drug development is crucial to success. In
contrast, I conjecture that paradigmatic innovation and application innovation may be
less size-dependent. Small companies may have a smaller stake in existing ways of
doing things and therefore are likely to be more favourable to unfamiliar ideas; but
they may be counterbalanced by the fact that they are likely to have less resources
necessary to develop a new drug. To answer these questions, case studies of newer
drug innovations, especially of biotechnology-based ones, and quantitative studies
based on the framework of this study would be useful. Second, how deep does the
process of social construction go in the shaping ofmedicines? To reveal this, more
internal and detailed evidence, more informants and the fuller use of the sociology of
scientific knowledge will help. Third, how are inter-organisational linkages related to
the shaping process of drugs? For example, how do knowledge transfers between
rivals, between universities and industries and between small biotech firms and large
pharmaceutical companies take place? How do these different organisations conflict
and collaborate with each other? How do these relationships contribute to drug
innovation? Studies of inter-organisational linkages in the drug innovation process
will be meaningful. Fourth, how applicable are the findings here to innovations in
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other industries? To answer this, comparative studies between different industries
based on our framework will be needed. To explore the shaping processes of drug
and other technologies fully, we should use different perspectives, different research
methods, and different data.
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